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ABSTRACT 
This thesis concerns the influence of healthcare systems regulation on firm-level 
capabilities and affordable healthcare technologies. Regulatory change is highly 
contentious, critics arguing that regulatory changes interfere with the efficiency of the 
market, and advocates arguing that well designed regulatory changes make markets 
more efficient and ensure market outcomes are more equitable. To date, very few 
studies analyze the influence of regulatory change on the medical device industry, and 
its ability to manufacture and supply affordable healthcare technologies.  
To respond to this gap, this research employs the Sectoral Systems of Innovation 
(SSI) approach as a theoretical framework to analyze the influence of regulatory 
changes on industrial capabilities in medical device industries and affordable 
healthcare technologies in South Africa and the United Kingdom. A mixed method 
approach, focusing on three cases of regulatory change, emphasised documentary 
analysis and questionnaire-guided interview to collect primary and secondary data 
from different sources in the healthcare systems of the two study countries. 
Regulatory changes facilitated some firms to create new strategies and innovative 
capabilities. Regulatory changes enabled some firms to develop close collaborative 
linkages with external providers in search of competitive advantage and improved 
market positioning. One reactive regulatory change in particular illustrated negative 
influence on innovative capabilities. Smaller firms were at a particular disadvantage 
in adapting to regulatory change. In the South Africa case, the more stringent 
regulatory requirements made it hard for domestic suppliers to enter the supply chain 
and led to joint ventures mainly with multinational corporations. The thesis argues, 
with empirical evidence, that a more enabling and discriminating regulation that takes 
into consideration of firms’ technological capabilities can achieve intended goals 
more efficiently and effectively, than constraining and indiscriminate regulation. 
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CHAPTER ONE 
 INTRODUCTION 
----------------------------------------------------------------------------------------------------- 
Medical device manufacturing firms operate in a regulatory-intensive environment. 
These firms need to understand how to adapt to and take advantage of exogenous 
changes such as regulations. As early as 1988, Mayo and Flynn (1988) noted that 
regulations can create significant new business opportunities since they often infuse 
radical effects on industries and firms. However, the changes in regulatory 
requirements represent huge challenges for many firms and are often viewed 
primarily as new restrictions on conducting business (Chowdhury, 2014). They can 
limit how firms design, develop and market their products. For some firms, 
regulations might be seen as a hurdle, since compliance requirements might hamper 
ambitions for business growth and innovation (Ashford et al., 1985). Regulations can 
force firms to make investments in projects that they must do, often in stark conflict 
to what the firm wants to do (e.g. innovation or product development) (Blind, 2012). 
The way in which the actors of change such as manufacturers in the industry are able 
to deal with the market environment is influenced by the internal capabilities of these 
actors.  
 
Regardless of how regulatory changes are perceived, they will influence the structure 
of industries and thereby also the position and fortune of firms (Altenstetter, 2008). 
Firms are obliged to understand that regulations will generate new requirements and 
consider how best to manage implementation. By understanding regulations as a key 
influencing factor, firms can identify new opportunities offered by the processes of 
regulatory change (Curfman and Redberg, 2011). Therefore, better insight into what 
firms do to manage regulatory change can result in new insight into the destiny of 
firms. 
 
This thesis contains two central themes. One is the evaluation of the effects of 
regulatory changes on overall industry capabilities. That is, how does the Sectoral 
System of Innovation (SSI) operate and how is it affected by regulatory change? The 
second theme is the evaluation of firms in two different regulatory environments with 
different characteristics. In this research the key characteristic is the experience firms 
have gained of the regulatory review process. To study the influence of regulatory 
 2 
change on firm level capabilities, it is critical to first understand the concepts of a 
healthcare system. 
1.1 Healthcare System 
Healthcare systems or health systems play a central role in helping people maintain 
and improve their health. A number of frameworks and models have been developed 
and published to illustrate what a health system looks like. Some of those frameworks 
that have been proposed at the national level include: the widely used World Health 
Organization (WHO) models (WHO, 2007; 2009), the reform focused model 
(Cassels, 1995) and the essential public health functions model (PAHO, 2008). In this 
research, the WHO (2009) health system framework (as shown in figure 1.1) is used 
to illustrate the six operational building blocks and the overall health system goals.  
 
 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
Figure 1.1: The WHO Health System Framework. Source: (WHO, 2009) 
 
 A strong health system is built on six building blocks: service delivery, health 
workforce, information, medical products, vaccines, and technologies, financing and 
governance (WHO, 2009). The various interactions among these components convert 
these building blocks into a system and if any of these components are missing, the 
health system cannot function at the level necessary to improve the health of the 
population. Each building block has its own unique challenges in terms of policy and 
organizational systems (WHO, 2011a). The areas of focus within the WHO health 
system framework to be examined in this study are the health technologies (medical 
devices) and governance (regulation), which are emanating from the fourth and sixth 
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building blocks of the framework.  
1.2 Health Technologies 
Based on functions defined by WHO, (2007), a well-functioning health system 
ensures equitable access to essential medical products, vaccines and technologies of 
assured quality, safety, efficacy and effectiveness. Healthcare technologies work 
towards the reduction of healthcare costs by conducting timely diagnosis, provision of 
effective treatment and reduction of pressure on hospital resources and staff (Matsoso 
and Fryatt, 2013). Liaropoulos (1997) drew a schematic representation (as shown in 
Figure 1.2) of the alternative definitions of biomedical, medical, healthcare and health 
technology: 
 
Figure 1.2: Outline of the categories in health technology. Source: (Liaropoulos, 
1997, p.126)  
 
As shown in figure 1.2 and starting from the top left of the list, drugs and devices are 
considered as technologies dealing primarily with the biological characteristics of the 
processes under which healthcare is provided therefore assigned to the category of 
biomedical technologies. The addition of procedures to the list refers us to the main 
domain of the clinical practice, thus drugs, devices, and procedures constitute medical 
technology. When organizational and support systems originating and operating 
within the broader health care system are added to the list, the category is considered 
Drugs 
Devices 
Procedures 
Organizational 
support systems 
In the health sector 
Outside the health sector 
Biomedical 
Technology 
Medical 
Technology 
Health Care 
Technology 
Health 
Technology 
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as health care technology. Health technology, on the other hand, includes all of the 
above as well as the societal organizational and system parameters that determine the 
final health outcome (Liaropoulos, 1997). 
 
Medical devices are a subset of health technologies as can be seen from figure 1.2. 
They play an important role in clinical practice and improving patients’ health 
(Altenstetter, 2008, Beksinska et al., 2011).  Medical professionals make critical 
decisions associated with healthcare after using the devices to identify the patient’s 
problem (Zuckerman et al., 2011). Medical devices include syringes, catheters, and 
face masks. There are also devices for wound management, ultrasound, artificial 
joints and prosthetics, invasive surgery, clinical and laboratory operations, and 
inhalation and infusion therapies. Others are audiometry and hearing aids, 
disposables, hospital supplies, kits and in-vitro diagnostics (Kramer et al., 2012a). 
 
However, the use of medical devices entails some considerable risks to human health 
(Altenstetter, 2008). Regulation is one mechanism to help balance the benefits and 
risks of new devices (Sorenson and Drummond, 2014). Therefore all health 
technologies must fulfil the regulatory requirements of their targeted markets and 
prove that they are developed in a way fitting with their purpose (Chowdhury, 2013). 
1.3 The Role of Regulation and the Need for Change 
The sixth building block of the WHO health system framework is leadership and 
governance. This component involves ensuring strategic policy frameworks exist and 
are combined with effective oversight and regulation of health technologies (WHO, 
2007). Regulatory institutions, policies, and processes have been developed by 
governments to authorize healthcare technologies for use on the market and to 
determine the terms of their coverage, reimbursement, and pricing. The Organisation 
for Economic Co-operation and Development (OECD) defines regulation as the 
implementation of rules by public authorities and governmental bodies to influence 
market activity and the behaviour of private actors in the economy (OECD, 1997).  
 
Scope of regulations in medical devices can be divided into several phases in the 
product life-cycle: pre-market, placing on-market, and post-market surveillance 
(WHO, 2003). Thus, regulation becomes crucial already in the development phase 
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(pre-market) as it is required to develop and document the product according to 
national regulations. During placing on-market phase regulation is needed for 
advertising and sales of products. After placed on-market, post-market surveillance 
must be in place meaning that products are monitored while on the use. 
 
Regulation is an important defining factor in the medical device industry because it 
influences the way in which technologies are innovated, tested and commercialized, it 
also influences how producers and consumers interact, and ultimately contributes 
heavily to the institutional structure and the innovation dynamics of the medical 
device sector (Beer et al., 2011). The need for regulation comes from information 
asymmetry between the producers on one side and patients and clinicians on the other 
side. Patients cannot assess safety or observe quality and efficacy of medical devices 
on their own, and neither can the medical practitioners who decide on their behalf 
(Harper, 2007). This is where regulatory bodies come in, by seeking evidence of 
compliance with guidelines, rules and regulations to give credibility and legitimacy to 
organizations inspected.  
 
Furthermore, regulation seeks to ensure that the health technologies are improved and 
offer reforms to healthcare services (Wood, 2010). The forces behind changes in 
regulations are diverse, emanating from firms, policymakers and regulators (Jacobides 
et al., 2006). Firms can turn to regulatory bodies for guidance on how to adjust to 
regulations (Brusoni et al., 2009). The objectives of regulation are the same in most 
countries, however the characteristics of different regulatory regimes can be quite 
different.  
1.3.1 Types of Regulations 
The regulatory requirements and other documentation for medical device safety come 
in different forms and compliance with some of them is mandatory and voluntary with 
others. There are also some differences in terms between issuing bodies. Figure 1.3 
outlines the different types of regulations, which will be discussed in this thesis in 
more detail. 
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Figure 1.3: Compliance requirements 
 
The EU law is divided into 'primary' and 'secondary' legislation. The treaties (primary 
legislation) are the basis or ground rules for all EU action. Secondary legislation, 
including directives, regulations and recommendations, are derived from the treaties 
(EU Law, 2018). Regulations are binding legislative acts that must be applied in their 
entirety. For example, when the EU wanted to make sure that there are common 
safeguards on goods imported from outside the EU, the Council adopted a regulation. 
Directives are legislative acts that set out goals that all EU countries must achieve. 
However, unlike regulations, it is the individual member countries who devise their 
own laws on how to reach these goals (EU Law, 2018).  
 
Standards are technical specifications defining requirements for products, production 
processes, services or test-methods. These specifications are voluntary and are 
developed by industry and market actors following some basic principles such as 
consensus, openness, transparency and non-discrimination. Standards ensure 
interoperability and safety, reduce costs and facilitate companies' integration in the 
value chain and trade (European Commission, 2016). 
  
In Europe, harmonised standards are developed and agreed by the three officially 
recognized European Standardization Organizations: the European Committee for 
Standardization (CEN), the European Committee for Electro technical 
Standardization (CENELEC) and the European Telecommunications Standards 
Institute (ETSI). They are created following a request from the European Commission 
to one of these organisations. Medical device manufacturers, other economic 
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operators, or conformity assessment bodies can use harmonised standards to 
demonstrate that products, services, or processes comply with relevant EU legislation 
(EU Law, 2018).  
 
The European Commission, standards development organizations also publish 
guidance documents on the application of standards and regulations. Such guidance 
offers more insight into the application of the standards or regulations, and thus helps 
achieve conformance with them. Technical information reports offer information 
much like standards, but are not subject to a formal process of committee approval, 
public review, and resolution of comments (European Commission, 2016). 
1.4 Medical Device Regulatory Challenges 
Over the past three decades the medical device sector in advanced countries has seen 
increased regulation and oversight (Altenstetter, 2008). Key areas relate to the ways 
in which new devices are trialled, approved, and ultimately marketed. In practice, 
regulation of medical devices has also seen inherent limitations and challenges 
(Curfman and Redberg, 2011). Some challenges of regulating medical device 
manufacturing sufficiently have been revealed by uncovering medical devices at the 
market that do not fulfill safety criteria to ensure patient protection and has led to 
patient harm and deaths (Kramer et al., 2012b). These challenges will be explored 
further in the literature review chapter.  
 
The medical device industry often maintains that the regulatory process is 
unpredictable and prolonged, thereby becoming a barrier to innovation and timely 
market entry of their products (Faulkner, 2012, Kramer et al., 2012b); regulators 
frequently face governmental pressures and stakeholder resistance (Peck et al., 2014), 
while health consumers (patients) often complain about not able to access new 
technologies (Matsoso and Fryatt, 2013). In most developing countries, however, 
regulation of medical devices is weak (Rugera et al., 2014). The majority of 
developing countries, and in particular those in the Africa, have a legal mandate to 
regulate but there is limited capacity to do so (Rugera et al., 2014). Furthermore, in 
these countries, most research has focused more on regulation and development of 
pharmaceuticals even though medical devices constitute a key component in the 
healthcare technologies (Kale and Mkwashi, 2015, Sorenson and Drummond, 2014, 
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Doherty, 2015). As a result, research on evolution of medical devices regulation, the 
new developments and in particular market authorisation in different countries and 
specifically, the global south remains a highly under-researched topic.  
In order to bridge this knowledge gap and provide a useful cross-country analysis of 
regulation of medical devices, this study investigate the evolution of regulatory 
changes in the medical device sector in the UK and SA and examine its influence on 
industrial capabilities and development of affordable healthcare technologies. The UK 
and SA have recently introduced or are currently debating reforms of medical device 
regulation, thus it is an opportune time to examine regulatory policies and practices in 
both countries and identify areas for additional improvement.   
1.5 Research Questions  
The overall research question guiding this study is: “How and to what extent has 
the evolution of medical device regulations in the UK and SA impacted industrial 
capabilities and contribution towards affordable health care technology 
development?”  
The main objective of this overall research question is to add to the existing 
knowledge on the effects of regulatory changes on industrial efforts to make 
affordable healthcare technologies in general and medical devices in particular, 
available in both developed and developing countries. To be able to adequately 
answer the overall research question, three sub questions were formulated, namely: 
Sub-Question 1: What changes have been made to regulation of medical devices 
and what approaches were utilised by regulators to implement the changes in the 
UK and SA? 
 
Sub-Question 2: What conditions, processes and events facilitated the changes to 
regulation of medical devices in the UK and SA? 
 
Sub-Question 3: How have regulatory changes affected firm level investment, 
production and linkage capabilities of medical device firms in the UK and SA? 
 
It is worth noting at this juncture that there is another key underlying principle besides 
the literature that has guided the formulation of these research questions. This 
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approach is adopted particularly to ensure that they will correspond with the overall 
motive of this research. It is indeed acknowledged that the key principal nature of 
regulatory requirements would typically highlight what needs to be achieved and 
therefore defines the expectations on the various deliverables required. In this regard, 
deliverables have been defined as all forms of outcomes that are expected to be 
achieved by medical devices manufacturing firms arising from the adherence to 
regulatory requirements.  
 
Therefore, the research questions have been designed to explore three key research 
issues i.e. the content, drivers and impact of regulatory changes. The research 
questions were developed after recognizing the importance of them being clearly 
focused, as well as in ensuring that they are related with one another and further to 
“form a coherent set of issues” (Bryman, 2008: p. 73). For ease of comprehension, a 
table outlining the sub research questions, their relevant research application as well 
as the associated chapters where they will be explained in detail, is presented in Table 
1.1 below: 
Table 1.1 Application of Research Questions and Associated Chapters 
Research Question (RQ) 
Application of Research Question Chapter 
RQ1. What changes have 
been made to regulation of 
medical devices and what 
approaches were utilised by 
regulators to implement the 
changes in the UK and SA? 
 To assess and understand the “content” of 
regulatory changes and the regulatory 
“approaches” utilised by regulators to 
implement the changes in the UK and SA  
 
2 
6 
 
RQ2. What conditions, 
processes and events 
facilitated the changes to 
regulation of medical 
devices in the UK and SA? 
To explore and determine the “drivers” that 
facilitated of regulatory changes in the UK and 
SA. 
 
2 
6 
RQ3. How have regulatory 
changes affected firm level 
investment, production and 
linkage capabilities of 
medical device firms in the 
UK and SA? 
To investigate the “effects” of medical device 
regulatory changes on industry capabilities and 
development of affordable medical devices in 
the UK and SA. 
 
7 
8 
9 
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Answering the above research questions is envisaged to generate evidence, which is 
generalizable in an analytical rather than statistical sense on the influence of 
regulatory changes on industrial capabilities and development of affordable healthcare 
technologies in developed and developing countries.  
1.6 Key Findings 
This study has shown that the interaction between medical device regulations, 
industrial capabilities and affordable healthcare technology development is complex 
and multi-faceted, such that assessing the impact of a given piece of regulation on 
innovation is often an empirical, case-by-case exercise. That said, our analysis has 
shed light, with the help of pre-existing literature, on the way in which different types 
of regulatory changes can affect firm level capabilities. More specifically, our main 
findings include the following: 
• Regulatory change can, under certain circumstances, be a powerful stimulus to 
innovation. Regulatory changes facilitated some firms to create new strategies and 
innovative capabilities.  
• Regulatory changes enabled some firms to develop close collaborative linkages 
with external providers in search of competitive advantage and improved market 
positioning.  
• Different types of regulatory approach can have different impacts on firms’ 
technological capabilities. Typically, we found that a more prescriptive, rigid 
regulatory change can hamper innovative activity by reducing the attractiveness of 
engaging in R&D, constraining modes of commercialization, and creating lock-in 
effects that force the economy into suboptimal standards. The more regulatory 
change is flexible and enabling, the more innovation can be stimulated. One 
reactive regulatory change in particular illustrated negative influence on 
innovative capabilities. Smaller firms who lack the resources to come up to strict 
legal requirements were at a particular disadvantage in adapting to regulatory 
change. In the South Africa case, the more stringent regulatory requirements made 
it hard for domestic suppliers to enter the supply chain and led to joint ventures 
mainly with multinational corporations (MNCs). 
• During the enforcement phase of regulatory change, we found that the lower the 
costs of compliance and the administrative burdens, the more positive were the 
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influence on firms’ technological capabilities.  
• In addition, after the regulatory change, firms tend to replicate extant technology 
combinations instead of introducing new ones. This result thus indicates that 
innovators become more risk averse toward novelty.  
The thesis argues, with empirical evidence, that a more enabling and discriminating 
regulation that takes into consideration of firms’ technological capabilities can 
achieve intended goals more efficiently and effectively, than constraining and 
indiscriminate regulation. 
1.7 The Structure of the Thesis 
This thesis contains ten chapters, each of which plays a particular role in defining, 
formulating, and addressing the research question to deliver the assumed contribution 
of this research. Following this introduction, Chapter 2 provides background details 
for the research relevant in answering sub questions one and two. It sets the scene for 
all the empirical chapters in this thesis (i.e. Chapter 7 to 9). It starts by presenting the 
current state of the global medical device market, followed by a discussion on the UK 
and SA medical device industry profiles such as the market size, distribution of 
medical technology companies and the major segments in medical technology. In 
addition, it discusses evolution of medical device regulations in the two study 
countries and associated requirements that are specifically affecting the medical 
device industries are presented. Finally, it also explains the key components of the 
current state of medical device regulatory frameworks in the UK and SA. 
 
Chapter 3 presents a critical evaluation of literature on health technology regulation in 
general and medical device regulation in particular to situate this research in the 
context of this literature. Particular emphasis is placed on literature on medical device 
regulation in both advanced and developing countries. In addition, literature on the 
effects of regulation on the industry is also examined. A summary of the key issues 
raised in each part of the literature review is provided such that knowledge gaps is 
identified and presented. 
 
Chapter 4 presents the theoretical framework of this study. This chapter first presents 
a graphical overview of conceptual framework for the research, used as a guide to 
flow through the study on medical device regulation and industrial capabilities, 
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through the Sectoral Systems of Innovation (SSI) lens, anchored in evolutionary 
theory. The main factors that influence the dynamics of the system are the actors and 
networks, knowledge and technologies, the extent of innovation and institutions in 
particular regulation. These elements are the centre of this study’s analytical focus. 
The chapter further describes other supporting theories, concepts and approaches used 
to unpack the effects of medical device regulatory changes on investment, production 
and linkage capabilities and development of affordable health technologies 
 
Chapter 5 presents the scope of the research, and details how the research was 
conducted. It will first present the philosophical position of this study and 
methodological issues leading to the choice of methodology. The research strategy 
then explains the reasons for using the case study approach and discusses key 
characteristics of case study quality. Case study design is explained, consisting of the 
importance of context, the unit of analysis, and a sample selection of the firms, as 
well as the criteria and process. Data collection methods and data analysis strategy 
employed are also presented. 
 
Chapter 6 presents three case studies of regulatory changes that have been selected for 
this study. The aim of this chapter is to, first, analyze and explore the two regulatory 
change cases in the UK that were highly significant for the medical device industry. 
Each regulatory change was different: one was a major extension of regulatory reach 
into software; the other introduced unannounced audit visits therefore toughening 
regulatory compliance processes. Second, the chapter will also analyze and explore 
the regulatory change case of radiation emitting devices in SA that promoted safety in 
the workplace and prevented unnecessary exposure to radiation. 
 
Chapter 7 is the first of three empirically based chapters that present and analyze the 
data collected. This chapter addresses research sub-question number three identified 
in chapter one using empirical data from a group of sixteen medical devices firms in 
the UK. This chapter is focused on firm level effects in a tightly regulated national 
environment. The empirical evidence that comprises of two kinds of data is then 
analysed. The analysis begins with a generic narrative contextualising the effects of 
regulatory changes on industrial capability based on the sixteen UK-based firms.  
Thereafter, a more comprehensive narrative of three purposefully selected firms is 
 13 
then presented. At the end of the chapter, the results of each regulation and each type 
of capability will be summarized and general characteristics of the firms’ responses to 
the new regulation will be further described so as to provide an informative overall 
perspective. 
 
Chapter 8 delves further in addressing research sub-question number three but using 
empirical data from a group of sixteen SA-based medical devices firms. The chapter 
draws its attention to the description of radiation emitting devices regulation and the 
subsequent changes. The analysis follows the same approach as used in chapter 7.  
 
Chapter 9 presents the final detailed cross-case analysis of firm cases in two 
countries. The chapter starts by setting out the analytical approach undertaken during 
the analysis of regulatory change effects. In addition, the three regulatory changes that 
have been identified is briefly described, before the cross-case analysis is summarized 
and presented. The chapter then proceeds to present data relating to investment, 
production and linkage capabilities. Within these capabilities, the chapter analyzes in 
some depth each regulatory change case looking for generalizable conclusions from 
the study’s various empirical firm data. At the end of the chapter, the results are 
summarized so as to provide an overall empirical and conceptual perspective. 
 
Finally, Chapter 10 presents a summary of the findings, discusses various policy 
implications and addresses the limitations of the study. It commences by outlining the 
summary of key findings, in relation to the research questions outlined in Chapter 1. 
Subsequently, the chapter provides the overall discussions based on the outcomes of 
the research. Furthermore, arising from the understanding and insights obtained 
throughout the analysis, regulatory recommendations, are presented. The 
recommendations, in this regard, are better suited to discover enabling regulatory and 
policy approaches that enables industrial capabilities. In addition, this chapter also 
articulates the policy implications of the research and highlights the limitations of the 
study; as well as identifying the opportunities for further research. 
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CHAPTER TWO 
 RESEARCH BACKGROUND 
----------------------------------------------------------------------------------------------------- 
2.0 Introduction 
This chapter outlines the contextual and background details of the research. It begins 
by presenting the current state of the global medical device market, followed by a 
discussion on the UK and SA medical device industry profiles. The chapter also 
discusses evolution of medical device regulations in the two study countries and 
associated requirements that are specifically affecting the medical device industries. 
Importantly, the discussion on the evolution of medical device regulations in this 
chapter contributes to answering the research sub-questions one and two aimed at 
assessing the drivers and contents of the regulatory changes in the UK and SA.  
2.1 The Global Medical Device Market 
Size of market 
The medical devices market is one of the fastest growing and most complex in the 
world (Sorenson and Kanavos, 2011). The sector in 2017 was made up of 
approximately 2 million devices that can be categorized into more than 22 000 
generic devices groups 1  on the global market (WHO, 2017). According to the 
statistics from the U.S. Department of Commerce, the global market sale of medical 
devices in 2016 reached $339.5 billion (see Figure 2.1). The global medical market is 
expected to grow at a compound annual rate (CAGR) of 4.1%, and reach $522 billion 
by 2022 (MedTech, 2017). Figure 2.1 illustrates the global market sale of medical 
devices for the period 2016-19.  
 
 
1 The Global Medical Device Nomenclature Agency listed more than 22 000 generic device groups for 
medical devices (Source: GMDN Agency). 
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Figure 2.1: Values of the global medical device market. Source; (U.S. 
Department of Commerce, 2016). 
Since innovation fuels the global medical device market’s on-going quest for better 
ways to treat and diagnose medical conditions, when coupled with patient life 
expectancy increasing and aging populations globally, the medical device market 
should continue growing at a positive rate in the future (U.S. Department of 
Commerce, 2016). Figure 2.2 illustrates the global medical device market size by 
region based upon manufacturer prices2 in 2016. 
  
Figure 2.2: The global share of medical devices by region based upon 
manufacturer prices in 2016. Source: (MedTech Europe, 2018)  
The United States currently has the largest medical device market in the world, with a 
market size of around $156 billion, and it represented about 40-43% of the global 
medical device market in 2016 (U.S. Department of Commerce, 2019, MedTech 
Europe, 2018). In the US, there are approximately 7,000 companies in the medical 
device market, which directly employ about 500,000 people and indirectly employ 
more than 2 million people (U.S. Department of Commerce, 2019).  
As Figure 2.2 shows, Europe currently holds nearly 30% of the global market with 
market value of about $110 billion. It is the second largest medical device market 
after the US. In Europe, in 2018, there were approximately 27,000 small and medium-
sized companies manufacturing medical devices, employing 675,000 people 
(European Commission, 2017). The U.S. and Europe control about 70% of global 
 
2 Market size estimated in manufacturers’ prices, not including margins, such as value added in the 
wholesaling and retailing, transportation costs, some taxes included in the final price, etc. 
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medical device market. The market size of the top 10 European countries based upon 
the manufacturer prices is presented in Figure 2.3. 
 
Figure 2.3: European Medical Device Market by country in 2016. Source; 
(MedTech Europe, 2018) 
As Figure 2.3 shows, the biggest medical device markets in Europe are Germany, 
France, the United Kingdom, Italy and Spain. 
Global medical devices industry structure 
The global medical devices industry is highly fragmented. It is characterised by the 
presence of a few large companies with a dominant position and a large number of 
small and medium enterprises (SMEs), which are responsible for the development of 
the technological breakthroughs of todays’ healthcare market (Amann and Cantwell, 
2012, Chowdhury, 2014). The SMEs, however have limited resources to demonstrate 
the evidence on safety and efficacy of medical device to meet the regulatory 
requirements, and in the face of a failure on the marketplace it is difficult for them to 
survive (Kaplan et al., 2004). The research and development (R&D spending in the 
global medical device industry, as a percentage of sales, was about 12%, in 2017 (US 
Department of Commerce, 2018).  However, most SMEs research focuses on factors 
that contribute to their survival such as financing, rather than a greater understanding 
of the medical device innovation development process (O'Regan et al., 2006). 
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The global medical device industry is divided into several device segments. Table 2.1 
presents ten biggest medical device market segments and related market value in 
2017.  
Table 2.1: Global TOP 10 device areas in medical devices industry. Source: 
(Evaluate MedTech, 2018). 
Rank Device segment Global sales value in 2017 
(in billion US dollars) 
1 In Vitro Diagnostics (IVD)  52.6 
2 Cardiology  46.9 
3 Diagnostic Imaging  39.5 
4 Orthopedics  36.5 
5 Ophthalmic  27.7 
6 General & Plastic Surgery  22.1 
7 Endoscopy  18.5 
8 Drug Delivery  18.5 
9 Dental  13.9 
10 Wound Management  13.0 
 
Table 2.1 shows that the In Vitro Diagnostics (IVD) segment is the biggest device 
area and an overall picture gives some hints about the volumes of investments in the 
global industry. Almost all high-tech medical devices have been designed and 
manufactured in advanced countries for use in industrialised countries, and 
subsequently the rest of the world. The global top 10 medical device companies are 
presented in Table 2.2. 
Table 2.2: Global TOP 10 medical device companies in 2017. Source: (Evaluate 
MedTech, 2018). 
Rank Company Country Company sales value in 2017 
(in billion US dollars) 
1 Medtronic USA 30.0 
2 Johnson & Johnson USA 26.6 
3 Abbott Laboratories USA 16.0 
4 Siemens Healthineers Germany 15.5 
5 Philips Healthcare The Netherlands 13.6 
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6 Stryker USA 12.4 
7 Roche Switzerland 12.3 
8 Becton Dickinson USA 11.0 
9 GE Healthcare USA 10.2 
10 Boston Scientific USA 9.0 
 
Table 2.2 shows that out of the top ten medical device companies, seven firms have 
headquarters in the USA. Medtronic achieved medical device sales of $30 billion, 
leading the top ten and giving the company a 7.4% market share (Evaluate MedTech, 
2018). 
The medical device industry in developing countries 
The medical device industries based in developing countries are few and focused on 
the low-tech part of the sector. The diversity and scale of health challenges in 
developing countries make the role of medical devices even more significant but 
according to WHO (2012) only 13% of manufacturers are located in developing 
countries.  
In developing countries, over 95% of the medical devices in public hospitals are 
imported, with very limited local production (Malkin, 2007). Moreover, most of the 
medical devices are inappropriate for local needs and unable to be sustained with the 
lack of local infrastructure (Lustick and Zaman, 2011). For example, WHO (2016) 
conducted a detailed analysis of medical devices policies from four selected countries 
in Africa (Ethiopia, Nigeria, South Africa and Tanzania) to identify opportunities for 
the development of local medical devices. The study found that there was a limited 
local manufacturing capacity and design mechanism to incentivize manufacturers to 
engage in the production of priority medical devices. The same study revealed that 
there was lack of funds for research and development (R&D) and support to bring 
products into the market and to final users that could be of high public health value. 
2.1.1 Medical Device Development Process 
Medical devices are regulated in different ways throughout their life cycle, because 
any phase during their life span can affect the safety and performance of the medical 
device. According to Blair & Goldenberg (2014), medical device development 
process generally includes steps such as recognizing an unmet medical need, doing 
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fundraising or budget, concept and feasibility studies, design and its validation, 
clinical studies, regulatory approval, manufacturing, reimbursement, product 
distribution, and post-market activities. Figure 2.4 below illustrates the major phases 
in the life span of a medical device from conception and development to disposal.  
 
 
 
Figure 2.4: Seven major phases in the life span of a medical device. Source: 
(WHO, 2003, p.5) 
 
The activity phases are simplified to make it easier to understand the regulatory 
system. For example, the development phase includes development planning, design 
verification/validation, prototype testing and clinical trials. In practice, the phases 
outlined below may overlap and interact (WHO, 2003, p.5). Following initial concept 
tests, the device is then registered for regulatory approval in the desired market(s). 
This step alone can take up to six years, depending on the risk category of the device 
and clinical trials required, and the total time for a new device to come to market can 
be as long as eight years (Fargen et al., 2013). It is vital in the new product 
introduction process in the medical device industry to get good clinical data because 
many times it is the main differentiator between competitors (Blair & Golden-berg, 
2014).  
The manufacturer, vendor, user, public and government are the stakeholders. All five 
play critical roles in ensuring the safety and efficacy of medical devices. The most 
important factor that ensures the cooperation of all these stakeholders is an informed 
and common understanding of the issues. Shared understanding and responsibility are 
achieved through communication and mutual education, which can be effectively 
achieved by having all stakeholders participate in establishing the process that ensures 
safety and performance of medical devices (WHO, 2003, p.5). The next section 
introduces the UK medical device industry. 
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2.2 The United Kingdom Medical Device Sector 
Size of market 
The UK medical device market is the third largest in Europe, behind Germany and 
France, and the sixth largest in the world (MedTech Europe, 2018). Domestic device 
manufacturing is characterized by a large number of small-scale medical device 
companies alongside a few global manufacturers with a significant presence in the 
market. Many large US companies operate subsidiaries in the UK. The market was 
estimated to have generated $26,444 billion turnover in 2015 and is forecast to grow 
at a USD billion 2015-2019 Compound Annual Growth Rate (CAGR) of 5.1%, 
making the UK the best performing market in the Western Europe region (BIS UKTI 
DH, 2015). The breakdown of the UK medical device firms is presented in Table 2.3. 
Table 2.3: Breakdown of Medical Device Companies in the UK in 2015. 
Compiled by author. Source: (BIS UKTI DH, 2015) 
*GBP/USD currency conversion was done using OANDA currency calculator tool at 
a rate of 1:1.25830 
Data in Table 2.3 show that, in 2015 the medical device sector and service and supply 
chain in the UK was comprised of an estimated 3,685 companies, which employed 
approximately 114,475 individuals (BIS UKTI DH, 2015). Such high numbers of 
employees prove that the UK medical device industry is a significant player in Europe 
and in its economy. The core companies include all firms whose primary business 
involves developing and producing medical devices (ranging from single-use 
consumables to complex hospital equipment, including digital health products). The 
service and supply companies are those that have significant activity in supplying 
services to the core companies such as specialist consultancy and regulatory expertise 
to the medical technology sector (BIS UKTI DH, 2015). The rest of the composition 
and distribution of the medical device companies in terms of the size of their annual 
turnover is shown in Table 2.4 below. 
Category Employment Turnover  
(in billion US 
dollars)  
Number of 
Companies 
Core companies 89,870 *21,505 2,683 
Service & Supply companies 24,605 4.939 1,002 
Total 114,475 26,444 3,685 
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 Table 2.4: Distribution of Medical Device Companies – broken down by 
company turnover. Compiled by author. Source: (BIS UKTI DH, 2015) 
2015 Annual 
Turnover size band 
Number of 
medical device 
core companies 
% of core 
companies 
Number of 
Service & Supply 
companies  
% of 
Service & 
Supply 
companies 
$0 – $62,000 352 13% 159 16% 
$63,000 - $125,000 195 7% 97 10% 
$126,000 - $313,000 386 15% 199 20% 
$314,000 – $628,000 385 14% 135 13% 
$629,000 – $1,2m 318 12% 97 10% 
$1,3m - $6,2m 534 20% 180 18% 
$6,3m+ 513 19% 135 13% 
Total 2683 100% 1002 100% 
*GBP/USD currency conversion was done using OANDA currency calculator tool at 
a rate of 1:1.25830 
 
Table 2.4 shows that, in 2015, out of the 3685 medical device companies in the UK, 
81% of the core companies had an annual turnover of less than $6.3 million while 
77% of the service and supply companies had a turnover of less than $6.3 million 
(BIS UKTI DH, 2015). 
The UK medical device industry structure 
The vast majority of medical device companies (98%) are small to medium-sized 
enterprises (SMEs). The SME status is based on the European definition that refers to 
businesses with fewer than 250 employees (BIS UKTI DH, 2015). Within the sector, 
68% are micro-companies employing less than ten people. The overall picture is that 
of a sector made up of small but well-established companies as indicated in Table 2.5 
below. 
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Table 2.5: Distribution of Medical Device Companies – broken down by 
employment numbers. Compiled by author. Source: (BIS UKTI DH, 2015) 
2015 Employee size 
band 
Number of 
medical device 
core companies 
% of core 
companies 
Number of 
Service & Supply 
companies  
% of 
Service & 
Supply 
companies 
0 – 4 1129 42% 532 53% 
5 – 9 438 16% 135 14% 
10 – 19 335 12% 119 12% 
20 – 49 390 15% 114 11% 
50 – 99 199 7% 54 5% 
100 - 249 122 5% 31 3% 
250+ 70 3% 17 2% 
Total 2683 100% 1002 100% 
 
According to the Department for Business, Innovation and Skills report, the largest 
segment by turnover in 2015 was single use technology (i.e. disposables) followed by 
in-vitro diagnostics, orthopaedic devices and wound-care (the top four segments 
accounted for 40% of the sector’s turnover (BIS UKTI DH, 2015). Figure 2.5 
illustrates the turnover of major segments in the medical device sector excluding 
service and supply in the UK.  
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* n.e.c - not elsewhere classified 
Figure 2.5: Turnover for the Major Segments in the Medical Device Sector in the 
UK. Source; (BIS UKTI DH, 2015) 
 
As illustrated in Figure 2.5, the products highlighted in red are some of the medical 
technology segments that develop and market stand-alone or embedded software 
devices.  One of the three regulatory changes analysed in this study targeted the 
production of software products and the influence of these changes will be discussed 
in more detail in Chapter eight. 
Figure 2.6 and 2.7 present the composition and distribution of the medical device 
sector in terms of the number of companies by segment registered in the UK. Figure 
2.6 shows the number of medical device core companies whilst Figure 2.7 shows the 
number of medical device Service & Supply companies 
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Figure 2.6: Number of Medical Device Core Companies by Segment.  
Source: (BIS UKTI DH, 2015) 
 
 
Figure 2.7: Number of Medical Device Service & Supply Companies by Segment 
(only segments with more than 20 companies shown). Source: (BIS UKTI DH, 
2015) 
Figure 2.6 shows that the digital health segment in 2015 was the second highest of all 
segments in the life science industry and had a total of 289 core companies. The 
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segment covers companies that develop and market software and/or devices that rely 
on software for their key functionality. As the main focus of digital health devices is 
on software that has high medical information content, the 2007 regulatory changes 
required them to be validated. The effects of such requirement will be analysed in 
Chapter eight. 
2.2.1 Evolution of Medical Device Regulations in the UK (EU) 
The Treaty Establishing the European Community, signed by six countries in 1957, 
marks the beginning of the EU (Altenstetter, 2003). Since then more countries have 
joined and the treaty has been amended several times. Member countries agree to 
follow the rules and regulations of the EU (Altenstetter, 2003). The evolution of 
medical device regulations in the UK, therefore, has to be seen in the light of the 
European Union’s development over the past decades (Chapman et al., 2014). The 
formal regulation of medical devices in the EU actually began in the 1990s, following 
the adoption of “the New Approach” principles of 1987. Prior to that, a consolidated 
legislation adopted in 1965 after the thalidomide crisis regarding medicinal products 
covered only pharmaceuticals, thus, there was great diversity amongst EU countries in 
how medical devices were regulated (Altenstetter, 2012).  
Harmonizing to create a ‘single market’ 
To harmonize the technical requirements across the EU region, the core legal 
framework that consisted of three directives was established, dated 1990, 1993 and 
1998 (see Table 2.6). The EU governments needed to put in place policies that would 
address all elements related to medical devices, ranging from access to high quality, 
affordable products, through to their safe and appropriate use, performance and 
disposal (European Commission, 1993, 2007). In order for the requirements in the 
directives to be mandatory, the directives were transposed to each member state’s 
legislation resulting in a vast and elaborate legislative framework (Bastawrous and 
Armstrong, 2013). The intention of these Directives was clearly to create a single 
market for medical devices based on Article 100a or Article 95 of the respective EU 
Treaties (Casteels and Rohde, 2013).  
Responsibility for the regulatory cycle 
The responsibility for the regulatory cycle was assigned to three types of 
organizations: competent authorities, manufacturers, and third-party certification 
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organizations (notified bodies) (Altenstetter, 1996). A competent authority ensures 
that the requirements of the directives are applied. In the UK it is the Medicines and 
Healthcare Products Regulatory Agency (MHRA) and the legislation is the Medical 
Devices Regulation 2001/618 (as amended) (Heneghan et al., 2011). In addition to the 
transposition of the medical device directives into National Law, the MHRA is also 
responsible for the surveillance of medical devices on sale in the UK and the 
evaluation of adverse incidents (MHRA, 2008b). Many medical devices and 
accessories require an objective third party inspection by a Notified Body (NB) as 
part of the required conformance assessment procedure. 
Notified bodies exist solely under New Approach Directives. Their function is to 
provide independent verification that particular aspects of the design, manufacture or 
quality system conformity have been carried out by manufacturers (European 
Commission, 2013b). Notified bodies are for-profit and funded by review fees from 
manufacturers (Kramer et al., 2012). Because of this, some have argued that there is 
an inherent risk of collusion between notified bodies and manufacturers (Cohen, 
2012).  
The New Approach Directives 3  imposed the sole and ultimate regulatory 
responsibility for a product and the satisfactoriness of its safety on the person who 
qualifies as its legal "manufacturer", who is the person who places it on the market 
under his own name (Casteels and Rohde, 2013). The legal manufacturer may, 
however, in practice subcontract some or all of the activities of design, production, 
labelling, packaging and distribution, although he retains full regulatory responsibility 
for designing and manufacturing the product in accordance with the essential 
requirements that apply to it, and for the carrying out of conformity assessment in 
accordance with a relevant applicable procedure (Chowdhury, 2014).  
Medical devices regulatory framework revisions in 2000-2017 
The three medical devices directives of the 1990s were a great success (Yaneva-
Deliverska, 2012). The CE mark became a recognized seal of quality and safety for 
medical devices and a single market had basically been created (Casteels and Rohde, 
2013). Together these European directives constituted a medical device legal system 
 
3  New Approach Directives do not contain a definition of "manufacturer" other than in Directives 
90/385/EEC (active implantable medical devices), 93/42/EEC (medical devices) and 1998/79/EC (in-
vitro-diagnostic medical devices) 
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(ibid). The medical sector, however, developed and evolved especially with the 
introduction of new innovative devices and thus made a revision of the directives over 
time necessary. Table 2.6 shows the ever-evolving amendments of Directives: 
Table 2.6: List of the Three Core European Directives and their Subsequent 
Amendments. Compiled by author. Source: (European Commission, 1998) 
 New/Amended 
Directive 
Old/Original 
Directive  
Description 
1990  90/385/EEC 
(AIMDD) 
Concerns active implantable medical devices 
(AIMDD 
1993  93/42/EEC (MDD) Concerns medical devices (MDD) and their 
accessories 
1998  98/79/EC 
(IVDMD) 
Concerns in vitro diagnostic medical devices 
(IVDMD) 
2000 2000/70/EC 93/42/EEC  Concerns, among others, medical devices 
manufactured using tissues of animal origin, the 
classification of certain medical devices and 
Common Technical Specifications for In vitro 
diagnostics (IVDs) 
2001 2001/104/EC 93/42/EEC  Included medical devices which incorporate, as 
an integral part, substances derived from human 
blood  
2003 2003/12/EC 90/385/EEC and 
93/42/EEC  
Reclassifies breast implants into Class III 
 
2003 2003/32/EC 90/385/EEC and 
93/42/EEC  
Introduces specifications concerning medical 
devices manufactured utilizing tissues of animal 
origin 
2005 2005/50/EC 93/42/EEC  Reclassifies total hip, knee and shoulder joints 
into Class III 
2007 2007/47/EC 90/385/EEC, 
93/42/EEC, and 
98/8/EC 
On approximation of the laws of the member 
state, technical revisions and concerning the 
placing of biocidal products on the market and 
medical device software.  
2011 2011/100/EU 98/79/EC 
 
Added ‘Variant Creutzfeldt-Jakob disease’ 
(vCJD) assays for blood screening, diagnosis 
and confirmation as requested by the UK 
2012 
 
 
Two new 
regulations, once 
adopted, will 
replace the existing 
three directives. 
90/385/EEC, 
93/42/EEC, and 
98/8/EC 
The European Commission adopted a Proposal 
for a Regulation of the European Parliament and 
of the Council on: 
i) Medical devices and  
ii) In vitro diagnostic (IVD) medical 
devices. 
2013 2013/172/EU 
(Recommendation) 
2001/83/EC Provisions on traceability of medical devices and 
in vitro diagnostic medical devices, in order to 
improve patient health and safety. 
2013 2013/473/EU 
(Recommendation) 
90/385/EEC, 
93/42/EEC, and 
98/8/EC 
Recommendation aim at ensuring that the 
notified body carries out a proper verification of 
the fulfilment of the legal requirements by the 
manufacturer. 
2017 Regulation 
(EU) 2017/745 
90/385/EEC and 
93/42/EEC 
A proposal for a regulation on medical devices 
(“MDR”), to replace the AMDD and MDD 
directives  
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NB. will only apply 
after a three-year 
transitional period 
 
2017 Regulation 
(EU) 2017/746 
NB. will only apply 
after a five-year 
transitional period 
98/8/EC A proposal for a regulation on in vitro diagnostic 
medical devices (“IVDR”), to replace the IVDD 
directive. 
 
Table 2.6 indicates that there have been significant changes in the regulation of 
medical devices in the UK. The significant aspect of the table is the introduction of 
major changes in 2007 and the 2012 adoption of a proposal to replace the existing 
core directives. In 2007, the European Medical Device Directive (MDD 2007/47/EC) 
made fourteen amendments to the original directive (93/42/EEC) that came into force 
on March 21st, 2010. A number of these changes directly affect the development of 
software for use in healthcare. There are four areas within the amendment of the 
MDD (2007/47/EC) with important significance to medical device software 
development, which are:  
(1) Standalone Software as an active medical device,  
(2) Validation of software as an active medical device,  
(3) Software localization and,  
(4) Safety Classification.   
The most significant change in relation to medical device software development is 
that standalone software was now seen as an active medical device (McCaffery et al., 
2011). For the first time, software is specifically included in the definition of medical 
devices. Prior to the release of the MDD (2007/47/EC) provision had been made 
within the MDD (93/42/EEC) for software to be used as a medical device. However, 
MDD (2007/47/EC) Article 1 Section 2 made explicit reference to software being a 
medical device (European Commission, 2007). The 2007 regulatory changes in 
relation to medical device software will be discussed in detail as a case study in 
chapter 6. 
However, other amendments state that manufacturers are required to appoint 
Authorized Representatives to act on their behalf if they are not located in the EU. 
The amendments also require that information about the technical factors and 
characteristics identified as hazards that can cause risks upon reuse of the medical 
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device should be clearly indicated and accompany single-use devices and that 
manufacturers must ensure that the Declaration of Conformity and Instructions for 
Use are controlled documents in the quality management system of the manufacturer 
(European Commission, 2007).  
 
Accordingly, the 2007 changes addressed the information exchange deficiency 
throughout the EU, by demanding the all-European information database to begin 
working by 2012. These revisions introduced were also some means to help establish 
the common vigilance system in Europe (European Commission, 2007). However, 
these amendments provoked discussions within the industry as some changes 
introduced make the approval process more complicated. Several weaknesses that 
undermine the main objectives of the three medical devices directives were identified 
in the Commission's 2008 public consultation4. In 2009, the MHRA received 9099 
reports of adverse events involving medical devices (MHRA, 2009) including 1885 
cases of serious injury and 202 deaths (Thompson et al., 2011).  
In 2011, the regulatory framework also came under harsh criticism, in particular after 
high-profile cases where too many unsafe medical devices were recalled. In 2010 a 
French company producing silicone breast implants (Poly Implant Prothèse (PIP)) 
was found to be using low-grade silicone not conforming to the type specified in the 
design and manufacturing files after an increasing number of implant ruptures. The 
certification of the implants was suspended and a global backlash of patients and 
national authorities followed (Donawa and Gray, 2012). In 2010, the UK’s MHRA 
released an alert for patients with metal-on-metal (MoM)5 hip implants as the revision 
rate was considerably higher than in conventional metal-on-polyethylene implants. 
Healthcare vigilance authorities in other countries soon followed (Drummond et al., 
2015). The wear or the joint surfaces against each other would cause metal debris to 
chip off over time, which created adverse reactions in the soft tissues and in some 
 
4 In mid-2008, the Commission held a public consultation on the recast of the general regulatory 
framework for medical devices. The consultation was published on the Commission's website. During 
2009, 2010 and 2011, the issues to be tackled in the context of the revision of the regulatory framework 
for medical devices were regularly discussed at meetings of the Medical Devices Expert Group 
(MDEG), the Competent Authorities for Medical Devices (CAMD) and specific working groups in the 
medical device sector. 
5 Metal-on-metal hip implants manufactured by DePuy were recalled worldwide because data from the 
National Joint Registry (NJR) of England and Wales showed that more people than anticipated had 
experienced problems and required a second hip replacement surgery 
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cases, a systemic contamination of blood with metal ions (ibid). In July 2011 U.S. 
FDA gave a warning regarding serious complications associated with surgical mesh 
for transvaginal repair.  
 
In light of these adverse events, in 2012 the European Parliament adopted a 
Resolution of the Parliament6, calling on the Commission to take “immediate action” 
and amend the medical device directives in order to make sure that the legislation 
would not allow events such as the steps leading to the PIP scandal or controversy 
surrounding the MoM hip implants to occur in the future. This was followed by a 
swift reaction approach from the EC, who proposed for new medical device 
regulation. In 2012, the European Commission (EC) published a proposal to introduce 
a new regulatory framework replacing existing medical device directives. In fall of 
2013, the European Parliament (EP) amended the proposal to be more rigorous and in 
June 2015 the European Council (ECO) presented its amendments based on the two 
formers (European Parliament, 2015). After four years of discussions on the expert 
level, and after an agreement with the ministers of the member states of the EU, in 
June 2016 the consolidated version of the new Medical Device Regulation was 
published. 
In the EU dialogue about a regulatory agreement, an entirely new approach to 
previous regulation of NBs and conformity assessment processes (CAP) was 
included. The focus was to tighten standards to the obligations of NBs when 
conformity assessing high-risk devices, for instance in the requirement of qualified 
employees. This tightening resulted in, among others, parts of the proposal being 
implemented to regulation “(EU) No. 920/2013”, as well as the “Commission 
Recommendation (of 24 September 2014) 2013/473/EU” on the unannounced audits 
and assessments performed by NBs in the field of medical devices. They comprise 
regulations pertaining to designation and supervision of NBs by competent authorities 
and recommendations to audits and assessments of manufacturers (European 
Commission, 2013a).  
 
6 Resolution of 14 June 2012 (2012/2621(RSP)); P7_TA-PROV(2012)0262, 
http://www.europarl.europa.eu/plenary/en/texts-adopted.html. 
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The publicized proposals met with controversy (Cohen, 2013) and raised the 
discussions in this study regarding their effect on involved stakeholders. Negotiations 
to the content of the regulation have been particularly complicated (Sorenson and 
Drummond, 2014). Several changes to NBs legislation directly affected 
manufacturers of medical devices. Some significant changes in the proposals were 
introduced in the structure and supervision of NBs where previous experiences have 
determined deficiencies. These deficiencies include a lack of transparency in NBs’ 
daily work, concerns about NBs’ competence and their independence against 
manufacturers that may affect decisions to CE marking (Galland, 2013). These 
challenges have amongst others, resulted in that all NBs will need to apply for re-
designation and be audited for compliance by joint competent authorities from several 
Member States (ibid). The requirements of technical, clinical and scientific 
competence have so far resulted in suspension or closedown of several NBs.  
On April 5, 2017, two new regulations were adopted replacing previous directives. 
Regulation (EU) 2017/745 on medical devices replacing Council Directives 
90/385/EEC on medical devices and 93/42/EEC on active implantable medical 
devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices 
replacing Council Directive 98/79/EC on in vitro diagnostic medical devices. By 
shifting from directives to regulations, a wider scope of protection and more effective 
implementation of the rules can be ensured. The new regulations will only apply after 
a transitional period. Namely, 3 years after entry into force for the Regulation on 
medical devices (spring 2020) and 5 years after entry into force (spring 2022) for the 
Regulation on In Vitro Diagnostic medical devices (European Commission, 2017). 
As the transitional period for the 2017 new regulations has yet to come, this thesis 
does not take them into account. However, it is worth mentioning that, while waiting 
for the transition period to come to pass, a recent article on faulty medical 
implants revealed that, in the UK alone, regulators received 62,000 “adverse incident” 
reports linked to medical devices between 2015 and 2018. A third of the incidents had 
serious repercussions for the patient, and 1,004 resulted in death (The Guardian, 
2018). Adverse events such as these are the ones that call for the need for a better and 
enabling regulatory framework in the medical device industry. 
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Medical device regulation has been evolving as a distinct legal framework separate 
from the drug structures in the EU since the early 1990s (Altenstetter, 2012). The 
regulatory changes have been effective in improving patient safety and enhancing the 
provision of satisfactory health care.  The changes allowed the notified bodies to be 
responsible for their activities (Amoore, 2014), enhanced the conduct of fair and free 
trade of the medical devices in these markets and ensured that industries meet the 
clinical requirements and manufacture high-quality medical technologies (Cooter et 
al., 2015). 
2.2.2 The Current State of Medical Device Regulatory Framework in the UK 
The current regulatory framework in the UK is characterized by critical market 
authority needs; whereby specific requirements are followed by the medical device 
manufacturers, sellers, buyers, and the medical professionals using the devices in 
hospitals (MHRA, 2016). As stated in the previous section, three overarching legal 
directives guide the development of medical devices including classification, CE 
marking, quality system requirements, and data requirements in the UK (Chapman et 
al., 2014):   
• Medical Device Directive (MDD 93/42/EEC),  
• Active Implantable Medical Device Directive (AIMDD 90/385/EE), and  
•  In Vitro Diagnostic Medical Device Directive (IVDMDD 98/79/EC).  
Table 2.7 summarizes the three European Council Directives. 
Table 2.7: List of the Core European Directives Regulating Medical Devices. 
Source: (European Commission, 1990, 1993, 1998) 
Year EU Council 
directive 
Description 
1990 90/385/EEC The Active Implantable Medical Devices (AIMDD). Covers 
all medical devices that are implanted into the human body 
and need to use a source of energy that is neither gravity nor 
energy from the body. 
1993 93/42/EEC The Medical Devices (MDD). Covers the majority of medical 
devices. 
1998 98/79/EC The In Vitro Diagnostic Medical Devices (IVDMD). Covers 
all those products used in vitro for examination of specimens 
from the human body and those used as diagnostics to 
provide information. 
The aim of these core directives is to ensure a high level of protection for human 
health and safety and a good functioning of the Single Market (European 
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Commission, 2015). In addition, there are also multiple EU guidance documents and 
articles governing the processes that contribute to regulatory adherence (European 
Commission, 2015; European Commission, 2012). The regulatory framework and 
hierarchy for medical devices is illustrated in Figure 2.8 
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Figure 2.8: Regulatory Framework and Hierarchy for Medical Devices in the EU 
with the most relevant parts identified. 
Guidance 
EU MEDDEVs 
- MEDDEV 2.1/5 Medical devices with a measuring function 
- MEDDEV 2.1/6 Qualification and classification of stand-alone software 
- MEDDEV 2.4/1 rev.9 Classification of medical devices 
- MEDDEV 2.14/1 rev.2 IVD medical devices borderline and classification issues 
Technical information reports 
ISO/TR 80002-2:2017 Medical device software - Part 2: Validation of software for medical 
device quality systems 
ISO/TR 24971:2013 Medical devices - Guidance on the application of ISO 14971 
EU Directives 
Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) 
- Article 3 Essential requirements 
- Article 9 Conformity assessment procedures 
- Annex I Essential requirements 
Council Directive 93/42/EEC on Medical Devices (MDD) 
- Article 3 Essential requirements 
- Article 9 Classifications 
- Article 11 Conformity assessment procedures 
- Annex I Essential requirements 
- Annex IX - Classification criteria 
Council Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDMD) 
- Article 3 Essential requirements 
- Article 9 Conformity assessment procedures 
- Annex I Essential requirements 
- Annex II List of devices referred to in article 9 (2) and (3) 
EU Harmonized Standards (and Other Standards) 
EN 62304:2006/AMD1: 2015 Medical device software - Software life cycle processes 
EN 14971: 2012 Medical devices. Application of risk management to medical devices 
EN ISO 13485:2016 Medical devices - Quality management systems - Requirements for 
regulatory purposes 
EN 60601 Series of Standards 
- EN 60601-1:2006 Medical electrical equipment. General requirements for basic safety and 
essential performance 
- EN 60601-1-6:2010 Medical electrical equipment. General requirements for basic safety and 
essential performance. Collateral standard. Usability 
Local Legislation (in the UK) 
Medical Devices Regulation 2001/618 (as amended) 
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Figure 2.8 points out that the directives encourage the use of harmonized standards. 
According to Deloitte (2016), the implementation of ISO 13485, ISO 14791 and ISO 
62304 can lead to CE-mark approval.  
• ISO 13485 provides the comprehensive quality management system 
framework for the design and manufacture of medical devices.  
• ISO 14791 provides fundamental guidance on a product’s intended use, 
determination of potential hazards, risk mitigation, and post-marketing 
surveillance methods.  
• ISO 62304 lays out a software lifecycle process for medical devices and refers 
to ISO 14971 in matters of risk management (IEC, 2017). 
Another facet that merits close attention is the guidance documents. The Medical 
Device Guidance Documents (MEDDEV) published by the European Commission 
are the most used guidelines by the manufacturers of medical devices and they 
promote a common approach to the implementation of the procedures. The current 
MEDDEV is part of a set guidelines relating to questions of application of EU 
Directives on medical devices. They are not legally binding, but they have been 
written in co-operation with EU officials, notified bodies, industry representatives and 
many other expert organizations. Many standards need to be taken into account when 
developing a medical device especially when software is included and each of them 
has a certain viewpoint. Annex C of EN 62304/AMD1: 2015 shows the relationships 
between key medical device standards as illustrated in Figure 2.9. 
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Figure 2.9: Relationships of key medical device standards. Source (IEC, 2017) 
Figure 2.9 shows that medical device management standards such as ISO 13485 and 
ISO 14971 provide a management environment that lays a foundation for firms to 
develop products. The ISO 14971 international standard provides a process to address 
risk management related to medical devices, which is included in the harmonized 
legal requirements in most countries (International Medical Device Regulators 
Forum, 2015). Standards such as IEC 60601-1 and IEC 61010-1 give specific 
direction for creating safe medical devices. When software is a part of these medical 
devices, IEC 62304 provides more detailed direction on what is required to develop 
and maintain safe medical device software (IEC, 2017). 
Medical Device classification process 
According to the Medicines and Healthcare products Regulatory Agency (MHRA), 
manufacturers must demonstrate compliance of their medical devices to the essential 
requirements described in the applicable directive (MHRA, 2016). The level of 
controls needed for conformity depends on the risk that the use of the device may 
pose. But first, it must be determined which of the three medical device directives 
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apply. 
Following the device type and thus the directive under which the device falls has been 
determined, the device classification needs to be determined. The class of the device 
determines the rigor of the conformity assessment procedures. The devices are 
classified according to criteria such as the degree of invasiveness, mode of action, 
impact on the body. Table 2.8 summarizes the medical device classes. 
Table 2.8: Medical Device Classification by Directive. Source: (Bastawrous and 
Armstrong, 2013). 
EU Council directive Device classification 
90/385/EEC 
Active Implantable Medical Device 
directive (AIMDD) 
No classes 
93/42/EEC 
Medical Devices Directive (MDD). 
Class III 
Class IIa 
Class IIb 
Class I (Class Is with sterile components, 
Class Im with measuring function) 
98/79/EC 
In Vitro Diagnostic Medical Devices 
(IVDMD) 
Annex II list A devices 
Annex II list B devices 
Self-testing devices 
Other devices 
Table 2.8 show that the Medical Device Directive defines four classes, and each 
group has different criteria that must be met in order to receive a CE mark of 
conformity. Low-risk device (class I) manufacturers may register with the MHRA and 
make a declaration that the product meets the statutory requirements to receive the CE 
mark. Class I has the loosest requirements. Medium-risk (classes IIa and IIb) and 
high-risk (class III) devices must meet a more stringent criterion (see (European 
Commission, 2010) for full classification rules).  
Obtaining a CE mark for medium-risk devices involves a declaration by the 
manufacturer that the product conforms to the provisions of the medical device 
regulations and the relevant essential requirements. Once products bear this mark, 
they can be marketed in all member states of the European Economic Area (EEA) and 
other countries that recognise the above-mentioned directives for medical devices. 
High-risk devices generally require clinical trials to demonstrate their safety. In order 
to conduct a trial in the UK, the MHRA has to agree to such trials (MHRA, 2016).  
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Post market surveillance 
Once a device is on the market, “manufacturers are required to implement a vigilance 
program according to National requirements, which includes reporting serious 
incidents to the relevant Competent Authority” (Sorenson and Drummond, 2014, p. 
121). In the UK, this information is collated into a central database, the European 
Databank on Medical Devices (Eudamed). In addition to vigilance information, 
Eudamed contains data on manufacturers, certificates issued, modified, suspended, 
withdrawn or refused, and clinical investigations (Kramer et al., 2012). The use of 
Eudamed has been mandatory since 2011. The SA medical device industry profile is 
discussed in the next section. 
2.3 South Africa Medical Device Sector 
Size of the market 
SA’s medical devices market was estimated at USD1.2 billion in 2014 and is forecast 
to grow at a USD billion 2014-2019 Compound Annual Growth Rate (CAGR) of 
2.2%, which will see the market reach USD1.3 billion in 2019 (BMI, 2016a). South 
Africa’s trade of medical devices experienced strong growth from 2004 to 2013. Over 
the ten-year period both exports and imports were at their highest level in 2013. South 
Africa’s exports increased by 41% in 2013, while imports increased by 13% (BMI, 
2016a). This is a clear indication of the high global demand for South Africa’s 
medical devices. The South African medical device market is well established in 
terms of the number of companies registered to sell medical devices, revenue 
generation and technology uptake, especially in the private sector (Friderichs, 2012). 
However, the wide diversity of product availability does not match local 
manufacturing and R&D capacity (Knijn and Patel, 2012). A study conducted by 
KPMG, (2014) indicated that the average revenue for MNCs was USD 20 million per 
annum, per company and USD5 million per annum for local medical device 
companies. The KPMG study also highlighted a company revenue split between 
multinationals and local companies as demonstrated in the Figure 2.10: 
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Figure 2.10: Revenue per Company split between Multinationals and Local 
Companies. Source: (KPMG, 2014) 
 
The difference of revenues between MNCs and SA local companies is commonly 
attributed to the high entry barriers for the high-end medical imaging market: 
producing more technologically advanced devices is capital-intensive, require lots of 
technical knowledge and generally has a long time to market (KPMG, 2014). The 
medical device market derives most of its revenues from clients in the private sector 
(70%) when compared with clients in the public sector (30%) and the industry 
employs over 3 600 people (KPMG, 2014).  SA imports 90% of medical devices used 
in the local market. An analysis of international trade flows of medical devices shows 
that the gap between imports and exports widened between 2004 and 2013 (SAMED, 
2016). An estimated sales value of selected SA medical devices in 2015 is presented 
in Figure 2.11 below. 
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Figure 2.11: SA’s 2015 estimated sales value of selected medical devices. Source: 
(BMI, 2016a) 
As Figure 2.11 shows, the products highlighted in red comprises electromagnetic 
medical devices or radiation emitting devices, the only categories of devices that are 
currently regulated and have high technical barriers in SA. The effects of the 
regulatory changes of these devices will be analysed in-depth in Chapter eight. In 
2015, Syringe, Needle and Catheter, Electro-Diagnostic and Imaging Parts and 
Accessories were the top three segments that together hold more than half of the total 
South Africa medical device market share (BMI, 2016a).  
Leading SA medical device industry players 
Currently a significant proportion of firms that occupy the SA medical device 
industry are MNCs such as Johnson and Johnson, Medtronic, GE healthcare, Siemens 
Healthcare and Philips Healthcare. Typically, these MNCs depend on their parent 
company to develop new products using R&D resources close to headquarters. Few 
MNCs have in-country control of their product development activities and spending 
on research and development (R&D) is inadequate (SAMED, 2016). 
Other key players within the medical device industry in SA include the National 
Department of Health (NDoH), Medicines Control Council (MCC), the Department 
of Trade and Industry (DTI), the Technology Innovation Agency (TIA), SABS, 
PATH, Medical device companies, Industry Associations, Global Health Innovation 
Accelerator (GHIA), Medical Research Council (MRC). 
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SA’s innovation ecosystem 
The medical industry in SA has not been very strong for a variety of reasons. It lacks 
a continuing pipeline of local production, scientific and technical status, and has had 
difficulty in attracting qualified employees. South Africa benefits from a legacy of 
health technology innovation, such as that by Nobel Prize winner (1979) Allan 
MacLeod Cormack for the theoretical work enabling the development of X-ray 
computerised tomography (CT) and by Dr. Christiaan Barnard’s first human to human 
heart transplant in 1967. Regrettably, the benefits of all these historical advances have 
not been equally spread. The country has instead, developed a distribution 
infrastructure based primarily on imported medical devices. The local device and 
diagnostics sector has not yet reached critical mass as a supplier to either South 
Africa’s public health system or as a contributor to the international market. This is in 
contrast with the local pharmaceutical industry, which with multinational 
engagement, local manufacturing and distribution, accounts for more than 70 percent 
of Sub-Saharan Africa’s annual pharmaceutical production (SAMED, 2016). 
2.3.1 Evolution of Medical Device Regulations in SA 
In the 1990s, South Africa undertook radical changes in the political and economic 
framing conditions of its innovation systems (OECD, 2007). The evolutionary 
national innovation system review of SA by OECD pointed out that the dynamics of 
the country’s system involved not only steady expansion and incremental evolution of 
structures and institutions but also a radical transformation under a unique set of 
constraints and opportunities (OECD, 2007).  
At present, only electromagnetic medical devices or radiation emitting devices are 
regulated through the Hazardous Substances Act, No. 15 of 1973 (RSA DoH, 1973). 
Early studies on X-rays such as one done by Mole (1990) recognised that chronic 
exposure to lower levels of radiation may result in cancer. However, the use of X-rays 
plays an indispensable role in the clinical management of patients. Concerns about the 
possible effects of exposure to radiation on the human body were raised to a high 
level during the 1980s and 1990s, therefore driving the need to propose basic safety 
standards to control and limit exposure to such radiation (Herbst and Fick, 2012). The 
Department of Health (DoH) in South Africa then, through its Directorate: Radiation 
Control (DRC), adopted the radiation safety standards. In addition, the Ministry of 
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Health is mandated to administer the Hazardous Substances Act of 1973 by granting, 
suspending or revoking licenses to importers, manufacturers and users of electro 
medical products (X-rays). The license is issued if the product and usage comply with 
legislative and international requirements for safety and performance (Herbst and 
Fick, 2012).  
In 2014, South Africa published for public comment draft regulations designed to 
regulate all health products, devices and pharmaceuticals (SA Government 
Communications, 2014). The draft regulations include a provision for a four-tiered, 
risk-based classification system of medical devices and in vitro diagnostic medical 
devices (IVDs); the Medicines Control Council (MCC) 7  would determine the 
classification of devices. The regulations would require the registration of all devices 
with the MCC before they can be sold or used in South Africa.  
While the draft regulations did not appear to impose a specific time frame for the 
completion of a regular registration process, they would permit expedited registration 
of devices if for example; the medical devices in question are in short supply or are 
unavailable. In these instances, the MCC is required to inform the applicant of its 
decision within nine months of the receipt of the application (Deloitte, 2014).  
The proposed new regulatory framework was leaning towards European Community 
guidelines. Products would need to carry the CE mark in addition to FDA approval. 
The exception is electro-medical devices (radiation emitting devices), which are 
regulated by the South African Health Ministry: Directorate Radiation Control. FDA 
approved only devices will no longer be acceptable.  
In order to rectify some of the inefficiencies of the MCC, a Medicines and Related 
Substances Bill was considered by parliament to transform MCC into a new entity 
called the South African Health Products Regulatory Agency (SAHPRA) and extend 
the mandate to include medical devices, including in-vitro diagnostics. Some of the 
proposed medical device legislations for SAHPRA include regulation for licensing, 
device classification and labelling regulations (SAMED, 2016).  
 
7 The Medicines Control Council (MCC) is a “statutory body that regulates the performance of clinical 
trials and registration of medicines and medical devices for use in specific diseases.” 
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2017/18 was a landmark year in which medical technology devices and their products 
became subject to statutory regulation for the first time in South Africa’s democratic 
era. The Medicines and Related Substances Act of 2015, promulgated in June 2017, 
along with regulations on medical devices that preceded it, paved the way for medical 
technology and IVD manufacturing and distributing companies to be licensed by 
August 2017, while wholesalers were given until February 2018 to lodge applications 
for licensing. Compliance with these developments and implementation of licensing 
requirements created a fair degree of uncertainty among our members. The 
regulations still require some adjustment to align with the amended Medicines and 
Related Substances Act of 2015, which was promulgated in June 2017. The evolving 
amendment of South Africa’s public Act is presented in Table 2.9 below. 
Table 2.9: List of the SA’s Core Public Health Acts and their Subsequent 
Amendments. Source: (SAMED, 2016) 
 New/Amended 
Act 
Old/Original 
Act  
Description 
1919  Public Health 
Act of 1919 
South Africa’s first national public health measure. 
1971 Public Health 
Amendment Act 
of 1971 
Public Health 
Act of 1919 
The legislative control of electronic products the first time 
introduced. 
Added section 133A to the Public Health Act of 1919, 
allowing the Minister of Health to make regulations 
mandating the Secretary of Health to grant, suspend and 
revoke licenses in respect of electronic products and 
prescribe conditions and requirements for the categories of 
electronic products, premises and persons in control of the 
equipment. 
1973 The Hazardous 
Substances Act, 
1973 
Public Health 
Amendment 
Act of 1971 
Comprehensive regulations concerning the use of X-ray 
equipment in terms of the 1971 Amendment Act. These 
regulations pertaining to hazardous substances are still in 
force 
1992 Hazardous 
Substances 
Amendment Act, 
No. 53 of 1992 
 
Repeal of 
section 133A 
of Act 36 of 
1919, and Act 
42 of 1971 
Control and division of substances or products into groups 
in relation to the degree of danger. Substances included 
those which may cause injury or ill-health to or death of 
human beings by reason of their toxic, corrosive, irritant, 
strongly sensitizing or flammable nature. 
2008 Medicines and 
Related 
Substances 
Amendment Act 
of 2008  
 
 • The main aim of the act was to register medicines, 
products, medical devices, certain foodstuffs and 
cosmetics 
• Although the Act has yet to come into operation, the 
new regulator (the South African Health Products 
Regulatory Authority (SAHPRA)) was expected to 
have started functioning in April 2012 and is destined 
to replace the Medicines Control Council (MCC) 
2014 Proposed draft 
for public 
comment 
Medicines and 
Medicines 
and Related 
Substances 
Act, 1965 
Concerns the applications to import, export, manufacture 
and supply medical devices and IVDs. The key elements of 
the regulatory control of medical devices and IVDs 
include: 
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Related 
Substances Act, 
1965 (Act 101 of 
1965 as 
amended) 
(Act 101 of 
1965) 
• Requirements for a person or entity to hold a license to 
manufacture, import, export, wholesale and or 
distribute a medical device and or IVD in South Africa. 
• Product requirements for quality, safety, and 
performance.  
• Options as to how compliance with the Essential 
Principles can be demonstrated. 
• Ongoing monitoring of medical devices & IVDs that 
are available on the market.  
• Regulatory controls for the manufacturing processes of 
medical devices& IVDs. 
• A range of corrective actions that may be taken if there 
is a problem with a medical device or IVD. 
2017 The Medicines 
and Related 
Substances Act 
72 of 2008 and 
Act 14 of 2015, 
promulgated in 
June 2017 
Amended 
Medicines 
and Related 
Substances 
Act of 2015 
• Landmark year in which medical technology devices 
and their products became subject to statutory 
regulation for the first time in South Africa’s 
democratic era. 
• Provides for the establishment of a new regulatory 
authority (SAHPRA)  
• Provides for the transition of MCC to SAHPRA 
• Provides for expansion on the regulatory oversight of 
Medical Devices  
• Provides for the licensing of Scheduled substance 
Manufacturers and Wholesalers  
• Promulgation: June 2017  
•  
 
As Table 2.9 shows, there has been a steady evolution and implementation of the 
country’s regulatory system. From 1973 to 2017, SA was relying only on the 
regulations concerning the use of X-ray equipment in terms of the 1973 Act. The 
South African medical device sector is now in a transition phase. The first phased 
implementation of the new regulatory changes was clinical trials. As of 1 June 2017, 
all protocols for clinical trials with medical devices must be approved by SAHPRA 
prior to initiation of the trial (SAMED, 2018).  
Importantly, the end of the transition period will not mark a point when the regulatory 
environment for medical devices is complete, for managing such a large and vast field 
as medical devices will always be work in progress, but it will nevertheless introduce 
a considerably higher level of quality to the management of medical devices in SA 
than ever before. The next section briefly compares the UK and SA regulatory 
frameworks. 
2.3.2 The Current State of Medical Device Regulatory Framework in SA 
South Africa does not have a comprehensive regulatory framework governing 
medical devices. As mentioned before, at present, only listed electronic products (also 
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known as electromagnetic medical devices or radiation emitting devices) are 
regulated through the Hazardous Substances Act, No. 15 of 1973 8  and must be 
registered (CE certification) before they can be sold, leased, used, operated, or applied 
in South Africa (DoH South Africa, 2014).  
The interpretation of the Hazardous Substances Act and Regulations by the 
Directorate Radiation Control DRC are described in the Code of Practice, 
Requirements for quality control tests and guideline documents from the DRC. The 
Code of Practice document (DRC 2011) provides references and refers readers to 
guideline documents and also provides a link to the DRC website9. The regulatory 
framework and hierarchy for radiation-emitting medical devices in SA is illustrated in 
Figure 2.12.  
 
8  Hazardous Substances Act, No.15 of 1973, available on the University of Pretoria website, at 
http://www.lawsofsouthafrica.up.ac.za/index.php/browse/medical-and-health/hazardous-substances-
act-15-of- 1973/act/15-of-1973-hazardous-substances-act-24-feb-2000-to-date-pdf/download.   
9 The SA DRC website: https://sites.google.com/site/radiationcontroldoh/. 
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Figure 2.12: Regulatory Framework and Hierarchy for Radiation-Emitting 
Medical Devices in SA with the most relevant parts identified. 
 
The contents of regulations (Regulation 1332) pertinently indicate that a holder of a 
license shall be accountable for the all-inclusive scope of radiation protection. The 
requirements contained in the mentioned document include:  
1. “Effective protection organization and continual conscientious regard for optimum 
methods of working with particular reference to routine operations;  
2. Technical investigations to ensure reliability and overall technical excellence of 
equipment, buildings and interlocks;  
Republic of South Africa Government 
-Hazardous and Substances Act No 15 
-Regulations concerning the control of electronic products (Regulation R1332) 
 
DRC Guideline documents  
-Medical examinations for radiation workers (10/2009)  
-Request for medical X-ray examinations (10/2009) 
-Holding of patients during X-ray procedures (10/2009) 
-Patient dose measurements in diagnostic radiology (10/2009) 
-Bone densitometer – shielding, monitoring and positioning of operators (10/2009) 
-Reducing radiation risk from computed tomography for pediatric and small adult 
patients – (10/ 2009) 
-Regulatory control of X-ray equipment used in the mining industry in South Africa to 
screen workers for security purposes (30/11/2011) 
-Monitoring of radiation workers in a theatre (11/2011) 
-Radiation monitoring requirements and Radiation occurrences (11/2011)  
-Display and format of radiation warning signs at entrances to rooms containing X-ray 
units  
-Minimum requirements for fixed diagnostic X-ray installations 
-Personal monitoring when a lead rubber apron is worn – medical and veterinary use 
of X-ray equipment 
-Protective Clothing 
-Management of pregnant radiographers and other staff members 
-Dental radiography  
-Radiation protection of personnel in theatre 
-Design of X-ray rooms  
 
 
Directorate Radiation Control (DRC) licensing conditions  
-Code of Practice for users of medical X-ray equipment (DRC 2011) 
-Requirements for license holders with respect to quality control tests for diagnostic 
X-ray imaging systems (DRC 2012) 
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3. The display of appropriate warning signs or notices which are easily intelligible to 
all persons, at the entrances to or at appropriate places in all areas where persons may 
enter and may be exposed to ionizing radiation; and  
4. Ensuring that radiation workers and members of the public are subjected to 
minimal risks from radiation exposure and that the maximum permissible doses and 
dose limits are not exceeded” (RSA DoH, 1973).  
The licensing of medical equipment is subject to the prescribed conditions, the 
Director-General may in each case, issue to any person a license to sell, let, use, 
operate, install or apply any Group III hazardous substance. The refusal or granting of 
a license will be notified in writing. Non-compliance with prescribed conditions will 
result in the suspension or cancellation of licenses (Doh South Africa, 2012). 
Inspectors are appointed and certified to indicate for which groups of hazardous 
substances they have been thus appointed. The powers of inspectors are prescribed 
with clear reference to inspection, entrance to premises, demanding information and 
placement of a restriction.  
The applicant for the license must be knowledgeable and experienced regarding the 
basic principles of radiation protection in general, as well as radiation protection as 
applicable to the installation. Although the licensee may appoint a medical physicist 
as the "responsible person", not all practices have the luxury of having the benefit of 
this essential service. An inspector must be allowed to confirm evidence of 
compliance, therefore manufacturers and suppliers as license holders must be 
equipped with the knowledge and skills to be able to meet the stipulated requirements 
(BMI, 2016a). 
The researcher includes the Code of Practice for users of medical x-ray equipment 
(DRC 2011) document as part of this thesis for information purposes in order for the 
reader to be acquainted with the current interpretation of DRC regarding the 
Hazardous and Substances Act as well as Regulation 1332. The content of the Code 
of Practice, Act and regulations will be further presented in detail in chapter seven in 
order to ascertain their impact on medical devices manufactures involved in radiation 
safety in SA. 
 
Another guidance document significant and very relevant to this study is requirements 
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for license holders with respect to quality control tests for diagnostic X-ray imaging 
systems (DRC 2012). The DRC published a second document that is provided as part 
of the diagnostic license conditions with respect to quality control (QC) tests in order 
to outline the requirements for the acceptance- and quality control tests of diagnostic 
X-ray equipment. As from 31 March 2009 an Inspection Body (IB), approved by the 
Department of Health (DoH) or an appropriately trained professional registered with 
the HPCSA as a medical physicist, must be used to perform all the acceptance tests as 
well as the routine tests. The significant aspects of these requirements for Quality 
Control Tests Document include the requirement of the license holder to acquire the 
relevant quality control manuals or compile in-house written protocols, which 
describe each test step by step to ensure that QC tests listed in the Requirements for 
Quality Control Tests Document are correctly performed. The quality control tests are 
influenced by the age, stability, make, model, etc., of the equipment, but must be 
performed at the prescribed frequencies as specified in the Requirements for Quality 
Control Tests document. The image display monitors and reporting monitors must 
comply with the requirements in of the said document (Doh South Africa, 2012). 
 
South Africa currently has no mandatory quality standard for medical devices other 
than those of a radiation emitting nature. Currently, all such regulation is left to the 
discretion of individual procurers. In order to rectify this, the introduction of an 
internationally graded and compulsory Quality Management Standards (QMS) needs 
to be introduced as like the standard for most of the developed countries. This, in turn, 
will prevent substandard products from entering the healthcare market and equalize 
opportunities for local manufacturers whilst ensuring patient safety (Deloitte, 2014).  
 
There is little enforcement, verification or validation of compliance of all other 
medical devices with the exception of those of a radiation emitting nature. This has a 
negative effect of allowing products of a sub-standard quality to enter the market 
impacting patient safety and undercutting the local manufacturing industry and thus 
inhibiting upgrading and development of local industry (SAMED, 2016).  
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2.4 Comparative Summary of the UK and SA Medical Devices Markets and 
Regulatory Frameworks 
This chapter has provided some historical background and structural information of 
the UK and SA medical device markets and regulatory frameworks. The UK medical 
device industry is one of the most competitive in the world, recognized for its ability 
to continually design, develop, and place innovative medical devices in the UK and 
foreign markets (BMI, 2016b). This can be attributed in part to a higher level of R&D 
investment and greater availability of venture capital, compared with the SA industry, 
which lacks government support and funding in the areas of R&D and technological 
development (Deloitte, 2014).  
 
Compared to the UK, which has a robust local product development capability and 
strict regulation (BMI, 2016b), the SA medical device market is supplied primarily by 
imports and has limited regulation requirements, providing excellent opportunities for 
foreign device manufacturers. Despite the milestones in healthcare provision, the UK 
and SA healthcare technologies are not easily affordable because of their increased 
costs associated with R&D, approval, compliance, and quality control. To that end, 
this study aims to further examine the impact of regulatory changes on industrial 
capabilities and development of affordable medical devices for the local population in 
the UK and SA. A summary of the key factors associated with the two countries’ 
medical device sectors is presented in Table 2.10 below. 
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Table 2.10: Comparative summary of the UK and SA Medical devices markets and regulatory frameworks  
Area of 
comparison 
 
UK 
 
SA 
Medical 
device market 
growth 
Estimated at USD11, 3 billion in 2014 and is forecast to grow at 
a US$ billion 2014-2019 CAGR of 5.1%, which will see market 
reach USD14.5 billion in 2019. 
Estimated at USD1.2 billion in 2014 and is forecast to grow at a US$ 
billion 2014-2019 CAGR of 2.2%, which will see market reach 
USD1.3 billion in 201910. 
Export trade 
status 
UK exported medical devices to the SA worth approximately 
US$ 228 million between the period 2004 and 2013. 
SA exported medical devices to the UK worth approximately US$32.1 
million between the period 2004 and 201311. 
Regulatory 
framework 
• Operates under the three core EU directives of the 1990s.  
• The framework has often been viewed as superior to many 
countries, given its somewhat faster regulatory process for 
devices and earlier access to some high-risk technologies 
• At present, only electromagnetic medical devices or radiation 
emitting devices are regulated through the Hazardous Substances 
Act, No. 15 of 1973. 
• Considered to have had a relatively ‘good’ system of electro-
medical device regulation in place, which started in 1971 
compared to the rest of the African countries 
Regulatory 
changes 
• The 1990s three main directives have been supplemented over 
time by several modifying and implementing directives, including 
the last technical revision brought about by the MDD 2007/47/EC 
• Since September 2012 the UK through the European Commission 
adopted and have been debating a new proposal to reform current 
regulation of medical devices, and, once adopted, will replace the 
existing three device directives 
• On April 5, 2017, two new regulations were adopted replacing 
previous directives. 
• The Public Health Act of 1919 which is country’s first national public 
health measure has also been supplemented over time by amendments 
such as Public Health Amendment Act of 197112 and the last technical 
revision concerning the use of X-ray equipment brought about by The 
Hazardous Substances Act, No. 15 of 197313 
• Since 22 April 201414, South Africa published for public comment draft 
regulatory changes designed to regulate all health products, devices and 
pharmaceuticals 
• Act 14 of 2015, promulgated in June 2017 
 
10 Medical device market growth figures source: (BMI, 2016a: 2016b) reports. 
11 Export trade figures source: (Deloitte, 2016). 
12 SA Government. Act no 42: Public Health Amendment Act. (GN 888 in Government Gazette 3119 of 26/5/1971). 
13 SA Government. Regulation R1332: Regulations concerning the control of electronic products. (GN R1332 in Government Gazette 3991 of 3 August 1973). 
14 Government Gazette No 37579 of 22 April 2014 – Notice R 315 “Medicines and Related Substances Act (101/1965).   
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What stands out in this table is the dominance of the regulatory frameworks and the 
constant changes associated with them.  The constant regulatory changes have been 
influenced by the need to improve societal safety (Sorenson and Drummond, 2014). 
The scandals witnessed in the UK related to the usage of the medical devices, such as 
hip replacement and breast implants were key drivers of regulatory change (Cohen, 
2012). In contrast, SA regulatory changes came about as a result of concerns about the 
possible effects of exposure to radiation on humans (Herbst and Fick, 2012). The 
processes that also drove regulatory changes included; the process of ensuring 
consistency amongst EU member states in the recognition of notified bodies, process 
of better coordination in the supervision of notified bodies; use of unannounced 
checks of manufacturer premises by notified bodies, improving vigilance systems and 
leveraging tools for traceability of medical device (European Commission, 2012)15.  
 
The increased demand for the health technologies led to changes in how the devices 
are manufactured and the rules followed in the supply of those devices in the market 
(Seedat and Rayner, 2012).  The changing law associated with medical care provision 
and the complaints raised by health consumers following poor health care services 
remains other drivers to change. As such, there is a gap in our understanding of the 
processes of market entry and how regulatory changes impact efforts to make 
affordable healthcare technologies in general and medical devices in particular, 
available in both advanced and developing countries. For this reason, this study aims 
to help bridge the gap left by the previous studies. The next chapter provides a critical 
evaluation of existing literature focusing on healthcare technology and medical device 
regulation. 
 
 
 
 
 
 
 
 
 
 
 
15 (For specific regulatory changes see ec.europa.eu/health/medical-devices/documents/revision/) 
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CHAPTER THREE  
LITERATURE REVIEW 
----------------------------------------------------------------------------------------------------- 
3.0 Introduction  
This current chapter will present a critical evaluation of literature on health 
technology regulation in general and medical device regulation in particular to situate 
this research in the context of this literature. Particular emphasis is placed on literature 
on medical device regulation in both advanced and developing countries. In addition, 
literature on the effects of regulation on the industry is also examined. A summary of 
the key issues raised in each part of the literature review will be provided such that 
knowledge gaps will be identified and presented.  
3.1 Regulation and Technological Capabilities: Health Technology Regulation in 
Advanced Countries 
As described in chapter one, health technologies include medicines, medical devices, 
assistive technologies, techniques and procedures developed to solve health problems 
and improve the quality of life (Liaropoulos, 1997, WHO, 2011a). Such technologies 
play a major role in contemporary health care systems and contribute directly to the 
quality of patient care (Cohen, 2012). However, the use of health technologies entails 
some considerable risks to human health (Altenstetter, 2008). Regulation is therefore, 
one mechanism to help balance the benefits and risks of new devices (Sorenson and 
Drummond, 2014). Regulation influences the way in which healthcare technologies 
are tested, commercialized and innovated, how producers and consumers interact, and 
ultimately contribute heavily to the institutional structure and the innovation dynamics 
of the medical device sector (Bloom et al., 2014). 
3.1.1 Regulation and Technological Capabilities: Insights from the 
Pharmaceutical Industry 
Health technology regulation has a long and significant history in national and global 
health policies (WHO, 2011a). Since the beginning of the 21st century, academic and 
policy research interest in health technology regulation has elevated and become more 
visible. However a majority of studies in advanced countries have concentrated 
mainly on effects of regulation on pharmaceutical markets with regards to product 
safety, drug development costs, patent life, and other issues   including (Abraham and 
Davis, 2005, Grabowski and Wang, 2006, Katz, 2007, Chowdhury, 2013, Cullmann et 
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al., 2012, Eisenberg, 2012, Griffin et al., 2013, Tobin and Walsh, 2008, Smith, 2005, 
Wood, 2010). These studies discuss various negative and positive influence of 
regulation on the pharmaceutical industry.  
 
The negative influence of regulation includes the contention by Griffin et al. (2013) 
that the tightening of regulation for pharmaceuticals in advanced countries such the 
US and the UK has at least doubled the cost of new product development in the last 
two decades. In a study exploring European regulation and the effect on regulatory 
uncertainty in the marketing authorization of medical products, Chowdhury (2013) 
argues that the health technology industry exhibits high level of regulatory uncertainty 
that undermine the effectiveness of the regulatory framework. The study found that 
although the sources of uncertainty varied across sectors, firms developed complex 
compliance strategies that allowed them to tolerate and in certain circumstances even 
circumvent regulatory uncertainty. Equally, Grabowski and Wang (2006) found that 
the direct effect of regulation on some (typically smaller) firms ultimately causes 
some of them to exit the industry. However, Eisenberg (2012) argues that the indirect 
effect on the industry is that the remaining incumbent firms benefit from reduced 
competition and increased revenues. Eisenberg further argue that the patent system 
works in tandem with drug regulation to defer market entry by competitors, thereby 
preserving profitable exclusivity in the market for a new product more effectively 
than patents could do without the regulatory assist. 
 
On the positive side of the impact of regulation, Abraham and Davis (2005) found 
that firms in the US pharmaceutical industry had fewer product safety withdrawals 
because the regulatory agency applied more stringent pre-market review, which took 
longer than UK regulatory checks, but prevented unsafe products marketed in the UK 
from entering the US market. Katz (2007) argued that the regulatory review of new 
drugs is an efficient mechanism for assuring the quality of medicines. Similarly, this 
points to the argument by Tobin and Walsh (2008) that drug regulation can provide 
the quality assurance necessary to persuade consumers to purchase drugs and increase 
the expected returns from innovation. In this sense, the regulatory framework is not 
solely a burden imposed on the industry but it also provides a valuable service to the 
industry (Katz, 2007). 
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3.1.2 Regulation and Innovation: Insights from Emerging Health Technologies 
Some studies have looked at emerging health technologies regulation, such as 
nanotechnologies, that are posing significant challenges to regulatory governance due 
to the uncertainties of development trajectories, product properties, and potential risk 
problems (Paradise et al., 2008, Dorbeck‐Jung et al., 2010, Bannister and Wilson, 
2011). Due to the complexity, ambiguity, and uncertainty of risk problems, 
Dorbeck‐Jung et al. (2010) noted that governments and regulators appear to have the 
unenviable task of balancing innovation and benefits against scientific uncertainty and 
the need for risk management.  
 
Paradise et al. (2008) argued that medical innovations using advances in 
nanotechnology are confusing the existing product classification scheme. This is 
because many products containing nanomaterials fall into the so called “combination 
products” or products in “borderline cases” involving medicinal products, human 
tissues and cells, or biocidal products, that are classified according to their “primary 
mode of action”. In the European Union, the study of the Working Group on New and 
Emerging Technologies in Medical Devices (2007) concluded that existing legislation 
is adequate to deal with nanotechnology-based medical devices. However, devices 
presenting risks associated with nanomaterials have to be subjected to a systematic 
pre-market review (European Commission, 2008). Bannister and Wilson (2011) 
explore the relationship between emerging technologies, citizen autonomy and the 
regulatory state. They argue that technology already enables a significant increase in 
the level of governmental interference in and control of the lives of citizens. They 
outline two frameworks: the activating state, and the regulatory state to analyse 
possible developments and their implications. Many researchers have agreed that 
there are inherent limitations and challenges to regulation in practice, given the 
multiplicity of available health technologies (Faulkner, 2012, Chowdhury, 2013).  
3.1.3 Health Technology Regulation and Innovation in Production 
The influence of regulation on health technology production, innovation 
entrepreneurship and small businesses in general has attracted some attention 
(Herzlinger, 2006, Blind, 2012, Tait et al., 2017). Firms see regulation as one of the 
core factors influencing the innovation process (Herzlinger, 2006). Most studies have 
looked at the impact of regulation on innovation in quantitative terms, for example, 
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examining the number of patent applications (Golec et al., 2010, Mayfield, 2016) or 
the number of new products introduced (Nemet, 2009). Golec et al. (2010) found that 
policy uncertainty related to price controls can reduce R&D spending well before the 
regulation is in effect, but also change the nature of innovation from developing 
expensive breakthrough drugs to cheaper patentable innovations that do not require 
heavy R&D investment.  
 
 Tait et al. (2017) conducted a study on the role regulations, guidelines and standards 
on innovation. The study argues for deregulation and support for the short-term 
interests of businesses by making “governance systems more proportionate and 
adaptive to the needs of innovative technologies” (Tait et al., 2017, p5). The study 
proposes a responsible innovation framework tailored to companies, which presumes 
that companies can be certain about the risks and benefits of their products, and 
certain about public concerns. Blind (2012) embarked on the study to find out what 
types of institutions affect innovation. The author identified six types of institutions, 
including competition legislation, price controls, product legislation, environmental 
laws, intellectual property rights and legal and regulatory frameworks; and adopted 
the endogenous growth approach as a conceptual analysis to examine the impact of 
the different types of institutional settings on innovation. Blind (2012) argued that, 
although regulation, innovation, and competitiveness in global health technology 
markets have been discussed for several decades, little progress has been made to 
understand the effect of regulation on the ability of industries to innovate. To fill this 
gap, the current study examines how regulatory changes enables or, in contrast, 
constraints innovation in production of affordable healthcare technologies in the UK 
and SA industries. 
3.1.4 Health Technology Regulation and Market Entry 
Previous regulatory studies have shown that the majority of health technologies 
require regulatory approvals before entering the market (Abraham and Davis, 2005, 
Cullmann et al., 2012). However, some researchers have argued that there have been 
high regulatory barriers to market entry, such as the number of procedures, extended 
approval timeframes and the compliance costs (Chataway et al., 2007, Faulkner, 2012, 
Kramer et al., 2012a). Previous studies have also noted that high health technology 
regulatory entry barriers have a strong influence on the industry capability, reducing 
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productivity, employment and increasing labour costs (Tobin and Walsh, 2008), 
decreasing research and development (R&D) efficiency and hindering innovation 
(Cullmann et al., 2012). Griffin et al. (2013) postulate that new cost-effective health 
technologies have a substantial impact on patient quality of life, the health budget, 
and the wider economy; therefore, slow uptake means these important benefits are 
delayed. Some researchers suggest that governments seeking to promote new health 
technologies should focus on the longer-term effects of the regulations on the industry 
(Wood, 2010, Smith, 2005). Furthermore, as new health technologies are largely 
driven by competition, the governments should seek to lower the barriers to entry for 
new companies (Preissl, 2000).  
 
The pharmaceuticals are not the only sector in which research on health technology 
regulation would be of interest. However, the pharmaceutical industry is closely 
related to the medical device industry. It is also the industry for which a 
comparatively rich literature is available. While the pharmaceutical and medical 
device industries are related, the industrial dynamics are not necessarily similar 
(Wood, 2010, Chowdhury, 2013). A detailed assessment of the medical device 
industry, and particularly the high-risk sector, will thus provide additional insights. 
3.2 Medical Device Regulation in Advanced Countries    
The regulation of medical devices is a vast and rapidly evolving field that is often 
complicated by legal technicalities (WHO, 2011b). Over the past twenty years, there 
has been an effort to study medical device regulation in advanced countries, however 
the studies are very few compared to those that have focused on pharmaceutical 
regulation.  
3.2.1 Medical Device Regulation and Innovation in Production  
Some studies have appeared examining the effects of regulation and regulatory 
change on innovation in the medical device sector (Crafts, 2006, Curfman and 
Redberg, 2011, Faulkner, 2009, Bergsland et al., 2014, Bloom et al., 2014, Guerra-
Bretaña and Flórez-Rendón, 2018, Davey et al., 2011). The literature about the impact 
of medical device regulation on innovation discusses and focuses upon concepts such 
as resource scarcity, allocation, and exchange. Crafts (2006) notes that, regulatory 
constraints influence innovation in two different ways. First, regulatory changes are 
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associated with different costs. Second, regulation may potentially enable innovation 
by providing larger expected profits (Crafts, 2006). However, Craft argues that the 
larger expected profits could either be associated with a higher level of production 
output or come from the regulatory effect on the potential entry of the products. 
According to Faulkner (2009) the most obvious cost of regulation is that productive 
resources are used for compliance rather than for product output. 
Faulkner (2009) addresses the role that regulation plays in processes of technological 
innovation. The study provides a view that regulation 'lags behind' innovation. 
Conversely, Bergsland et al. (2014) found that the introduction of innovative medical 
devices to the health service is slower than for other consumer products due to the 
regulatory barriers to innovation.  
Davey et al. (2011) argues that open innovation models can allow medical devices 
firms to manage the ideas of multiple stakeholders and lower existing barriers for 
reaching the market more quickly. Successful case studies exist of collaboration 
between academia, health institutions, industry and regulatory agencies for 
developing innovative medical devices (Bonutti et al., 2008, Courvoisier, 2016, 
Markiewicz et al., 2017), overcoming the barriers to innovation in medical products 
by coordinated efforts among critical stakeholders. 
In a recent study on innovation under regulatory uncertainty: evidence from medical 
technology, Stern (2017) considers that the regulatory process strongly affects market 
entry patterns of the small firms and that they are less likely to be pioneers in new 
devices because of the relatively higher costs of doing so for more financially 
constrained firms. In this study we will contribute to the existing literature by 
considering how regulation influence of the entire cycle of innovation, which includes 
resource allocation for the innovation process, the innovation process itself, 
production, firm linkages and the sales/use of final products 
3.2.2 Medical Device Regulation and Patient Safety Concerns 
Some studies gave attention to patient safety concerns, product recall and regulation 
(Heneghan et al., 2011, Thompson et al., 2011, Cohen, 2012, Zuckerman et al., 2011).  
Heneghan et al. (2011) noted that the number of medical devices subject to recalls or 
warnings in the UK has risen dramatically. A substantial number of these devices may 
have caused serious adverse effects in patients and contributed to healthcare costs. To 
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that end, significant problems exist in the UK with a lack of access to transparent data 
and a registry of the highest-risk devices (ibid). Similarly, Thompson et al., (2011) 
contend that the UK regulatory system for medical devices fails to show sufficient 
transparency and especially in the context of device recalls. A study done by Cohen 
(2012) examines the evidence of risk from metal-on-metal hips, the manufacturers’ 
inadequate response, and how the regulatory bodies failed to give doctors and patients 
the information they need to make informed decisions. This study concluded that after 
a series of failures, device regulation is in need of radical change as there is some 
doubt that the current regulatory system is fit for purpose. 
 
The most important conclusion of these studies on patient safety concerns is that, 
despite the fact that strong regulations exist, the risk of putting into the market 
insufficiently tested devices still remains, and that the effective review process is still 
an issue of academicians, industry, government and social concern (Zuckerman et al., 
2011). 
3.2.3 Medical Devices Regulation and Industrial Conformity and Compliance  
Due to the fact that medical device regulation is not static, conformity and compliance 
to regulatory changes have been major challenges to the industry. A few studies have 
examined industrial conformity and compliance to regulation (Jefferys, 2001, Lee et 
al., 2006, Sorenson and Drummond, 2014). Conformity assessment is the key 
mechanism for assuring that a medical device is safe and performs as intended 
through meeting the essential principles. The requirements for conformity assessment 
become more stringent as the risks associated with the medical device increases 
(Sorenson and Drummond, 2014).  
Lee et al. (2006) criticized the second core directive for medical devices (MDD 
93/42/EEC) for burdening the medical device manufacturers with high approval costs.  
A conformity assessment study by Jefferys (2001) described the role of medical 
device regulation and argued that long and complicated authorization procedures 
hinder development of new devices and increase complexities needed to meet local 
requirements. Therefore, timeliness of regulatory decisions during the compliance and 
approval procedures and access to technology is a major concern for the stakeholders 
in the medical device industry (Sorenson and Drummond, 2014).    
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Blanchard and Giavazzi (2001) conducted a study on the effects of regulation on 
labour markets and argued that there are high entry costs challenges faced by the 
manufacturers. This argument has also been supported by Djankov et al. (2002) 
whose study on regulation of market entry in 85 different countries noted that official 
costs of entry are extremely high in most countries. 
By reviewing evidence of regulation effects in various OECD countries, Craft (2006) 
concluded that whether the regulation influence is negative or positive, depends on 
the extent of the compliance cost and the incentive. Regulatory compliance and 
conformity is indeed a requirement in the medical device sector. However as shown in 
literature more studies are needed that not look at regulatory compliance but also on 
the overall effects of regulation on industrial technological capabilities and thus what 
this study is trying to achieve. 
3.2.4 EU and US Medical Device Regulatory Frameworks 
A field of comparison studies of EU and US medical device regulatory frameworks 
reflecting on development commonalities, differences and challenges have also been 
published (Abraham and Davis, 2005, Altenstetter, 2012, Kramer et al., 2012a, 
Kramer et al., 2012b, Sorenson and Drummond, 2014, Sorenson and Kanavos, 2011). 
From these previous studies, they found that the two systems differ in a few aspects: 
for example, the U.S. system is highly centralized, i.e., the Food and Drug 
administration (FDA) has control of all procedures for the admission of a product to 
the market. On the contrary, European law on medical devices has “outsourced” the 
certification of safety criteria to external entities, called notified bodies.  
Moreover, U.S. regulation has been seen as more stringent, and sometimes this has 
been seen to have a negative effect on the speed of innovation. On the other side, 
European patients have faster access to certain devices, but these products are 
marketed with less rigorous proof of effectiveness and may have a greater chance of 
later-identified adverse events (Kramer et al., 2012a, Sorenson and Drummond, 
2014).  
The comparative studies have shown that the US regulatory authority is a 
governmental entity, and as such it is equipped with considerable powers. Yet in the 
European system the privately organised product certification partner, the Notified 
Body, is often a much smaller player than the firm seeking approval (CE certification) 
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for its product. It can happen that a product is certified for the EU market earlier than 
it is approved for the US market, simply because firms are able to pass through the 
necessary steps more easily in Europe. The Notified Body certification appears to be a 
lower hurdle than the government agency-owned process in the US. The comparative 
studies  found that device classification decision in both regulatory systems is initially 
performed by the manufacturer who decides according to available guidelines into 
which class a specific product should fall and applies for approval accordingly 
(Altenstetter, 2012).  
3.2.5 Harmonization of Medical Devices Safety Regulation  
Some studies have examined harmonization of medical device safety regulation in 
advanced countries (Kaplan et al., 2004, Altenstetter, 2008, Marchant and Allenby, 
2017, Pombo et al., 2016). Kaplan et al. (2004) found that important differences have 
evolved in the clinical-regulatory environment between the United States and Europe 
that have impacted the location of clinical testing and the relative timing of 
commercial availability. This has led to substantial differences in the speed of 
introduction and the extent of testing of these devices in the United States and Europe. 
Pombo et al. (2016) pointed out that harmonization reduces regulatory load and 
promotes industry compliance. However, Altenstetter (2008, p. 230) argued that 
“countries instituting medical device programs should be cognizant of ongoing 
international harmonization  effects so as to preclude regulatory controls that conflict 
with actual harmonized rules and guidelines or with the spirit and goals of on 
international hamonization.”  
Marchant and Allenby (2017) explored the role of soft law in governing emerging 
technologies, arguing that there are at least ten different reasons why nations may 
seek to harmonize their oversight of a specific technology. A new generation of more 
informal international governance tools are being explored, often grouped under the 
term "soft law." They include private standards, guidelines, codes of conduct, and 
forums for transnational dialogue. However, Pombo et al. (2016) pointed out that the 
implementation of harmonized regulations depends on the national regulatory 
capabilities. Therefore, these capacities have to be strengthened to allow the 
incorporation and deployment of common standards in all countries. 
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3.2.6 International Collaboration on Medical Device Regulation 
A study on international collaboration done by Altenstetter (2005) argued that, 
regulation raises complex issues which require highly specialized scientific and 
technological knowledge and skills that often surpass the capability of national 
regulators. The pooling of resources, knowledge and expertise at the global and 
regional levels is seen as producing the most appropriate regulatory solutions based 
on the latest state-of-the-art medical technology in a host of different disciplines. 
While the pooling of resources has benefits, it also carries a heavy price. That price is 
dependence on the knowledge and expertise of a small number of industry scientists, 
clinical innovators, and regulatory affairs specialists of multinational companies with 
little accountability. In this study we want to investigate these complex issues further 
but not only restricted to the capability of national regulators’ point of view but also 
from the firm level capabilty’s point of view. 
3.2.7 Evolution of the EU Regulatory Framework 
A recent study that is in line with this research has been done by (Casteels and Rohde, 
2013) who looked at the evolution of the EU regulatory framework. The study found 
that the strength of the decentralized European regulatory framework for medical 
devices has been to provide timely access to life-saving and life-enhancing 
technologies to patients and doctors in the EU (and beyond) while guaranteeing a high 
level of safety. Conversely, the study argues that the EU framework needs now to be 
reformed to respond to increased expectations and technological advances and to 
avoid incidents such as the fraudulent PIP breast implant case. The study however 
makes no attempt to consider the impact of the evolutionary changes on the industry 
dynamics and also fails to compare the evolution with other frameworks outside the 
EU. This is what this study sets out to examine further. 
3.3 Health Technology Regulation in Developing Countries 
A considerable amount of literature has been published on health technology 
regulation in developing countries. These studies include: (Kale, 2013, Rugera et al., 
2014, Sheikh et al., 2015, Ensor and Weinzierl, 2007, Chataway et al., 2007, Mori et 
al., 2013, Harmon and Kale, 2015). A major challenge some researchers have pointed 
out is that the absence of regulation has an impact on the development of health 
technologies and development of health sectors (Kale, 2013, Rugera et al., 2014). 
This augment is supported by Pigou’s (1938) public interest theory of regulation that 
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suggested that unregulated markets would be destined to frequent failures (Djankov et 
al., 2002).  
Sheikh et al. (2015) adopted a stepped research methodology to map health 
technology regulatory institutions and argued that ineffectiveness of health 
technology regulation in developing countries is widely observed, but there is little 
empirical research exploring the reasons for these failures. This argument is in line 
with Ensor and Weinzierl (2007) who had also looked at  health technology regulation 
in low and middle-income countries and argued that there is need to invest in 
structures and institutions especially in Africa to encourage a more coherent 
regulatory approach. Chataway et al. (2007) states that health technology 
developments are evolving faster than relevant policy and regulatory systems and 
many of the new emerging products cross the boundaries of existing regulatory 
systems.  
Mori et al. (2013) conducted a study in Tanzania to identify whether reforms of 
pharmaceutical policy were undertaken to improve efficiency or whether they just 
presented an opportunity for vested interests.  Findings from the study highlighted the 
influence of politics on decision making at many levels of the reform process, with 
regulation remaining a challenge. There is a call on governments to limit the political 
influence on policy, in the interests of appropriate public health outcomes for the 
populations of developing countries. A study on multiple roles for medical research 
and products regulation in Argentina and India by Harmon and Kale (2015, p. 21) 
argues that “both sound healthcare interventions and socially useful innovation may 
be best encouraged through regulatory innovation, and emerging jurisdictions are in a 
strong position to ‘leapfrog’ developed jurisdictions reliant on more entrenched 
regulatory instruments and pathways”.  
A number of studies reviewed in this literature on health technology regulation in 
developing countries highlighted the challenges and shortfalls of current regulatory 
systems. However, very little is known about the effects of regulation on firm level 
capabilities and affordable healthcare technology development, the concern of the 
current study.  
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3.4 Medical Device Regulation in Developing Countries 
Most developing countries do not have their own regulations on medical devices, but 
many refer to the EU or US normative system, including the International Medical 
Device Regulators Forum (IMDRF) to facilitate the manufacturing and selling of their 
products in Europe, US and to the rest of the world (Shah and Goyal, 2008). For 
instance, WHO (2005) reported that only 7% of the 46 sub-Saharan African countries 
had National Medicines Regulatory Authorities (NMRA) in place. Of the remaining 
countries, 63% had minimal regulation and 30% had no regulation. As a result, 
studies on medical device regulation in developing countries have recently started to 
receive some attention (Deloitte, 2014, Herbst and Fick, 2012, Kale, 2013, Lamph, 
2012, Sheikh et al., 2015, Rugera et al., 2014, Saidi, 2016, De Maria et al., 2018, 
Saidi and Douglas, 2018). The need for such research is notable to ensure safe and 
effective healthcare in developing countries.   
 
One of the few studies conducted on regulation of medical devices in developing 
countries has strongly indicated that streamlining and harmonizing regulatory 
processes is needed in order to reduce delays, unnecessary expense and improve 
access to new medical devices (Rugera et al., 2014). In their study of six countries 
(Burundi, Kenya, Rwanda, Tanzania and Uganda), Rugera et al. (2014) indicated that 
some countries are taking steps towards strengthening medical device regulation and 
these countries are receiving support through a project with the WHO.  
 
De Maria et al. (2018) conducted a study aimed at comparing the certification route 
that manufactures must respect for marketing a medical device in some African 
Countries and in European Union. The study found that in developing countries, poor 
regulatory control results in the use of substandard devices, and often it becomes a 
constraint for those wanting to produce, sell, or even donate these devices. Similarly, 
Saidi (2016) explores the importance of medical device regulation in promoting 
access to high quality, safe and effective medical devices. The study emphasizes that 
medical device regulation in developing countries helps to prevent the importation 
and use of substandard devices thereby protecting the users from falling prey to 
unscrupulous market influences that put patients’ lives at risk. To that end, 
governments have the responsibility of putting in place regulations aimed at 
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addressing all elements related to medical devices, ranging from access to high 
quality, affordable products through to their safe and appropriate use and disposal. 
 
 Kale (2013) conducted a study focusing on regulatory policies and their impact on 
innovation and technology capability development in the Indian medical device 
industry and argued that regulation can have many beneficial effects, therefore 
neglecting to regulate, or deregulating where frameworks already exist, is not 
necessarily the way forward. Herbst and Fick (2012), whose study focused on SA 
regulation, radiation protection and the safe use of X-ray equipment indicated that 
poor management of regulatory system, lack of financial resources and deficient 
human regulatory capacity put the health and safety of the local population at risk. 
Accordingly, Saidi and Douglas’s (2018) study found that the absence of specific and 
comprehensive regulations that guided the manufacturing and sale of medical devices 
had far reaching repercussions on the health delivery system in SA. This is because 
good and functional medical devices are produced when the manufacturing process is 
adequately regulated. 
 
In a case study of SA medical device regulatory framework, Poluta (2006) argued that 
regulation of medical devices is well established in industrialised countries with 
increasing standardization and harmonization. In developing and poor resourced 
countries, however, there is a much greater degree of variability and implementation. 
The scope of Poluta (2006)’s  research, however, was relatively narrow, being 
primarily concerned with proposing  a compact framework model. The study makes 
no attempt to consider the historical background of the current framework and the 
broader implications of regulation on industry capability.  
3.5 Medical Device Regulation Effects on Industry 
The medical device industry includes both large global firms and a large number of 
small entrepreneurial companies and start-ups (Chowdhury, 2013). Previous studies 
on the effects of regulation on research and product development (R&D) have argued 
that regulation can cause new innovations to concentrate in larger, multinational firms 
that are better able to deal with the compliance costs (Bloom et al., 2014), therefore  
reducing competition in the industry, resulting in less market innovation and thus a 
decline in the supply of affordable medical devices (Curfman and Redberg, 2011, 
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Bergsland et al., 2014). However, Kale (2009) argues that innovation capabilities in 
the case of firms in developing countries differ in complexity in comparison with 
firms in advanced countries. In some cases, regulation in developing countries may 
not directly influence innovative R & D of multinational companies as this might be 
influenced by their corporate strategy rather than be subjected to the policies of the 
developing country. But governments may dictate that multinational companies 
develop local firms in order to gain entry into those markets. These local firms usually 
result in local innovations on products as the demands of the market are easier to 
understand. Healthcare policy researchers have argued that a strong local capability 
for both technological and social innovation in developing countries represents the 
only truly sustainable means of improving the effectiveness of health systems (Hsieh 
and Tsai, 2007). 
Using the concept of co-production of science and society in his comparative study 
Faulkner (2012) argued that bringing together empirical and theoretically informed 
research to analyze industrial regulatory trends in a range of health technologies have 
implications for human health. This study wants to examine this further and 
understand whether medical device regulatory implications are bringing positive 
outcomes in particular access and affordability outcomes and if not then how can the 
system be improved. 
3.6 Concluding Remarks and Knowledge Gap 
Kale (2013) pointed out three major reasons why regulation is criticised: the first 
criticism is that it increases cost of innovation therefore reducing possibilities of 
affordable healthcare technologies; the second is that the presence of regulation may 
effectively prevent disruptive technological improvements from occurring. This 
argument is based on the theory of disruptive innovation (Hwang and Christensen, 
2008). The author lastly, points out that regulation can constrain growth of a sector by 
creating rigid entry barriers that slow evolution of the sector.  
 
Malerba and Mani (2009, p.21) claimed that the separation of research from 
development and production capabilities could be very harmful for innovation and 
development. Smith (2005) argued that the capabilities of the industry cannot be 
understood in isolation from the system of regulation and, increasingly, the 
international regulatory structures, and from what is happening elsewhere in the 
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regulation of science. Intarakumnerd and Fujita (2009) argued that in developing 
countries, production capability is as important as innovation capability. How 
technological change affects market structures have been investigated thoroughly by 
many researchers including (Cohen and Levinthal, 1989, Suarez and Utterback, 1993, 
Von Tunzelmann, 2003). However, the effects of regulation and regulatory change on 
the industry capabilities have attracted much less attention. Few studies reported on 
specific firms and their implementation activities. Also, no studies differentiate the 
performance of individual firms’ capabilities in responding to new regulations. 
Indeed, we can gain new insight into firms' behavior by investigating the 
implementation actions that they take in response to a specific regulatory change.  
 
Some studies have surveyed the dynamics of industries, e.g. the pharmaceutical 
industry, from patenting to productivity (Pammolli and Riccaboni, 2004, Scherer, 
2000, Syverson, 2004). However, the medical device industry has not been 
investigated much in this regard. This argument is further supported by a legislative 
and policy framework study done by Rugera et al. (2014) that also argued that studies 
on pharmaceutical products regulation and development have received more attention 
and that less attention has been placed on the regulation and development of medical 
devices. 
 
Some efforts have been made to study the regulation of medical devices but only by a 
few researchers as shown in this literature. Despite the ever-expanding knowledge 
base, more research is needed, especially to assess new regulatory developments and 
evolutions in practice (Sorenson and Drummond, 2014). Kramer et al. (2012a) used a 
systematic review process to compare US and EU medical devices regulatory 
systems. The authors argued that changes are necessary for the evolution of regulatory 
systems, however this systematic review did not provide some insights for 
policymakers or regulators seeking to reform device regulation. To avoid this 
limitation, this study will deploy the sectoral systems of innovation approach as it 
provides valuable recommendations to policy-makers designing national, sectoral or 
regional-level innovation policies (Malerba and Mani, 2009).  
 
While studies have shown that there is medical device manufacturing capacity in both 
the UK and SA (BMI, 2016), though at different levels, there are no systematic 
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studies that identify from an evolutionary perspective, the impact of medical device 
regulation on industrial capabilities to develop healthcare technologies as well as the 
barriers to commercializing them at an affordable cost. In this regard, a study 
enhancing our understanding in this respect would indeed be an interesting area that is 
worth further exploration.  
 
This study chose to do a comparison of regulatory change cases using empirical data 
from the UK and SA based firms because: first, both countries have oriented their 
regulatory processes for medical devices on the EU system. Second, SA is one of the 
African Biomedical Engineering Consortium (ABEC) 16  countries that has 
implemented or harmonized with European directives in its legislation, despite the 
fact that the legislation is particularly strict (De Maria et al., 2018). Third, the 
legislative frameworks of the UK and SA both adopt the International Medical Device 
Regulators Forum (IMDRF) philosophy of accelerating international medical device 
regulatory harmonization and convergence (IMDRF, 2020). For this reason both study 
countries adopted the Risk Classification System formulated by the Global 
Harmonization Task Force (GHTF). Fourth, the UK was a pioneer in risk-based 
regulation following the Hampton Review (Hampton, 2005), and the UK’s regulatory 
reforms have drawn the interest of policymakers and regulators in other countries 
(Etienne et al., 2018) including those in SA. To that extent, SA has replicated 
regulatory tools or frameworks that were initially developed in the UK17.  
 
 But while there may be some convergence of regulatory objectives and substantive 
principles, the character of national regulatory institutions is still best understood 
within each jurisdiction’s culture. In the words of Foster (1992, p.417) ‘while the 
underlying economic principles and therefore the regulatory offences should be 
relevant in all economies, how the offences should be expressed, monitored and 
controlled can only be decided in the context of the constitution, laws and political 
habits of the individual country’  
 
 
16 The African Biomedical Engineering consortium was founded in 2012 with the mission of pursuing 
capacity building in Biomedical Engineering for sustaining local healthcare systems. 
 
17 Much of the Better Regulation drive at EU level can be traced back to UK initiatives (Etienne et al., 
2018). 
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Another limitation of existing studies is that most of the studies were conducted after 
the regulation was significantly revised. Considering the interactive learning within 
the innovation ecosystem, the impact of regulation observed in this period could be 
different after the regulation has been implemented and stabilized. It is these gaps that 
this research aims to fill. The importance of a study of this nature can further be 
attributed to the anticipation that more, as well as stricter regulations are likely to be 
imposed in the future.  
 
Our examination of literature in this chapter not only provided a basis for articulating 
the relevant research gaps on how firms manage regulation and regulatory change but 
also provide a starting point for the identification of suitable theories for studying the 
issue of firms’ management of the impact of regulatory change. The next chapter, 
therefore, will present the theoretical framework and conceptual framework 
developed to answer the research questions of this study. 
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CHAPTER FOUR 
THE STUDY THEORETICAL FRAMEWORK 
----------------------------------------------------------------------------------------------------- 
4.0 Introduction 
This chapter presents the theoretical framework of this study. The chapter will first 
present an overview of the conceptual framework of the research. We use a flow-
guide that flows from medical device regulation and industrial capabilities, through 
the Sectoral Systems of Innovation (SSI) lens, anchored in evolutionary theory. The 
main factors that influence the dynamics of the system are the actors and networks, 
knowledge and technologies, and the institutional dynamics associated with a 
particular regulation. These elements are the centre of this study’s analytical focus. 
The chapter further describes other supporting theories, concepts and approaches used 
to unpack the effects of medical device regulatory changes on investment, production 
and linkage capabilities and development of affordable health technologies. Figure 4.1 
below shows the conceptual framework: 
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Figure 4.1: Conceptual framework bringing together theoretical and analytical 
components of the study. Source: (Malerba and Mani, 2009)  
 
In the above diagram, the main object is regulation of medical devices. The main 
impact factors to be considered in this study are, industrial technological capabilities 
and the development of affordable healthcare technologies. In order to examine the 
dynamics within the medical device sector under consideration, the SSI approach is 
used to unpack the elements of medical device manufacturing processes that have 
been compiled from the literature which include industrial capabilities and 
development of affordable health technologies. The adoption of the SSI approach in 
the study has the potential to enhance our understanding of the process of regulatory 
change, drivers behind the changes, and impact of the changes on industrial capability 
to develop affordable healthcare technologies. The SSI concept is anchored in 
evolutionary theory, which will be used to analyse the changes and transformations, 
the links, the interdependencies and the sectoral boundaries between regulation, 
industrial capability and the development of affordable healthcare technologies. 
4.1 Industrial Capabilities  
The previous chapters provided information on medical device regulatory systems, 
and the literature survey showed that the UK medical device industry has witnessed 
radical transition during the past three decades. Medical device industry operations, 
however, require specific knowledge and skills in technology that may be called 
“capabilities” of the firm as illustrated in Figure 4.1. These firm-level technological 
capabilities are examined in this study from the perspective of Lall’s definition as a 
“complex array of skills, technological knowledge, organizational structures, required 
to operate a technology efficiently and accomplish any process of technological 
change” (Lall, 1992). Castellacci (2008) suggested that in any given historical era, 
industrial sectors whose knowledge base and capabilities are closely related to the 
constellation of emerging radical innovations face a broader set of opportunities and 
tend therefore to follow dynamic trajectories. By contrast, industries less directly 
involved in the production and use of the new general-purpose technologies 
experience a lack of opportunities and are therefore forced to move along less 
dynamic paths.  
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Importance of technological capability 
 
Technological capabilities play a strategic role in affecting the competitive advantage 
of a company, an industry, and even a country (Lall, 1992). Thus, the development of 
technological capabilities is critical for companies, especially those manufacturing 
companies in the countries that are in a catch-up phase of industrialization. The 
development of technological capabilities has also attracted extensive attention both 
from the theoretical and empirical viewpoint. In addition, extensive research on the 
development of technological capabilities is carried out not only in emerging 
countries (Kim, 1997, Lall, 2003) but also in advanced countries (Miyazaki, 1995).  
 
Technological capabilities are therefore crucial both in order to effectively use 
technologies that have been developed elsewhere (i.e. other countries or other 
organizations) as well as to be able to adapt, improve and create new, own 
technologies (Lall, 1992, Bell and Pavitt, 1995). The technological capabilities 
approach therefore highlights the very crucial role of technological learning. 
 
Relationship between government regulatory systems and industrial capabilities 
 
There is a strong relation between government regulatory systems and industrial 
capabilities. For example and as mentioned before, “the New Approach” principles of 
the 1990s assigned responsibility for the regulatory cycle to three organizations: 
competent authorities, manufacturers, and third party certification organizations 
(notified bodies) (Altenstetter, 1996). Whilst competent authorities and notified 
bodies ensure that the requirements of the regulations are applied, the manufacturers’ 
capacity to respond to the new regulatory environment resides in the capabilities of 
the firm, defined by Teece et al. (1994, p.18) as “a measure of the firm’s ability to 
solve both technical and organizational problems”. The firm-level technological 
capabilities therefore determine what the firm is potentially able to do in response to 
the new regulatory demands. Figure 4.2 illustrates the link between government 
regulation and industry. 
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Figure 4.2: Government regulation effect on industry 
Adapted from (Hermans et al., 2009) 
 
 
As presented in the conceptual framework (see figure 4.1), regulation will shape 
industrial dynamics and in most countries, regulatory authority for medical devices 
resides at government level as shown in figure 4.2 above. The changed structure will 
have an effect on the industry conduct and capabilities i.e. on how the actors in an 
industry will act, respond and how will they interact, leading to different competitive 
strategies by the companies in the industry. Thus, industry structure and conduct will 
have an effect on the industry performance (Gaynor and Haas-Wilson, 1998). 
Ultimately, industry performance will lead to different macroeconomic outcomes for 
societies that include affordability of health technologies. Whether the outcomes will 
be positive or negative concerning social welfare, is dependent on how the industry 
has reacted through its structure and conduct to the changes in government regulation 
and whether the changes in the industry have led to a net efficiency gain or only to an 
increase in market power (Hermans et al., 2009).  
4.1.1 Theoretical Perspectives of Industrial Capabilities 
As illustrated in the conceptual framework (Figure 4.1), this study sets out to examine 
in some depth the influence of regulatory changes on industrial capabilities. These 
industrial capabilities can be studied on various theoretical perspectives. One relevant 
theoretical strand of thought is “evolutionary theory” developed by Nelson and 
Winter (1982), and explained in Nelson (1987) and Dosi (1988). They argue that 
firms are modeled as having, at any given time, certain capabilities and decision rules. 
Over time these capabilities and rules are modified as a result of both deliberate 
problem-solving efforts and random events (Nelson and Winter, 1982, p.4).  Random 
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events are defined as (‘the timely appearance of variation under the stimulus of 
adversity’ (ibid, p. 11). 
 
In the evolutionary theory of the firm, it has been argued that the firm is a repository 
of knowledge (Nelson and Winter, 1982) and this knowledge exists in the 
organizational capabilities of the firms, which then determine the performance of the 
firm. The capabilities addressed in the evolutionary theory of the firm are routines, 
routinized patterns of behavior that in turn are products of organizational learning and 
knowledge (Nelson and Winter, 1982). Organizational learning has been 
characterized as a social and collective phenomenon (Teece and Pisano, 1994) that 
involves joint problem solving and coordinated search. Moreover, organizational 
learning is cumulative and path-dependent in nature. What has been learned is stored 
in routines and expressed in the firms’ capabilities. 
 
Teece et al. (1997) developed a theoretical concept of “dynamic capabilities”, an 
extension of the resource-based view of the firm. The concept refers to capabilities 
within the firm, which allow the firm to create new products and processes and to be 
in a position to respond to changing market environments. The term ”dynamic” is 
referred to as “the capacity to renew competences so as to achieve congruence with 
the changing business environment” (Teece et al., 1997, p. 515). Helfat et al. (2009, 
p.4) define a dynamic capability as ‘the capacity of an organization to purposefully 
create, extend, and modify its resource base’. The ‘resource base’ includes the 
‘tangible, intangible, and human assets (or resources) as well as capabilities which the 
organization owns, controls, or has access to on a preferential basis’. Helfat and 
Peteraf (2009) also state that dynamic capabilities have a direct effect on firm 
performance and competitive advantage, as well as an indirect effect through resource 
reconfiguration. Dynamic capabilities thus reflect an organization’s ability to achieve 
new and innovative forms of competitive advantages given the path dependencies and 
market positions. 
 
In constantly changing environments, the dynamic capabilities approach can give a 
more substantive picture than traditional views of how competitive advantage is 
gained and sustained (Levitas and Ndofor, 2006). The dynamic capabilities approach 
is an especially useful lens to examine firms in rapidly changing business 
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environments (Blyler and Coff, 2003, Davies and Brady, 2000). The importance of 
responding to a rapidly changing environment is a plausible explanation as to how 
young resource constrained firms can enter markets and even outperform large 
competitors (March, 1991).  
 
However, dynamic capabilities are only one tool among other explanations in 
understanding how firms change (Winter 2003). Indeed, in addition to utilizing stable 
and learned change patterns (dynamic capabilities), firms constantly change 
themselves by learning, experimenting, and creating new solutions without relying on 
existing dynamic capabilities. This type of change sometimes leads to the formation 
of new dynamic and ordinary capabilities (Zollo and Winter, 2002), but it sometimes 
only happens as a single event of creative problem solving (referred as ad-hoc 
problem solving in Winter 2003). Either way, firms that are more flexible in terms of 
learning, knowledge creation, and problem solving, are also likely to be continuously 
successful in changing environments. 
 
An example of a dynamic capability is strategic decision making (“in which managers 
pool their various business, functional and personal expertise to make the choices that 
shape the major strategic moves of the firm” (Eisenhardt and Martin, 2000, p.1107). 
Other dynamic capabilities focus on for instance “reconfiguration of resources within 
firms”, as well as “transfer processes, including routines for replication, and brokering 
are used by managers to copy, transfer and recombine resources, especially 
knowledge-based ones, within the firm” (ibid). 
 
At the firm level, the technological capability development is the outcome of 
company-level efforts to build up new organizational and technical skills, its ability to 
generate and tap information, the development of an appropriate specialization vis-a-
vis other industry actors, and the formation of linkages with suppliers, buyers and 
institutions (Lall, 1992). Bell and Pavitt (1995) proposed the category of supportive 
capabilities to look at the interactions among actors within the system of innovation. 
In this regard, supportive capabilities include technology transfer that is necessary for 
a further diversification into new products and new industries. Viotti (2002) proposed 
the category of improvement capabilities to stress the importance of internal 
technology upgrading. This function may be encountered in other categories such as 
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production capabilities. Ernst et al. (2003) proposed the category of strategic 
marketing capabilities to emphasize behavioral patterns related with suppliers as well 
as the importance of building close customer links as a competitive advantage.   Lall 
(1992) classify firm-level technological capabilities according to the different 
functions they perform and their degree of complexity (i.e. different levels ranging 
from basic via intermediate to advanced). This study adopts Lall (1992)’s firm level 
technological capabilities functions model, made up of  "investment", "production" 
and "linkage" capabilities.  
 
Investment Capabilities  
Lall (1992, p. 168) defined investment capabilities as “the skills needed to identify, 
prepare, obtain technology for, design, construct, equip, staff and commission a new 
facility (or expansion)”. This includes the capabilities to assess the feasibility and 
profitability of a project, define specifications, what technology is required, 
negotiations of the purchase, recruit and train skilled personnel and design the basic 
process and supply the equipment. Investment capabilities determine the capital costs 
of the project, the appropriateness of the scale, product mix, technology and 
equipment selected, and the understanding gained by the operating firm of the basic 
technologies involved (Lall, 1992). The medical device industry is a high-tech 
industry with high investment in R&D and the capability of firms to shape technology 
investments into innovation is likely to be influenced by firm-specific resources such 
as managerial skills, know-how, experience, the presence of technical experts, and 
prior technological investments (Koellinger, 2008).  
 
Production Capabilities 
Lall (1992) defined production capabilities as skills and knowledge required to carry 
out activities in the manufacturing or production area. Production capabilities range 
from basic skills such as quality control, operation, and maintenance, to more 
advanced ones such as adaptation, improvement or equipment “stretching,” to the 
most demanding ones of research, design, and innovation (Lall, 1992). They also 
cover both process and product technologies as well as the monitoring and control 
functions included under industrial engineering (Viotti, 2002, Lall, 1992). 
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Linkage Capabilities 
While investment and production capabilities have been specified as primary 
activities (Bell and Pavitt, 1995), linkage capabilities are supporting activities with the 
ability to link up with other actors in the economy. Lall suggested a broader definition 
of linkage capabilities as “skills needed to transmit information, skills and technology 
to, and receive them from, component or raw material suppliers, subcontractors, 
consultants, service firms, and technology institutions” Lall (1992, p. 168). Amann 
and Cantwell (2012) suggested that firm linkages with other firms could be in the 
form of local and international links that includes local universities, and public 
research institutes, consultants, industry associations, regulatory bodies and training 
institutions. The majority of such linkages are informal in character (Amann and 
Cantwell, 2012) and affect not only the productive efficiency of the firms but also the 
diffusion of technology through the industrial structure, which would have been 
affected by the government regulation either directly or indirectly (Hermans et al., 
2009).  
 
The discussion above shows why technological capabilities are at the center of the 
conceptual framework presented at the beginning of this chapter in Figure 4.1. In this 
regard, Lall (1992) claimed that in developing countries, the success or lack thereof 
for the development of technological capabilities is a function of the response of firms 
to the policy market and institutional framework. These capabilities are the most 
refined resources needed in the commercialization of innovations and can be used to 
build firm competitive advantages (Lall, 1992). Thus, the conceptual framework 
allows us to develop questions pertaining to the regulatory changes that influenced the 
development of firms’ technological capabilities.   
4.1.2 Industrial Capability and Affordability 
Industrial capabilities are strongly related to the affordability of healthcare 
technologies (as shown in Figure 4.1). The medical device industry is highly 
competitive, and cost-effectiveness is one of the priorities of any organization 
engaged in the manufacturing of medical devices. However, there is a paradox with 
regard to affordability. The medical device industries have to ensure the highest 
standards of quality for their services and products, irrespective of affordability of the 
healthcare technologies. Such standards are mandatory for regulatory compliance 
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(Spiegelberg et al., 2003). The products and services developed should guarantee 
appropriate quality assurance to the clients. At the same time, medical device 
industries should prioritize cost-effective processes and discourage unnecessary 
expenditure in building industrial capabilities. As illustrated in Figure 4.1, the process 
of change and transformation allows questions to be developed that probe whether or 
not affected capabilities, ultimately influenced affordability of healthcare 
technologies. 
4.2 Evolutionary Theory: Principal Characteristics and Applications to Medical 
Device Sector 
According to Malerba and Mani (2009, p.5) “The notion of sectoral systems has  
evolutionary theory and the innovation systems approach as building blocks”. 
Evolutionary theory places a key emphasis on dynamics, processes, and 
transformations at the centre of the analysis (Malerba and Mani, 2009). The purpose 
of using evolutionary theory is “to explain the movement of something over time, or 
to explain why that something is what it is at a moment in time in terms of how it got 
there; that is the analysis is expressly dynamic” (Dosi and Nelson, 1994, p.154).  
 
In this study evolutionary theory is used to explain the changes of medical device 
regulations over time. The behavioural foundation of evolutionary theory rests on 
learning processes involving adaption and new discoveries (Dosi and Nelson, 1994). 
Knowledge produced through learning by interaction is conveyed to the key elements 
in the change process that takes place within economic systems (Hodgson, 1993, 
Metcalfe, 1998, Saviotti and Metcalfe, 1991). Evolutionary theories surfaced in 
reaction to the rather static neo-classical economic theories, which simplify the 
characterization of economic processes, firms and the way these firms use knowledge 
(Duysters, 1995).  
 
Some scholars have suggested innovation can be understood as an evolutionary 
process, however the evolution in innovation is a relatively new economic approach 
that was roughly modelled on Darwinian concepts in biology with regard to variation 
and selection (Dosi and Nelson, 1994, Nelson and Winter, 2009). Some might not 
accept the correspondence to evolution in a biological sense, but the evolutionary 
perspective aligns well with a systemic view of an industry (Malerba and Mani, 
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2009). All the developments and their outcomes in medical devices sector are 
considered as interconnected, and the outcomes act as inputs to the ongoing 
evolutionary process. Within the SSI, the evolutionary theory is related to the 
theoretical concept of change and transformation in sectors. 
4.2.1 Process of Change and Transformation Concept 
A sectoral system undergoes processes of change and transformation through the 
coevolution of its various elements (Malerba, 2002).  The concept may be used “to 
analyze sectors in several aspects, namely for better understanding, dynamics and 
transformation of sectors, for the identification of factors affecting performance and 
competitiveness of firms and for the development of new public policy proposals” 
(Intarakumnerd and Fujita, 2009, p.207). Some scholars have discussed these 
processes at the general level by focusing on the interaction between technology, 
industrial structure, institutions and demand (Metcalfe, 1998, Nelson, 2006). The 
direction and the pace of evolution depend very much on existing absorptive 
capabilities of agents, strength of their linkages and their process of collective 
learning to withstand the threats and exploit the opportunities (Malerba and Mani, 
2009).  
In this study the main elements to be interrogated using the change and transformation 
concept as indicated in section 4.1.2 are; industrial capabilities and affordability of 
healthcare technologies. Often co-evolution is related to path dependent processes, 
which brings changes among different components within a system (Arthur, 1989, 
David, 1985). It is anticipated in this study that within the medical device sector 
changes come about through co-evolution of the various elements in the system, and 
primarily as a result of regulation. 
4.3 National Innovation Systems (NIS)  
The concept of Sectoral Systems of Innovation (SSI) followed, to some extent, the 
innovation system approach that was articulated initially at the national level, namely 
the National Innovation Systems (NIS). In the NIS framework, the nation component 
is presented from different aspects by various contributing authors. Some researchers 
stress the importance of national public policy and the structure of national production 
systems as influential factors in innovation (Edquist, 2005, Lundvall, 2010). Johnson 
(1992) discusses the dependence of innovative capabilities on interactive learning and 
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communication, which are in turn dependent on geographic and cultural proximity. In 
taking a NIS analytical approach to the examination of the medical devices sector, this 
study requires an investigation of the organisations, or formal structures that are 
involved in innovation in this national sector. 
 
The limitations in the NIS framework are perceived as being a failure to take into 
account the supply side or the demands of consumers, and the relevance of the nation 
state in an age where science and technology production is becoming increasingly 
globalised (Senker et al., 1999). Due to these limitations and also the fact that NIS 
literature presents less of a formal theory, but more a conceptual framework for 
analysing country specific factors at the macro-level. It considers in detail the 
concepts of innovation, learning, system and nation. This research will therefore, 
integrate co-existing NIS not only at the same but also across different analytical 
levels. However the perspective most applicable to the medical device sector is the 
sectoral perspective, therefore, the main approach of this study follows the conceptual 
framework of Malerba’s Sectoral System of Innovation and Production (Malerba and 
Mani, 2009).  
4.4 Sectoral Systems of Innovation (SSI) 
The Sectoral Systems of Innovation (SSI) is a framework that “considers a wide range 
of factors that affect innovation and production in a sector. It places firms and the 
related capabilities and learning processes as the major drivers of innovation and 
production” (Malerba and Mani, 2009, p.3). At the same time the framework pays 
central attention to other relevant factors such as the variety of actors, networks, 
demand and institutions (Malerba and Mani, 2009). In this study, regulatory changes 
in the medical device sector, both intended and unintended are considered as factors 
that affect the ability to manufacture and supply affordable healthcare technologies, 
thus a suitable example for analysis in the framework of a SSI. The approach of SSI 
has a dynamic perspective and takes a process view in a co-evolutionary setting 
(Malerba and Mani, 2009). This study takes an evolutionary perspective, therefore the 
concept of SSI is considered an appropriate framework.  
 
Breschi and Malerba (1997, p.131) first introduced the SSI and defined the approach 
as “…a system (group) of firms active in developing and making a sector’s products 
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and in generating and utilising a sector’s technologies; such a system of firms is 
related in two different ways: through processes of interaction and cooperation in 
artefact-technology development and through processes of competition and selection 
in innovative and market activities”. Another definition was later provided by 
Malerba as a “…set of new and established products for specific uses and the set of 
agents carrying out market and non-market interactions for the creation, production 
and sale of those products” (Malerba, 2002, p.250).   
 
The SSI builds on five pillars as shown in Figures 4.1 and 4.3, which are: knowledge 
and technologies, actors (i.e. firms and other organizations) and networks, as well as 
institutions (e.g. standards, laws, rules and regulations) (Malerba, 2002, Malerba and 
Mani, 2009, Malerba and Orsenigo, 1999). Thus, in order to understand the dynamics 
and the innovation processes of a given sector, due consideration to these key 
elements should be given. According to SSI thinking, successful new technologies 
emerge from a favourable combination of all of these factors. 
 
The literature on SSI strongly emphasizes differences in the knowledge base, the 
heterogeneity of agents, and the variety of organizations involved in sectoral 
innovation systems (Castellacci, 2008). This focus on specific sectoral characteristics 
leads scholars to suggest that sectoral innovation systems are characterized by the 
interactions between agents and institutions at various geographical levels (Carlsson 
et al., 2002, Malerba, 2004).  
4.5 Sectoral Systems of Innovation Building Blocks 
Whilst the NIS fails to consider industrial factors in its conceptual framework, the SSI 
concept allows mapping out of actors and innovation capabilities at the industry level 
(Malerba and Mani, 2009). As previously mentioned, the notion of sectoral systems 
has the evolutionary theory and innovation systems approach as building blocks. This 
study seeks to examine three main elements within the medical device sector, which 
are the regulatory changes (content), the drivers of regulatory change and the impact 
of regulatory change on industrial capability to develop affordable health technologies 
for the local population. Using building blocks of SSI initially presented in Figure 4.1, 
the three complex phenomena under examination are mapped accordingly as shown in 
Figure 4.3 below and is followed by an explanation of each building block 
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Figure 4.3: Malerba and Mani (2009)’s building blocks of sectoral systems of 
innovation. Author’s additions in red. 
4.5.1 Knowledge and Technologies in SSI  
The evolutionary theory places major emphasis on dynamics, which in general means 
constant change. The same holds for the SSI technology building block.  The history 
of technology is contextual to the history of industry structure associated with that 
technology (Dosi, 1982). Technologies change over time and affect an organization’s 
learning and production processes (Patel and Pavitt, 1997). Technologies tend to 
increase (rather than decrease) specialization and complexity in the organization 
(Pavitt, 1998). Technologies come in different forms (Granstrand and Sjölander, 
1990).  Dosi (1982, p. 152) defined technology in a broader sense as “a set of pieces 
of knowledge, both directly “practical” (related to concrete problems and devices) and 
“theoretical” (but practically applicable although not necessarily already applied), 
know-how, methods, procedures, experience of successes and failures and also, of 
course, physical devices and equipment’.  
 
The medical devices sector is a high technology multi-disciplinary sector whose key 
components are medicine, engineering and information technologies. It is in close 
relation with pharmacy and has been reported to converge with pharmacy as well. 
This study aims to put forward the main building blocks of the medical devices sector 
in the UK and SA. While doing so, pharmaceuticals are taken as a reference point at 
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times since medical devices and pharmaceuticals are two relevant components of a 
healthcare supply and pharmaceuticals are subject to more variety and number of 
studies than medical devices. 
 
The mechanisms of learning are at the heart of the evolution-based SSI approach. In 
this regard, Lundvall (1992) suggests that the most important resource in the modern 
economy is knowledge and, accordingly, the most important process is learning. 
Malerba and Mani (2009, p.10) state that ‘knowledge affects the types of learning 
processes and the relevant capabilities that firms have in order to be competitive and 
innovate’. Knowledge, especially technological knowledge, involves varying degrees 
of complexity, complementarity and independence, and differs in terms of its source, 
domains and its application (Cowan et al., 2000, Malerba and Adams, 2014). In terms 
of learning, firms accumulate knowledge through internal processes as well as 
through processes that involve interaction with external actors that have varied 
knowledge and capabilities (Malerba and Adams, 2014). Capabilities refer to the 
ability to absorb, develop, and integrate tacit and codified knowledge and to use it for 
specific functions, application and technological and productive transformations (Dosi 
et al., 2000). The analytic framework in this study is underpinned by the notion of 
technological capabilities as shown in Figure 4.1, thus the SSI knowledge base 
building block will be used to help unpack the complexities related to industry 
capabilities such as technology transfer and domestic independent R&D. 
4.5.2 Regulation as a Defining Institutional Element of the SSI  
Institutions are the rules of the game, they not only shape the interactions of actors, 
but they are also shaped by the interactions and activities of actors (Malerba, 2004, 
Fagerberg and Godinho, 2005). This view is based on evolutionary theory which 
emphasize that a wide range of institutions (infrastructure, regulation) are shown to be 
co-evolving with technology (Nelson, 1995). Regulation is viewed in this study as a 
dominant feature of the institutional environment. These institutions affect the actions 
of sector participants (Malerba, 2005).  
 
As shown in Figure 4.1, regulatory regime is not static, but changes over time and is 
the product of a long-term process of regulatory decision-making (Kramer et al., 
2012a). Because of regulatory change, access to the market becomes more complex 
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and burdensome for medical devices manufacturers (Eisenberg, 2012, Kaplan et al., 
2004). However, inefficiency of regulatory change is not always a consequence of the 
policies design; it can arise from their inadequate implementation (Von Tunzelmann, 
2003). It is with this thought in mind that this study focuses on further research by 
asking the question what is the impact of regulatory changes on industry’s ability to 
manufacture and supply affordable healthcare technologies. 
4.5.3 Actors and Networks in SSI 
A sector is composed of heterogeneous agents ranging from individuals to 
organizations (Malerba 2004). Individuals include: consumers, entrepreneurs, and 
scientists influencing the innovation process of the sector. Organizations include firms 
and non-firm organizations too, such as university, financial institutions, government 
agencies, trade unions, local authorities and technical associations. Firms are the key 
actors of SSI, they play a big role in the innovation and production processes, in the 
sale of products, the generation, adoption and use of technologies. The evolutionary 
perspective considers that firms evolve over time when they attempt to adapt 
themselves to their regulatory environment (Malerba and Mani, 2009). It is 
anticipated in this study that the adaptation process has implications on activities 
undertaken by firms in the production of affordable new healthcare technologies as 
indicated in Figure 4.1. The actors specifically analysed in this study are firms 
operating in the medical device sector and regulators in the UK and SA. 
 
In terms of networks, the variety of links and connections among agents greatly 
affects the dynamics of sectoral systems (Malerba and Adams, 2014). In 
manufacturing firms, it is important for R&D departments to be connected to 
production (Pavitt, 1994). In cases where knowledge is not produced in R&D 
departments but elsewhere, network connections between actors (individuals and 
organizations) are important connections, which can exist along supply, production 
and distribution channels as well (Bell and Pavitt, 1995, Sutton and Barto, 1998).  
 
In examining the medical device sector using the help of the SSI framework, its 
theoretical bases and its building blocks, it is anticipated that the study will be able to 
identify in detail factors such as knowledge base underpinning regulation, innovative 
and production activities in the medical device sector. 
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4.6 Institutional theory  
Institutional theory has traditionally been concerned with how organizations establish 
their positions and achieve legitimacy in order to survive and make profit. This has 
been done by conforming to the rules, norms and social structure of the institutional 
environment (Meyer et al., 1991, Schot and Geels, 2007). The institutional 
environment is set up of institutions, a term that refers to the regulatory, social and 
cultural aspects that exert pressures on organizations to adapt to the surrounding 
environment. These aspects define what is considered appropriate behavior and 
therefore exert conforming pressures on organizations not to act in an unacceptable 
manner (DiMaggio and Powell, 1991). Scott (2005) summarized the pressures of the 
institutional environment first identified decades ago into three pillars. These are 
regulative, normative and cognitive pillars.  
 
The regulative pillar guides organizations behavior by governmental legislation, 
industry agreements and standards for example. The normative pillar guides 
organizations in interaction with other actors by defining what is expected and 
appropriate in different situations, such as social or commercial situations. Values and 
norms are central to the second pillar, establishing the softer rules that organizations 
conform. The last and third pillar is derived from social behavior at a more individual 
level, such as cultural differences and language. This cognitive pillar is important 
because it highlights the taken-for-granted and preconscious behavior present in the 
institutional environment that defines the right thing to do and is important for new 
actors to understand. These three pillars may resemble each other and often reinforce 
one another in a particular institutional environment (Scott, 2005). The importance of 
these pillars is significant because if a company fails to understand any of them the 
company can risk losing legitimacy (Kostova and Zaheer, 1999).  
 
Organizational legitimacy is defined by Suchman (1995) as “a generalized perception 
or assumption that the actions of an entity are desirable, proper, or appropriate with 
some socially constructed system of norms, values, beliefs and definitions”. 
Therefore, in order to be successful, the firm needs to fit in with different institutions 
(authorities, potential business partners, customers or governments) that defines the 
normative, cognitive and regulative rules (Kostova and Zaheer, 1999). If the firm 
breaks the rules and thus do not obtain adequate legitimacy at any market, it can 
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hinder company survival.  
Institutional theory is a dominant theory that “has been widely used to analyse and 
explain corporate responses to environmental and social issues” (Hahn et al., 2010, p. 
221). Institutional theory not only concerns how organizations are influenced by 
external pressures, but also describes how organizations influence others (DiMaggio 
and Powell, 1983). With the guidance of this theory as presented in the conceptual 
framework in Figure 4.1, it is believed that this study will be able to unpack and 
further understand the effects of regulatory change on organizations that are seeking 
to establish their market positions and achieve legitimacy in order to survive. 
4.7 Regulation and Policy Instrument 
Enabling policies are likely to have a more rapid impact and are less expensive to 
monitor and enforce. The third research objective of this thesis is to investigate the 
“effects” of medical device regulatory changes on industry capabilities and 
development of affordable medical devices in the UK and SA. The intended outcomes 
therefore should be evidence based. To unpack this research objective, a regulation 
and policy instrument that reflects perspectives from company managers in 
responding to regulatory initiatives and emphasizing on the effectiveness and 
efficiency of regulatory instruments will be adopted (see Figure 4.1). Chataway et al. 
(2006) proposed this instrument by categorizing policies and regulations according to 
whether they are perceived as enabling or constraining by industry managers or 
whether they were seen as indiscriminate or as discriminating among products.  
 
On the one hand, enabling or constraining regulatory policies can have a major impact 
on their effectiveness and on the cost of implementation. On the other hand, 
indiscriminate policies are usually much less effective than intended, or can even have 
negative, counter-intuitive effects on the regulatory target (Chataway et al., 2006). 
Enabling regulation serves both as the legislative mandate for the competent 
authorities to act, and as a starting point for these regulators’ discretion and oversight. 
The enabling content will allow for the control and the evaluation of the performance 
of the regulation. The latter can only be carried out where a well-defined and focused 
set of objectives in the founding regulation exits (Frank, 2003). Good governance is 
most likely to be achieved by creating a policy and regulatory environment that is 
enabling in the desired direction, rather than being constraining and restrictive, and 
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also that discriminates among products on the basis of the most relevant criteria 
(Chataway et al., 2006). 
4.8 Conclusion 
This chapter has reviewed theories, concepts, and research studies regarding medical 
device regulation and industrial capabilities. The Sectoral Systems of Innovation 
(SSI) approach as a theoretical framework has been emphasized and will be employed 
to analyze the influence of regulatory changes on industrial capabilities. The study of 
regulatory reforms is a study of a change process. Generally, the SSI, anchored in 
evolutionary theory, has a dynamic perspective and takes a process view in a co-
evolutionary setting (Malerba and Mani, 2009), therefore the concept of SSI is 
considered as an appropriate framework. Evolutionary theory is used to explain the 
changes of medical device regulation over time. The behavioural foundation of the 
evolutionary theory rest on learning processes involving adaption and new discoveries 
(Dosi and Nelson, 1994). In the evolutionary view, technological development and 
innovation play an important role in the sense that innovation brings about the 
changes in the system and influences the selection process.  
 
 The analytic framework in this research is underpinned by the notion of technology 
capabilities. As Dosi et al. (2000) point out that a firm can only successfully develop 
if it comprehensively utilize its present capabilities. Essentially, the effects of 
regulation on firm level technological capabilities will be examined in the rest of the 
chapters in this study using Lall (1992)’s functions model, which is made up of  
"investment", "production" and "linkage" capabilities.  
 
As a methodological and empirical contribution, this study has used Chataway et al. 
(2006) policy and regulatory instrument empirically, in a detailed way. It was 
previously used only in a generic way. We have been able to show its utility in the 
analysis of different types of firm capabilities in a specific way. The next chapter 
presents the scope of the research, and details how the research was conducted. 
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CHAPTER FIVE 
THE STUDY RESEARCH METHODOLODY 
----------------------------------------------------------------------------------------------------- 
5.0 Introduction 
The previous chapter presented the theoretical framework of this study. This chapter 
presents the scope of the research, and details how the research was conducted. It will 
first present the philosophical position of this study and methodological issues leading 
to the choice of methodology. The research strategy then explains the reasons for 
using the case study approach and discusses key characteristics of case study quality. 
Case study design is explained, consisting of the importance of context, the unit of 
analysis, and a sample selection of the firms, as well as the criteria and process. Data 
collection methods and data analysis strategy employed are also presented. 
5.1 Research Philosophy 
The research questions in this study focus on how medical device regulations have 
evolved, the impact of changes on industry capabilities and contribution to affordable 
healthcare technologies. Therefore the underlying approach to the research strategy 
and research design is based on the regulatory realities in terms of knowledge, 
technologies, institutions, actors, networks, process of change and transformation 
within the medical sector (Malerba and Mani, 2009). A research philosophy is a belief 
about how data about a phenomenon is gathered, analysed and used. There are two 
main research philosophies commonly used in western traditional studies namely the 
positivist and interpretivist paradigms (Galliers, 1991). There is also a philosophical 
position called ‘‘Critical realist’’, formulated by Bhaskar (1975) and extended by a 
number of authors including (Archer, 1995, Collier, 1994, Danermark et al., 2001, 
Lawson, 1996, Layder, 1990, Outhwaite, 1987, Sayer, 1992).  
Positivism is largely concerned with the testing, confirmation and falsification, and 
predictive ability of generalizable theories about an objective, readily apprehended 
reality (Orlikowski and Baroudi, 1991). The positivist position was considered as a 
possible option, but not used for this study because the position adopts a hypothetic-
deductive approach (Hempel, 1965), where hypothesis are tested (mainly 
quantitatively) in line with Popper’s principle of falsification (Grennes, 2001). This 
study however does not intend to formulate a hypothesis. Interpretivism on the other 
hand focuses on understanding the subjective meanings that participants assign to a 
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given phenomenon within a specific, unique context (Orlikowski and Baroudi, 1991). 
The interpretivist position will also not be used for this study for two reasons; firstly, 
the position adopts a relativist stance ‘‘such that diverse meanings are assumed to 
exist and to influence how people understand and respond to the objective 
world’’(Gephart, 2004, p.456). Secondly, interpretivists aim to ‘‘interpret the 
meanings and actions of actors according to their own subjective frame of reference’’ 
(Williams, 2000, p.210). 
Critical realism is a theory-driven approach focussed on understanding the mechanism 
of what works for whom in what circumstances and how structures worked or did not 
work in their contextual setting, rather than simply measuring outcomes (Pawson and 
Tilley, 1997). The nature of reality of critical realism is objective, stratified reality, 
that is, domains of the real, actual, and empirical (Bhaskar, 1975, Sayer, 1992). 
Domains of “empirical” include observable experiences. Domain of “actual” includes 
actual events, which have been generated by mechanisms. Finally, the domain of 
“real” includes the mechanisms that have generated the actual events, Figure 5.1 
illustrates the three categories in the realm of realism (Bhaskar, 1975). 
 
 
Figure 5.1: Schematic representation of three domains of critical realism 
Source: (Willcocks and Mingers, 2004) 
According to the critical realism perspective, knowledge can be required of that 
reality through abduction mechanisms (Sayer, 1992). Critical realism acknowledges 
the role of subjective knowledge of actors in a given situation as well as the existence 
of independent structures that constrain and enable these actors to pursue certain 
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actions in a particular setting (Wynn and Williams, 2012). 
The philosophical position of this study is critical realism. The basis for the choice for 
this approach is that this philosophical position provides more detailed explanations 
of a given set of phenomena or events in terms of both the actors’ interpretations and 
the structures and mechanisms that interact to produce the outcomes in question 
(Wynn and Williams, 2012). This study proposed not only to examine events 
(regulatory changes and impacts) in the empirical domain, but also aims to understand 
the generative mechanisms in the real domain leading to the event (drivers). Given the 
epistemological principles of critical realism, Easton (2010, p.123) states that “the 
research questions could be of the form ‘What caused the events associated with the 
phenomenon to occur?’” By asking about the causes of specific events, we are 
targeting the how question associated with explanatory case research (Yin, 2003). A 
critical realist philosophy provides an appropriate framework to investigate the impact 
of evolving medical device regulation on industrial capability to develop affordable 
healthcare technologies and will guide the development of the research strategy.  
5.1.1 Research Strategy 
Having adopted critical realism as the philosophical position of this research, and in 
order to provide some valid and reliable scientific claims from the research process, a 
concurrent mixed-methods data collection and analysis approaches was used 
(Bryman, 2007). Mixed methods, in which quantitative and qualitative methods are 
combined, are increasingly recognized as valuable, because they can capitalize on the 
respective strengths of each approach (Jick, 1979, Tashakkori and Teddlie, 2010). 
Exposure to a broader range of perspectives and experiences can in turn assist with 
the formulation of explanation (McEvoy and Richards, 2006, Borkan, 2004). The 
combination of qualitative and quantitative methods enables research findings, to be 
further reinforced (McEvoy and Richards, 2006). 
5.2 Case Study Research Methodology 
This study consists of three case studies of regulatory changes (two of them set in the 
UK and one in SA) and uses a variety of methods to generate data.  A case study 
methodology is defined as an intensive investigation of a contemporary phenomenon 
within its real-life context, and where the boundaries between phenomenon and the 
context are not clearly evident (Yin, 2009, Benbasat et al., 1987). Cases can include 
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studies of decisions, individuals, organisations, processes, programs, neighbourhoods, 
institutions and events (Yin, 2003). Case studies are also the preferred research 
strategy when researching a topic on which very little is known (Bengtsson et al., 
1997, Schwandt, 1997). The approach is based on compiling multiple sources of 
evidence to examine; the relationships, complex links and working procedures that 
requires continuous interaction between the research questions and the data being 
collected (Yin, 2013). Furthermore, this study aims to trace the regulatory changes 
and the premarket entry activities of the medical device firms over time, and thereby 
understand the connection between them. Case study research is an ideal research tool 
for processual studies (Langley, 1999, Pettigrew, 2012) as it can open up the 
processes that lead to individual and organized actions (Doz, 2011), and is able to 
interpret the complexity of context (Birkinshaw et al., 2011).  
 
There are some criticisms made of case study research methods due to “the problem 
of relevance of other cases, sometimes expressed in other traditions as 
generalizability” (Gerrish and Lacey, 2006, p.303). In other words, critics of case 
study methods believe that the findings cannot be generalized to similar populations 
especially when they are single case studies or if the sample sizes are considered 
small (Kader, 2006). However, Eisenhardt (1989) indicates that using comparison of 
the emergent concepts or theory with existing literature can enhance generalizability 
of multiple-case studies. In short, the use of theory, in conducting a multi-case study, 
not only supports the appropriate research design and data collection, but also 
becomes the main vehicle for generalizing the findings of the case study (Yin, 2003). 
Furthermore, when conducting multiple-case, the findings are generalized from one 
case to the next on the basis of a match by means of conceptual or theoretical grounds 
for the underlying theory or for the research setting/context not on representative 
grounds and not to a large universe (Miles and Huberman, 1994). 
 
This study is an empirical inquiry of the evolution of medical device regulation and its 
impact on industrial capabilities and development of affordable healthcare 
technologies. Very little is known about this topic, especially in Africa, hence 
necessitating the need for a case study approach. In addition, historical, political and 
cultural contexts in which the cases are situated present many variables that affect the 
development of affordable devices and their commercialization. A number of similar 
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studies reviewed adopted the case study approach, for example, studies such as those; 
on national health biotechnology innovation systems (Chataway et al., 2007, 
Mugwagwa, 2010, Smith, 2005); on regulatory and industrial policy hurdles for 
medical device industry (Davis and Abraham, 2011, Ensor and Weinzierl, 2007, 
Heneghan et al., 2011, Rugera et al., 2014, Gollaher and Goodall, 2011) and on health 
social technologies (Chataway et al., 2010). 
5.2.1 Selection of Regulatory Change Cases  
It is well recognized that proper case selection is imperative for understanding the 
phenomenon under study (Yin, 2003). In the context of multiple case study research, 
the chosen cases need to be similar in some ways, be relevant, provide sufficient 
diversity across cases, and present good opportunities to learn about complexity and 
contexts (Yin, 2009). In this study, the selection criteria for the three regulatory 
change cases were established based on theoretical considerations, factors of the 
research design and the research question. Criteria included the presence of significant 
perceived impact, indications of differences in impact between firms, and the 
availability of empirical data relevant to the study. In particular, the two regulatory 
change cases in the UK were highly significant for the medical device industry; and, 
each regulatory change was different: one was a major extension of regulatory reach 
into medical device software; the other a major toughening of regulatory compliance 
and therefore a strong strengthening of regulatory processes. The selection criterion 
for the SA radiation emitting devices regulatory change was based on the fact that this 
was the only type of formal medical devices regulation in the country that had been 
implemented long enough to provide empirical data relevant to this study. A better 
understanding of the impact of the selected regulatory changes will reveal differences 
in the firms’ responses and thereby uncover key dynamics related to firm strategy, 
innovation and operations. The three selected regulatory change cases were informed 
by a group of firms whose activities were related to the development of healthcare 
technologies. (In-depth case study details of the three regulatory changes are 
presented in chapter six).   
5.2.2 Criteria for Selecting Medical Device Firms in the United Kingdom 
The study adopted purposive sampling method in selecting suitable manufacturing 
firms. Purposive sampling, also called judgement sampling, is a non-probability 
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sampling technique, which involves selecting study participants deliberately because 
of some qualities/characteristics they possess (Tongco, 2007). The first criterion set to 
identify suitable UK-based firms for this study was that the firm should fall under 
medical device software segment. The study was interested in eliciting the most 
important challenges with respect to developing embedded or standalone software for 
medical purpose, understanding the extent to which the regulations that have been 
developed, recognized and have affected the industry’s capabilities. Another reason 
for selecting firms involved in the development of medical device software was that, 
today, many medical devices cannot fulfill their intended use without the software 
embedded within them, which implements a variety of functions and features. 
Surveys of trends in the medical device industry indicate that software is one of the 
most decisive factors for producing innovative products with new capabilities, and 
predict that the importance of software will only further increase in the future (Denger 
et al., 2007). 
 
A second criterion was set based on the longevity of the firm’s operations in the 
medical device industry. The firm should have been registered and in operation in the 
UK since the publication of first major regulatory changes in 2007. Potentially, the 
longer these firms were in the UK medical device industry, the more changes in 
operations they may have encountered, which may have been made in response to the 
change in the external regulatory environment. The long establishment also indicates 
firm learning to adjust quickly to regulatory changes so that they can continue 
operating.  
 
The third requirement was to pursue firms that had available public company accounts 
so that annual reports and other public records could be examined to make sure these 
UK firms have operated for more than ten years18 and establish whether regulatory 
changes had influenced firm’ technological capabilities such as investment and 
production capabilities. A sample of 16 firms selected in the UK is presented in the 
Table 5.1 below. 
 
 
18 Ten years is an arbitrary figure. However, based on UK Company house reports, several medical 
device firms that have been in operation for more than ten years are significantly more profitable than 
those counterparts with less than ten years’ experience. 
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Table 5.1: United Kingdom firm selections (source: author calculations, company 
website and annual reports) 
Firm 
Name 
Respondent 
Position 
Firm 
Background 
Device Segment/ 
Key Product(s) 
Alpha 
Ltd  
 
Quality 
Manager  
 
-Year established: 1975 
-Size: SME 
-Employee size band: 20 - 49 
-2017 Turnover: £1.3 million 
-Exports to over 28 countries 
-Approved supplier to a wide range of 
customers, including the UK NHS and private 
hospitals 
-Embedded software 
devices 
-Oxygen-therapy products 
-Electrical magnetic 
products. 
Bravo 
Ltd 
 
Medical 
Devices 
Principal 
Consultant 
 
Year established: 2006 
Size: SME 
Employee size band: 0 - 4 
2017 Turnover: £500 000 
- Orthopaedics 
- Biosensors 
- Embedded software 
Charlie 
Medical 
 
Director of 
Regulatory 
Affairs 
 
Year established: 1978 
Size: SME 
Employee size band: 100 -249 
2017 Turnover: £17.2 million 
- Embedded software 
- Wound care products 
- Blood processing 
products 
Echo 
Ltd 
 
CEO 
 
Year established: 2007 
Size: SME 
Employee size band: 5 - 9 
Turnover: Not disclosed 
 
- Medical device software  
- Radiotherapy simulators 
- Software in radiotherapy 
liner accelerators 
- DNA specification 
technology 
Foxtrot 
Ltd 
 
Chief 
Operations 
Officer  
 
Year established: 1992 
Size: SME 
Employee size band: 50 - 99 
2016 Turnover: £5.2 million 
The firm has over 3,000 CardioQ-ODM 
systems 
Exports their product to over 40 countries 
-Cardiac flow monitoring 
devices 
- Fluid 
Management devices 
Garner 
Ltd 
 
 
 
Senior 
Quality 
Assurance 
Director  
 
Year established: 1977 
Size: SME 
Employee size band: 100 - 249 
2016 Turnover £24.4 million 
-Innovative diagnostic test 
kits 
 
Hex 
Ltd 
 
Technical 
Director  
 
Year established: 1994 
Size; SME 
Employee size band: 10 -19 
Turnover: £825 904 
Medical device software 
development 
Indigo 
Ltd 
 
Managing 
Director 
 
Year established: 2007 
Size: SME 
Employee size band: 0 - 4 
2017 Turnover: <£100 000 
-Embedded software 
-Surgical instruments 
decontamination products 
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Kilo 
Ltd 
 
Chairman 
 
Year established: 1986 
Size: SME 
Employee size band: 50 - 99 
2017 Turnover: £6 million 
-Urodynamic products 
CT3000 
Delta  
Ltd 
 
Associate 
Director 
Regulatory 
Affairs  
 
Year established: 1998 
Size: MNC 
Employee size band: 250+ 
R&D employees – 122 
Sales & marketing -113 
Administration – 48 
Manufacturing – 29 
Total employees - 312 
2016 Turnover: £1.51b 
-In-Vitro  
Diagnostic products 
-Oncology products 
- Novel technologies for 
the analysis of DNA  
- Gene sequencing 
 
JM 
Medical 
 
 
Managing 
Director 
 
Year established: 1971 
Size: MNC 
Employee size band: 250+ 
Production employees – 701 
Administration and support -110 
Sales employees – 124 
Total employees - 935 
2016 Turnover: £206.2m 
Two Nobel Price-winners in the world. 
Ranked in the third place among the medical 
device manufacturers in the world. 
-Cardiac conduit monitors 
-Diagnostic cardiology 
-Ultrasound 
-Patient monitoring 
- CT scanning 
-MRI 
Lima 
Medical 
 
Head of 
Operations  
 
Year established: 1991 
Size: MNC 
Employee size band: 250+ 
Average number of employees – 1 802 
2016 Turnover: £579m 
-Radiology 
-Radiosurgery 
-Proton therapy 
-Wound care 
Med 
Tec 
Ltd 
CEO 
 
Year established: 1986 
Size: MNC 
Employee size band: 250+ 
2017 Turnover: £408 million 
-Oncology products  
-Radiotherapy products 
-Software development 
 
Neiva 
Medical 
 
Director  
 
Year established:  
Size: MNC 
Employee size band: 250+ 
2016 Turnover: £3.78b 
-Knee and hip implants 
- Arthroscopic enabling 
technologies 
- Advanced wound care 
devices 
 
Optics 
Ltd 
 
Director  
 
Year established: 1954 
Size: MNC 
Employee size band: 250+ 
2016 Turnover: £58.1m 
-Diagnostics systems 
- Integrated analytics 
solutions technologies 
- Infusion devices and 
software 
 
As Table 5.1 shows, care was taken to study both MNCs and SMEs. The firms 
highlighted in darker shade are SMEs and the non-highlighted are MNCs. The 
rational for choosing UK-based firms for this study is because the UK represents the 
global north with sophisticated medical systems, it meets the criteria for 
appropriateness of the study as it has advanced local healthcare technological 
capability (BMI, 2016b), has a highly regulated industry structures and there has been 
a significant but complex regulatory evolution since the 1990s. The UK medical 
device industry was considered a well-developed market in a global comparison 
(Evaluate Medtech, 2017). Hence, the observation of this industry promises insights 
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that should be of relevance also for a global audience (including academic and 
practitioners alike). 
 
Given the nature of the research question, this study consisted of two kinds of 
empirical data (Chapter 7) and it was considered valuable to focus first on data from 
sixteen UK-based manufacturing firms presented in Table 5.1. The sixteen firms all 
have distinguished histories and well-known reputations for providing advanced 
healthcare technologies. The sixteen firms were selected to develop a deeper 
understanding and provide a broad scope of the effects of the two significant but 
different regulatory changes on the firm level technological capabilities. Among the 
sixteen firms, three were found to have appropriate data to support their inclusion for 
detailed firm specific empirical analysis. Therefore, the second empirical data 
involved a more comprehensive narrative of these three purposefully selected UK-
based firms.  
5.2.3 Criteria for Selecting Medical Device Firms in South Africa 
Some criteria were set to identify suitable SA-based firms for this study. First, the 
firm should have been involved in the manufacture or supply of electromagnetic 
medical devices or radiation emitting devices. The reason was that this is the only 
segment that has been regulated for a longer period through the Hazardous Substances 
Act, No. 15 of 1973 (DoH South Africa, 2014). Devices for use in radiology usually 
are not targeted at individual patients but at hospitals and doctors’ practices. They 
include ultrasound and microwave imaging and treatment devices, and magnetic 
resonance imaging equipment (MRI). The second criterion was simply based on the 
longevity of the firm’s operations in the SA medical device industry. Company 
selection was made with these key criteria but the chosen firms were otherwise 
diverse with respect to geography, core technological focus area(s), and capabilities 
not directly related to innovation, ownership structures, history, age, local context and 
so on. The approach taken to select the final firms was essentially based on the 
approach proposed by Yin (1994), which involves screening “candidate” firms and 
choosing the best among them. 
 
To illustrate more specifically, my approach for the SA firms was to first make a 
database of all companies that I could find, which met the two key conditions (this 
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resulted in a list of over 50 firms). I then looked for and recorded any information that 
indicated whether a given firm undertook innovative activities. The latter was 
complemented by consultation with individuals who were knowledgeable with 
domestic medical device firms. These efforts helped me to identify an initial 12 
companies, which were then instrumental in identifying more firms along with other 
local informants that I met as I travelled through SA. A sample of 16 firms selected in 
SA firms is presented in the Table 5.2 below. 
 
Table 5.2: South Africa firm selections (source: author calculations, company website 
and annual reports) 
Firm 
Name 
Respondent 
Position 
Firm 
Background 
Device Segment/ 
Key Product(s) 
Southmed 
(Pty) Ltd 
Managing 
Director 
 
Year established: 1987 
Size: SME 
Employee size band: 100 -
249 
 
-Electro-medical devices and medical 
consumables 
- Ultrasound imaging 
- Radiology devices 
DK med 
Supplies 
CEO 
 
Year established: 2007 
Size: SME 
Employee size band: 0 - 4 
- X-RAY Imaging Systems 
 
BV Medical 
 
Projects 
Manager 
  
Year established: 1994 
Size; SME 
Employee size band: 10 -19 
Turnover: £825 904 
Medical imaging:  
-X-ray Machines 
-CR - Computed Radiography 
-DR - Digital Radiography 
-RIS - Radiology Information 
 
SISA 
Manufacturing 
company 
Regulatory 
Affairs and 
Quality Officer  
 
Year established: 1989 
Size: SME 
Employee size band:  20 - 
49 
 
- Diagnostic equipment: 
-X-ray Machines 
-Ultrasound medical products 
AA Biomedical 
(Pty) Ltd 
Reimbursement 
and Regulatory 
Affairs 
Manager  
 
Year established: 1998 
Size: SME 
Employee size band: 50 - 
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- Cardiac diagnosis and Cardiac 
Rhythm Management product range 
- Electrophysiology 
TM AFRICA 
(Pty) Ltd 
 
Director 
 
Year established: 2001  
Size: SME 
Employee size band: 20 - 
49 
- Radiology equipment 
- Magnetic Resonance Imaging (MRI) 
UMC (Pvt) Ltd  Managing 
Director  
 
Year established: 1991 
Size: SME 
Employee size band: 20 - 
49 
-Radiology 
-Radiosurgery 
-Wound care 
Gabler Medical CEO 
 
Year established: 1963 
Size: MNC 
Employee size band: 250+ 
- Electric and pipeline suction 
equipment 
- Flow meters 
CR  
Medical 
CEO 
 
Year established: 1960 
Size: MNC 
Employee size band: 250+ 
- Medical imaging equipment for 
breast cancer diagnosis 
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PH 
Healthcare 
Senior Quality 
& Regulatory 
Systems 
Manager  
Year established: 1919 
Size: MNC 
Employee size band: 250+ 
- Radiology products 
 
SSA (Pty) 
Ltd  
 
Strategic & 
Key account 
Manager  
Year established: 1864 
Size: MNC 
Employee size band: 250+ 
- X-RAY Imaging Systems  
Northmed 
Healthcare  
Projects 
Manager 
Year established: late 1892 
Size: MNC 
Employee size band: 250+ 
 
- Embedded software 
- Wound care products 
- Blood processing products 
Medtech 
Solutions 
 
Director 
 
Year established: 1987 
Size: MNC 
Employee size band: 250+ 
 
- Electronic implantable hearing aids 
- X-ray units 
- X-ray machines  
BS 
Medical 
Specialists 
Health 
Economics & 
Government 
Affairs 
Manager  
Year established: 1979 
Size: MNC 
Employee size band: 250+ 
Radiology equipment 
PE 
Medical 
company 
Sales Account 
Manager  
 
Year established: 1975 
Size: MNC 
Employee size band: 250+ 
- Screening and diagnostic equipment 
 
 
The rational for choosing SA-based firms for this study was because they represent 
global south countries that are less often included in comparative studies but offer 
valuable insights to the healthcare technologies that are often overlooked. In addition 
to the SA medical device industry’s suitability from a research design perspective, 
there is also a good theoretical fit. The effect of implementing new requirements in 
connection with regulatory change could be expected to evolve over long periods of 
time (Jacobides and Winter, 2010). SA has low local healthcare technological 
capability (BMI, 2016a), has less regulated industry structures and slow regulatory  
evolution over the past three decades. To isolate the effects of a regulatory change, it 
is to our advantage if the other dynamics of the SA medical device industry are slow, 
because the firms’ actions will be more visible. However, SA has a relatively large 
economy and has the largest medical device market share in Africa. The above 
combination of empirical and theoretical factors offers a solid rationale for studying 
this industry with a historical approach over a long time period (Ferraro and Gurses, 
2009). 
 
The empirical evidence from SA presented in this study (Chapter 8) also comprised of 
two kinds of empirical data. The first type of empirical evidence involved 
comparative analysis of sixteen SA manufacturing/distribution firms that supply 
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medical and dental diagnostics as presented in Table 5.2. The second type of 
empirical evidence involved a more comprehensive narrative of three purposefully 
selected SA-based firms. Criteria for selection of the three firms were based on 
availability and accessibility of the firm’s empirical data pertinent to the study. 
5.2.4 Analytical Units  
Yin (2009, p.29) suggests that analytical units are selected according to the research 
topic and can include single individuals, programs, events, decision and so on. This 
research employs evolutionary theory which takes the firm as its unit of analysis, with 
the proposition that organizational capabilities are central to an understanding of firms 
and industries (Malerba and Mani, 2009, Nelson and Winter, 1982). Building on that 
the analytical units to be used in this research are regulation and medical devices 
firms. Among the possible analytical units, the regulatory policies are frequently 
chosen as analytical units for the comparisons with each other.  
5.3 Data Collection Methods 
It was the aim of the research that the answers to each sub-question would inform the 
overarching question at the center of this study. Accordingly, four data collection 
methods were used some of which were used in parallel to address the sub-questions. 
The methods used were in-depth interviews, focus groups, document analysis, and 
archival research.  
Interviews: The main method of collecting primary data for this study was semi-
structured in-depth interviews and was conducted mainly in the respective firms. Part 
of the objective of using interviews was to be able to access and subsequently 
understand the regulation of medical devices phenomenon through descriptions of it, 
in the participants’ own words. This format allows the respondent to identify and 
describe concerns or concepts that may not have been anticipated or considered by the 
researcher (Curry et al., 2009).  The study aimed at eliciting in-depth responses, 
personal accounts and experiences from actors in the medical device sector which 
provided insights and understanding of their identities, values, perceptions, 
experiences and the meanings they attach to regulation of medical devices and 
interviews are the best way to do this (Britten, 1995, Patton, 1999).  
  
A total of four pilot interviews guided by the broad checklist of questions were 
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conducted telephonically and face-to-face with some stakeholders in the UK and SA 
during a field study between October 2016 and May 2017. After these pilot studies, 
which helped identify, confirm and shape key issues around medical devices 
regulatory changes in the UK and SA, a total 73 defined as guided conversations or 
semi-structured were conducted (see Appendix 6 for the full list of interviews 
conducted). The interviews were conducted with a consistent line of inquiry that was 
two-fold: (1) Understanding the process of regulation and regulatory changes; (11) 
Understandings of the impact of regulatory changes. The chosen line of inquiry was to 
an extent based upon the theoretical framework in order to facilitate as easy and 
accurate analysis (Eisenhardt and Graebner, 2007). The interviews conducted with 
various stakeholder categories within the medical device sector are shown in Table 
5.3. 
 
Table 5.3: Categories of stakeholders who participated in the study 
Stakeholder category Number of 
interviews in the 
UK 
Number of 
interviews in the 
SA 
Totals 
Government/ Competent authority 1 3 4 
Regulatory agency/Notified body 4 2 6 
Academic and research institution 0 3 3 
Health facility 0 1 1 
Medical device manufacturing 19 32 51 
Industry association 1 7 8 
Totals 25 48 73 
 
As Table 5.3 shows, actors such as the notified bodies (that are involved in regulatory 
enforcement), national competent authorities and industry associations were also 
included. Although the focus was on medical device firms’ perceptions (identified as 
the primary ‘regulatees’), the study also wanted to know whether these were different 
from the views of other stakeholders. Most of the interviews took place in natural 
setting of the interviewees. Visits were made to the working sites (i.e. business 
premises or hospitals) of the participants to conduct the research. This enabled the 
development a level of detail about the individual or place in actual experiences of the 
participants. In some cases, the participants did provide medical devices company 
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records such as manual books and regulatory compliance documents to support the 
evidence of their innovative solution and regulatory challenges.  
 
The duration of interviews and the number of questions varied among different 
participants and was determined by knowledge and willingness of participants to 
discuss issues. On average most interviews lasted for fifty minutes. All the interviews 
were digitally recorded and transcribed. Each interviewee was asked to suggest a 
person who may provide more information on the topic (referral sampling or 
‘snowball’ method). Interestingly, most of the respondents referred to other potential 
respondents who were previously or planned to be interviewed confirming our 
approach. When getting references for further interviews I was careful to follow 
guidelines suggested by Dexter (2006): get introductions from trusted sources and 
avoid intermediary explanation of the project to avoid bias. This continued until the 
point of theoretical saturation, whereby no new information was being obtained from 
new interviewees. The interviews assisted in constructing the narrative and building 
up the analysis of this study. The interviewing protocol can be found in Appendix 1 
and 2.  
 
Besides getting references from previous interviewees I also participated in events 
and seminars where high-level representatives of government and medical device 
industry associations spoke. For example, I facilitated a session on Regulation in the 
diagnostics sector at the Southern Africa Network for Biosciences (SANBio) Annual 
Event held in February 2017 in South Africa; virtually all medical device sector 
representatives participated.19 This provided me with valuable opportunities to make 
contacts and arrange new interviews.  
 
Focus Groups: Data collection in this study included a participant-focus group that 
was held at CSIR offices in SA. By participant-focus group, we refer to the mode in 
which the researcher was not merely a passive observer. The researcher participated 
in the SAMED/SALDA (medical device manufacturers) focus group in SA in 
 
19  Proceedings and summary report of the SANBio annual event the researcher participated and 
facilitated can be found on http://www.nepadsanbio.org/sites/default/files/2017-
05/SANBio%20Annual%20Event%202017%20-%20Proceedings.pdf 
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November 2016 (See Appendix 6). The group discussion focused on the guideline on 
essential principles of safety and performance for medical devices and IVD's, the 
regulatory requirements as well as question and answer session focusing on the 
industry’s regulatory challenges.  
 
Another focus group was conducted with three participants from the national 
medicines and healthcare products regulatory authority of Zimbabwe (MCAZ) via 
Skype to gather data from a regional point of view (See Appendix 6).  This guided 
discussions with small groups of people who share a common characteristic central to 
the regulation of medical devices proved useful as a method of collecting primary 
data (Krueger and Casey, 2000). The goal for using focus groups in this study was to 
understand differences in perspectives between different stakeholder groups or 
categories of people and uncover factors that influence regulatory changes and the 
ability to develop affordable healthcare technologies in the medical device sector. 
This approach widened the range of responses and activated forgotten details of 
individual experiences (Krueger and Casey, 2000). 
 
Document review: A wide variety of legal written materials served as a valuable 
source of data in this study. Documents included; institutional documents and 
organizational records such as clinical test records, compliance test records, R&D 
records, public medical device regulatory historical documents, legislative documents 
and approval documents. The documents were searched for and collected from the 
UK and SA’s departments of health databases (e.g. the UK MHRA and SANAS 
databases), UK and SA’s medical device industry association databases such as the 
ABHI and SAMED and also from EU commission database. The bibliography 
contains reference to each document reviewed. The study applied content analysis as 
a method to review documents. A content analysis is a strategy that generates 
inferences through objective and systematic identification of core elements of written 
communication (Holsti, 1969). 
 
Collecting archival data: Archival research was performed in this study by 
examining historical records of organizations. Historical archives are well recognized 
in the case study method in both a historical and contemporary context (Easton, 1995, 
Yin, 2003). They can enable longitudinal research to cover a considerably longer 
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period of time to observe process and change, and they can provide the generous 
descriptions that case studies require (Pettigrew, 2012).  
 
Some researchers consider archival research as a type of secondary data analysis, 
where the researcher will probably not have been involved in the data collection, but 
extracts information to answer their research questions (Bryman, 2007). Archival 
research could be considered as a continuation of the efforts of the interviewer to 
provide concrete evidence for the findings through the interview (Cassell and Symon, 
2004). It deserves mention that using secondary data in archival research could save 
time and cost during the research process (Cassell and Symon, 2004).  
 
The archival data collected in this study includes newspapers, company archives, 
public records, governmental announcements, etc. The archival data for the firms 
includes company histories, annual reports, press releases, and presentations 
throughout the years, as well as past interviews given by the executive and managers. 
These documents were obtained mainly from the firms through their corporate 
websites, and in some cases were requested directly during the interviews. In addition, 
technical and industrial journals and newspapers were scanned to identify relevant 
articles about these firms. These archival materials about the activities of the firms are 
valuable as they are rich in detail, which allows the researcher to have a better 
understanding of these past events. A weakness of historical data can be the 
difficulties of verification (Welch, 2000). As this research also includes interview data 
as well as a cross-check done whenever possible, it is therefore less of a concern. 
 
Institutional Support and Practicalities of Data Collection 
NEPAD-The Southern Africa Network for Biosciences (SANBio) and the Medical 
Imaging and Radiation Sciences Department (MIRS), University of Johannesburg in 
SA hosted the fieldwork visits (see Affiliation Letter in Appendix 7).  The researcher 
was attached to these research and academic institutions whilst undertaking data 
collection. This afforded the opportunity to present the project proposal and findings 
to personnel at NEPAD SANBio and experts in the field of medical devices. This 
methodological cross-checking is perhaps worth noting. Association with these 
institutions also facilitated gaining access to certain individuals and organizations. 
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Data collection is SA was divided into two stages. An initial visit of two and a half 
months from the beginning of October to mid-December 2016 and a second visit of 
another two and a half months from mid-February to end of April 2017. There are 
certain advantages of designing the data collection phase as two distinct parts. For 
example, the interim provided a useful breather to reflect and if required ask for any 
clarifications. The interim period was also used to collect data from the UK-based 
firms. 
5.4 Ethical Considerations  
Ethical considerations are vital in the conduct of this research as it involves collection 
of data from people and organizations. A project registration and risk checklist for the 
research detailing the methods, nature of information being sought and types of 
participants was prepared for each type of data collection activity. It also included an 
assessment of the types of issues that may arise. The project registration, risk 
checklist and participant consent form were submitted and ethics approval obtained 
from the Open University Ethics Committee for all phases of this research (see 
Appendix 3 for the research ethics approval memorandum). The necessary steps for 
ensuring anonymity and confidentiality were designed into the research schedule. 
Prior to the interviews, informed consent to participate in the interview was obtained 
from each interviewee as outlined in the ethical procedure spelt out from the Open 
University Ethics Committee. A copy of the consent form used for this study is 
provided in Appendix 4. 
5.5 Data Analysis Methods 
5.5.1 Thematic Analysis 
The nature of the findings was mostly qualitative in this research (regardless of the 
findings of archival research). There was more emphasis on opinions and perceptions, 
rather than the numerical differences between the responses from different 
respondents. The qualitative interview data was therefore analyzed thematically with 
relevance to the research questions (Gillham, 2005). Thematic analysis can be defined 
as the interpretation of qualitative data through organizing it into codes, categories 
and themes (Boyatzis, 1998). It is a method by which patterns (themes) within the 
data can be identified, analyzed and reported, allowing the researcher to both organize 
data and interpret the research topic (Braun and Clarke, 2006). Extracting and 
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analyzing emerging themes, categories and codes from the data was an ongoing 
process throughout the research.  
 
Both the UK and SA study questionnaires (see Appendix 1 and 2) were formulated 
on the basis of the research questions and also on the conceptual framework. It was 
divided into three parts. The first part was entitled background information – this was 
to elicit information about the nature and scale of operations of the company, 
regulator, industry association, notified body, consultant, etc. The second part was 
entitled understandings on regulation and regulatory changes. The aim here was to 
document what interviewees considered to be the primary norms operating within the 
regulatory space, whom did they identify as the key stakeholders and to benchmark 
what they considered to be the most important regulatory changes. The changes could 
relate to both normative as well other physical changes in the industry. In the third 
part, the interviewees were asked about their perception of the effects of regulatory 
changes on industrial capabilities and development of medical devices. 
5.5.2 Thematic Analysis: the process 
After the audio recordings were transcribed and checked, the scripts were re-read to 
gain further familiarity with the text. Coding, the process whereby all data (individual 
sentences and/or chunks of text) are assigned a descriptive label, was then conducted. 
The NVivo program was used to tabulate the transcribed data. Coding is referred to as 
“the transitional process between data collection and more extensive data analysis” 
(Saldana, 2009, p.4). In making sense of this mass of data, at the first stage key 
themes were generated, guided mainly by the research questions, the theoretical 
framework used and also by aspects that were reiterated by the interviewees. 
Thereafter, the ultimate analytical categories were selected through a process of 
iteration. The categories when seen as a set could help envelop the entire gamut of 
responses in a logically related manner that would address the research questions. The 
linkage between the analytical categories and the research questions have been further 
explained and presented in chapters 7 and 8 detailing the case study results. 
5.5.3 Data Matrices  
A data matrix is a way to present qualitative data as well as make an analysis. 
Matrices are essentially tables that consist of columns and rows representing 
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theoretical concepts and observations from research units. Data matrices were initially 
introduced by Miles and Huberman (1994) as a device to present data. Yet the 
decisions of the columns and rows need to rest on theoretical analysis of the data. 
Hence, data matrices can possess both a descriptive and an explanatory function Miles 
and Huberman (1994). Data matrices are frequently adopted by researchers 
conducting analyses on multiple units of research, e.g., firms or regulation (Nadin and 
Cassell, 2004, Averill, 2002). In this study, cross-case data was analyzed through a 
matrix containing different firm capability theoretical themes and the selected 
regulatory changes (categorized as either enabling or constraining and their sub-
categories). Levels of sub-categories are included to indicate whether the regulatory 
changes were discriminating or indiscriminate among products on the basis of 
intended target. Detailed data matrix analysis is presented in the Cross-case analysis 
Chapter 9. 
5.6 Conclusion 
This chapter has described the methodological approaches employed in obtaining and 
analyzing data for this study, including the practicalities and ethical issues faced by 
the researcher. The data collection and analysis approaches employed all reflect a 
desire to adopt a holistic approach in dealing with this complex relationship between 
firms, institutions, health technologies and regulatory changes. Following on from this 
presentation and discussion of methodological issues, the next chapter gives further 
details on the three selected regulatory change case studies. 
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CHAPTER SIX 
CASE STUDIES ON MEDICAL DEVICES REGULATORY CHANGES IN 
THE UNITED KINGDOM AND SOUTH AFRICA 
----------------------------------------------------------------------------------------------------- 
6.0. Introduction 
This chapter presents three case studies of regulatory changes that have been selected 
for this study. The research question discussed in this chapter is: What changes have 
been made to regulation of medical devices and what approaches were utilised by 
regulators to implement the changes in the UK and SA? Therefore, the aim of this 
chapter is to, first, analyze and explore the two regulatory change cases in the UK that 
were highly significant for the medical device industry. Each regulatory change was 
different: one was a major extension of regulatory reach into software; the other 
introduced unannounced audit visits therefore toughening regulatory compliance 
processes. Second, the chapter will also analyze and explore the regulatory change 
case of radiation emitting devices in SA that promoted safety in the workplace and 
prevented unnecessary exposure to radiation.  
 
As discussed in the research methodology chapter, selection criteria of these three 
regulatory changes included the presence of significant perceived impact, indications 
of differences in impact between firms, and the availability of empirical data relevant 
to the study. The dates of the regulatory changes are sufficiently far back to permit 
long-term analysis, but not so distant as to make data access difficult. These changes 
are also well suited for exploring the impact areas outlined in the theoretical chapter 
(i.e. investments, production, and linkage capabilities). As such, the case narratives 
serve as an important basis for the analyses that follows this chapter. 
6.1. Regulatory Change Case: Software as Medical Device in the UK 
Failures in medical device software in the past have resulted in severe or fatal 
consequences. Between 1985 and 1987, according to McHugh et al., (2012) four 
people died and two were left permanently disfigured by a software-controlled 
radiation therapy machine known as Therac-25. Therac-25 used software to control a 
beam spreader plate, which reduced a patient’s exposure to radiation. However, due to 
software malfunctions, the plate was not in place when required and patients received 
massive doses of radiation. This case highlighted the need for adequate safety 
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measures to protect patients and third parties i.e. clinicians, using medical devices 
controlled by software (ibid).  
A revision to the European Medical Device Directive (MDD) 2007/47/EC was 
motivated by the past software failures and the request of the member states to expand 
and cover all aspects of community regulatory framework for medical devices made 
amendments to the original directive (93/42/EEC). The revision included all areas 
relevant to medical devices including risk and quality management.  
6.1.1 New Requirements for the Development of Medical Device Software 
The MDD 2007/47/EC regulatory changes required manufacturers to provide proof of 
clinical efficacy for all devices. In addition, the amendments made it mandatory for 
all customized medical devices to undergo post-market surveillance. It was also 
required that the patient for whom the device was customized should be given 
particular information (European Commission, 2007).  
The most significant amendment within the MDD 2007/47/EC was the provision for 
standalone software to be used as an active medical device. The MDD 2007/47/EC 
Annex IX Section 1.4 states: “stand-alone software is considered to be an active 
medical device”. It defines an active medical device as “any medical device operation 
which depends on a source of electrical energy or any source of power other than that 
generated by the human body or gravity” (European Commission, 2007).  
 
The new regulatory requirements highlighted that software was to be considered as a 
medical device if its intended purpose is to be used for diagnosis, monitoring, 
treatment or alleviation (Klümper and Vollebregt, 2009). For software that qualifies 
as a medical device but is not yet CE-marked or is a new version that is not covered 
by the previous CE mark (for example, because it is an update to remedy a flaw that 
caused an incident), a manufacturer is prohibited from running that software in human 
tests outside of an approved clinical trial setting (Klümper and Vollebregt, 2009). 
 
Therefore, safeguards must be put in place to ensure that such software is safe and fit 
for purpose. To ensure this, the amendment also states: “the software must be 
validated according to the state of the art taking into account the principles of 
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development lifecycle, risk management, validation and verification20” (European 
Commission, 2007). The MDD 2007/47/EC, therefore, marks the introduction in the 
European Union of stricter rules for software used with medical devices (Klümper and 
Vollebregt, 2009).  
 
Since this requirement was introduced, software development firms must validate 
software whether integrated or standalone, regardless of device class. The “state of the 
art” medical device software processes is understood within the industry as 
developing software in accordance with the harmonised standard “International 
Electro-technical Commission (IEC) 62304” and other standards that are aligned with 
it (McCaffery et al., 2011).  
 
IEC 62304 contains a number of processes for medical device software development 
and maintenance which firms are recommended to follow in order to implement 
medical device software best practices and to streamline the process of achieving 
regulatory approval. IEC 62304 as it is a software development standard; it does not 
cover or provide full guidance on system level activities such as validation and 
release. As a result, IEC 62304 roles off the system processes to aligned standards 
such as ISO 13485 which provides the comprehensive quality management system 
framework for the design and manufacture of medical devices and ISO 14971 which 
provides fundamental guidance on a product’s intended use, determination of 
potential hazards, risk mitigation, and post marketing surveillance methods 
(McCaffery et al., 2011).   
 
To summarise, IEC 62304 is a medical device software development lifecycle process 
standard. Software developed that follows to IEC 62304 activities and tasks is 
established upon the principle that the software is developed in accordance with a 
quality management standard (e.g. ISO 13485), a risk management standard (ISO 
14971) and a product level standard (EN 60601-1) (Fiedler, 2017).  
 
20 Software verification and validation (V&V) is performed in order to ensure the quality of 
the software. Verification ensures that the software or product meets the requirements for it. 
In other words, that the software works as specified. Validation on the other hand is 
concerned with whether the software meets the customer needs and requirements. In other 
words, does the software work in its intended use.  
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The relationship between these standards and the EU medical device regulation is 
shown in table 6.1. 
Table 6.1: Applicable Directive, Standards and Technical Report for the development 
of medical device software and achieving regulatory approval. Source: (Fiedler, 2017) 
 
European Regulation Medical Device Directive 93/42/EEC  
(Amendment 2007/47/EC) 
 
Applicable Standards 
ISO 13485 – Quality Management Systems,  
IEC 62304 – Software Lifecycle Processes, 
IEC 60601-1 Medical Electrical Equipment, 
ISO 14971 – Application of Risk Management 
Technical Reports IEC TR 80002-1 
 
As Table 6.1 shows, medical device manufacturers wishing to achieve regulatory 
conformance are recommended to follow the relevant applicable standards. Evidence 
of the applicable standards can improve the process of achieving regulatory 
conformance.  
 
Furthermore as shown in the Table 6.1 above, the device manufacturers’ were 
required to prepare the technical documentation for the medical devices to 
demonstrate the conformity of the device with the MDD. Technical documentation 
has to cover the following aspects of the medical device: device description; raw 
materials and component documentation; intermediate product and sub-assembly 
documentation; final product documentation; packaging and labeling documentation; 
and design verification which includes the results of qualifications tests and design 
calculations relevant to the intended use of the device (MHRA, 2008a). Clinical data 
and manufacturing testing records are also required as part of the technical 
documentation (MHRA, 2008a). Manufacturing and test records are required to show 
compliance with the defined procedures and specifications. In the case of implantable 
devices, and in addition to existing requirements, manufacturers were now required to 
retain the technical documentation for at least 15 years from the last date of 
manufacture and keep it available for the national authorities (European Commission, 
2007). 
 
As part of the MDD 2007/47/EC amendment, there are other major areas, which have 
had a huge impact on medical device manufacturers: One area is that, prior to the 
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release of MDD 2007/47/EC, clinical data was only required when seeking regulatory 
approval for Class IIa, Class IIb and Class III devices. However, this has now 
changed and as a result clinical data must be supplied when seeking regulatory 
approval regardless of device classification. Clinical data is defined as safety and/or 
performance information that is generated from the use of a medical device (McHugh 
et al., 2012). 
6.1.2 Outsourced Design and Manufacturing Process Requirement 
The other area within the amendment of the revised MDD 2007/47/EC with important 
significance to medical device software development is outsourced design and 
manufacturing process. As part of the MDD 2007/47/EC amendment, should a device 
manufacturer outsource any part of the design or manufacturing process, then the 
manufacturer must be able to demonstrate that adequate controls over the whole chain 
of development of the software concerned have been put in place (European 
Commission, 2007). 
 
Firstly, the medical device manufacturer must ensure that the supplier is fully utilising 
a quality management system such as the ISO 13485.  
 
Secondly, the manufacturer must ensure that the development process of the software 
fits the requirements imposed by the new regulation and the applicable standards, 
such as EN 62304 (European Commission, 2007). To achieve this, the manufacturer 
must ensure that they know from where all the elements of their software originate i.e. 
the software should not contain any software of unknown provenance.  
 
Thirdly, the manufacturer must ensure that all of the elements of the software have 
been developed according to the requirements in the annexes to the MDD and the 
applicable standards (European Commission, 2007). This means that it is also 
mandatory for third parties to conform to these requirements and standards.  
 
Fourth, the manufacturer must ensure that they have access to or preferably ownership 
of the third-party developer’s data that must be submitted in the technical file for CE-
marking (European Commission, 2007).  
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Finally, the manufacturer must require that its subcontractors report any design 
changes in their software, as design changes may necessitate notification to the 
notified body that audited the software before it was altered and should be included in 
the manufacturer’s technical file (Klümper and Vollebregt, 2009).  
 
 In summary, the effects of this first regulatory change are far-reaching, determining 
overall company strategies, which types of company succeed, and ultimately the 
structure and dynamism of the sector as a whole. The firms’ actions related to the 
implementations of new requirements had an influence on their in-house capabilities 
and position in the market vis-a-vis other firms. This regulatory change allows us to 
assess firm response to a major extension of regulatory reach.  The next section 
describes the second regulatory change case selected for this study that introduced the 
unannounced audit visits to medical device manufacturers and their critical suppliers. 
 
6.2 Regulatory Change Case: Introduction of unannounced audit visits in the UK 
In May 2008, the European Commission launched a public consultation for a ‘recast’ 
of the medical devices legislations. This was met with some amount of surprise and 
skepticism by the industry and some national competent authorities (NCA) given that 
recast was close on the heels to the significant amendments that introduced the new 
Directive 2007/47/EC, which entered into force on 11 October 2007 (Chowdhury, 
2014) (discussed in the last section). This was followed by the NCA’s coming 
together to establish the Central Management Committee in September 2010, partially 
in response to the implied criticisms of the enforcement deficits within the current 
regulatory regime (Horton, 2012). 
 
On 24 September 2013, the European Commission (EC) published new guidance on 
the designation and supervision of Notified Bodies (NBs) in the field of medical 
devices and on the audits and assessments performed by the NBs (recommendation 
2013/473/EC).  The new regulation was formed “in response to the most frequent 
shortcomings of the previous practices” (European Commission, 2013a). The need 
for routine unannounced audits by all NBs was stipulated specifically as part of the 
Commission’s response to strengthen and tighten controls on medical devices and 
restore public confidence in the regulatory system following the Poly Implant 
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Prothèse (PIP) breast implants scandal (European Commission, 2013b). Although the 
main industry association EUCOMED sought to underline that this was a case of 
willful violation of the legal obligations of the manufacturer and not as such a failure 
of existing regulation, questions has been raised about the fundamental effectiveness 
of the legislations (Chowdhury, 2014). 
 
Unannounced audits are additional audits where the auditors commissioned by the 
notified body will arrive on the sites to be audited and undertake the audit without 
giving the manufacturer prior notice. This type of audit came in addition to the initial, 
surveillance or renewal audits of the three-year certification cycle (European 
Commission, 2013a).  
 
The EC recommendation 2013/473/EC regarding the audits performed by the NB has 
a distinct effect on medical device manufacturers, as three annexes address the 
evaluation of their products and their Quality Management System (QMS), and the 
structure of the unannounced audit visits. The features of the new recommendation for 
the evaluation of the device most relevant to the manufacturer include the following.  
 
Firstly, the NB should verify, where relevant, the fulfillment of the essential safety 
and health requirements contained in Directive 2006/42/EC.   
 
Secondly, they are instructed to facilitate the verification of the technical 
documentation, the manufacturer’s device identification system and the declaration of 
conformity (European Commission, 2013a).  
 
Within the assessment of the QMS of the manufacturer, the NB verification should 
ascertain that the application of the quality system assures the conformity of the 
devices with the legal requirements. In the case of production or product quality 
assurance, the verification should ascertain that the application of the quality system 
ensures the conformity of the devices with the device type (European Commission, 
2013a). 
6.2.1 Modalities for Conduct of unannounced audit visits 
The most radical reformation within the NB instruction concerns their audit policy or 
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the modalities for conduct of assessments. First, the NB should audit not only the 
premises and processes of the manufacturer, but also those of its critical 
subcontractors or its crucial suppliers (European Commission, 2013a).  
 
Secondly, the NB is instructed to perform unannounced audits at least once every 
three years. Nevertheless, the frequency of the audits may be increased if the devices 
present a high risk, if the types of devices are often found to be non-compliant and/or 
complaints were high in the previous audit reports, and if some information leads to 
suspicion of lack of conformity in the devices themselves, or on the manufacturer’s 
premises (European Commission, 2013a).  
 
Furthermore, NB should verify the manufacturer’s system ensuring traceability of 
materials and components, from the entry into the manufacturer’s, suppliers’ or 
subcontractors’ premises to the delivery of the final product. Verify that experience 
gained in the post-production phase, in particular user complaints and vigilance data, 
is systematically collected and evaluated for the devices covered by the application of 
the manufacturer. At each annual surveillance audit, the notified bodies should verify 
that the manufacturer correctly applies the approved quality management system and 
the post-market surveillance plan (European Commission, 2013a).  
6.2.2 Enforcement of the unannounced audit visit rules 
Independent assessors also known as notified bodies are the first in line enforcers of 
unannounced audit visit rules. Their principal role is to review the measures taken by 
manufacturers identified as the primary ‘regulatees’ to ensure that they fulfil their 
regulatory obligations, this procedure is formally referred to as the conformity 
assessment (Chowdhury, 2014). Two important aspects of conformity assessment 
within this regulatory change should be noted. First, the manufacturers in the UK are 
free to choose any notified body operating within the European Union. Thus there is 
no territorial linkage between manufacturing site and the location of the notified body. 
 
In summary, the European Commission played a very important role in this regulatory 
change case, as it was not only the principal architect of the Directives but it also 
played an active role by periodically publishing interpretative documents that clarified 
provisions from these Directives. They also are the prime movers in undertaking 
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legislative amendments and revisions of the regulatory structure as is evident from 
this discussion. So far, this chapter presented two cases of regulatory change set in a 
tightly regulated medical device national environment. The next section focuses on a 
regulatory change case set in a different national environment. 
6.3. Regulatory Change Case: Radiation emitting devices (REDs) in South Africa 
The medical device industry in South Africa was conspicuous by the absence of a 
comprehensive system of regulation until the enactment of the Medicines and Related 
Substances Amendment Act of 2015 (SAMED, 2016). There were no specific 
regulations governing the sale and use of medical devices in SA, except for a few 
medical technology product categories, which emit radio frequencies and 
electromagnetic waves. Though there are two types of radiation (i.e. ionizing, non-
ionizing), the greatest concern for patients and healthcare workers comes from 
ionizing radiation because of the harmful impact on human genetic structure that can 
result from accumulated exposure (Fiedler, 2017).  In fact the Department of Health 
(DoH) recognized that industrial radiography devices emit sufficient ionizing 
radiation to constitute a significant health hazard unless adequately shielded and 
handled with proper care (DoH South Africa, 2011). To promote safety in the 
workplace and to prevent unnecessary exposure to radiation, the DoH had to put 
radiation control measures in place. 
6.3.1 Historical Legal Framework for Radiation Control in SA 
The legislative control of electronic products was for the first time introduced by the 
Public Health Amendment Act of 197121 that added section 133A to the Public Health 
Act of 1919, allowing the Minister of Health to make regulations mandating the 
Secretary of Health to grant, suspend and revoke licenses in respect of electronic 
products and prescribe conditions and requirements for the categories of electronic 
products, premises and persons in control of the equipment. The Directorate: 
Radiation Control (DRC) of the Department of Health was assigned to be the body 
responsible for enforcing the Hazardous Substances Act, which was introduced in 
1973 (Act 15 of 1973)22 applicable to Group III and Group IV hazardous substances, 
as well as the regulations published under this act. In 1992, new conditions for 
 
21 SA Government. Act no 42: Public Health Amendment Act. (GN 888 in Government Gazette 3119 
of 26/5/1971). 
22 SA Government. Regulation R1332: Regulations concerning the control of electronic products. (GN 
R1332 in Government Gazette 3991 of 3 August 1973). 
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licensing of Group III hazardous substance were introduced by the Hazardous 
Substance Amendment Act, 1992 (Act no. 53 of 1992)23. The latest change is the 
Medicines and Related Substances Amendment Act 14 of 2015, which included 
Group III and IV Hazardous Substances contemplated in the Hazardous Substances 
Act, 1973 (Act No. 15 of 1973) in its definition of a medical device. 
 
The Hazardous Substances Act was created because early studies on X-rays had 
recognized that exposure to high levels of radiation may cause tissue damage, and that 
chronic exposure to lower levels of radiation may result in cancer (Herbst and Fick, 
2012, Fiedler, 2017). However, the use of X-rays is key part of diagnosis and plays an 
indispensable role in clinical management of patients (ibid). The innovative use of 
radiation, and specifically X-rays, imposes risks if inadequately controlled by 
manufacturers, suppliers, users and the government. Furthermore, because diagnostic 
imaging involves a multi-step process that include human and equipment factors, not 
controlling the imaging process properly can produce sub-quality images. This may 
affect accuracy of diagnosis and result in repeat exposures that increase both patient 
dose and costs to the medical facility (Grundlingh, 2015).  
 
The Hazardous Substances Act (1973), therefore, prohibits and controls the 
importation, manufacture, sale, use, operation, application, modification, disposal or 
dumping of substances and (electronic) products that may hurt or kill human beings 
by reason of their detrimental direct or side effects (RSA DoH, 1973). The Act 
classifies such substances and products in groups according to the degree of danger. 
The Act therefore, provided protection against radiation, however the act was 
undermined by poor administration and uncertainty about regulations and licensing 
conditions (Herbst and Fick, 2012). 
 
The Hazardous Substances Act (1973) indicated “the Minister may regulate 
manufacturing, modification, import, storage and transportation as well as disposal of 
the hazardous substance. The application for a specific purpose is regulated, including 
prohibiting that the grouped hazardous substance is sold, advertised or named under a 
 
23  SA Government. Act no. 53: Hazardous Substances Amendment Act, 1992. (GN 13955 in 
Government Gazette 1237 of 6 May 1992). Commencement date: 1 March 1993 
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name other than a name so prescribed. The procedures to be followed, the forms to be 
completed, the records to be kept and the other requirements to be complied with in 
connection with issuing licenses in respect of Group III hazardous substances and in 
respect of the premises on which they are installed, are described explicitly” (RSA 
DoH, 1973).  
 
The regulations further prescribe the precautions to protect from injury the persons 
involved in manufacturing, operation, application or disposal of the substances. The 
appointment of committees, or the duties to be performed by inspectors, is also set out 
(RSA DoH, 1973) 
 
The licensing of medical equipment (RSA DoH 1973) is subject to the prescribed 
conditions, the Director-General may in each case, issue to any person a license to 
sell, let, use, operate, install or apply any Group III hazardous substance. The license 
will be issued in the public interest. The refusal or granting of a license will be 
notified in writing. Non-compliance with prescribed conditions will result in 
suspension or cancellation of licenses. Inspectors are appointed and certified to 
indicate for which groups of hazardous substances they have been thus appointed. The 
powers of inspectors are prescribed with clear reference to inspection, entrance to 
premises, demanding information and placement of a restriction. Persons will be 
guilty of an offence if any restriction is removed without permission from the 
inspector. Penalties include a fine or imprisonment. No person, including the State, 
shall be liable in respect of anything done in good faith in exercising or the 
performance of a power or duty conferred or imposed by or under this Act” (RSA 
DoH, 1973). 
6.3.2 Licensing Conditions for Owners of Medical and Dental Diagnostic X-ray 
Equipment 
The regulatory practice of X-ray equipment used in industrial radiography published 
under the Hazardous Substances Act, 1973 as amended in terms of Article 3 (1) 
prescribed that when a license is issued to the license holders, (i.e. the owners of 
medical and dental diagnostic X-ray equipment), the Directorate: Radiation Control 
(DRC) should attach licensing conditions as an annexure to the license (DoH South 
Africa, 2011). Generally, the annexure refers to only two conditions directly but to 
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more conditions indirectly. The annexure does not contain the licencing conditions 
but refers the license holder to documents containing the licensing conditions on the 
Department of Health website. These web-based documents therefore possess legal 
authority as license requirements, but may change without further notice to the license 
holder (Herbst and Fick, 2012). The two specific licensing conditions are elaborated 
in the next section.  
6.3.3 The Code of Practice for Industrial Radiography - X-ray Equipment 
The first licensing condition namely the “Code of Practice for industrial radiography 
- X-ray Equipment 2011” and was drawn up in order to limit the risk of overexposure 
of workers and members of the public, and to keep radiation doses as low as is 
reasonably achievable. The holder of a license must ensure that the requirements laid 
down in the “code of practice” are adhered to at all times (DoH South Africa, 2011). 
The code of practice called for a number of administrative and medical requirements 
from those applying for the license. These requirements have a significant impact on 
the license holders, as they must show that they possess the necessary equipment, 
facilities and trained personnel to ensure that the radiographic work will be performed 
in a safe manner.  
 
Furthermore, the license holder must nominate a person to act as Responsible Person 
who must either be a full-time employee or the owner. The person nominated to act as 
Responsible Person must pass an approved examination before he/she can assume this 
position. Candidates must have an approved Level II Industrial Radiography 
qualification with two years experience. A service contract must be compiled between 
the holder and the responsible person in terms of Paragraph III.3 of the Regulations 
Concerning the Control of Electronic Products (Regulations No R1332 of 3 August 
1973) as amended. Responsibilities for the transfer of duties when resigning or when 
the contract expires must be included in the service contract (DoH South Africa, 
2011). 
 
In addition, the holder of the license must ensure that a document is drawn up 
outlining correct working procedures. The document must include details of all 
relevant safety procedures laid down by the Directorate (i.e. it is recommended that 
the code of practice form a major part of the document) and must specify what actions 
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are to be taken in the event of an emergency. The holder of the license must take steps 
to ensure that his employees adhere to the correct working procedures (DoH South 
Africa, 2011). 
 
The licensing requirements further stipulate that, industrial radiation workers must be 
declared medically fit by a company appointed doctor before employment. A copy of 
this pre-employment medical evaluation must be entered into the health register of the 
worker concerned. A medical examination must also be performed at termination of 
radiation work with the employer. A copy of the post-employment medical evaluation 
must be kept in the health register of the relevant worker (DoH South Africa, 2011). 
 
Lastly, the license holder must not transfer any industrial radiography X-ray units 
unless this is done with the prior approval of the Directorate. This requirement refers 
to situations where X-ray units are transferred between firms and when X-ray units 
are permanently transferred between different sections of a company (ibid). 
 
6.3.4 Requirements for License Holders with respect to Quality Control tests for 
diagnostic X-ray imaging systems  
The second licensing condition attached to a license enforces annual quality assurance 
according to a prescribed list (Herbst and Fick, 2012).  The DRC provided this second 
document as part of the diagnostic license conditions with respect to quality control 
(QC) tests in order to outline the requirements for the acceptance and QC tests of 
diagnostic X-ray equipment. The tests ensures that medical and dental diagnostic X-
rays and the overall technical performance of equipment are reliable and limits the 
dose to the patient to the lowest value compatible with successful diagnosis or therapy 
(DoH South Africa, 2011). 
 
Since September 2000 it is a regulatory requirement that suppliers and license users of 
diagnostic x-ray equipment must ensure that a series of specific QC tests at 
frequencies mandated by the DoH are done on all diagnostic x-ray units and 
processors (Grundlingh, 2015). The regulatory program was implemented in 
September 2000 specifically to assist medical facilities to recognize when parameters 
are out of limits (ibid). The out of limit parameters could result in poor quality images 
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and could give rise to unnecessary radiation exposure to the patient (Fiedler, 2017). 
Quality control tests play an important role in diagnostic imaging to limit the 
population dose growth. Results of QC tests must be reported to the DoH and the 
DRC analyzes the results (Grundlingh, 2015). 
6.3.5 The Introduction of the Accreditation System and Inspection Bodies (IBs) 
The SA government recognized:  
(i) the need for an internationally recognized national accreditation system as a 
crucial element of a well-functioning technical infrastructure that is aligned with 
international best practice;   
(ii)  the importance of ensuring that the accreditation system of SA continues to 
support the needs of their enterprises competing in a fast-paced global economy 
and  
(iii) the importance of supporting public policy objectives in terms of health, safety 
and broad-based black economic empowerment (B-BBEE) compliance issues 
(DoH South Africa, 2007).  
 
This led to the Accreditation for Conformity Assessment, Calibration and Good 
Laboratory Practice Act, 200624. The purpose of this Act was to first, provide for an 
internationally recognized and effective accreditation and compliance monitoring 
system for SA. Secondly, it was to establish the South African National Accreditation 
System (SANAS) as a public entity and as the only accreditation body in the Republic 
responsible for carrying out the accreditations in respect of conformity assessment25, 
calibration and monitoring of good laboratory practice (GLP)26 compliance to the 
Organization for Economic Cooperation and Development (OECD) principals; and 
lastly to provide for matters connected therewith (DoH South Africa, 2007). 
 
In an effort to overcome the insufficient number of inspectors in SA for more than 6 
500 license holders and 16 000 X-ray machines (Herbst and Fick, 2012),  SANAS 
 
24 SA Government. Act no 19, 2006: Accreditation for Conformity Assessment, Calibration and Good 
Laboratory Practice Act, 2006. (GN 29712 in Government Gazette of 16 March 2007). 
25 “Conformity assessment” means the procedure used to determine, directly or indirectly, that the 
relevant requirement in technical regulations, standards or any other relevant and validated 
documentation has been fulfilled. 
26 “GLP” (good laboratory practice) means a quality system concerned with the organizational process 
and the conditions under which non-clinical health and environmental safety studies are planned, 
performed, monitored, recorded and reported. 
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was mandated by the DoH to accredit companies/users to perform the prescribed 
acceptance and QC tests and to ensure through this process that a high standard of 
testing is maintained that will directly benefit the patient. These companies/users are 
called Inspection Bodies (IBs) once they are accredited by SANAS (Grundlingh, 
2015).  
 
In addition to being accredited, IBs are also approved by the DoH before they may 
start operating. This implies that “routine” tests/inspections are performed by IBs and 
in doing so; it increases the capacity of the DoH by allowing its own DRC inspectors 
more time to focus on problem areas. Inspection bodies that have been accredited 
against international standards also inspect diagnostic imaging machines providing 
services such as MRI Ultrasound and CT scans (Grundlingh, 2015). This results in the 
assurance of safe, high quality care with reliable outcomes that patients can trust.  
 
As from 31 March 2009 an IB approved by the Department of Health (DoH) or an 
appropriately trained professional registered with the HPCSA as a medical physicist, 
must be used to perform all the acceptance tests as well as the routine tests listed in 
the requirements for Quality Control Tests Document. Acceptance tests are the initial 
tests performed directly after installation and before any X-ray equipment is put into 
clinical service or substantially upgraded (DoH, 2011).  
 
It is the duty of SA regulators and all suppliers to monitor products available and to 
provide reasonable levels of protection against unscrupulous behavior of suppliers and 
or users (Rogers, 2015). The over-riding intention of market surveillance, including 
pre-market assessments and approval systems and post-market surveillance activities, 
is to enhance patient and user protection, in the context of limited resources (ibid). 
Accreditation of Conformity Assessment Bodies means that these certification bodies 
certifying medical device manufacturers and distributors to ISO 13485 are operating 
to global levels of assurance (Doh South Africa, 2012, Rogers, 2015). Accreditation 
certification is used to assess conformity of quality management systems and medical 
devices against an international and appropriate standard (Fiedler, 2017). The 
development of the conformity assessment capabilities in SA and accreditation 
thereof by SANAS to global levels of assurance are critical elements in the successful 
implementation of the medical device regulatory framework (Rogers, 2015). The 
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introduction of SANAS had distinct effects on medical device 
manufacturers/suppliers and users in SA, as they had to put new strategies to meet 
annual conformity assessments.  
6.4 Conclusion 
This chapter has focused on the specificities of the three selected regulatory changes, 
the drivers that led to the changes have been discussed, why the changes were 
important for the two medical device industries and how they have been strengthened 
over the years. Since regulatory requirements such as those contained in these three 
case studies are hardly ever revoked, and new ones continue to be endorsed 
(Eisenberg, 2012), it might be essential for firms to view compliance activities as an 
opportunity to directly enhance their capabilities and the value to business. However, 
the prospect of more stringent regulatory requirements to be implemented may 
inevitably place a substantial demand on the already stretched organizational 
resources, and further influence their associated opportunity costs. The three 
regulatory changes explored in this chapter, now allow us to assess firm responses to 
these major toughening of regulatory compliance processes and therefore, the next 
chapter will discuss and analyze the actions of the firms implementing the regulatory 
changes. 
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CHAPTER SEVEN 
THE EFFECTS OF REGULATORY CHANGE ON TECHNOLOGICAL 
CAPABILITIES OF MEDICAL DEVICE FIRMS IN THE UNITED 
KINGDOM 
----------------------------------------------------------------------------------------------------- 
7.0 Introduction: 
The aim of this chapter is to collate the empirical findings of the two major regulatory 
change cases in the UK. This chapter addresses research sub-question number three 
identified in chapter one: How have regulatory changes affected firm level investment, 
production and linkage capabilities of medical device firms in the UK? using 
empirical data from a group of sixteen medical devices firms in the UK. This chapter 
is focused on firm level effects in a tightly regulated national environment.  
 
This study includes two kinds of empirical data. The first empirical data involved 
sixteen UK manufacturing firms. Therefore, the general context and implications 
narrative of the two new regulations will first be constructed based on the sixteen 
firms.  Then a more comprehensive analysis of three firms will be presented. The 
narratives are organized in accordance with patterns emerging from the empirical 
data. At the end of the chapter, the results of each regulation and each type of 
capability will be summarized and general characteristics of the firms’ responses to 
the new regulation will be further described to provide an informative overall 
perspective. 
  
To analyze the effects of regulatory changes, this chapter applies an evolutionary 
economic understanding of industrial capabilities, focusing particularly on 
technological capabilities at the firm level. This framework of industrial analysis is 
also used in the subsequent chapters in this research. 
7.1 Effects of the first regulatory change (software) on firm level technological 
capabilities   
This section will describe data from the sixteen UK-based firms showing the effects 
of the two significant regulatory changes on three aspects of technological 
capabilities. The two regulatory changes examined in this study are also considered to 
be institutional changes and refers to the process of regulations and laws being 
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modified (Malerba, 2006).  The analysis therefore is guided by Lall (1992)’s firm 
level technological capabilities functions model, which is made up of "investment", 
"production" and "linkage" capabilities (1992). Technological capabilities refer to the 
dynamic and competence-building activities firms undertake to generate new 
products, process and services (Malerba and Mani, 2009, p.161).  
 
Once the new requirements of the first regulatory change were presented by the 
European Commission, UK firms were supposed to take a range of actions in 
response. In fact, the country’s industrial policies, regulations and market governance 
influence the direction and extent of technological capability, the network of the 
sectoral actors’ dynamism and trajectory (Marques and de Oliveira, 2009, Malerba 
and Mani, 2009). The actions taken by firms in reaction to regulatory changes, in turn, 
affected their business operations. Such effects depended on how each firm tried to 
acquire the regulatory standards or develop the assets to deal with the change. From 
the interviews conducted with different stakeholders, firms responded in different 
ways to changes in regulations depending on their management, product offerings and 
position in the market. 
7.1.1 Effects of the first regulatory change (software) on firm level investment 
capabilities 
Investment capability refers to the skills for expanding and establishing new 
production facilities (Malerba and Mani, 2009, p.162). The investment capabilities 
determine the capital costs of the project, appropriateness of the scale, product mix, 
technology and equipment selected, and the understanding gained by the operating 
firm of the basic technologies involved (Lall, 1992). 
 
 Research and Development (R&D)  
The approach to implementation of new regulation and firm structure significantly 
affect the propensity of regulated firms to engage in R&D activities (Mayo and Flynn, 
1988). Firms that invest in R&D extend their technical knowledge base, which allows 
them to design and develop new innovative products or services (Malerba and Mani, 
2009). However, the extent to which firms can extract value from their R&D efforts to 
develop innovative output depends on institutional quality. Associate Director of 
Regulatory Affairs of Delta Ltd noted:  
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“Our R&D expenditure increased after the new regulation. Our directors regarded 
investment in this area as a prerequisite for the success in the medium to long-term 
future” [Res O57 (MAN), Jan, 2017]. 
 
The effects of the first regulatory change on R&D elicited various responses among 
the medical device firms.  Some firms highlighted that the impact of new regulation 
on R&D created substantial shifts in the distribution of inventive efforts to meet 
market requirements. However, the interview results also indicated that R&D 
expenditures were positively related to firm size, the degree of specialization in 
medical device sales, and the earned rate of return on investments. CEO of Med Tech 
and Director of Neiva Medical shared the same views on the need to increase the level 
of investment in R&D in spite of the stringent regulated environment:  
 
 “After the 2007 regulation, we continued to increase our level of investment in R&D 
commensurate with our objective of our market place and enhancing our competitive 
position” [Res O72 (MAN), Apr, 2017]. 
 
 “The changes in regulation made us to increase our investment in R&D.  In fact, we 
dedicated 5% of our revenue towards R&D activities and innovation [Res O73 
(MAN), Apr, 2017]. 
 
The new amendment specified that a manufacturer is prohibited from running any 
software “that qualifies as a medical device but is not yet CE-marked”, in human tests 
outside of an approved clinical trial setting (Klümper and Vollebregt, 2009). The 
Chairman of Kilo Ltd indicated that this regulatory change curtailed R&D 
considerably as reflected in the following remark: 
 
 “In the past, the process of R&D and placing of a medical device on the market, as 
long as it was safe, was fairly easy to do. Now almost any product change or new 
product development has to go through a whole series of regulatory hoops before you 
can get a CE mark” [Res O66 (MAN), Jan, 2017].  
 
Majority of firms emphasized that the introduction of the new regulation made the 
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approval times much longer, therefore directly affecting the time to market, which, in 
turn, impacted return on investment made for product development. Director of JM 
Medical remarked:  
 
“In 2008, our firm’s investment on R&D activities reduced to £45.8m from (2007 
£54.1m). The decrease was due to a reduction of projects in pre-clinical trials as 
compliance cost had rose steeply and delays in regulatory decision times” [Res O65 
(MAN), Jan, 2017]. 
 
This suggests that changes in regulations can lead to undesirable impact in terms of 
increased barriers to entry and decreased investments in R&D, which are 
counterbalanced by favorable effects, such as reduced risk in investments and 
minimized product turnovers. 
 
 
Recruitment and training of skilled personnel 
 
The study identified “capacity and expertise” as critical determinants that support the 
capability of implementing new regulatory requirements.  The introduction of the first 
regulatory changes had dual competitiveness at domestic and international levels that 
required adequate staff training. At the domestic level, the medical device firms had 
the opportunity to improve the quality and innovativeness of their software beyond 
the CE mark approval and ISO certification benchmarks by training their employees. 
Furthermore, the new regulation created competitiveness among the UK firms as the 
staff members received training to new rules and standards regulating software design 
processes, and technological scalability. Associate Director of Regulatory Affairs of 
Delta Ltd and the CEO of Foxtrot Ltd commented:  
 
“The MDD 2007/47/EC made us create more jobs within our firm and increase our 
in-house training so that we could have a competitive local market advantage” [Res 
057 (MAN), Jan, 2017].  
 
“In response to the new regulation, in 2008, we took in-house responsibility for 
training of personnel while engaging the help of a local distributor for regulatory 
support” [Res 059 (MAN), Jan, 2017]. 
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The quotes above reinforce the notion that, a highly skilled workforce with regulatory 
expertise was an important competitive factor in the medical device software segment 
to meet the EU 2007/47/EC requirements. This is reflected in the following two 
quotes from the Managing Directors of Indigo Ltd and Neiva Medical:  
 
“We had to increase our recruitments and staff training to meet the requirements of 
EN/IEC/62304 such as software devices planning, requirement analysis and 
implementation, verification, integration and software release at different stages 
within our firm [Res 064 (MAN), Jan, 2017]. 
 
“Our employee numbers increased to 453 in 2010 from 439 in 2009 in order to cope 
with the new regulatory requirements” [Res 072 (MAN), Apr, 2017]. 
 
Evidence also suggests that the firms that had skilled and trained employees managed 
to comply with the MDD 2007/47/EC requirements and compete more effectively in 
the global market. Some respondents emphasised that the regulatory change affected 
the companies whose primary market was the UK but expanding their business 
outside Europe to other advanced countries such as the USA. Chairman of Kilo Ltd 
noted: 
 
“We were now forced to employ people that we would train and nurture for them to 
be able to comply with the USA and the rest of the world registration requirements” 
[Res 056 (MAN), Jan, 2017]. 
 
Other respondents said that the level of scrutiny of all aspects of the medical devices 
and the level of regulatory documentation had a cost effect on: first, the sheer amount 
of manpower and labour to comply with the regulatory requirements; and secondly, 
the kind of qualifications and the cost of the skilled personnel that a firm needs to 
employ. Chief Operations Officer of Foxtrot Ltd had the following to say on this 
issue: 
 
“It is very difficult to find people who are skilled software engineers and used to 
comply with the medical device standards. We have been looking across the whole 
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area here on the South Coast, and I have to say that we haven’t found anybody that is 
looking for the job and has got the experience." [Res 059 (MAN), Jan, 2017] 
 
Majority of interviewees pointed out that firms have to invest significantly in training 
of their engineers involved in product development with diverse aspects of the 
regulatory documentation. This emerged as a time-consuming exercise as it was 
argued that approximately 70% of the project (time and cost) has been spent on 
regulatory documentation and recording for audit purposes. However, some MNCs’ 
recruitment and training needs were scarcely affected by the new regulation as 
remarked in the following quote from Lima Medical’s Head of Operations: 
 
“As a MNC, the recruitment of personnel was not a big issue for us; we actually 
remained static even after the new changes” [Res 069 (MAN), Apr, 2017]. 
7.1.2 Effects of the first regulatory change (software) on firm level production 
capabilities 
Production capability consists in the ability to operate production processes and adapt 
them to changing market circumstances (Malerba and Mani, 2009, p.162). The 
functions of the production capabilities range from basic skills such as quality control, 
operation, and maintenance, to more advanced ones such as adaptation, improvement 
or equipment “stretching” (Lall, 1992).  
 
Innovation in production 
The OECD (2009) highlights the direct relation that exists between regulation and 
innovation. Innovation capability consists of the ability to carry out activities for 
creating and implementing changes in techniques and organizational processes (Lall, 
1992, Malerba and Mani, 2009). The MDD 2007/47/EC stringent regulatory change 
affected innovative efforts of the medical device manufacturers by imposing the 
fulfillment of rigorous safety and quality requirements for the commercialization of 
any medical device software.  The Technical Director of Hex Ltd said,  
 
“Well, after the strict 2007 regulatory change, our innovation activities and focus 
moved towards improving our old products instead of introducing new ones because 
the requirements were too costly for us” [Res 063 (MAN), Jan, 2017]. 
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This quote indicates that the increased regulation has made some innovative firms 
more risk averse and adopt incremental instead of radical innovation approach. 
Incremental innovation does not bring fundamental change in a treatment, nor does it 
bring about a crucial change in the product (Schumpeter, 1942). While radical 
innovations are generally defined as breakthroughs that create discontinuity in the 
technology trajectory, and destroy the existing equilibria (Dosi, 1982). The Managing 
Director of Indigo Ltd highlighted the challenges they faced in trying to develop a 
radical innovation while at the same time trying to meet the new software requirement 
on risk assessment in the remark below: 
 
“A big dilemma we face is, you can’t simply sit down and upfront say what problems 
you are going to encounter and this is really the risk assessment part of the regulation 
which asks you to exactly to state what risks are associated with a particular 
approach to solutions and particular approach to software and sometimes you simply 
don’t know because you haven’t tried that before [Res 064 (MAN), Jan, 2017]. 
 
Stringency relates to how difficult and costly it is for firms to comply with new 
regulatory requirements using existing ideas, technologies, processes and business 
models (Baldwin et al., 2012). The technical constraints required by the regulation 
were imposed by the standards such as the ISO 13485 and IEC 62304 which are 
uniformly applied to an entire medical device software development process. These 
requirements have imposed direct constraints on firm conduct, lowering product 
innovation. According to Ashford (1985) stringency is the most important factor 
influencing technological innovation. The Medical Devices Principal Consultant of 
Bravo Ltd commented, 
 
“Having been in this industry since the 1990s from my personal experience I feel that 
the new regulations were too stringent for us small companies to create new 
products” [Res 054 (MAN), Jan, 2017]. 
 
Further, some of the firms agreed that the new regulations imposed certain 
requirements on product development such as requiring clinical data regardless of 
device classification and that has limited the exploitation of their opportunities to 
introduce new devices. The Chief Operation Officer of Foxtrot Ltd noted,  
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“The new regulation slowed down product development time and innovation 
substantially" [Res O59 (MAN), Feb, 2017].  
 
This supports D’Este et al., (2012), who suggested that regulation barriers limit the 
drive for innovation. Further, some small firms could not able to comply with the 
requirements and therefore, dropped off potential ideas and opportunities due to the 
risk of not meeting the regulatory requirements. This stringency in the first regulatory 
change was considered a barrier to the innovation as reflected in the remark below by 
the CEO of Echo Ltd: 
 
“The 2007 regulatory changes have definitely affected innovation to a very large 
extent because they are now so strict especially with the fact that most of the 
innovation comes from small companies and also the compliance level if you want to 
develop a new product, the clinical data requirements, the evaluation requirements, 
the need for transparency and so many more regulatory requirements are really 
affecting our innovation capabilities”.  [Res O58 (MAN), Jan, 2017]. 
 
There was also evidence of positive impact of first (software) regulatory change on 
the innovation in some firms. The senior managers from these firms argued that the 
strict regulations fostered innovation by creating opportunities for change and 
improvements through mandatory requirements. For instance, the introduction of a 
new regulation enhanced the creation of completely new processes or products 
because it was too costly to fulfill the regulatory requirements with the existing 
technology, and significant technological change was required. Two respondents 
remarked the following on this issue: First, the Associate Director Regulatory Affairs 
of Delta Ltd said, 
 
“In 2007 we actually improved our operations by launching our innovative genome 
analyser and cluster station” [Res O57 (MAN), Jan, 2017].  
 
And second, the Chief Operation Officer of Foxtrot Ltd noted, 
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“At the moment innovation is a good. It might in some instances mean that the 
innovation is slower to appear as a commercial product but then again I think that is 
a good thing because its ensuring safety for the patient” [Res 069 (Man), Jan, 2017]. 
 
The controversy in the impact of regulation on innovation among the firms had been 
discussed earlier in academic literature. On the one hand, complying with regulations 
is likely to increase costs or restricts firms’ freedom of action (Palmer et al., 1995). 
On the other hand, well-designed regulation may guide or even force firms to invest 
in innovative activities, implement innovative processes or release innovative 
products (Porter and Van der Linde, 1995).  
 
According to Porter and Van der Linde (1995) regulation can yield progressive effects 
when it fulfills three characteristics: First, it must create the maximum opportunity for 
innovation, leaving the approach to innovation to industry and not the regulation-
setting agency. Second, it should foster continuous improvement, rather than locking 
in any particular technology. Third, the regulatory process should leave as little room 
as possible for uncertainty at every stage.  
  
Some stakeholders indicated that the first regulatory change (software) has directly 
affected the innovative process, while others argued that innovation and technological 
change have also significantly impacted regulation. The co-evolution of these 
elements are worth mentioning since the analysis of sectoral systems requires a 
careful understanding of the processes of interaction and cooperation (Malerba and 
Mani, 2009). Over time, a sectoral system undergoes the process of change and 
transformation through the co-evolution of its various elements (ibid). Thus, it is not 
surprising that industrial technological capabilities have also a reverse influence on 
government policies and regulation. Head of Global Medical Device Services of a 
regulation-setting agency noted that: 
 
 “In terms of innovation, I think we have had situations where a manufacturer brings 
in a truly innovative product. We all had to scratch our heads a little bit and figure 
out how we were going to regulate this because for example, sometimes the product 
does not naturally fall within classification and then there isn’t a standard to compare 
to” [Res 068 (NB), Jan, 2017]. 
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 Quality control 
 
The software controlled by the first regulatory change has increasingly emerged as an 
integral part of modern medical devices and affects the diagnosis or treatment of 
patients. Therefore the software itself and its development are scrutinized to ensure its 
quality, safety and efficacy (Sudershana et al., 2007). When asked about the effects of 
regulation on software development quality control, the Medical Devices Principal 
Consultant of Bravo Ltd remarked: 
 
“Quality system regulation states, that software which is used in medical device 
production or in implementation of the quality system must be validated for its 
intended use. So yes the introduction of the 2007 regulation has improved the quality 
of our products” [Res 054 (MAN), Jan, 2017]. 
 
The Quality Management System (QMS) in the new regulation required that 
whenever the firms update their software, they have to potentially perform a re-
evaluation of that software. If there is a major change in the way that the software 
runs the product, they might even have to re-CE mark the product. This process was 
considered costly and slowed down product entry into the market as reflected in the 
quote below by the Technical Director of Hex Ltd: 
 
“After the introduction of the new regulation, we were asked to gather additional 
clinical evidence for our software update for quality purposes and this process slowed 
down the launch our new software version into the market, the approval process was 
very long” [Res 063 (MAN), Jan, 2017]. 
 
The quality system regulation requires more skilled personnel to deal with documents 
and records to be maintained of practically everything that is related to the quality 
system compliance i.e. device history, design history, complaints, procedures, reviews 
etc. and it was seen as the positive development by some firms. The Medical Devices 
Principal Consultant of Bravo Ltd comments: 
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“These records are needed to prove to regulatory authorities that quality system 
regulations have been fulfilled and to me that is a positive move” [Res 054 (MAN), 
Jan, 2017]. 
 
One of the key findings of this study is the primary advantage associated with the 
introduction of the MDD 2007/47/EC (software) regulation is that it ensured quality 
and safety of the new as well as existing medical devices entering markets. The CE 
marked software brought positive reputation to the product quality and helped it gain 
confidence among customers as captured in the two quotes below from the Senior 
Quality Assurance Director of Garner Ltd and the Managing director of Indigo Ltd:  
 
“The software we produced under the new regulation provided a competitive 
advantage for our firm, because it had a harmonized standard EN/IEC/62304 
associated with it. That meant producing products with improved quality, increased 
safety and efficacy” [Res O61 (MAN), Jan, 2017]. 
 
“One of the positive outcomes of new requirements is that if you adhere to regulation 
and you have done testing, evaluation according to the standards as a company you 
also gain confidence in the quality of your products” [Res O64 (MAN), Jan, 2017]. 
 
In general, although the new regulation imposed certain compliance cost to the 
innovation activities, there were usually compensating benefits elsewhere. The 
empirical results from the sixteen firms interviewed in this study demonstrated that, in 
a transition period of regulatory environment change, firms experienced adverse 
consequences. However, in the long term, the regulatory framework for medical 
device software had affirmative effects on the industry with respect to the quality of 
new product offerings. 
 
 Compliance cost 
The changes in medical device industry regulation did not come without cost. 
Compliance cost refers to the cost for demonstrating compliance with regulation 
before entering the market (Baldwin et al., 2012). As indicated by the interviewees, 
the MDD 2007/47/EC (software) regulation increased costs, resulting in firms 
needing to divert resource outflows to meet regulatory requirements reducing their 
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availability for innovation activities within the firms. Compliance cost consists of 
expenditures for developing, manufacturing and testing of products to pass the 
regulatory requirements. The Senior Quality Assurance Director of Garner Ltd 
indicated: 
 
“Due to a series of harmonised standards which go alongside the MDD 2007/47EC, 
we had to increase the appropriate level of software testing and the complexity of 
setting up and validating all the appropriate test methods, that meant increased 
compliance cost” [Res O61 (MAN), Jan, 2017]. 
 
Amid all the other differences in views of the effects of MDD 2007/47/EC regulation, 
all the firm respondents shared one view that the costs of compliance were too 
significant. Compliance with the new regulation targeting software safety and efficacy 
was viewed as a costly venture before a firm receives certification or accreditation to 
export to the European and the global market. The cost factor was mostly in the due 
diligence and massive documentation procedures. Thus, the changes tightened the 
medical device software specifications by requiring medical device manufacturers to 
provide additional documentation to prove compliance with further safety and 
efficacy standards. One Director of Optics Ltd remarked: 
 
 “In complying with 2007/47EC regulation, we had extremely low tolerance for risk. 
So our firm’s compliance budget went up” [Res O73 (MAN), Apr, 2017]. 
 
Some respondents reported that changes in regulations limited how they design, 
develop and market their products, services or solutions for their customers. The firms 
incurred unique costs such as forgone opportunity costs associated with much longer 
product approval times; requirements for conducting additional clinical trials to 
acquire safety data equivalent to that obtained in previous trials and accepted by 
regulators in other markets. The Associate Director Regulatory Affairs of Delta Ltd 
and the Managing Director of JM Medical reflected on this issue in the two quotes 
below: 
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 “The increased regulatory costs means that we have to take our costs elsewhere in 
the business and that includes who is too smart in the production” [Res 057 (MAN), 
Jan, 2017].  
 
“In 2010 our product development expenses increased due to investment in clinical 
trial studies and regulatory cost to bring new products to the market” [Res O65 
(MAN), Apr, 2017]. 
 
Business Operations capabilities 
The nature of regulation significantly influences the structure and dynamism of the 
sector, firm level strategy and types of firms that can succeed. The first regulatory 
change had opposing impact on firms’ operating conditions depending on their 
approach towards the regulation and resources to manage the change. Some firms 
with strong resources such as MNCs had proactive approach to regulations and 
managed to adjust when the change in the regulations were introduced.  These firms 
became successful in the market evidenced by following responses:  
 
“Because we invested more in R&D and regulatory compliance, we improved the 
overall company performance and turnover increased over the years after 2007 
regulatory changes” [Associate Director Regulatory Affairs of Delta Ltd, Res 057 
(MAN), Jan, 2017]. 
 
“Our firms’ production and sales capability increased in 2010. We sold 14,415 
products compared to 10, 440 in 2009, an increase of 38% in the number of patients 
treated. A remarkable strong performance in a very difficult regulated market” 
 [Chief Operations Officer of Foxtrot Ltd, Res 059 (MAN), Jan, 2017]. 
 
“Even though complying with the new regulation was burdensome, we were proactive 
and we increased our medical devices export sales. Our highest export sales growth 
was from 2007 to 2013. Eventually, in 2013 we received the Queen’s Award for 
Enterprise – International Trade” [Chairman of Kilo Ltd, Res O66 (MAN), Jan, 
2017]. 
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In contrast, some firms with limited resources that failed to realise the possibilities 
inbuilt in regulatory change requirements, ended up as failures in the market. The 
CEO of Echo Ltd remarked: 
 
“Our products’ speed to market was reduced, thus the time to market got longer, and 
the net present value of our products went down” [Res O58 (MAN), Jan, 2017]. 
 
This shows that regulatory change affected business operations of both the SMEs and 
the MNCs as well as the structure of the entire industry. This dualistic impact of 
regulation is also observed in the literature. For example, a contemporary study by 
Hansen et al. (2013) showed that regulatory change can hamper opportunity but can 
also be the springboard for new firms and solutions in the market. Similarly, Tee and 
Gawer (2009) point out that regulations can constrain the launch of a new business in 
a market and thereby influences firms’ ability to develop a business.  
7.1.3 Effects of the first regulatory change (software) on firm level linkage 
capabilities 
This section focuses on the impact of regulatory change on the firms’ linkage 
capabilities. Linkage capability refers to the ability to transmit technological 
information and receive it from other organizations (Malerba and Mani, 2009, p.162). 
These linkages are supposed to assist the firm to improve its productive efficiency and 
also the diffusion of technologies (Lall, 1992). They are also grouped as supporting 
activities and signify to the ability to link up with other actors in the economy (Bell 
and Pavitt, 1995). 
 
The majority of medical device firms outsource certain aspects of operations to 
independent firms to reduce operating costs and focus on core strength. The MDD 
2007/47/EC amendment stipulated that the manufacturer must be able to demonstrate 
that adequate controls over the whole chain of development of the software concerned 
have been put in place including outsourced work and supplier network (European 
Commission, 2007). Therefore, medical device manufacturers required a well-
organized network of subcontractors and suppliers, who had the capacity and 
proficiency to supply quality products or components, in order to meet regulatory 
standards and also keep pace with global market demands. The Medical Devices 
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Principal Consultant of Bravo Ltd and the Managing Director of Indigo Ltd reiterated 
the need for strong links within the sector in the remarks below: 
 
“It became increasingly necessary for us to develop relationships with all the links in 
their supply chain after the 2007 changes” [Res O54 (MAN), Jan, 2017]. 
 
“We had to learn how to collaborate better and by collaboration, I mean we had to 
find out how to share resources” [Res O64 (MAN), Jan, 2017]. 
 
Most of the firms interviewed successfully broadened their outsourcing models to 
include foreign firms with offshore production facilities. With the new regulatory 
requirements in place (MDD 2007/47/EC), establishing an effective supplier 
relationship became an important issue for medical device firms and it was one of the 
ways through which the firms could improve their performance. However, monitoring 
the supplier base as required by new regulation was considered a huge challenge for 
the manufacturing firms as reflected in the remark below by the Quality Manager of 
Alpha Ltd: 
 
“Since software validation of our critical supplier required a lead auditor of which 
we did not have, we were forced to link up with local consultants in order to validate 
and monitor our supplier” [Res O53 (MAN), Jan, 2017]. 
 
In fact, the outcomes suggest that the capability of a country to benefit from cross-
country linkages is influenced by its internal network structure. Thus, changes took 
place in the interactions between different layers of the industry, and between firms 
within those layers, placing demands on businesses’ ability to integrate. 
7.1.4 Summary: Effects of the first regulatory change (software) on firms’ 
technological capabilities  
In summary, introduction of the first regulatory change drove most UK-based firms to 
invest substantial resources in R&D to standardize their software products. Most 
manufactures of medical devices software that were proactive had positive income 
returns that improved after they invest towards compliance with the regulatory 
change. 
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It is clear that the software product-focused regulatory change was an important step 
to guarantee the acceptance of products in a broad geographical market. The 
regulatory change repositioned medical device software in a more transparent manner 
because manufacturing standards, procedures, tests, validation, and accountability 
were all improved to reduce device recall statistics. However, one of the biggest 
weaknesses of product regulation governing medical device software is that 
compliance costs are very high. For example, clinical tests are very expensive to 
conduct. The expected return on a device limits the amount of testing that a firm is 
willing to perform. A summary of the effects of the MDD 2007/47/EC on medical 
device firms in the UK is presented in Table 7.1. 
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Table 7.1: Effects of EU Directive 2007/47/EC on medical device firms in the UK 
Firm EU Directive 2007/47/EC  
Introduction of software as a medical device, 
Risk and quality management, 
Outsourced Design and Manufacturing 
Affected Capability 
Alpha 
Ltd  
 
INVESTMENT  PRODUCTION LINKAGE 
• Validation of software production line costing the firm about £15-
20 000. Thus increased compliance costs 
• The firm complained about the process of conformity assessment, 
and called for reducing clinical data requirements 
• Due to skills shortages firm outsourced design therefore increasing 
the need to externally monitor the supplier’s QMS 
• Due to increased risk management paper work, design times increased and 
slowed down products’ time to market 
• The firm increased the workforce training on the EN/IEC 62304 standard for 
efficiency and competitiveness in operations. 
• Validation of critical supplier requires a lead auditor of which they were and 
are in short supply 
Validation of critical supplier 
requires a lead auditor of which 
they were and are in short supply 
Bravo 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• The firm’s software developers took quite long to catch up and 
understand that they were developing not just an ordinary software 
but a software regulated as a medical device, therefore increasing 
the need for more in-house training and recruitment of skilled 
personnel 
• Demonstration of risk assessment of products including hazard analysis and 
mitigations that the firm put in place to resolve issues during the design and 
development process improved. 
• Increased the cost of producing a safer device 
Increased reporting obligations for 
manufacturer 
Charlie 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• Increased scrutiny during conformity assessments • The firm’s expected acceleration of its embedded software product “XXXX” 
was limited due to the continued time taken to get product registration through 
the regulatory agencies due to internal processing delays. 
• The firm had a general belief that the 2007/47/EC, EN/IEC/62304 and the rest 
of the applicable standards had met expectations in enhancing the safety of 
medical devices. 
Created an additional burden of 
paying for the cost of new supply 
agreements 
 
Delta  
Ltd 
 
INVESTMENT  PRODUCTION LINKAGE 
• Created more jobs within the firm and increasing in-house training.  
• Invested more in R&D and regulatory compliance.  
• R&D expenditure increased by 9% in 2007 
• The directors regarded investment in this area as a prerequisite for 
the success in the medium to long-term future 
• In 2007 the firm improved its operations by launching their genome analyser 
and cluster station. 
• Increased market share 
• Improved the overall company performance 
•  
Echo INVESTMENT PRODUCTION LINKAGE 
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Ltd 
 
• Firm has been facing some liquidity problems because the 
investment into R&D and the cost of compliance to EN/IEC/62304 
are expensive. 
 
• Products’ speed to market was reduced, thus the time to market got longer 
therefore, net present value of their products went down. 
• Firm did not take on board the regulatory system.  
• Developed the software in an unstructured way, therefore resulting products 
that were not safe and effective. 
Due to increased regulatory cost in 
the UK the firm moved production 
to China however the quality of 
their products reduced 
 
Foxtrot 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• In response to the new regulation, in 2008, the firm took in-house 
responsibility for training of personnel while engaging the help of a 
distributor for regulatory support. 
• R&D efforts on the firm’s (xxxx) monitor improved 
• The company recruited an additional 4 regulatory affairs personnel 
in 2007 adding the total number of employees to 49 
• The costs of trialling the firm’s products increased 
 
• In 2007 the firms’ production and sales capability increased. They sold 14,415 
surgical probes compared to 10, 440 in 2006, an increase of 38% in the number 
of patients treated. A remarkable strong performance in a very difficult 
regulated market 
• New regulation slowed down product development time and innovation 
substantially. 
• The quality of the firm’s probe they made in 2007 remained the same as the 
one they made 1998, thus, the new regulation did not improve product quality. 
An encouraging result in product 
sales in international markets saw a 
growth of around 30% as a result of 
strong international linkages 
 
Garner 
Ltd 
 
 
 
INVESTMENT PRODUCTION LINKAGE 
• Due to a series of harmonised standards which go alongside the 
2007/47EC, the firm had to increase the appropriate level of 
software testing and the complexity of setting up and validating all 
the appropriate test methods, that meant increased cost opportunity 
of products, time and manpower. 
• Decreased the firm’s return on investment. 
• The revision to the risk management life cycle of devices (expectable level of 
risk) has made the firm to question to the interpretation of what is expectable 
risk for a device and that slowed down the release of new products 
 
Hex 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• Training cost increased 
• Number of employees went up. 
• The software produced under the new regulation provided a competitive 
advantage for the firm, because it had a harmonized standard EN/IEC/62304 
associated with it. That meant producing products with increased safety and 
efficacy. 
• The changes made the manufacturers to gather additional clinical evidence 
Re-negotiate supply chain 
agreements, and alter 
documentation and quality 
management systems. 
Indigo 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• The firm had to increase their in-house training needs to meet the 
requirements of EN/IEC/62304 such as software devices planning, 
requirement analysis and implementation, verification, integration 
and software release at different stages within the firm. 
• Due to the fact that the environment is an open market with no price 
control regulation. The firm saw a lot of discrepancies in the costs 
of getting the ISO 13485 
• The risk assessment part of the regulation requires the firm to exactly state 
what risks are associated with particular approach to software and in many 
cases the firm simply didn’t know because they would not have tried the new 
technology. 
• The regulation added quite a lot of complications to firm’s product 
development because it required a lot of scrutiny on the risk assessment, 
required lot of documentation to be prepared when they were writing software. 
•  
JM 
Medical 
 
 
INVESTMENT PRODUCTION LINKAGE 
• In 2007, the firm’s investment on R&D activities reduced to £45.8m 
from (2006 £54.1m). The decrease was due a reduction of projects 
in pre-clinical trials. 
• Their return on invested capital increased by 39.9% from (2006 
27.9%) 
• The firm performance increased.  
• In 2010 the product development expenses increased due to investment in 
clinical trial studies and regulatory cost to bring new products to the market 
•  
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Kilo 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• Increased medical devices export sales growth from 2007 to 2013.  
• In 2013 Received the Queen’s Award for Enterprise – International 
Trade 
•  
• New regulation has not affected the firm’s market entry capability apart from 
the costs of getting the CE mark 
• The new regulation increased the level of documentation for the technical files 
from 4 to 78 and maintaining those files was said to be burdensome and taking 
a lot of time and manpower for the firm.  Therefore, slowed down products’ 
time to market. 
The firm outsource its medical devices 
software from USA and China therefore 
faced cost implication challenges of 
externally monitoring its critical 
supplier’s QMS.  
Lima 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• The firm’s operations were not seriously affected by the regulatory 
change. Even though turnover fell to £392m in 2011 from £394m in 
2010 and (2009 £449m). This was primarily driven by loss income 
from wound care division and restructuring their supply chain. 
• As a MNC, the recruitment of personnel was not a big issue; they 
remained static even after the new changes. 
• Managed to stabilize and improve expenditures on R&D each year after the 
new regulation.  
• Commended the new regulation as a positive move as it ensured that products 
are safe and effective 
• Innovation was made slower to appear as a commercial product but they took 
that as a good thing because it was ensuring safety for the patient 
•  
Med Tec 
Ltd 
INVESTMENT PRODUCTION LINKAGE 
• After the new regulation, the firm continued to increase its level of 
investment in R&D commensurate with its objective of its market 
place and enhancing its competitive position. 
• Employee numbers increased to 453 in 2007 from (2006 439). 
• Business operations consisting principally of the manufacture and sale of 
medical equipment and associated software increased and 2007 saw a turnover 
of £149m compared to (2006 £145m). 
•  
 
Neiva 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• After the new regulation, the firm continued to increase its level of 
investment in R&D.  The firm also dedicated 5% of its revenue 
towards innovation. 
• In complying with new regulation, the firm had extremely low 
tolerance for risk. The firm’s compliance budget went up. 
• The new regulation increased the firm’s requirements for a lot of regulatory 
and quality functions. Thereby increasing in-house training needs. 
• The firm however felt that 2007 changes did not have a huge impact on them, 
as things such as clinical evaluation and validation of software were not 
necessarily new and they were actually there in the existing guidance, however 
they were just not very clear. 
•  
 
Optics 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• One of the firm’s products is the infusion pump that has embedded 
software within it. The 2007/47/EC requires this to be validated and 
verified to show that the embedded software runs the product as 
intend. The overall process has increased costs, time a lot. 
• Usability software standards have been fed into process of 
criticality, thereby increased need for highly qualified software 
engineers 
• The QMS in new regulation demand that whenever they update that software 
they have to potentially perform a re-evaluation of that software. If there is a 
major change in the way that the software runs the product, they might even 
have to re-CE mark the product. This process was considered costly and 
slowed down product entry into the market. 
• Upgrading quality systems to the new regulatory environment required 
significant investment as well as increased senior management involvement in 
both the upgrade process and on-going management of the QMS 
•  
Compiled by author from empirical data 
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7.2 Effects of the second regulatory change (unannounced audit visits) on firms’ 
technological capabilities 
After analyzing the effects of the first regulatory changes covering medical device 
software on firms’ capabilities in the previous sections, this section delves into the 
analysis of effects of the second regulatory change regarding unannounced audit visits 
on firms’ technological capabilities categorized under three main themes; investment, 
production and linkage capabilities. 
7.2.1 Effects of the second regulatory change (unannounced audit visits) on firm 
level investment capabilities 
In-house technological effort seems to be essential for firms' performance, starting 
from their investment capabilities. However, when regulations have the unintended 
effect of discouraging or disrupting investment, they need to be identified and 
reviewed. 
 
Research and Development (R&D) capabilities 
Innovation and a strong commitment to R&D were the principal competitive factors 
most frequently cited by the firms as critical to their success. The medical device 
industry is R&D-intensive, driven by constant innovation and short product life cycles 
(Altenstetter, 2012). The introduction of the EC 2013/473/EU, the second regulatory 
change on unannounced audit visits was radical in nature. This provision was not 
entirely new but effective enough to eventually disrupt some existing medical device 
firm’s investment capabilities. The unannounced audits placed additional obligation 
on both manufacturers and NBs. Some firms became more risk adverse and reluctant 
to invest in radical innovations. The Technical Director of Hex Ltd and the Director 
of Regulatory Affairs of Charlie medical noted: 
 
“I think less innovation is coming from within the big medical devices companies 
now, we had a couple of engineers working on process development and developing 
new ideas and in reality what they actually produced was a manufacturing process 
upgrade” [Res 063 (MAN), Jan, 2017]. 
 
“We reduced innovation and the R&D department has gone down from 12 to 3 
members. Now we invest more in smarter production due to regulatory cost and for 
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the first time, we are going to other markets in search of return on investments due 
regulatory change” [Res 056 (MAN), Jan, 2017]. 
 
These quotes indicate that the significant R&D expenses for majority of MNCs were 
used to modify and enhance existing products, while lesser proportion of resources 
are devoted to the invention of a new product completely from scratch. This 
innovation investment strategy protected firms from the rejection of products by the 
new regulation and also facilitated market acceptance of much improved existing 
products.  However, those firms that increased their innovation activities and R&D 
investments in spite of the strict regulated environment improved their business 
financial performance and operational efficiencies. The Chief Operation Officer of 
Foxtrot Ltd and the Director of Optics Ltd commented:  
 
“At the onset of the new regulation we invested highly in R&D and innovation thereby 
maximised our return on investment and had a strongly increased cash generation. 
‘The investments was focused on our new innovative monitor as a result we improved 
our company operations and the turnover increased to £6.8 million and this was in 
2013” [Res O59 (MAN), Jan, 2017].  
 
“Some of the bigger players do have relatively large R & D budget similar to a 
pharmaceutical companies and therefore would bring some innovation in that respect 
through the R & D” [Res 073 (MAN), Jan, 2017]. 
 
Some firms indicated that the second regulatory change did not have a significant 
impact on their innovation activities. Instead these firms started setting up more 
suitable and appropriate quality agreements and commercial contracts in place to 
make sure they identify the roles and the responsibilities for those within the supply 
chain. 
 
 Recruitment and training of skilled personnel 
In accordance with new recommendations on the audits and assessments by NBs, 
auditors now visit firms, their critical subcontractors or suppliers without any prior 
notice, and at any time (European Commission, 2013a). The manufacturers, 
contractors and suppliers need to host NB teams and facilitate the audit in satisfactory 
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conditions. One such provision is to invest in qualified persons to function such as 
‘person responsible for regulatory compliance’, or appoint qualified persons already 
in their organization, who may need additional training for the tasks required of that 
person (ibid). The new regulation therefore, induced some firms to invest more in the 
recruitment and training of skilled personnel. The CEO of Med Tec Ltd and the 
Director of Neiva Medical mentioned that: 
  
“Well, our firm depend on our capability of producing advanced medical equipment, 
which require highly qualified personnel. So we managed to attract and retain 
qualified personnel and that had a significant impact on the success of the company. 
In fact, in 2013 our turnover increased to £442m from £352m in 2012)” [Res O72 
(MAN), May, 2017]. 
 
“The introduction of the random NB audits prompted us to increase training 
programmes for all employees responsible for regulatory compliance” [Res O73 
(MAN), May, 2017]. 
 
According to the interviews, the introduction of EC 2013/473/EU had mixed 
consequences for recruiting employees because the managers were seeking highly 
qualified personnel, and their compensation had high cost implications. Some firms 
ended up making some of their workers redundant as they pursue efficiency and cost-
cutting goals. One Director of Regulatory Affairs of Charlie Medical remarked: 
 
“Last year, our firm made 9 people redundant as a result of the regulatory change” 
[Res O56 (MAN), Jan, 2017]. 
 
In case of outsourcing of the production via subcontractors or suppliers and importing 
and exporting of products, expertise in regulatory affairs, reimbursement and 
import/export was reportedly critical in the new regulation. Some firms had to 
implement new recruitment strategies that would have to factor recruitment of staff 
with international regulatory exposure as the Director of Regulatory Affairs of Charlie 
Medical highlighted: 
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“We had to invest in additional human resources with international regulatory affairs 
experience to cope with the impact of the new regulations, because of inadequately 
qualified personnel to deal with the impact” [Res O56 (MAN), Jan, 2017]. 
7.2.2 Effects of the second regulatory change (unannounced audit visits) on firm 
level production capabilities 
The scope of unannounced audits is to include all the medical devices covered by the 
CE marking certificates issued by the NB. Therefore during the audit, sampling is to 
be carried out among these medical devices to verify that legal obligations are 
respected on a daily basis by reinforcing the evaluation of the coherence between the 
provisions in the quality system and the data in the technical documentation 
(European Commission, 2013a). 
 
Quality control 
The EC 2013/473/EC audits and assessments led to more rigorous product 
assessments and more frequent post-market inspections. Unannounced inspections 
required a commitment to the implementation and maintenance of effective QMS.  
Firms were required to establish a fully comprehensive QMS covering all aspects of 
their business. Accordingly, over their audit, the NB inspects the adequacy of the 
manufacturer’s QMS and the technical file of their products (European Commission, 
2013a). The new regulation impacted some firms’ QMS processes. Due to the 
requirements governing unannounced audit inspections, firms had to formulate new 
strategies including altering QMS safety and performance processes, processes for the 
device design and development, subcontracting, manufacturing, etc. The Medical 
Devices Principal Consultant of Bravo Ltd reflected in the quote below: 
 
“The continuous changes in the regulation led to our firm not only have to alter our 
QMS processes to comply forward going but also to retrospectively ensure the 
existing product meets compliance” [Res 054 (Man), Jan, 2017]. 
 
Creating a full QMS requires skills, expertise and resources. According to the 
interviews, it is estimated that for a small company, it requires from five to twelve 
months of full-time work of around two employees to create a QMS appropriate for 
producing medical devices that conform to the relevant regulations. The Chief 
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Operation Officer of Foxtrot Ltd noted: 
 
“The new regulation increased the level of QMS scrutiny and documentation for the 
technical files and maintaining those files is too burdensome and taking a lot of time 
and manpower for the firm” [Res 059 (Man), Jan, 2017]. 
 
The QMS consists of NBs verifying whether the manufacturer’s business organisation 
is appropriate for ensuring the conformity of the quality system and of the medical 
devices. In particular, the following aspects were to be examined: the organisational 
structure, the qualification of managerial staff and their organisational authority, the 
qualification and the training of other staff, the internal auditing, the infrastructure, 
and the monitoring of the quality system in operation, including with regard to 
involved third parties such as suppliers or subcontractors (European Commission, 
2013a). The manufacturer’s business organisation requirements had a huge impact on 
management responsibilities. These verifications of management responsibilities were 
welcomed by some firms as they induced the strengthening of their in-built 
management systems as remarked in the two quotes below: 
 
“Our company has had to ensure even before these additional checks or unannounced 
visits that these things were in place so we interpreted the changes as re-enforcing” 
[Head of Operations - Lima Medical, Res 069 (Man), Jun, 2017]. 
 
“We actually welcomed unannounced audit visits positively as we were already 
committed to implementing programmes and supporting resources to ensure product 
quality and regulatory compliance, including analysis of customer complaints and 
adverse event data” [Director - Neiva Medical, Res 073 (Man), Jun, 2017]. 
 
The audit of medical device manufacturers also includes suppliers of services, which 
are needed for compliance with QMS or regulatory requirements, e.g. internal audit 
contractors. The second regulation (2013/473/EC) extended the unannounced audits 
to cover critical suppliers and led to: reduced firms’ product errors, less cited non-
conformities, less product recalls and encouraged better collaborations in the supply 
chain as reflected the two quotes below: 
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“The extension of the regulatory scope helped to create a close network between us 
manufacturers and our suppliers and since the new regulation, our margin of error 
has gone down and we have less product recalls but remember this also came with 
huge compliance cost implications. So it’s a catch 22 situation” [CEO – Med Tec Ltd, 
Res 072 (Man), Jun, 2017]. 
 
“Our reviews and monitoring of their critical suppliers increased due additional 
peripheral regulations” [Senior Quality Assurance Director – Garner Ltd, Res 061 
(Man), Jan, 2017]. 
 
The QMS further addressed the after-sales measures by defining adequate processes 
for measurement, analysis and improvement including the definition of how to handle 
the internal and external feedback, to control nonconforming products and what 
measures should be taken for improvement for example corrective and preventive 
actions (European Commission, 2013a). These new changes had an impact on the 
manufacturing firms, as they now required new QMS training initiatives and 
education of both their employees and their medical device customers. Some firms 
had to address customer feedback and relationship through communication efforts, 
which were performed in collaboration with the external providers of both products 
and processes. 
 
Compliance cost 
 It is stated in the EC Recommendation 2013/473/EU that the costs associated with 
unannounced audits are paid for by the manufacturer, including the audits performed 
on the premises of its critical subcontractors/crucial suppliers. In case the 
manufacturer refuses to pay, the contract between NB and the manufacturer may 
potentially be breached, resulting in a suspension, or even the withdrawal of 
certificates. To fulfill the regulatory requirements on effectiveness, sometimes, firms 
needed to collect additional clinical data to meet CE mark certification expectation, 
which leads to the substantial amount of additional investment to obtain approval. The 
Medical Devices Principal Consultant of Bravo Ltd reflected on the high cost of 
compliance associated with new regulation in the following quote: 
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“The additional scrutiny in the new regulation increased the difficulty of new product 
introductions due to indeterminate timescales and additional costs” [Res 054 (Man), 
Jan, 2017]. 
 
One criticism particularly from the SMEs was that of the costs associated with 
unannounced audits, not only the NB fees, but also the need, ability, and resources to 
be able to support the on-site audit along with the issue of a potentially 
disproportionate audit duration to the size of company where a limited range of 
devices are produced. For example, a small company with less than five employees 
manufacturing one device still is subject to a minimum audit of one day by two 
people. The Quality Manager of Alpha Ltd reflected on this issue in the quote below: 
 
“And if you think in the medical device industry, there are a lot of SMEs where 
innovation is happening, they just cannot afford this kind of cost at the beginning” 
[Res 053 (Man), Jan, 2017]. 
 
The stakeholders highlighted that in general MNCs have strong financial strength and 
a high degree of credibility, which makes it easy to obtain loans from the international 
financial institutions. The Managing Director of JM medical remarked: 
 
“As the regulations get stricter it costs more money to comply with those regulations, 
and for the MNCs, we can absorb those costs and carry on. For the medium sized 
companies it is not that difficult but the small companies it has a huge impact so that 
would be my answer. Yes, the small companies are really struggling with the 
increasing level of regulation.” [Res 065 (MAN), Jan, 2017]. 
 
Another respondent points out that their firm might go out of business because their 
business operations have been heavily strained by regulatory costs. The Director of 
Regulatory Affairs of Charlie Medical had the following to say:  
 
“Regulation has increased significantly the cost of compliance and the type of firms 
that have been affected the most are the SMEs because they don’t have that huge 
amount of cash flow. It has cost our company about £400 000 just to implement these 
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new changes. The company is small enough to go out of business because it is very 
unfair” [Res 056 (MAN), Jan, 2017. 
7.2.3 Effects of the second regulatory change (unannounced audit visits) on firm 
level linkage capabilities 
Some firms indicated that before the introduction of the second regulatory change (EC 
2013/473/EU), they had an adversarial type of relationship with their critical 
subcontractors27 and crucial suppliers28. The Senior Quality Assurance Director of 
Garner Ltd confirmed that the linkages were weak before the strengthening of 
regulation as reflected in the quote bellow: 
 
“There is no doubt that since the inception of the new approach in the 1990s the 
relationship between manufacturers, suppliers and notified bodies has been more 
professional and more separated” [Res 061 (Man), Jan, 2017]. 
 
The second regulation (unannounced audit visits) also regulated operations of 
suppliers and that forced firms to move towards collaborative relationship with their 
suppliers. This regulation also brought more scrutiny and responsibility to diverse set 
of medical device sector actors including manufacturers, suppliers, sub-contractors, 
authorized representatives, importers and distributors, Figure 7.1 shows the impact of 
EC Recommendation 2013/473/EU on the supply chain.   
 
 
 
27 A critical subcontractor ensures all or part of the medical device's design, or performs all or part of 
the manufacturing processes, or carries out all or part of an activity in relation to regulatory 
requirements (e.g.: post-market data collection) 
28 A crucial supplier provides finished devices, or key sub-assemblies essential to the performance of 
the MD, or critical raw materials. 
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Figure 7.1: The EC 2013/473/EU Supply chain flow and compliance. Source: BSI 
(2015) 
 
The new regulations compelled each actor in the supply chain to independently verify 
compliance of the previous actor (figure 7.1). Each actor became responsible for 
implementing vigilance, notifying authorities of non-compliant devices and taking 
corrective action if required. As a result, the previous responsibilities in the supply 
chain for medical devices changed considerably, and firms now needed to reflect this 
in their distribution contracts. This regulatory requirement forced to firms to move 
away from short-term arrangements with suppliers and contractors to deeper 
relationships with them that involved assistance to perform for the benefit of the 
entire supply chain. This investment of time and resources became vital and emerged 
as key source of competitive advantage and improved market positioning. The 
collaborative, win-win relationship between the manufacturer and the supplier is one 
where both parties communicate more regularly, cooperatively share relevant business 
information and resolve conflicts through dialogue (Bastl et al., 2012). This link is not 
solely restricted to the purchase of products, components and services from the 
suppliers, but also necessitates a high degree of commitment by both parties (Lall, 
1992). Such relationship leads to higher levels of performance and economic benefits 
over the long-term as reflected in the quote bellow from the Managing Director of JM 
Medical:  
 
“We chose to collaborate with our critical suppliers on long-term basis so that we 
could achieve lower cost through shared problem solving and also to ensure that our 
components would be readily available whenever they are needed” [Res O65 (MAN), 
Jan, 2017]. 
 
The introduction of the unannounced audits had a huge effect on supplier agreements 
between actors and throughout the whole supply chain as the level of scrutiny had 
increased. For example, if a subcontractor(s) and/or supplier(s) refuse access to the 
audit team, then this could result in a suspension, or even the withdrawal of 
certificates. The actions of NBs thereby influenced the level of integration between 
firms as well as the conditions for integration. The Director of Regulatory Affairs of 
Charlie Medical noted:  
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“A lot of our suppliers are not entirely medical device suppliers so they have all had 
hard times. So what we had to do is change our supplier agreements. So our legal 
agreements with those suppliers ensured that there was a clause in there that they will 
be inspected any time and they are to notify us of any dates of which they are not 
available” [Res O56 (MAN), Jan, 2017]. 
 
The exchange of information between the local and international regulatory bodies 
improved considerably. Notified bodies introduced the use of a co-end system 
whereby if one NB feels that they can’t issue a certificate to a manufacturer or if they 
have issued a refusal, they then notify the rest of NBs around Europe and all the 
member states. This had an effect on manufacturers as the system stipulated tighter 
regulations and stopped them from shopping around for an alternative NB after 
certificate refusal and that was considered as a huge improvement. The Technical 
Manager of one the Notified Bodies summed up the regulatory effect on firm linkages 
with the following remark: 
 
 “Certainly the regulatory changes have had an impact globally on the network of 
actors who are interested in the CE certification system” [Res 060 (NB), Jan, 2017]. 
 
Operational efficiencies are the results of better relationships in the supply chain that 
allows processes to be streamlined and simplified (Lall, 1992). Therefore, the 
introduction of the EC 2013/473/EU enriched the medical supply chain relationships 
which in turn, stimulated better understanding of partner activities, and enhanced 
exchange of information and resources, reducing operational down-times, product 
recalls and more cited non-conformities as reflected in the two quotes below: 
 
“Changes within the new regulation requirements fundamentally changed the way 
NBs interact with us as more rigorous audits has resulted in more cited non-
conformities” [Director – Optics Ltd, Res 074 (Man), Jun, 2017]. 
 
“After the new regulation, we developed linkage capabilities in close collaboration 
with other key research leaders in the field to secure the proceeds of our product 
portfolio research investments” [CEO – Med Tec Ltd, Res 072 (Man), Jun, 2017]. 
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7.2.4 Summary of the effects of the second regulatory change (unannounced 
audit visits) on UK firms’ technological capabilities 
Most firms were active in understanding the view of the new regulation and thereby 
managed to implement new requirements in their business, in turn, they became 
successful. The development of new capabilities and resources in the turbulence 
created by the EC 2013/473/EU regulatory change contributed to the firms’ success. 
These firms pursued implementation of the regulatory change as a central element of 
gaining competitive advantage. Products and processes were designed with significant 
support from external providers, and linkages were formed between new and existing 
products and processes.  
 
On the other hand, some firms especially the SMEs struggled to implement 
requirements related to the EC 2013/473/EU regulatory changes due to organizational 
constraints. These firms criticized the need, ability and resources required to support 
the on-site audit along with the issue of audit duration for a company with limited 
product range. Furthermore, some firms failed to see the possibilities inherent in 
regulatory change requirements. These firms ended up as losers in the market because 
they addressed the changes only as factors restricting them and not as new 
opportunities.  
    
Some big manufacturing firms even though they had the market advantage felt more 
risk averse and put less completely radical innovations on the market. Here, some 
firms were torn between the desire to introduce new and innovative solutions and the 
need for safe and secure implementation. This innovative behavior protected firms 
from the rejection of products by the new regulation and also promoted easier 
acceptance by the market, due to the fact that the new product is an improvement of a 
previous one, already in use. The following table shows the summarized effects of EC 
Recommendation 2013/473/EU on medical device firms in the UK. 
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Table 7.2: Effects of the second regulatory change (unannounced audit visits) on medical device firms in the UK 
Firm EU Recommendation 2013/473/EU  
Ensuring that the notified body carries out a proper verification of the fulfilment of the legal requirements by the manufacturer. 
Affected Capability 
Alpha 
Ltd  
 
INVESTMENT  PRODUCTION LINKAGE 
• The changes affected the firm’s operational costs, and 
staff competency requirement and therefore affecting the 
firm’s medical device product lines. 
• The company had to invest in additional human 
resources to cope with the impact of the new regulations, 
and reported that the organization was inadequately 
qualified to deal with the impact. 
• The new regulation slowed down firm’s product development and 
innovation substantially.  
• The duration of the approval process increased 
The firm had to re-negotiate supply chain agreements, 
and alter documentation and quality management 
systems. 
Bravo 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• The firm had to recruit additional qualified staff to help 
manage the transition, ensuring that the organization has 
comprehensive clinical and technical data for their 
product families. 
• The additional scrutiny in the new regulation increased the 
difficulty of new product introductions due to indeterminate 
timescales and additional costs. 
The organization had to improve their well 
preparedness for audits, and review the arrangements 
for post-market surveillance. All this had to be done 
at high cost 
Charlie 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• In 2016, the firm made 9 people redundant as a result of 
the regulatory change 
• The firm’s return on investment was almost immediate 
prior to the regulatory change but now because it is 
taking between 8-12 months to get CE approval of the 
same type of product, thereby only seeing the return after 
one and half years. 
• The amount of inspection days when the auditors come on sight 
doubled after the new regulation, therefore increased in 
compliance costs 
• Firm’s Technical files scrutiny after the new regulation increased, 
before they used to be reviewed in a day but now it takes three 
days to review. Thus, the increased review time is also paid by 
the manufacturer 
• The firm has reduced innovation and their R&D department has 
gone from 12 to 3 members 
• Now invest more in a smarter production due to regulatory cost 
• For the first time, the firm is now going to other markets in search 
of return on investments due regulatory change 
As one NB’s license was revoked due to changes in 
regulation. This has cost the company about £400 000 
just to implement these new changes (drawing in a 
new NB required an admin fees, re-inspection fees, 
transfer fees, and on-going surveillance cost). 
 
Delta  
Ltd 
 
INVESTMENT  PRODUCTION LINKAGE 
• While operating in a competitive and increased 
regulatory environment the firm improved innovation 
performance. R&D expenditure increased by 50%  £ 
123, 699, 262 in 2013 and increased its headcount by 
71% to 229 employees 
• Regulation increased the production process efficiency 
• Company products reduced life cycles because of development of 
competitive technologies and increased time to market due to new 
regulatory huddles 
• Increase the product safety 
• Increased regulatory costs 
• Tighten up the firm’s processes and make them robust and more 
reliable 
• Re-negotiate supply chain agreements 
Echo INVESTMENT PRODUCTION LINKAGE 
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Ltd 
 
• Complex standards and regulatory requirements added to 
the cost of bringing products to market and delayed 
product approval, and thus, impeded the success of firm 
in that market 
• Issued a notice for compulsory strike-off in Jan 2015 in March 
the same year suspended the strike off. In Dec 2017 the firm 
issued another notice for compulsory strike-off. This strike offs 
have been attributed to increased regulatory costs. 
• Re-negotiate supply chain agreements 
Foxtrot 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• Firm invested highly in R&D with total expenditure of 
£727,000. The investment was focused on new 
innovative (xxxx) monitor. 
• The number of employees remained the same (63) in 
2013 compared to 2012. Thus, there was no effect of 
regulatory change on recruitment of skilled manpower 
• The new regulation increased the level of documentation 
for the technical files and maintaining those files was 
said to be burdensome and taking a lot of time and 
manpower for the firm. 
• Improved operations and the turnover in 2013 increased to £6.8 
million.  
• Increased innovation thereby maximised return on investment and 
strongly increased cash generation. 
• Received NBs visits three times in a year, one to do a technical 
audit, one to do a re-certificate audit and one to do a microbiology 
audit was onerous and increased compliance cost. 
• The continuous change in the regulation led to the firm not only 
have to alter their processes to comply forward going but also to 
retrospectively ensure the existing product meets compliance. 
2013 International revenues increased by 26% to 
£1.537,000 compared to £1,223, 000 in 2012 partly 
due strong international links. 
 
Garner 
Ltd 
 
 
 
INVESTMENT PRODUCTION LINKAGE 
• -The core regulation did not have a big impact on the 
firm, apart from the fact that they ended up with a 
suitable and appropriate quality agreement and 
commercial contract in place to make sure they identify 
the roles and the responsibilities for those within the 
supply chain. 
• The new regulation did not affect the firm’s innovation processes  
• The firm’s reviews and monitoring of their critical suppliers 
increased due additional peripheral regulations 
-Linkages through educational establishment grow 
 
Hex 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• The regulatory change affected both training and 
administrative costs linked to preparation of contracts 
and auditing. 
• The regulation affected the level of available skilled 
personnel necessary to carry out innovation 
• Timelines for reporting serious incidents were reduced from 30 to 
15 days under the new regulation. The firm had to ensure they 
have sufficient staff and adequate internal systems to meet the 
new requirements. 
The firm increased their focus more on post-market 
surveillance and vigilance. 
Indigo 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• The firm highlighted instead of investing £20 000 on the 
regulation they would rather spend it purely on materials. 
• The financial impact of the new regulations was significant for 
firm. The new regulation increased cost of compliance. 
• Extended product’s time to market 
Because the regulation allowed critical supplier 
audits. The firm’s linkage capabilities were heavily 
affected as they had to put systems in place to 
accommodate new terms and new supply contracts. 
JM 
Medical 
 
 
INVESTMENT PRODUCTION LINKAGE 
• The firm continued to invest heavily in R&D their 
product pipeline continued deliver innovative profitable 
products in spite of the stringent regulated environment. 
The firm spend £46m on R&D projects 
• In 2013, the firm’s operations and performance remained static. 
The product sales were £181.7m (2012 £181.6m) 
The firm had strong linkage capabilities with its 
suppliers and proactively reviewed its customer 
contracts to leave the company well placed to 
maximise supply. 
Kilo INVESTMENT PRODUCTION LINKAGE 
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Ltd 
 
• The new regulation has added at least a year before the 
firm can launch new products having to go through the 
regulatory approval tests 
• Innovation capability increased. In 2017, Her Majesty Queen 
presented the company with another award under the Innovation 
category, for its technical and clinical excellence 
The unannounced audits have heavily increased 
regulatory cost on the firm; on top of that they have 
to pay first class plane tickets for auditors who would 
have gone to their critical suppliers in China. 
Lima 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• Overall companies operation and performance continued 
to increase with a turnover of £610m in 2014 from (2013 
£562m) 
• The company has had to ensure even before these additional 
checks or unannounced visits that these things were in place so 
they interpreted the changes as re-enforcing. 
After new regulation, the company did spend more 
money in making sure that they are complying with 
the unannounced visits 
Med Tec 
Ltd 
INVESTMENT PRODUCTION LINKAGE 
• The firm depended on their capability of producing 
advanced medical equipment, which required highly 
qualified personnel. 
• The firm managed to attract and retain qualified 
personnel and thus had a significant impact on the 
success of the company. 
• In 2013 the turnover increased to £442m from (2012 
£352m) 
• Change in regulations increased the firm’s costs and delayed the 
development and introduction of new products. 
• The firm’s production site depends on a number of suppliers for 
components. After the new regulation, there was a high risk that 
those suppliers might change their terms. The firm therefore 
increased their follow-up strategies on critical suppliers regarding 
delivery precision and quality of components. 
•  
After the new regulation, the firm developed their 
linkage capabilities in close collaboration with other 
key research leaders in the field to secure the 
proceeds of their product portfolio research 
investments. 
 
Neiva 
Medical 
 
INVESTMENT PRODUCTION LINKAGE 
• Increased training programmes for all employees 
responsible for regulatory compliance. 
• The firm took on board the regulatory changes and 
recognised that the cost of non-compliance with policy, 
regulation and standards governing products and 
operations regarding registration, manufacturing and 
distribution was higher than complying. 
•  
• The firm increased its strategy on reviewing product safety and 
compliance data. 
• Welcomed unannounced audit visits positively as they had 
already implemented programmes and supporting resources to 
ensure product quality and regulatory compliance, including 
analysis of customer complaints and adverse event data. 
• The new regulation slowed down the time to market of the firm’s 
products. The NBs moved away from offering the CE 45 or CE 
90 where a manufacturer could get a quicker approval by going 
for a 45 or 90 days approval. 
The new regulation forced the company to have 
appropriate technical agreements, quality agreements 
as well as the commercial contracts with their 
suppliers 
 
 
Optics 
Ltd 
 
INVESTMENT PRODUCTION LINKAGE 
• The firm’s R&D and innovation was not affected 
• Increased regulatory affairs personnel 
•  
• The review of technical files and design dossiers by NBs has also 
resulted in more comments that must be addressed before the 
reviews are completed. Leading to longer review times at the cost 
of the manufacturer 
• The firm had to change supplier agreements and in some cases re-
assess some of the key critical suppliers at a relatively high cost 
for these additional scope of services and liability 
• Changes within the new regulation requirements 
fundamentally changed the way NBs interact 
with the manufacturer as more rigorous audits 
has resulted in more cited non-conformities 
Compiled by author from empirical data 
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7. 3 Detailed Analysis of Three UK-based Firms 
This section will analyze three studies in more detail within the context of the two 
regulatory changes i.e. the MDD 2007/47/EC and the EC 2013/473/EU regulation. 
The actions are derived from the descriptions presented by knowledgeable 
respondents through interviews and in published or archival documents.  
7.3.1 Alpha Ltd  
Alpha Ltd was established in 1975 as a family run business set up to provide medical 
equipment and services to a wide range of customers, including the UK NHS and 
private hospitals. The company had a turn over of £1.3 million in 2016 and wide 
range of in-house designed products. Over the years Alpha has established a strong 
reputation for design, manufacture, quality and excellent customer service with full 
technical support and advice. The firm can be categorised as a SME with an 
employment size band of 20-49 people and has an international reputation for 
supplying medical equipment and exports its products to over 28 countries. Alpha’s 
international operations played a crucial role for its long-term growth. In 2005, Alpha 
entered a joint venture agreement with another company. Alpha held 60 percent share 
of this joint venture and provided technical knowledge for the production and sales of 
the products.  Alpha manufactures medical devices with a focus on oxygen-therapy 
products and electrical magnetic products.  The purpose of the joint venture and the 
move away from export and sales representation, Alpha’s Quality Manager argued, 
was less about the cost savings aspect and rather a change to be in closer contact with 
the growth in UK. 
 
“The real reason for starting this joint venture was that we wanted to strengthen 
Alpha’s presence in UK. The drive was to tap into UK’s production competence” 
(Quality Manager - Alpha, 2017). 
 
The joint venture factory in the UK was inaugurated in 2005, but after a year of 
operation the joint venture was still not running smoothly. Alpha soon realized that 
the management team assigned by the other partner to manage the factory was 
spending more time inspecting Alpha to make sure it did not double-cross them, than 
supervising factory operations. Alpha then decided to buy out its joint venture partner 
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in 2006 and turned into a wholly owned family run business again. Although it had to 
invest more financial capital and bring in professional management, Alpha was able 
to gain complete control over operations and build direct contacts with the 
international suppliers. By 2009, the business operations had improved. 
 
The firm outsourced some parts of its software to a company in the USA up till 2011 
when compliance related problems arose. Consequently, the firm terminated its 
supply contract with their USA based supplier and that led to changes in their 
production processes.  Their assembly is now carried out in-house by their fully 
trained engineers, enabling full control from component conception right through to 
the finished product. In addition, Alpha began local sourcing activities for basic 
materials, and gradually expanded the sourcing activities in the UK in terms of 
volume and sophistication.  The Quality Manager of Alpha remarked: 
 
“We started from very basic items and now we can source relatively complicated 
units. Our sourcing team has grown and become more competent along with these 
suppliers. It has been an experience of mutual learning” (Quality Manager - Alpha, 
2017). 
 
Alpha provides personal monitors, which offer a unique method of determining 
individual risk to harmful exposure from waste anaesthetic gases in a clinical 
environment. It has been known for many years that exposure to waste anaesthetic 
gases may be harmful to the health of exposed employees (Guirguis et al., 1990). The 
areas of potential significant exposure include: operating theatres, recovery rooms, 
dentistry, maternity units and veterinary surgeries (ibid).  
 
 The firm also has a long history of supplying medical device systems components to 
nearly every NHS hospital department, which has earned the company a reputation 
for providing a friendly, flexible service with competitive pricing. Moreover, the firm 
operates a comprehensive schedule of maintenance contracts to ensure continued 
accuracy and reliability of its range, together with a recalibration service, so its 
customers can always have complete confidence (Alpha, 2017). 
 
All products of Alpha are CE marked and is annually audited and fully meets the 
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requirements of the medical device quality system – ISO 62304, ISO 13485 and 
conform to Directive 93/42/EEC as amended by the software regulation (MDD 
2007/47/EC). Alpha adhere to regulations and procedures for raising equity for 
expansion and research, however, they face some challenges in maintaining the ISO 
13485 and IEC 62304 standard, which they viewed as too aggressive. To that effect, 
the Quality Manager Alpha commented: 
 
“We are a small company therefore struggling a little bit to maintain ISO 13485 
because it is really a strong requirement which cover the design phase and everything 
else” (Quality Manager - Alpha, 2017). 
 
 Effects of the first regulatory change (software) on Alpha Ltd.’s investment 
capability 
The introduction of the software regulation (MDD 2007/47/EC) required that 
safeguards pertaining the risk management be put in place to ensure that such 
software is safe and fit for purpose (European Commission, 2007). Alpha emphasized 
that risk analysis mandated by the software regulation start at the initial R&D phase 
and cover supply chain, manufacturing, design transfer, software integration, and also 
aligns with the post market surveillance. The introduction of the risk management led 
to a reduction of the firm’s device recalls. However, due to massive documentation 
procedures such as additional technical reporting and provision of information 
concerning validation and verification introduced in the new regulation, the new 
requirements were seen as limiting investment opportunities and increasing the 
responsibilities for the firm. The Quality Manager of Alpha said: 
 
“The validation of software production line costing us about £15-20000. This has 
increased compliance costs and also limited our investment opportunities as a 
company (Quality Manager - Alpha, 2017). 
 
Alpha management also raised some concerns about requirement of clinical data for 
conformity assessment. Conformity assessment entails clinical evaluation of medical 
devices which includes a process of compiling clinical data in form of the safety 
and/or performance related data that is generated over the use of a medical device 
(Chowdhury, 2013). It can be obtained from clinical investigation(s) of the device 
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concerned or from clinical investigation(s) or other studies of a similar device 
reported in scientific literature if the equivalence of the device to the one concerned 
can be demonstrated (Fiedler, 2017). Nelson and Winter (1982) suggest that internal 
R&D activities look to regulations and changes in regulations for guidance and 
evaluation of new solution. Alpha described the guidance and evaluation process 
requirements as too complex resulting in the firm having to increase its expenditures 
on R&D compliance activities and increased design times and ultimately slowing 
down products’ time to market. The Quality Manager of Alpha mentioned that: 
 
“We complained about the process of conformity assessment to the competent 
authorities, and called for reducing clinical data requirements” (Quality Manager - 
Alpha, 2017). 
 
The software regulation (MDD 2007/47/EC) led the firm to redefine the training 
needs for innovations, prototyping, design, testing, validation, and release processes. 
A highly skilled workforce, which included researchers, engineers, and staff with 
regulatory expertise, was an important competitive factor for the firm. Expertise in 
regulatory affairs was critical, as each new and improved product had to be approved 
through the new regulation.  An increased number of staff devoted to regulatory 
affairs was needed to help the firm boosts its returns. The Quality Manager of Alpha 
commented: 
 
“We were forced to increase the workforce training on the EN/IEC 62304 standard 
for efficiency and competitiveness in operations” (Quality Manager - Alpha, 2017). 
 
However, the need to devote substantial resources to regulatory matters reduced 
resources that would have otherwise be available to support product development and 
commercialization. The firm had to increase the workforce training on the IEC 62304 
standard for efficiency and competitiveness in operations and training of the risk 
management system process activities. The firm indicated that it had spent 
approximately £100,000 per year on training of small teams. The Quality Manager of 
Alpha stated,  
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“We are always happy to evolve existing product ranges, or create new ones to meet 
customer and new regulatory requirements, however during manufacturing you need 
to validate your validation line which is very expensive, to validate a production line 
it costs about £15-20 000 and that is affecting us” (Quality Manager - Alpha, 2017). 
 
The following table shows the firm’s turnover from 2010 to 2016. 
Table 7.3: Alpha’s turnover from 2010 to 2016 
Year 2010 2011 2012 2013 2014 2015 2016 
Turnover £413,560 £522,491 £185,907 £282,989 £495,496 £656,327 £1,356,593 
 
As shown in the table above, Alpha’s financial performance in 2012 was below 
expectations, as reflected in its revenue growth at £185,907 compared to £522,491 in 
2011.  The firm attributed the turnover reduction partly to high cost of compliance. To 
improve the company’s revenue performance, the firm had to cut cost in various 
operational areas such as shortening the research life cycles.   
 
 Effects of the first regulatory change (software) on Alpha Ltd.’s production 
capability 
The influence of the software regulation (MDD 2007/47/EC) in product development 
created significant changes in Alpha’s allocation of inventive efforts to meet market 
requirements. The new regulation established disruptive requirements for the firm 
since they could not be met with existing products and technology (Bell and Pavitt, 
1995). They forced the firm to establish new initiatives to develop new solutions and 
introduced the need to consider integration between the new and existing products. 
The new standards and regulatory requirements added to the cost of bringing products 
to market and delayed product approval, and thus, impeded the expected success of 
the firm in that market. The Quality Manager of Alpha remarked:  
 
“For us to meet those requirements we needed to spend huge sums of money 
recruiting more people in terms of production because of a lot of new regulatory 
paperwork involved and new control measures. The changes affected the product 
development process and our existing product” (Quality Manager - Alpha, 2017). 
 
At the same time, the firm echoed that the MDD 2007/47/EC regulation facilitated 
better understanding of products by demanding product content transparency and 
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reliability of same products through the validation processes. By requiring increased 
transparency, the new regulation drove the demand for the unbundling of the medical 
device software lifecycle process into smaller parts relevant to each production 
process phase. As a consequence, the IEC 62304 standard associated with the 
2007/47/EC led to the firm’s software development process improvement. The 
Quality Manager of Alpha highlighted: 
 
“So you create a procedure, you create a quality manual you create a form then you 
invite the notified body in. All that helps of transparency in the production line” 
(Quality Manager - Alpha, 2017). 
 
Furthermore, empirical results demonstrated that, in a transition period of regulatory 
change, the firm experienced adverse consequences. However, in the long term, the 
regulatory framework for medical device software had affirmative effects on the firm 
with respect to the quality of new product offerings. 
 
Effects of the second regulatory change (unannounced audit visits) on Alpha 
Ltd.’s production capability 
The unannounced audit visits regulation (EC 2013/473/EU) put an extra burden on 
Alpha’s costs associated with the process of complying with these audits. The firm 
highlighted that medical device manufacturers are required to pay for the audit and 
the current cost in the UK is approximately £5000 per visit. The firm expected at least 
one unannounced audit during a three-year period and two auditors are typically 
involved in the audit. The Quality Manager of Alpha remarked: 
  
“The calculation of the cost were too high and depended on several parameters 
including the number of days the audit lasted, the number of auditors, the place where 
the audit took place (travel expenses), the administrative and report fees, tests 
performed for any samples taken and the safety measures of the auditors” (Quality 
Manager - Alpha, 2017). 
 
The firm indicated that their unannounced audit identified potential concerns with the 
management of critical suppliers, which then triggered a second unannounced audit to 
that supplier. The cost of this second audit was also charged to Alpha increasing the 
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compliance cost even more. This also led to delay in getting approval due to lengthy 
process associated with audit. According to the interview with the CEO of Alpha the 
new regulation limited the number of innovations, delayed entry for products in the 
market and adversely influenced the expected rate of return. But the new regulation 
also created opportunities for firm to improve the production process and stimulate 
creativity as mentioned earlier.  
 
Effects of the first regulatory change (software) on Alpha Ltd.’s linkage 
capability 
The new regulation demanded changed conditions for firm’s collaboration due to new 
challenges in the interface between actors. Alpha had to change their linkage 
processes with their suppliers and contractors as a result of the new regulation. Alpha 
initiated development parts of the software design through outsourcing to bridge skills 
shortages and these software parts were then integrated into the medical devices 
manufactured by Alpha. The Quality Manager of Alpha said: 
 
“Yes we have one software related product and we use a contract manufacturer to 
develop the software because there are not a lot of skilled people out in the medical 
device industry” (Quality Manager - Alpha, 2017). 
 
In response to software regulation, the firm took certain precautions to ensure its 
control over the whole chain of development of the software concerned. 
 
“We needed to approve our USA based supplier, by approving them we needed the 
time to go and audit them onsite bearing in mind that we didn’t have the lead auditor. 
Also, we needed to create what is called a quality technical agreement so that 
agreement covers our relationship” (Quality Manager - Alpha, 2017). 
 
Alpha ensured that the development process of the software fits the requirements 
imposed by the annexes to the MDD 2007/47EC and the applicable standards, such as 
EN 62304 by documenting all the elements of software development process. This 
process proved extremely onerous for the firm as the supplier was based in the USA 
and was accustomed to FDA regulations that were different to the software 
regulations. This led to termination of agreement with US based suppliers and forced 
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Alpha to identify local sources. The Quality Manager of Alpha had the following to 
say: 
 
“Because of some regulatory complications we had no choice other than to terminate 
our contract with the international supplier and looked for another option” (Quality 
Manager - Alpha, 2017). 
 
Effects of the second regulatory change (unannounced audit visits) on Alpha 
Ltd.’s linkage capability 
Alpha’s delivery of products and processes was dependent on complements in the 
chain of production and new regulation prompted the inclusion of external process or 
product providers in audits. From a contractual point of view, the new provisions had 
an impact on the content of contracts. The firm had to revisit their procedures for 
planning and execution as well as set up new contracts with the NB and external 
providers at a higher cost. 
 
Summary of Alpha’s implementation actions  
Evidence presented in Alpha case study highlights that the firm viewed the changes in 
the regulation as new restriction on business practices and found regulatory 
requirements costly, time consuming and restrictive. This put additional pressures on 
firm’s limited resources impacting its competing advantage through the loss of agility.  
7.3.2 Bravo Ltd  
Bravo Ltd was launched in 2006 as an innovative, medical technology focussed, and 
standards driven company. It can be categorised as a small firm with an employee size 
of less than ten people and had a turnover of half a million pounds in 2017. Bravo 
products include, orthopaedic restorative devices, dental restorative composite, and 
biosensor medical devices. In addition, the firm is involved in providing expert 
technical advice in medical and healthcare technology industries worldwide, 
including environmental management and related sustainable technologies (Bravo 
Ltd, 2017). 
 
From 2007 Bravo was involved in providing both on and off-site support with 
regulatory affairs, quality assurance and product development on long term and 
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interim projects to a variety of clients and taking product innovations to the EU 
market. By 2012, Bravo had extended its product innovations to the USA and other 
global markets.  The firm is made up of scientists, engineers, and business innovators, 
with in-depth industry expertise, working closely with their clients to turn great ideas 
into innovative products and services.  
 
Since its foundation, Bravo’s business development experts have played a pioneering 
role in a broad spectrum of sectors including biotechnology, pharmaceutical and 
medical technology. In many cases, the firm’s core technology is created in-house but 
it also outsources some of its products components. The scope and variety of their 
projects can be very different, but involves usual business processes of identifying the 
need, assessing the market opportunity, creating the solution and then transferring the 
output into a manufacturing supply chain (Bravo Ltd, 2017). 
 
Effects of the first regulatory change (software) on Bravo Ltd.’s investment 
capability 
Bravo’s success was built on innovation and a strong commitment to R&D with R&D 
emerging as key part in the life cycle of their products. The introduction of the 
software regulation (MDD 2007/47/EC) led to increase in Bravo’s operational 
expenditures. Approximately 20% of the increased expenses were for legal services, 
compliance submissions, and supply chain development. The firm’s viewed the new 
regulation as quite stringent thereby affecting all the processes involved in the 
developing new products.  The Principal Consultant of Bravo Ltd remarked: 
 
“The UK regulators are quite stringent but they are just as the German regulators, 
perhaps not as stringent as Eastern European countries because of resources and that 
entire thing” (Medical Devices Principal Consultant - Bravo Ltd, 2017). 
 
In some cases the firm lacked in-house capability to test clinical safety of their device 
and these devices were then sent to a university or a research and development 
institution to conduct those tests. Preclinical investigation is the stage in the product 
life cycle that incorporates and resolves conflicts between requirements and 
manufacturing capabilities (Fiedler, 2017). While in this stage, the product is 
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subjected to verification and validation (V&V) processes as required by the MDD 
2007/47/EC.  
 
Product development from the earliest phases requires active involvement of 
practicing clinicians. These clinicians are essential to conduct animal testing (or 
clinical studies, as needed) while engineers will focus on bench testing (Fiedler, 
2017). Bravo could not manage to meet these new regulatory requirements on its 
own; the firm didn’t have the capacity and capability. The Principal Consultant of 
Bravo Ltd revealed that: 
 
“These days you are obliged to do some sort of clinical testing to produce some sort 
of data for the notified bodies to be confident to say yes you have done enough to 
convince us that the medical device is clinically safe to use” (Medical Devices 
Principal Consultant - Bravo Ltd, 2017). 
 
Moreover, the preclinical investigation activities permit Bravo’s engineers to obtain 
the required knowledge about product performance, failure modes, and risk mitigation 
strategies. Bravo’s safety concerns during first clinical use and pilot phase mandated 
collaboration between engineers, inventors, and clinicians. At this phase, the clinician 
frequently takes on the leadership role but needs support of regulatory expert. Thus, 
the new regulations kept up the firm’s cost of producing a safer device for the market 
but enhanced strong collaborative relationships. The Principal Consultant of Bravo 
Ltd elaborated: 
 
“ As the manufacturer you have to do some sort of testing to support the literature 
review route and say yes even if it is similar and all that, I have also done this clinical 
testing to support what is being published out there before it is accepted” (Medical 
Devices Principal Consultant - Bravo Ltd, 2017). 
 
Despite Bravo’s increased investment in regulatory compliance, the firm’s 
management was efficient in resource management and took on board well the 
implementation of the new regulation. The Principal Consultant of Bravo Ltd 
underscored that:  
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“The MDD 2007/47EEC enhanced the clinical evaluation, the depth of risk 
management and the emphasis on batch reconciliation so that we should be able to 
account for every device that has been manufactured within certain given periods” 
(Medical Devices Principal Consultant - Bravo Ltd, 2017). 
 
From an overall industry context, Bravo placed strong emphasis beyond the impact of 
regulatory change on investment in recruitment and training of skilled personnel as 
reflected in the quote below by the firm’s Principal Consultant: 
 
“To start off, the industry really needed education to accept that software was now a 
medical device and as such, has to be regulated as a medical device and it even took 
quite long for software developers to catch up to the understanding that now what 
they were developing wasn’t just an ordinary software but is a software regulated as 
a medical device” (Medical Devices Principal Consultant - Bravo Ltd, 2017). 
 
The MDD 2007/47/EC created new firm needs for retraining of staff to improve the 
success rates of the respective software-embedded devices. The changes called for 
recruiting staff members who would provide the company with skills and productivity 
to propel profitability.  
 
Effects of the second regulatory change (unannounced audit visits) on Bravo’s 
investment capability 
Bravo had to implement the provisions needed to provide answers to the auditors' 
questions. This meant the firm had to increase their investment budget in recruiting 
and training of additional “key regulatory affairs” staff members and define 
procedures regarding temporary replacements and delegations required for the 
unannounced audit to be performed in satisfactory conditions. The Principal 
Consultant of Bravo Ltd noted: 
 
“Now when we produce the technical file that governs the medical device, the people 
that perform the testing and the processes are required to produce a CV and attach to 
that particular piece of work that they have done. Such that when the auditors come 
to review what we have done they will also have the confidence that the person that 
did it is competent enough to have been able to do a successful work, previously it 
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wasn’t like that, anyone could just do anything with a little bit of training” (Medical 
Devices Principal Consultant - Bravo Ltd, 2017). 
 
Effects of the first regulatory change (software) on Bravo Ltd.’s production 
capability 
The MDD 2007/47/EC forced the firm to change their practices to create safe and 
quality software. The firm had a general belief that the IEC 62304 had met 
expectations in enhancing the safety of medical devices. Before the software 
regulation (MDD 2007/47/EC) there was a minor flaw for the company’s software 
systems that were not in straight contact with patients. There was not any regulation 
for finding out the possible risks and fix them. With the introduction of the new 
regulation, the Principal Consultant of Bravo Ltd commented: 
 
“Now every software that is to be developed as a medical device has to go through a 
process of analysing the risk associated with the software, the disability of that 
software and the risk associated with the disability and not just the use of it but the 
end output of it” (Medical Devices Principal Consultant - Bravo Ltd, 2017). 
 
The regulatory change influenced the firm’s process of manufacturing their products, 
leading to improvements in quality. The firm applied the external new regulation and 
standards as guidelines to modify their own internal regulatory compliance processes. 
In this way, the firm exerted their regulatory processes across their different products, 
thereby improving the quality of all their product offerings. However, the changes in 
regulation increased the time required to introduce new products and technologies to 
the market. 
 
Effects of the second regulatory change (unannounced audit visits) on Bravo 
Ltd.’s production capability 
The 2013/473/EU regulatory change influenced Bravo’s organizational practice 
associated with manufacturing of devices since the delivery of their product 
innovation required input beyond the internally available components. The regulation 
thereby influenced businesses’ consideration of whether to make or buy parts of their 
products. In the end the firm decided to make 95% of its products parts, thus the 
change opened up space for the firm to take full responsibility for most of its different 
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parts of their products and experienced fewer product recalls. 
 
To get the ISO 13485 certification for QMS, the firm had to go through the process of 
initial audits and then certification audits. One concern mentioned by the Principal 
Consultant of Bravo Ltd was impact of these audits on the firm’s compliance cost 
associated with the 2013/473/EU audit process:  
 
“The initial audit alone cost us around £5000 and then the actual certification audits 
cost a little bit extra. A day’s work for an auditor will cost between £1 300 to £1 700. 
That is the time that they have spent on site, but extra costs do come on top. They are 
several times as a manufacturer we had to pay the auditor’s travel and hotel 
expenses. The writing of the report can take about one and half days and again we 
had to pay for that also. By the time they finished, the whole certification cost us 
about £12 000” (Medical Devices Principal Consultant - Bravo Ltd, 2017). 
 
Effects of the second regulatory change (unannounced audit visits) on Bravo 
Ltd.’s linkage capability 
Unannounced auditing and monitoring procedures raised issues in the relationship 
between the Bravo and audited suppliers. Reported issues include reduced trust and 
commitment and also increased coordination efforts. It was very important that as part 
of Bravo’s preparation for compliance with the 2013/473/EU Commission 
Recommendation that the firm review and revise as applicable, the 
contracts/agreements to ensure their sub-contractors and suppliers understood their 
obligations. However, the management had to disintegrate their interactions with one 
of their crucial suppliers at a very high cost due the suppliers’ nonconformities that 
affected the safety and performance of Bravo’s products. 
 
Furthermore, Bravo revealed that the overall medical device industry collaborative 
linkages efforts were so weak and not enhancing the firm’s innovation process. 
Therefore, the firm took a pro-active approach and wrote to the competent authorities 
requesting them to give actors in the industry access to a system called EUDAMED. 
EUDAMED is an information system database for exchanging legal information 
related to the application of the EU Directives on medical devices and information 
about products of manufacturers but it is only accessible to the competent authorities. 
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By giving access to actors, the firm considered that this would increase efforts to 
communicate and improve collaborative linkages within the medical device industry 
network. The Principal Consultant of Bravo Ltd remarked: 
 
 
“We wrote about this because Europe tends to use a database run and managed by 
the FDA called the MAUDE. This database houses information about any complaints 
that have been launched against the medical device on any market, which the FDA 
regulates. So if we are to develop a new device, and be able to check on the database 
system and see something wrong against a device that is similar to ours then we will 
know how to design the new device to eliminate problems that might come later 
(Medical Devices Principal Consultant - Bravo Ltd, 2017). 
 
Summary of Bravo’s implementation actions  
Adopting the new regulation contributed to Bravo’s products safety improvement, 
better product quality, efficacy, and reliability, while company experienced fewer 
product recalls. Since Bravo is a firm that is both a manufacturer and a critical 
subcontract to other MNCs and SMEs, the EU 2013/473/EU subjected them to two 
unannounced audits according to its two activities. This however had a huge impact 
on the overall firm’s compliance costs. Bravo was a proactive proponent after the 
regulatory change, both facilitating contacts between regulators and the companies in 
the market and making direct contact with the persons at the regulatory agency who 
would be responsible for supervising implementation. 
7.3.3 Charlie Medical Ltd  
Charlie Medical Ltd is a creative development, engineering, production and research 
company. Founded in 1978, the company design and manufacture a wide variety of 
wound care products, all of which are packed and sterile and constitute 80% of the 
business. As well as wound care dressings, the firm also design and contract 
manufacture airway management products such as Laryngectomy Protectors, Voice 
Prosthesis Brushes and Endotracheal (Charlie Medical, 2017).  
 
In addition, the company specialises in the development of innovative blood-
processing equipment. The firm develops embedded software or firmware in their 
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ground-breaking blood recycling devices “XXXX” (product name) in collaboration 
with one university. The devices recover blood spilled during open heart and major 
trauma surgery, cleans and concentrate the blood cells and return them to the patient. 
This meant reduced risk, quicker recovery, better outcomes and potentially huge 
savings for hospitals, because less donor blood is required (Charlie Medical, 2017).  
The firm is a SME that has an employment size band of between 100 to 249 people. 
The following table shows the firm’s key financial highlights: 
 
Table 7.4: Charlie Medical’s key financial highlights from 2011 to 2017 
 2011 2012 2013 2014 2015 2016 2017 
Turnover £13.4m £14.8m £15.3m £14.5m £14.8m £14.9m £17.2m 
Gross Profit 
margin 
46% 49% 42% 43% 42% 36% 40% 
Operating 
Profit/Loss 
733K 1,030K 826k 392k 1.364k (224k) 644k 
 
In 2017 the company’s turnover grow by 15% to £17.2 million. Other areas of growth 
for the firm were in export and medical device development of £0,5million. On the 
onset of the MDD 2007/47/EC the firm was investing more in R&D, as it believed 
that the way forward was the continued development of its existing product lines as 
well as expansion into new product areas. In 2012, despite the national and global 
medical devices continuing to be in a depressed state, Charlie Medical had a very 
successful year. Turnover increased in excess of 10%. With the level of uncertainty in 
the global market, the firm continued to maintain strong links with customers and 
suppliers as well as maintaining active control over operational costs (Charlie 
Medical, 2017).  
 
Crucial to the company’s success was the development of new innovative products, 
thus in 2013 the firm launched a new surgical trading division around its new blood 
recovery system “XXXX” product. In 2014, a year after the EU Regulation 
2013/473/EU was introduced, the firm’s turnover fell back to £14.5m from £15,3m as 
a result of expected reduction in third party sales and unexpected length of time taken 
to get product registration. This was down to processing delays within different 
governmental regulatory agencies. By then, the firm’s ground-breaking blood 
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recycling innovative device was subjected to unexpected delays that had cost the 
company 12-18 months (Charlie Medical, 2017).  
 
By end of 2014, the firm’s “xxxx” product had already received Canadian national 
approval following highly successful clinical trials, however, at the same time there 
were still on-going clinical trials at several UK hospitals. Turnover grow by 2% in 
2015 and a difficult decision was made to close down two of their subsidiaries and 
move across to a distribution model. The decision was essential to get back on a 
sound footing because their key product was still subject to regulatory approval 
delays. Yet again four years later in 2017 the firm’s “xxxx” product still had on-going 
trials at UK hospitals. Their product went through minor design changes to facilitate 
better growth going forward and was anticipated that the launch of a significant 
improved CE marked product would be in early 2018 (Charlie Medical, 2017). 
 
Effects of the first regulatory change (software) on Charlie Medical Ltd.’s 
investment capability 
The implementation of the new regulation forced Charlie Medical to change its 
investment strategies, as such, the firm started to invest more in a smarter production, 
because they were getting a lot of regulatory costs. The increased regulatory costs 
meant that the firm had to reduce costs elsewhere in the business. Charlie Medical 
took a radical decision to reduce R&D spending and invest more into smart 
automation production. The regulatory changes forced the firm to reduce the 
innovation; their R&D department reduced from 12 to 3 members. The introduction 
of the MDD 2007/47/EC had mixed consequences for recruiting employees because 
the firm was seeking those with top skills, and their compensation had cost 
implications on the project for each EN/IEC/62304 compliance software release.  
 
Effects of the second regulatory change (unannounced audit visits) on Charlie 
Medical Ltd.’s investment capability 
The firm had to lay off many workers as they pursued efficiency and cost-cutting 
goals.  The employee layoffs trend was further heightened by the introduction of 
2013/473/EU regulation, which caused the firm to make nine people redundant in 
2016. The Director of Regulatory Affairs of Charlie Medical commented: 
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“In 2016, the firm made 9 people redundant as a result of the regulatory change” 
(Director of Regulatory Affairs - Charlie Medical, 2017). 
 
The firm highlighted the its return on investment was almost immediate prior to the 
introduction of 2013/473/EU but after changes it was taking between 8-12 months to 
get CE approval of the same type of product, thereby only seeing the return after one 
and half years. 
 
Charlie Medical had historically been active in placing multiple new products on the 
market. The EU Regulation 2013/473/EU caused the firm to consider investing on 
one product offering at a time. Moreover, the firm’s target market focus changed after 
the new regulation, and for the first time they took their products directly to the USA 
first because their regulatory pathway (FDA 510k) process for products on the market 
was considered far simpler and cheaper in the long run than the UK regulatory 
framework. The Director of Regulatory Affairs of Charlie Medical noted: 
 
“Because of the high cost of compliance we are now working on one product at a 
time and bring it to the market place and in fact now we are actually going to other 
markets first, which is the first time it has ever happened and the reason for that is we 
are looking at the return on investment” (Director of Regulatory Affairs - Charlie 
Medical, 2017). 
 
Effects of the first regulatory change (software) on Charlie Medical Ltd.’s 
production capability 
Charlie Medical indicated that the MDD 2007/47/EC amendment made them to be 
more consistent in practices of software material designs and created widespread 
commitment within the firm to improve device quality, thus resulting in lower device 
recalls and failure incidences that cause harm to the users or the medical device 
operators. The firm had a general belief that the MDD 2007/47/EC, EN/IEC/62304 
and the rest of the applicable standards had met expectations in enhancing the safety 
of medical devices. However, the firm also had a growing sense that overly 
burdensome and complex regulations threaten to choke off continued innovation and 
limit the exploitation of their opportunities to introduce new devices. The firm’s 
expected acceleration of its embedded software product “XXXX” was limited due to 
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the continued time taken to get product registration through the regulatory agencies 
due to internal processing delays. The Director of Regulatory Affairs of Charlie 
Medical remarked: 
 
“We do not disagree that there should be increased scrutiny for the public health but 
the level at which they are going has a huge impact on us” (Director of Regulatory 
Affairs - Charlie Medical, 2017). 
 
Effects of the second regulatory change (unannounced audit visits) on Charlie 
Medical Ltd.’s production capability 
The impact on production capabilities following the 2013/473/EU regulatory change 
was mostly inherent in the unannounced audit processes. The firm highlighted that   
frequency of audits that they must accomplish to ensure compliance had increased. 
The amount of inspection days when the auditors came on their site doubled. 
Furthermore, the firm’s Technical files scrutiny after the new regulation increased, 
before they used to be reviewed in a day but now it takes three days to review. The 
increase in audits review times means additional cost to the firm and extended periods 
of bringing new products to the market. In 2016, Charlie Medical had their eight-man 
day’s scheduled annual audit and received an unannounced inspection visit at the 
same time. As a small team, the firm had to comply with both visits but the huge 
strain was said to be unbearable. The Director of Regulatory Affairs of Charlie 
Medical highlighted that the approval process of new products has increased since the 
introduction of the 2013/473/EU regulation.  
 
“Prior to the new regulation, a product review by the NB would take two months, thus 
making the firm’s return on investment to be almost immediate but now because it is 
taking between 8-12 months to get CE approval of the same type of product, thereby 
only seeing the return after one and half years” (Director of Regulatory Affairs - 
Charlie Medical, 2017). 
 
Effects of the second regulatory change (unannounced audit visits) on Charlie 
Medical Ltd.’s linkage capability 
The firm had to reassess decisions across the supply chain involving external 
providers. The new regulation required actions concerning both relationships with 
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external providers and the business’s internal technological focus. The company 
explained that the new changes increased its responsibility to establish relationships 
with the stakeholders in the network. This was fundamental as the firm wanted to 
have an impact on the uptake of its medical devices. Regrettably, the firm’s NB had 
their license revoked after the introduction of the 2013/473/EU regulation due to its 
inability to demonstrate that they were able to assess appropriately. The revoke of the 
NB license did not only affect the links and collaborative efforts between the NB and 
Charlie Medical but it also affected about 305 other clients. In addition, Charlie 
Medical revealed that the new regulation had cost the company about £400 000 just to 
implement these new changes, which include: drawing in new contractual agreements 
and establishing new relationships with a different NB and new critical suppliers, 
meeting the required administration fees, re-inspection fees, transfer fees, and on-
going surveillance cost. 
 
This evolution resulted in the firm creating new processes of sharing tasks in the 
firm’s supply chain. According to the interviewee, collaborative relationship with new 
key suppliers helped improved the quality of both the supplied components and the 
firm’s products, since Charlie Medical and its critical suppliers were both now 
working towards achieving zero defects. The Director of Regulatory Affairs of 
Charlie Medical reflects this regulatory effect in the quote below: 
 
“The relationship with our new key supplier afforded us to audit their quality system, 
as such quality defect on matured products are more or less non-existing” (Director 
of Regulatory Affairs - Charlie Medical, 2017). 
 
The firm further indicated that collaborative relationship with the key suppliers has 
helped them to have reliable components supplies with little or no disruption in their 
production operation, since the firm operates a just in time product delivery with the 
suppliers, which reduces unnecessary product and components inventory stock and 
improves the lead time. 
 
The collaborative relationship provided the critical suppliers with knowledge of 
Charlie Medical’s production processes. The firm and their critical supplies were 
engaging in frequent communication and information sharing on product 
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improvement. This gave the suppliers good understanding of Charlie Medical’s 
business and enabled them to contribute to the improvement of the production 
process, through joint research and design of quality and innovative products. The 
relationship had positive effect on time to market of the company’s products. 
 
This wide-ranging impact of regulatory change involved the firm’s various 
organizational units and called for various types of implementation resources. Despite 
the operational complexities around the new regulation, the firm leaders had a view 
that did not seek to avoid but rather embraced and implemented the changes in an 
effective manner. 
 
Summary of Charlie Medical’s implementation actions 
  
Despite continued regulatory changes, the firm kept the business on a sound footing 
to continue their growth and expansion plans. The continued uncertainty in the global 
market and specifically the austerity regulatory measures affecting the firm were a 
major concern. This was seen in the ever increasing regulatory and registration 
requirements not only affected the time to market for new products stifling innovation 
and patient care but also added considerable overheads to the day-to-day costs of 
maintaining compliance. By strengthening the firm’s internal regulatory department 
and staying at the absolute forefront of technology both for products and 
manufacturing techniques the firm minimised principal risks. By maintaining strong 
links with their customers, critical suppliers, and crucial sub-contractors as well as 
retaining tight control of operational costs the firm positioned itself to withstand any 
future risks and changes in regulations. 
7.4. Summary of the empirical accounts 
7.4.1 MDD 2007/47/EC – Software as medical device summary 
The influence of the MDD 2007/47/EC regulatory change crossed over the entire 
cycle of firm level technological capabilities. The extension of regulatory reach into 
software added cost. The MDD 2007/47/EC introduced new requirements. The first 
impact was on the products provided, since the regulation introduced a framework 
within which medical device companies could offer a new set of CE marked 
standalone or embedded products. The product requirements included a new set of 
processes such as validation and verification procedures, provided new harmonized 
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standards such as EN/IEC/62304 and new functionalities, which influenced the 
development process of products. Firms responded to this opportunity by taking 
subsequent actions concerning the development processes. To reach customers with 
the new products, distribution processes were modified. The continued evolution of 
these processes involved employee education as well as the design modifications.  
 
The MDD 2007/47/EC opened new software market opportunities to companies that 
invest heavily in R&D because the safety and efficacy standards outlined in the 
EN/IEC 62304 had emerged as a global standard for the software development life 
cycle and thereby achieved global harmony. This amendment further empowered 
oversight authorities to take firm action against nonconforming companies and their 
products. The empirical data revealed that MDD 2007/47/EC enlightened the medical 
device industry on procedures for conforming to international regulations to reduce 
incidences of device recalls.  
 
Data from some firms showed that MDD 2007/47/EC has helped SMEs in the 
medical device manufacturing to catch up with larger organizations because the same 
quality standards apply all. The MDD 2007/47/EC has enhanced collaboration efforts 
within the supply chain of the medical device industry. However the interview 
findings indicated that the training cost significantly increased as leaders of firms 
were seeking compliance with the Directive and its applicable standards. The study 
established that the training needs were at the quality and operational level. As such, 
the first regulatory change had proactive effects on most firms that led to the 
development of organizational capabilities and resources that may be potential 
sources of competitive advantage and that affect a firm’s ability to gain financial 
benefits from improved business operations. 
7.4.2 EC Recommendation 2013/473/EU-routine unannounced audits summary 
The introduction of EC Recommendation 2013/473/EU increased the surveillance, 
not just through the unannounced audit visits but also through internal audits of the 
medical device manufacturing systems to minimize device recalls and failure 
incidences that put the lives of the users in danger. One responded described an 
unannounced audit as nerve-wracking for even the most buttoned-up organizations.  
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The EC 2013/473/EU forced the manufacturers to create or update procedures that 
cover supplier quality. The manufacturing firms had to identify which suppliers are 
critical subcontractors, which are crucial suppliers, and define the criteria for 
evaluation. The EC 2013/473/EU prompted the manufacturing firms to apply more 
stringent criteria to suppliers of products and services that have a direct impact on the 
safety and performance of their medical devices. 
 
Compliance to the EC 2013/473/EU created widespread commitment among the 
medical device manufacturers to improve device quality and communication among 
the stakeholders. It was expected by the regulatory authorities that intensified control 
on NBs would increase the quality of conformity assessments and reduce approvals 
lacking sufficient clinical evidence. This had a direct effect on manufacturers, 
whereby the regulations required increased involvement of competent authorities 
when conformity assessing high-risk devices. This in turn increased costs and the 
duration to reach market approval and consequently, patient availability. The EC 
2013/473/EU enriched the medical supply chain relationships, which in turn, 
stimulated better understanding of partner activities, and enhanced exchange of 
information and resources, reducing operational downtimes, product recalls and more 
cited non-conformities. Compared to the first regulatory change that had proactive 
effects on most firms, the second regulatory change seem to have had more reactive 
effects on most firms as they did not need extensive expertise in dealing with new 
unannounced audit processes. Rather the firms needed to change their in-house 
strategies such as developing strong collaborative links with their critical suppliers. 
 
Overall, the two different but significant types of regulations led to negative effects, 
such as increased barriers to entry and decreased investments in R&D on SMEs, 
which were counter balanced by positive effects, such as reduced risk in investments, 
enhanced collaborative relationships and minimized turnovers. The results of the 
research indicated overwhelming competitive advantages for the complying device 
firms, including certification and quality marks on the products preferred by both 
private and public hospitals. Additionally, according to the empirical data and 
literature, medical devices that comply with the MDD 2007/47/EC had less product 
recalls, which often trigger huge income losses to the medical device manufacturers. 
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7.4.3 Investment capability empirical account summary 
The case studies established that leaders of the medical device manufacturing 
companies invest substantial resources in R&D to standardize their products. The 
findings from this study indicated that manufactures of medical devices software had 
positive income returns that improved after they complied with the MDD 
2007/47/EC. The findings indicated the changes of the MDD 2007/47/EC led to 
redefining of the training needs for innovations, prototyping, design, testing, 
validation, verification and release processes.  
 
Staff training was needed to ensure better efficacy and accountability from the 
medical devices firms. The interviews established that MDD 2007/47/EC created new 
needs for retraining medical device manufacturers to improve the success rates of the 
medical device software. The interview responses included the extended training costs 
that the firms factor in their R&D going forward. The other impact of introducing the 
MDD 2007/47/EC was demand for highly skilled personnel or specialized employees. 
The changes called for recruiting staff members who could provide the companies 
with skills and productivity that would propel profitability.  
 
This case study revealed that some firms struggled with recruitment of highly skilled 
personnel such as software engineers and lead auditors. The synergy of skills such as 
software design and development was crucial for medical device manufacturers to 
nurture for research sustainability and better returns on investments. 
7.4.4 Production capability empirical account summary 
The empirical accounts revealed that regulatory changes yielded some positive effects 
on innovation in some firms: For example, it created the maximum opportunity for 
innovation, leaving the approach to innovate in the hands of the firms and not the 
regulation-setting agency. It also fostered continuous product improvement, rather 
than locking in some particular technology.  
 
The other effects of introducing the MDD 2007/47/EC include: increased product 
market entry time and lengthened the R&D life cycles. The manufacturers called for 
improvements of these affected areas as they in turn, affect their competitiveness in 
the market. The empirical data further revealed that compliance criteria introduced by 
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the new regulations were slowing down many operations among the medical device 
manufacturers who pursue industry innovations at the same time.  
 
Additionally, some medical device manufacturers tend to view the EC 
Recommendation 2013/473/EU as a bureaucratic system that imposes additional cost 
through increased random and scheduled audit visits. The firms criticized having two 
different types of the audits (unannounced and scheduled) in the same regulatory 
framework and called for a substitution strategy. However, and in line with 
substitution approach, we also argue that regulation should always include a small 
element of random audit inspection in order to check on the validity of the risk 
assessment system. A value of random inspection, on this view, is that it holds out the 
prospect of uncovering new risks and risk-creators in a way that is unlikely to flow 
from a scheduled audit inspection that is based on analyses of previously identified 
risks. 
7.4.5 Linkages capability empirical account summary 
The changes in regulation introduced by the MDD 2007/47/EC promoted strong 
linkages between the manufacturers and the rest of the actors involved in the whole 
chain of development of the software. With the introduction of the MDD 2007/47/EC, 
most of the firms interviewed successfully broadened their outsourcing models to 
include foreign firms with offshore production facilities.  The firms established strong 
supplier relationships to enable them have access to resources outside of their 
organization, reduce costs of manufacturing and operation, shorten product 
development life cycle, and improve product quality, and productivity. To some 
extent, this regulatory reach into software changed the expected profitability by 
providing a guarantee of product quality. 
 
The EC Recommendation 2013/473/EU regulatory demands changed conditions for 
firm collaboration due to new challenges in the interface between actors. Some firms 
indicated that before the introduction of the EC 2013/473/EU, they had an adversarial 
type of relationship with their critical subcontractors and crucial suppliers. After the 
new regulation, firms were forced to move from adversarial relationship towards 
collaborative relationship within the network. The move was driven by the fact that 
the supply chain operations of medical device industry were now much more 
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regulated than it used to be before the introduction of the unannounced audit visits.  
 
The collaborative relationships further developed from short-term to long-term. A 
long-term relationship with critical subcontractors and crucial suppliers enhanced the 
firms’ efficiency in procurement and also enabled the medical device manufacturers 
to be more effective in delivering quality products. The strong linkages also facilitated 
diffusion of their technologies. Exchanging information, keeping industry actors 
informed was considered very important for generating technological changes and 
transfers.  
 
The empirical accounts described the actions taken by the industry actors when 
implementing the new requirements arising from the regulatory change in the UK. 
The case studies revealed both common patterns and individual differences in how 
each firm addressed the new regulatory requirements. To explore these patterns and 
differences further, the empirical accounts will be viewed through the lens of the 
theoretical framework in the cross-case chapter 9. The next chapter presents an 
analysis of the effects of the third regulatory change on the capabilities of firms based 
in South Africa. 
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CHAPTER EIGHT 
THE EFFECTS OF REGULATORY CHANGE ON TECHNOLOGICAL 
CAPABILITIES OF MEDICAL DEVICE FIRMS IN SOUTH AFRICA 
----------------------------------------------------------------------------------------------------- 
8.0 Introduction 
This chapter, like chapter 7, addresses research sub-question number three, this time 
using empirical data from a group of sixteen medical devices firms in South Africa 
(SA). This chapter is focused on firm level effects in a national environment where 
the regulatory authorities were not so equipped to assess the hidden costs of 
regulation or to ensure that regulatory powers were used cost-effectively and 
coherently. The objective was investigated through the following research question: 
How have regulatory changes affected firm level investment, production and linkage 
capabilities of medical device firms in the SA?  
 
The analytical evidence from SA presented in this chapter also comprises two kinds 
of empirical data. As in chapter seven, the first type of empirical evidence involves 
comparative analysis of sixteen SA manufacturing/distribution firms that supply 
medical and dental diagnostics. This section focuses on the effects of radiation 
emitting devices regulation and its successive changes on firm level technological 
capabilities on these sixteen firms.  Thereafter, a more comprehensive narrative of 
three purposefully selected firms will be presented. This chapter concludes with the 
summary of the findings focusing on the key characteristics of the firms’ responses to 
the new regulation. 
8.1 Effects of the third regulatory change (Radiation emitting devices) on firm 
level technological capabilities 
The effects of the third regulatory change on the technological capabilities of the SA-
based firms are analysed by looking at various dimensions of the production system in 
which local manufacturers of medical devices operate. The analysis starts with the 
effects of regulatory change on investment capabilities. 
8.1.1 Effects of the third regulatory change (Radiation emitting devices) on firm 
level investment capabilities 
The manufacturing and supplying radiation-emitting devices such an X-ray puts 
financial burden on firms. These high-margin medical devices require high 
investment in R&D and the development time up until clinical testing takes around 2-
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3 years and costs between 1 to 20 million US dollars (Fiedler, 2017). All this 
determines that such type of medical devices rely on more investment funding.  
 
Research and Development (R&D)  
The effects of regulation under the Hazardous Substances Act 15 on R&D elicited 
various responses among the medical device firms. The majority of respondents 
echoed that the regulatory changes introduced within the product category of radiation 
emitting devices had little impact on a large number of local SMEs firms’ R&D 
capabilities. Some respondents reflected this notion in the following quotes: 
 
“Not much R&D is done here because it's an importers market dominated by 
distributors or importers. Where you will find some pockets of R&D happening 
locally, it would be with a few local manufacturers that are truly innovative.” 
[Executive Officer – Industry Association, Res 005 (IS), Oct, 2016]. 
 
“We do very little R&D ourselves, we do some products but it is just merging up of 
some components into a bigger solution. So from an R&D point of view it’s just 
merging components into a bigger solution if I can put it like that” [Director – TM 
Africa, Res 028 (MAN), Nov, 2016]. 
 
“So there is no R&D done in SA in that regard. We only have the specialists and the 
professors that are specifically doing patient research or clinical research but not 
research on the machines” [Strategic and Key Account Manager – SSA Ltd, Res 014 
(MAN), Oct, 2016]. 
 
The underpinning argument why there is less R&D as reflected in the above quotes is 
the limited local manufacturing base that, following the reasoning of most 
respondents, is an existential criterion to have in place for R&D. Because of this base 
being so small, no critical mass is created for R&D investments to result in a positive 
Return-On-Investment (ROI). For example, the South African Medical Technology 
Industry Association (SAMED) indicated that in 2014 total spend on R&D amounts 
to approximately USD1.5 million on R&D. This equates to less than 1% of their total 
average operational expenditure (SAMED, 2016). 
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A majority of respondents pointed out that the regulatory changes did not directly 
influence investment in R&D of MNCs as most of their R&D activities were 
conducted in the advanced countries. The CEO of CR Medical remarked:  
 
“I don't think that regulation has had that much of an impact on us in that respect 
because our company being a multinational, the R&D take place from an external 
perspective and not in South Africa so I think that’s something that would be better 
asked to the local manufacturers and to SAMED as an industry” [Res 008 (MAN), 
Oct, 2016]. 
 
SAMED, the medical device industry association in SA indicated that currently SA 
medical device industry is dominated by MNCs and typically these firms depend on 
their parent company to develop new products using R&D resources close to 
headquarters. Therefore, there was much less regulatory impact on investment 
capability in R&D in the SA medical device industry.  
 
On a more positive note it was mentioned that, specifically the MNCs, could draw 
upon local skills and can contribute to medical device R&D in the country through 
collaboration with academia and tertiary hospitals. Indeed, some few MNCs indicated 
they already have R&D projects with several universities in the country and 
contribute to learners at academic institutions. Others indicated that regulation 
increased the quality and safety of products and the design process as a result of their 
increased R&D investment, which in turn gave them a competitive advantage in the 
market.  The Managing Director of Southmed and the CEO of DK medical supplies 
remarked: 
 
“Regarding R&D, regulation helped our company to focus on upfront design process 
before bringing a product to market. [Res 003 (MAN), Oct, 2016]. 
 
“The change in regulation has actually added R&D investments because it has 
allowed us to have inspections and to do modifications to systems and upgrade” [Res 
009 (MAN), Oct, 2016]. 
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The quotes above reinforces the notion that regulatory change in SA came about not 
just as an obligation requiring compliance, but instead as a possibility for firms to 
improve their products and competitive position in the market. 
 
The lack of trained local human capital and absence of venture capital funding were 
echoed as critical concern by some firms in terms of access to appropriate skills to 
perform R&D to an internationally required standard. The Managing Director of 
Southmed notes: 
 
“It's hampers us to a certain extent because funding that could have gone to R&D 
now goes into flying auditors from Europe to here and also from a timing perspective 
things get slowed because we can’t speak to the auditor in Johannesburg we have to 
speak to somebody in Europe, and we may not be their highest priority” [Res 003 
(MAN), Oct, 2016]. 
 
“The problem has been we don’t have a venture-funding environment” [Res 003 
(MAN), Oct, 2016]. 
 
Recruitment and training of skilled personnel 
The introduction of accreditation and compliance monitoring system through the 
South African National Accreditation System (SANAS) enhanced the need for firms 
to recruit skilled personnel or the need to provide adequate periodic staff training.  
According to SAMED, the total expenditure on training on medical technology was 
USD2.1 million in 2014. The expenditure on training by MNCs was significantly 
higher (USD1.4 million) when compared with local companies (USD758 thousand) 
(SAMED, 2016). However, most respondents in the interviews emphasized that there 
was a shortage of skilled and semi-skilled personnel in SA. These senior managers 
argued that as long as the lack of skilled and semi-skilled personnel is not resolved, 
manufacturing of even the simplest of low technology products would not be viable. 
The Senior Manager of Medtronic and the Managing Director of Southmed expressed 
concerns about this regulatory requirement in the two quotes below: 
 
“We supply a lot of high end technology or high-risk medical devices so we are 
operating in those fields. We are in the AIMD field, we are in surgical technologies 
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where we supply electromagnetic medical equipment that are high tech and we have 
to have well-qualified people for that and we do look actively for highly qualified 
people but unfortunately there a massive shortage of skilled people” [Res 004 (MAN), 
Oct, 2016]. 
 
“That is also difficult because we have to use accredited companies to do our 
validation. So if we get audited, and we have used a piece of equipment they want to 
see that the people that audited the equipment or validated the equipment are 
themselves skilled to be able to do that and in a country like South Africa where the 
skill set is growing from a low base but isn’t improving all time that has been part of 
the challenge” [Res 003 (MAN), Oct, 2016]. 
 
On the local front, many of the high level skill shortages in SA are blamed on the 
education system, which is still struggling to overcome decades of “neglect and 
dysfunction” under apartheid, when the education of black people was under funded 
and of poor quality (Breier and Wildschut, 2006). A Senior Quality & Regulatory 
Systems Manager of PH Healthcare reflects: 
 
“I think there is now a massive scramble for highly skilled regulatory affairs people 
here in SA. They have never been more needed before and all of a sudden, people 
such as clinical engineers, field service engineers, people who have got a background 
like yours who have studied formally regulatory science are on high demand. At the 
moment there is nowhere here in SA you can get a Regulatory Science Degree” [Res 
012 (MAN), Oct, 2016]. 
 
However, even though the respondent above cited shortage of highly skilled people, 
South Africa has established institutions for biomedical/clinical engineering education 
and research as well as training programs for medical device technicians. For 
example, biomedical/clinical engineering training exists at the leading SA universities 
such as Tshwane University of Technology, University of Cape Town, University of 
Stellenbosch, and Witwatersrand University (WHO, 2015). The Clinical Engineering 
Association of South Africa also provides training to medical device technicians 
(CEASA, 2018). The role of the government is significant in ensuring support for 
local production, but equally critical is the role of academia to train biomedical 
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engineers, clinical engineers and other professionals capable of translating local needs 
into action and finding appropriate local solutions based on international best 
practices.  
 
Further, regulatory changes have prompted firms to invest in training and 
development of people who work with these devices more seriously. For instance the 
authorised representative responsible for adhering to regulation has to have advance 
level of understanding of the medical devices and of the regulatory landscape in SA. 
Moreover, the Department of Health (DoH), Directorate Radiation Control (DRC), 
lists the responsibilities of license holders of medical X-ray equipment in the Code of 
Practice for users of medical X-ray equipment. The license holder and responsible 
person, apart from complying with equipment requirements, must ensure that 
radiation workers are identified and issued with Personal Radiation Monitoring 
Devices (PRMDs). The code further requires every radiation worker to receive 
education regarding the risks and safety rules of ionizing radiation (DRC, 2011). The 
education and or training pertaining to ionising radiation safety of these staff 
members is the responsibility of each license holder. In that sense regulatory changes 
has raised the bar for the firms’ training requirements.  The Regulatory Affairs and 
Quality Officer of SISA comments,  
 
“Because we do export to Europe and so now we make sure that we do get the 
competent people involved and our company also do spend a lot of money on training. 
I mean I have been sent overseas a couple of times to go and get training there” [Res 
015 (MAN), Oct, 2016]. 
 
The quote emphasises that, after the regulatory changes, it was important for medical 
device firms personnel e.g. biomedical engineers to be appropriately trained and 
knowledgeable not only in matters related to technical specifications and 
performance, but on how to evaluate products and manufacturers to be in compliance 
with regulatory standards and processes (e.g. manufacture, process, marketing, post-
market surveillance). 
 
Some firms indicated that the introduction of inspection bodies induced enormous 
challenge for local firms given that the regulatory environment in SA lack regulatory 
 186 
affairs human resources and that there is quest for skilled manpower. The Director of 
TM Africa and the Strategic and Key Account Manager of SSA Ltd summed up: 
 
“Basically what the inspection body added was a fair amount of stress because all of 
a sudden you had a specific number of your engineers doing the service and 
maintenance of spares on a big installed base now you suddenly had to find time and 
more people to be able to do all the inspection testing which puts the service under a 
very large amount of stress” [Res 028 (MAN), Nov, 2016]. 
 
“The drain on organisations is that suddenly you have got a significant amount of 
regulatory labour that has to be performed by highly qualified people. So staffing 
issues are now suddenly a problem” [Res 014 (MAN), Oct, 2016]. 
 
The regulatory change exposes the South Africa’s lack of trained human resource 
challenges and specifically country’s inability to sufficiently retain highly trained 
individuals.  
 
8.1.2 Effects of the third regulatory change (Radiation emitting devices) on firm 
level production capabilities 
South Africa’s trade of medical devices experienced strong growth from 2004 to 2013 
(BMI, 2016a) as discussed in section 2.3 of Chapter 2. However, healthcare provision 
remains inequitable and challenges in access to quality, affordable healthcare 
technologies persist in large parts of the country. The medical devices sector plays a 
critical role at each stage of the healthcare continuum. Although it has been 
instrumental in improving access and affordability of healthcare services, a number of 
regulatory constraints have led to a high dependence on imports for addressing 
domestic demand. 
 
Innovation in production 
The regulatory environment or lack thereof, is a key issue for manufacturers in South 
Africa. It should be considered an issue of vital importance to be addressed for the 
development of the medical devices sector. The regulatory environment in the country 
affects innovation because it determines the ability of firms to operate freely 
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(Malerba, 2005).  However, it is also worth mentioning that innovation in the context 
of developing countries and in particular African countries is not so much a matter of 
pushing back the frontier of global knowledge, but more the challenge of facilitating 
the first use of new technology in the domestic context (Dahlman, 2007). Innovations 
should be considered broadly as improved products, processes, and business or 
organizational models. Development strategists ought to think not only of R&D and 
the creation of knowledge, but also attend to the details of its acquisition, adaptation, 
dissemination, and use in diversified local settings (ibid). It is useful, therefore, to 
view innovation activities in the African context as this taxonomy will help to 
understand the structure this analysis chapter.  
 
The majority of respondents indicated that regulation of radiation emitting devices did 
not bring about radical or disruptive innovations into the market, which involves 
discontinuities in innovation pathways (Tait and Banda, 2016) but instead it had an 
influence on incremental innovations. Product development and commercialization in 
SA currently involves local improvements of technologies developed elsewhere; 
modifying imported technologies to suit local conditions (usually focused on cost 
reduction); or less commonly, novel product development. CEO of Gabler Medical 
comments: 
 
 “We don't do much of that, so we have a product range where we improve the 
products and bring out new designs but these new designs are of products that are 
already on the market. So this isn't new product innovation it's more about 
repackaging old products in a better way, more pleasing, and easier to use as 
opposed to new product development” [Res 006 (MAN), Oct, 2016]. 
 
Even though manufacturing remains limited to producing low technology products, a 
few domestic companies and MNCs with manufacturing facilities in SA have 
successfully developed low cost products that are on par in terms of quality with 
existing products that require complex technical know-how to manufacture. One 
Regulatory Affairs and Quality Officer of SISA noted:  
 
“We recently introduced a new product into the market. So there are some 
innovations in SA, but the only thing is you can’t design a new product today put it on 
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the market tomorrow. You have to make sure that the device is safe, the clinical trial 
is done and get the IP rights. You have to get approvals which can take a long time, 
so that creates a delay in the innovation output” [Res 015 (MAN), Oct, 2016]. 
 
The first regulatory licensing condition “Code of Practice for industrial radiography - 
X-ray Equipment” was drawn up in order to limit the risk of overexposure of workers 
and members of the public, and to keep radiation doses as low as is reasonably 
achievable. This requirement has forced firms to formulate new strategies when 
innovating including altering Quality Management System (QMS) safety and 
performance processes as reflected in the following quote by the Chairman of 
SAMED: 
 
“I think from an innovation perspective, the regulation is now saying that you need to 
comply with many levels regarding safety, so it forced the companies when innovating 
to take the safety aspect into consideration. So it has guided the way innovation takes 
place. On the one hand, you have to control, monitor, evaluate and keep products 
safe” [Res 002 (IS), Oct, 2016]. 
 
Majority of SMEs argued that the bureaucratic protocols caused by the regulatory 
environment slowed the process of innovation. These firms stated that there are lots of 
documentations and administrative procedures to bring a product in to the market that 
inevitably impede innovative outputs. The Health Economics & Government Affairs 
Manager of BS Medical Specialists and the Projects Manager for BV Medical noted: 
 
“Sometimes regulations slow down innovation because you find that you have too 
many requirements which you need to comply with before you can bring a product 
into the market and like in our current situation that is the case” [Res 032 (MAN), 
Feb, 2017]. 
 
“Innovation is going down a little bit because at least you could develop the product 
sell it in SA without those requirements but now you are at that stage of regulatory 
change” [Res 013 (MAN), Oct, 2016]. 
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Majority of MNCs in SA emphasized that regulation had no effect on their innovation 
activities as that phase in the product lifecycle was done by their parent companies 
based outside SA. Some respondents note,  
 
“Well our innovation is done by our company oversees in German, so no effect” 
[National Sales Manager – ESA, Res 025 (MAN), Nov, 2016]. 
 
“No, not at all. Regulation has not affected our innovation. I mean our companies 
overseas are developing products all the time. The only problem, the impact that we 
have is the price” [Reimbursement and Regulatory Affairs Manager - AA Biomedical, 
Res 027 (MAN), Nov, 2016]. 
 
“We really don’t do the innovations, we don’t do the R&D ourselves on the bigger 
forms of devices like the CAT scan, MRI and the ultra sound and the like are 
innovated outside SA” [Director – TM Africa, Res 028 (MAN), Nov, 2016]. 
 
Quality control capabilities 
The introduction of regulatory change led to introduction of new processes 
concerning effective accreditation and compliance monitoring system in SA. The new 
SANAS players entered the market as control actors and certifiers of quality, a central 
role after changes in regulations. The regulatory change triggered new technical 
requirements for the industry, as has been similarly observed in the history of the UK 
medical device industry. There has been a strong focus on upgrading medical 
technology by manufacturers, hospitals and laboratories to comply with quality and 
accreditation requirements. 
 
An ineffective quality assurance program can lead to poor quality radiograms that can 
impair diagnosis, increase operating costs and contribute to unnecessary radiation 
exposure to both patients and staff (Fiedler, 2017). Most of stakeholders in SA were 
in agreement that the introduction of the acceptance test and annual Quality Control 
(QC) tests plays an important role in diagnostic imaging to limit the population dose 
growth, thereby improved quality control. Three respondents comment,  
 
“It has improved our quality control and innovation also so it’s given us more scope 
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so it has enabled us to work a little bit out of our boundaries but for a newcomer 
trying to come into the field this makes almost impossible [CEO – DK Med Supplies 
Res 009 (MAN), Oct, 2016]. 
 
“I think quality control is part of ISO and the regulatory process and I think that it 
would keep one honest in terms of quality control” [Programme Director - PATH, 
Res 010 (MAN), Oct, 2016]. 
 
“I think that when it comes to quality control we have been “forced” to actually step 
up our game. Now we are all being sat down and get told to do this and I think it is a 
good thing because even if it is something simple like ISO 9001 it just once again 
comes back again to the customer and its ensuring that the customer is getting 
adequate service” [Projects Manager – BV Medical, Res 013 (MAN), Oct, 2016]. 
 
The quotes above reinforce the notion that the regulatory change led to upgrading 
medical technology and better-quality products for the consumers. The QC tests 
include periodic quality tests, preventive maintenance procedures, administrative 
methods and training. They also includes continuous assessment of the efficacy of the 
imaging service and the means to initiate corrective action (Fiedler, 2017). The tests 
however come at a high cost and some respondents indicated that the implications of 
the increased regulatory cost was over burdensome for firms. The National Medical 
Physics Manager of Netcare noted: 
 
“When you look at the cost involved in quality control, it has increased since the 
changes were made in 2009-2010. When they said that you have to have accredited 
inspection body test the machines in most cases, of the suppliers and send the result to 
the DOH. They are expensive no doubt about that. It's an expensive test, so an annual 
quality control for a unit can vary from a few thousand Rands to twenty thousand 
Rands depends on the type of the machine” [Res 007 (HF), Oct, 2016]. 
 
Due to the cascading effect of the high cost involved in setting up of a quality 
management system and annual quality assurance, some firms indicated that 
consequently, this affect affordability of the devices for the patients. These firms 
usually transfer increased cost of regulatory compliance to the patient. The Managing 
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Director of UMC summed up this cascading regulatory effect in the following quote: 
 
“At the moment you have a regulation cost of QC and not necessarily the amount but 
the accreditation and cost involved and making sure that the QC is up to date. That 
eventually comes down to the patient, and their fees go up, and their medical aids go 
up, and they end up paying more, so it's a bad cycle. We have had to complain to 
SANAS about the calibration of QC devices which we use in chambers to measure out 
the radiation and the energy that the machines produce” [Res 035 (Man), Oct, 2016]. 
 
The introduction of the QC test not only improved quality control practices but also 
created need for appropriate training for all personnel with QC responsibilities and 
effort was required by management to ensure that adequate financial provision be 
available to meet this requirement. The CEO of Gabler Medical noted: 
 
“The annual QC test developed our quality control because we had very little so we 
have a lot more staff in quality control, and in those areas, there is and will be a lot 
more training. But skills development for our manufacturing is too low-tech for a lot 
of skills development” [Res 006 (MAN), Oct, 2016]. 
 
Compliance cost 
Some stakeholders considered compliance costs in South Africa as relatively high 
with implications for competitiveness of the local medical device industry in the 
international markets. Higher cost had an impact on the decision of firms to continue 
the project and eventually bring the product to the market. It emerged that obtaining 
the license to operate was considered as the first hurdle to firm entry and had a 
significant effect on the industry structure, competition, and on firm level 
profitability. Some of the interviewees also raised their concerns about the higher cost 
associated with stricter QMS requirements from the regulatory change. One Executive 
Officer of SAMED based on her experience from the industry, mentioned that: 
 
“And one of those requirements is that you have to have a QMS in place in your 
company. That is not necessarily inexpensive, it cost money to put those systems in 
place, and to maintain them but it ensures that the company is credible and it is doing 
what it should be doing concerning the risk category of devices that they are selling. 
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The licensing fee for the manufacturer at the moment is USD1500, and you hold that 
license for five years and distributors its USD896, but there are also renewal fees and 
annual retention fee as well” [Res 005 (IS), Oct, 2016]. 
 
The introduction of the licensing conditions through the code of practice for industrial 
radiography (X-ray Equipment) called for a number of administrative and medical 
requirements from those applying for the license and enforced annual quality 
assurance tests. These regulatory requirements had an effect on prices. Higher safety 
standards and other additional regulatory requirements required manufacturers to 
generate more (clinical) data to prove the safety of products, and required 
manufacturers to further invest in production facilities and thus reach the necessary 
quality standards. As a consequence, higher regulatory standards increased the level 
of investment needed to comply with the new requirements and contributed to higher 
prices for end products. The CEO of MDG stated: 
 
“Well so that's the challenge for the small companies because the cost of compliance 
is too high” [Res 002 (MAN), Oct, 2016]. 
 
Market size of South African industry is small, therefore the introduction of new 
licencing conditions were considered by many firms to be inhibiting local companies 
from investing in R&D and clinical trials. Moreover, the compliance cost even goes 
high if for example as a local manufacturer you intend to export. The CEO of Gabler 
Medical noted: 
 
“Compliance just goes with regulation if you don't, nobody here can afford to 
produce a product and not intend to export that product, and if you are going to 
export it, compliance with safety standards are the requirements. If you don't have 
that you will not export, nobody is going to buy it. Nobody can afford to manufacture 
medical devices for the SA market only; the South African market is tiny. If you are 
producing it here and it's for the South African market, it will also be for the Middle 
East, Africa and hopefully Europe; you just can't afford to produce for South African 
market only, it’s much too small” [Res 006 (MAN), Oct, 2016]. 
 
Local device and diagnostic manufacturers all spend significant time and financial 
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expense to obtain CE registration from European certified bodies. This is because 
South African medical device regulations have an affinity to European directives, 
despite the fact that the latter are particularly strict (De Maria et al., 2018). As most of 
the SA firms’ notified bodies are based in Europe, the challenge in this as indicated 
by most the firms is an increased burden of compliance cost especially when it comes 
to bringing in auditors for CE certification purposes. Currently, they must cover 
transportation and accommodation costs to fly representatives from these notifying 
bodies to South Africa for facility and product inspection. CE Mark requires annual 
ISO 13485 auditing. There is limited local capacity for auditing facilities for this ISO 
certification and the SABS certification has no recognized value outside of South 
Africa. The CEO of Gabler Medical and the Managing Director of Southmed points 
out,  
 
“It's much too expensive because the notifying bodies are based in Europe. We are 
billed based on European prices. Our currency is in a bad state. If I say guys come in 
out of Europe and the auditor is buying an air ticket out of Europe, and then he is 
maybe putting 10 % onto his costs, and then he is converting that to our currency, we 
get hammered. It's too expensive” [Res 006 (MAN), Oct, 2016]. 
 
“From an industry association side, we are negotiating with regulatory bodies to 
have local auditors, but you must remember that the field is so wide. If I have a spinal 
disc they can’t have an auditor that understands spinal discs here, so what happens is 
that my documentation still has to go to the expert in Europe and often that expert has 
to fly out to come and audit us, up till now we have not succeeded in having local 
auditors for any of our products, so our regulatory cost for the group are well in 
excess of 2 million rands a year” [Res 003 (MAN), Oct, 2016]. 
 
Another challenge most manufacturers are facing is lack of calibration29 authorities. 
The respondents highlighted that if they have equipment that might needs to be 
calibrated, the firms will have to send the equipment oversees and this process is very 
 
29 Calibration according to SANAS means a set of operations that establish, under specified conditions, 
the relationship between values of quantities indicated by a measuring instrument or measuring system, 
or values represented by a material measure or reference material, and corresponding values realised by 
standards whatever their uncertainty 
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expensive. This tall challenge is having an enormous challenge on many firms 
especially when they have to send the product once every year or two years. The CEO 
of DK Med Supplies and the Strategic and Key Account Manager of SSA Ltd 
explained this dilemma in the following quotes: 
 
“The biggest problem in SA we don’t really have calibrations authorities here..,. All 
these calibrations authorities are all in the UK all in Europe all in America and for us 
to send the equipment from here to there is a very large cost to get it calibrated is a 
large cost and then the down cost that you have with the equipment being oversees is 
also a massive cost so it becomes very expensive” [Res 009 (MAN), Oct, 2016]. 
 
“If one has equipment that needs to be calibrated. It cannot be calibrated locally in 
SA so once every year or two years depending on the equipment you have to ship it 
overseas crossing rates of exchange to be calibrated so you don’t get the use of that 
machine for that time period. You can’t do a recovery on your cost so it’s a very 
costly exercise with no return on the investment” [Res 014 (MAN), Oct, 2016]. 
 
The CEO of CR Medical explained how the regulatory challenges and high cost 
associated with regulatory compliance are creating problems of survival and growth 
in SA in the following quote:  
 
“Compliance is costly, for example in order for us to get a CE mark we have to have 
our system independently tested for the electronic magnet compatibility and electrical 
safety. There are no companies in SA that have the necessary certification in place to 
do that testing and to issue us with a certificate. There are some laboratories that can 
do the testing but they are not necessarily licensed. We have to send our system to 
Germany, France, and Britain and to the United States. We have a system sitting in 
the United States that has been there for a couple of months it  got damaged on the 
way but they have to get the testing done it’s going to cost us over  a million rand. A 
million rand in the deflated value of a pound so it’s over 50 000 pounds just to get the 
certificate and we cannot get the CE mark unless we have got that independent 
certificate. So for us to do business in medical devices in SA dealing with some of 
those issues like that is very expensive” [Res 008 (MAN), Oct, 2016]. 
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Business Operations capabilities 
An Executive Officer from the SAMED industry association highlighted the 
implications of the SA regulatory system on overall business operations in the 
following quote: 
 
“Well it is very costly to manufacture locally because we still don't have a 
comprehensive regulatory system for medical devices and the international quality 
management standard for the manufacture of medical devices is ISO 13485. Because 
we don't have regulations, there is limited capacity here in South Africa to audit 
companies to ISO 13485 which is what you need if you are going to manufacture. As 
a result, the local manufacturers have to pay for auditors to come from either Europe 
or America. They pay them in US$ or Euros; they fly business class, and this is 
extremely expensive [Res 005 (IS), Oct, 2016]. 
 
Most firms echoed that SA still lags behind most countries in terms of ease of doing 
business. Due to complex hazardous substances regulatory requirements, products 
now require multiple agency approvals and more skilled manpower to address the 
quality assurance requirements. This leads to time delays at multiple layers, at both 
the national and international levels. The Projects Manager of BV Medical noted: 
 
“The operations lines become a lot more process focused, because we started off as a 
small company, as a start-up and a lot of tasks were performed by the same person 
but now there is regulatory changes and implementation of a QA system which 
requires more skilled personnel” [Res 013 (MAN), Oct, 2016]. 
8.1.3 Effects of the third regulatory change (Radiation emitting devices) on firm 
level linkage capabilities 
Understanding the effects of regulation on linkages and interactions among the 
institutional actors involved in innovation activities or processes is crucial to 
improving SA’s technological performance. Two divergent and often conflicting 
discourses emerged when asked about the effects of regulation on linkages. On one 
hand, some firms reported that there were no formal structures for regular 
collaborative engagement between government and the private sector. As a result, 
interactions between government and the industry were often disjointed and 
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opportunities for effective collaboration for the benefit of stakeholders on both sides 
are limited. The Health Economics & Government Affairs Manager of BS Medical 
Specialists noted: 
 
“I think what has happened is that the regulator has not always been very good at 
communicating the intentions or the requirements and that caused a lot of panic and 
when people panic then; relationships do suffer so it has affected relationships 
negatively” [Res 032 (MAN), Feb, 2017]. 
 
On the other hand, some firms expressed that the new regulatory requirements 
fostered target-based collaboration between government and private sector, 
harmonized the industry actors and facilitated growth of the industry. The Programme 
Director of PATH offered explanations to this regulatory outcome as,  
 
“I think at the moment regulatory changes have harmonised the industry a lot 
because everyone is pulling in the same direction and everyone is making sure that 
the regulations do provide safety, information and efficacy” [Res 010 (MAN), Oct, 
2016]. 
 
Partnerships are key to accessing the new technologies, markets and skills that make 
growth possible.  Even though most of the South African medical device firms 
interviewed were involved in at least one domestic or international partnership, many 
highlighted the difficulty of forming collaborations. Reasons for this included 
geographic isolation, the small size of the local industry, lack of knowledge overseas 
about private sector activity in South Africa and, particularly, the perceived lack of 
credibility of ‘made in Africa’ products. The Compliance Officer of AEC Amersham 
remarked: 
 
“We have entered into several partnership agreements to bring innovated products to 
market in collaboration with different stakeholders some of those worked some of 
those didn’t work but we are very well engaged with all stakeholders” [Res 031 
(MAN), Nov, 2016]. 
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Most of the firms interviewed had domestic partnerships with universities and 
research institutions. Some of these partnerships were developed and driven by the 
need to meet new regulatory requirements in respect of conformity assessment, 
calibration and monitoring of good laboratory practice (GLP). A Projects Manager of 
BV Medical and a National Sales Manager of ESA commented,  
“The MCC is actually urging companies to be part of the SAMED association 
because it is their only mode of communication with us as companies, so it has 
affected us greatly but more to our benefit to be part of SAMED” [Res 013 (MAN), 
Oct, 2016]. 
 
“I wouldn’t say that it hasn’t really affected I think because we are part of these 
bodies and the like SAMED and SALDA there is a lot of linkage capabilities between 
the organisations that has been going on for many years now. I think now with the 
implementation of regulatory affairs its really bought us maybe closer together and 
really see what each of the challenges are in each every company there is such a 
diversity with the different companies not everybody is doing the same thing” [Res 
025 (MAN), Nov, 2016]. 
International company-to-company partnerships, usually with European companies, 
were much more common, and South African medical devices firms put significant 
effort into establishing these relationships after the introduction “routine” 
tests/inspections are performed by IBs. For a sector that needs to reach global markets 
to grow, such partnerships are vital, particularly for accessing necessary technologies 
and markets and raising local companies’ international and domestic reputation. 
Common alliances cited by companies were in the areas of manufacturing, 
distribution. The CEO of Gabler Medical said,  
“It has forced manufacturers to be more aware of purchasing, importing of 
components, importing from suppliers with some form of accreditation and better 
quality management systems themselves” [Res 006 (MAN), Oct, 2016] 
8.2 Detailed Analysis of Three SA-based Firms 
This section will analyze three case studies in more detail highlighting the specific 
actions of the firms within the context of the SA regulatory changes. The actions are 
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derived from the descriptions presented by knowledgeable stakeholders through 
interviews and in published or archival documents.  
8.2.1 Southmed  
Southmed is a private company that was founded in 1987, with a focus on the 
electrophysiology and respiratory markets. It is a distributor of electro-medical 
devices and medical consumables throughout Southern Africa. Southmed provides 
specialized equipment to meet the stringent expectations of specialist physicians, 
private clinics and hospitals including: operating theatres, critical care, high care 
units, trauma and emergency care.  The company has a workforce of over 200 people, 
generated an estimated revenue of £20m - £50m in 2016 and owns 4 subsidiaries. 
 
By 2000, the company’s position as one of the leading distributors of electro-medical 
devices in Sub-Saharan Africa was firmly established. Southmed had expanded its 
product base to include ultrasound imaging such as Cart-Based Ultrasound, Handheld 
Ultrasound, Tablet Devices and medical consumable products. The firm also provides 
radiology devices including: Digital Radiography Systems, Analogue Radiography 
Systems, C-Arms, Fluoroscopy Tables, Mammography, Specimen Radiography 
Systems and MRI Products.  
 
The company’s well-developed infrastructure and experienced team of clinical and 
technical specialists allow it to deliver a comprehensive range of products for an 
extensive array of medical applications. Southmed has a strong team of experienced 
national product managers who ensure that their product ranges are kept up-to-date 
with the latest advances in medical technology. Each national branch is self-sufficient, 
offering prompt service and full local technical and sales support. Southmed places an 
emphasis on a well-trained and highly proficient product development and sales team. 
As a result, the firm has managed to develop highly skilled and knowledgeable team 
of managers.   
 
Southmed is proficient in the installation and commissioning of medical devices 
including the provision of on-site and off-site clinical training and full technical 
support. With over 27 years of experience in the field, Southmed’s engineers are able 
to deliver on the most technically challenging and complicated installations, including 
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patient monitoring networks in intensive care units, Cardiac haemodynamic 
laboratories, Ultrasound DICOM networks and private practice diagnostic device 
networks. Southmed’s consumable products are assembled and sterilized in-house and 
conforms to the ISO 13485 global standard certification.  
 
In 2004, Southmed contracted another local company to manage its warehouse, 
logistical and technical support requirements nationally. The contracted local 
company was dedicated to incremental innovation of new products and technologies. 
The company was also undertaking activities related to development of several novel 
products in partnership with a local university. In May 2006 the two companies 
merged with the aim of improving efficiency and now trade as Southmed. The new 
company is fully compliant with industry standards at all levels including the 
requirements of the Health Care Charter and Broad Based Black Empowerment 
regulations. The firm scorecard according to B-BBEE Codes of Good Practice 
(Gazette Number 36928) in 2013 indicating that the firm is a level 3 contributor with 
51% of the company being black owned and 7.32% is women black owned.  
 
The firm’s client base spans the entire Southern African region. This is accomplished 
by strategic alliances in the African continent with direct representation in SA. The 
firm’s market comprises three segments: hospitals (which include all state, academic 
and private clinics and hospitals), blood transfusion services and medical 
practitioners. Over the last two decades Southmed has built a healthy partnership with 
leading suppliers, in order to guarantee compliant, state-of-the-art technology. 
 
Effects of the REDs regulation on Southmed’s investment capability 
Southmed indicated that REDs regulation to some extent impeded innovation by 
creating unnecessary barriers and cost but less efficient. The Managing Director of 
Southmed remarks,  
 
“So radiation control basically requires QC certification every year…. in the past it 
was just once for that product now it is every single year you have to get radiation 
control at some particular point in time. The amount that we pay for these annual 
tests could otherwise be invested in R&D activities” (Managing Director - Southmed, 
2016). 
 200 
 
The DoH, South Africa applies the international standards as legal requirements and 
guidelines through the DRC. The DRC issues a license if the product and usage 
comply with the legislative and international requirements for safety and performance 
(RSA DoH 1973). The firm further indicated that demonstrating compliance with the 
international standards in order get the product license as one of the biggest regulatory 
challenges. The Managing Director of Southmed articulates, 
 
“Introducing a new product to a market that needs radiation control approval here 
takes longer compared to other countries because of the unnecessary demands from 
the regulator. The RCD requires a CE mark and yet we don’t have local accredited 
CE auditors” (Managing Director - Southmed, 2016). 
 
The REDs regulation had a significant effect on the firm’s human resources. 
Southmed was forced to develop targeted training programs, and recruit highly 
trained personnel from overseas to fill in shortage of regulatory affairs personnel. The 
Managing Director of Southmed comments,  
 
“After the new regulatory requirement, we started offering on-site product 
demonstrations and level-one technical training, in the form of lectures and 
workshops, to our workers and to the end-user, where required” (Managing Director 
- Southmed, 2016). 
 
Efforts by the firm to train personnel domestically were not only time-consuming but 
faced challenges of their own. As a result, the firm developed a strategy of 
empowering individuals by identifying and then further developing their unique 
abilities and skills through educational support. The Managing Director of Southmed 
emphasizes: 
 
“A major focus of the company to meet the licencing condition was to empower 
individuals, by identifying and then further developing their unique abilities and 
skills. This is achieved through an on-going in-house skills development programme, 
tertiary degree and diploma support, and international training courses” (Managing 
Director - Southmed, 2016). 
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 Many training programs relevant to health technologies in SA are based in university 
systems, which have been traditionally isolated from industry. As a result they are not 
perceived to be effective at detecting and addressing changing industrial demands 
(Blankley and Booyens, 2010). 
 
Southmed highlighted that it was required to undertake a well-reasoned and 
documented risks and benefit analysis of device use for the patient or user of the 
medical device. These analyses have to recognize that a patient or user’s safety is 
paramount. The work, therefore that had to be undertaken by Southmed involved: 
demonstrating that a well-reasoned and documented risk analysis has been done, 
producing a documented review of relevant published literature, a review of 
manufacturer’s experience with device, assessing and documenting compliance of the 
device and its packaging with specifications and standards, reviewing and 
documenting the labeling and instructions for use of the device and reviewing and 
documenting final release procedures.  All these processes increased the firm’s R&D 
investment budgets.  
 
Another regulatory effect that negated the strength of the firm in clinical research was 
the significant delay in research ethics approval. The firm echoed that, SA is an 
attractive location for conducting clinical investigations in Africa. However, delays in 
the ethics approval process, estimated at six months on average, are thought to be a 
significant stumbling block preventing the industry from reaching its potential in 
clinical research. The involvement of multiple bodies, such as Southern African 
Radiation Protection Association (SARPA), the Medical Research Council (MRC) 
Ethics committee and Radiation Control Directorate (RCD) are contributing factors to 
these delays, with the last two perceived as primarily responsible.  
 
Effects of the REDs regulation on Southmed’s production capability 
Southmed indicated that lack of practical experience on the part of many health 
product regulators leads to the delays in the ethics approval process for clinical trials. 
This along with issues related to radiation safety remain major obstacles to medical 
devices commercialization in SA. The Managing Director of Southmed points this out 
this in the following quote,  
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“On the x-ray devices, we have waited 8 months to get a product approval for the 
device that hasn’t failed so timing is a problem. I think two reasons for this situation 
are: one, it’s a normal government bureaucracy and two, it might be that they under 
staffed in terms of what needs to happen. But if they are telling us it should happen in 
30 days then done months down the line. If there is a reason like the product failed 
registration because of x, y, z that is fine but if you give them all the documentation 
and you have to keep fighting and begging for product approval, then something is 
wrong with the system. I won’t mention people’s names” (Managing Director - 
Southmed, 2016). 
 
The respondent even went further and remarked: 
“The wheels are slow really, really slow in radiation control” (Managing Director - 
Southmed, 2016). 
 
Although the firm acknowledged that some regulators were highly educated and 
accomplished professionals (mainly in the pharmaceutical field), they cited lack of 
necessary medical device product development and manufacturing experience as a 
significant challenge. The Managing Director of Southmed captured this sentiment by 
stating: 
 
“MCC and the Radiation control department has hired highly educated people, but 
they lacked experience in the field or experience in production.... I think they will be 
ready in years to come and we will in the meantime have to bear the consequences” 
(Managing Director - Southmed, 2016). 
 
 Recognizing that MCC and the Radiation Control Department have made some 
important strides forward in recent years, the broad consensus is that the competent 
authorities needs to improve the efficiency of its decision-making process as the 
current situation was slowing down the firm’s products market entry. 
 
It emerged that the regulatory requirement has enhanced Southmed’s quality control 
systems and safety of their products. The firm had to demonstrate compliance by 
doing a risk and benefit analysis, produce evidence of appropriate testing to confirm 
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the design and production decisions resulting from the risk analysis, and produce 
evidence of appropriate radiation shielding. Further, the firm was able to demonstrate 
that appropriate control and indicator mechanisms have been incorporated into the 
device to ensure the operational consistency of variable parameters relevant to the 
emission of the radiation and the operation of the device.   
  
Effects of the REDs regulation on Southmed’s linkage capability 
The new regulations had a huge influence on Southmed’s entire approach to business 
collaboration and led to a restructuring of the firm. The changed structure had an 
effect on the firm leading to adoption of different competitive strategies and 
consolidation of business. For example, Southmed merged with another local firm and 
consolidated their business with the aim of improving efficiency and became fully 
compliant with industry standards at all levels including the requirements of the 
Health Care Charter and Broad Based Black Empowerment regulations.  The inter-
firm co-development interactions involved joint ventures, in an attempt to share, 
regulatory cost, development costs and minimize risks associated with innovative 
activities.  
 
Summary of Southmed (Pvt) Ltd.’s implementation actions 
Southmed indicated that REDs regulation to some extent impeded innovation, R&D 
efforts, created unnecessary barriers, and is very costly but not so much efficient. 
Demonstrating compliance with the international standards in order get the product 
license was one of the biggest regulatory challenges for the Southmed. On a positive 
note, REDs regulation played a significant role in facilitating the need to have more 
training of radiation workers.  The firm in turn developed a strategy of empowering 
individuals by identifying and then further developing their unique abilities and skills 
through tertiary and degree and diploma support. Lastly, the REDs regulation led to 
the Inter-firm co-development interactions that involved joint ventures, in an attempt 
share, regulatory cost, development costs, minimize risks associated with innovative 
activities and ultimately contributing to meet to meet the B-BBEE regulatory 
requirements. 
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8.2.2 Northmed Healthcare  
Northmed Healthcare is one of the leading MNC in the world operational in vivo 
diagnostics market. The firm was established in the late 1800s. Northmed holds more 
than 60,000 patents, has presence in 130 countries and two Nobel Prizewinners. The 
firm is a diversified multinational company, which has a set of technical, 
manufacturing and service industries as a whole, and is committed to be a global 
leader in each industry to obtain their business. The company has been supplying X-
ray machines since 1896 and developed a series of CT scanning, ultrasound, MRI as 
the representative in vivo diagnostics equipment, and gradually became the industry 
leader. The company has demonstrated proven expertise in medical imaging and 
information technologies, medical diagnostics, patient monitoring systems, 
performance improvement, drug discovery, and biopharmaceutical manufacturing 
technologies.  
 
In SA, the firm has over 1100 employees and participates in various business sectors 
of which healthcare is one of the sectors. The firm’s presence in SA can be dated back 
to 1898, with the first office having been opened in Johannesburg in that year. In 2016 
Northmed opened a R500M Africa Innovation Centre in Johannesburg, SA. This is 
Northmed’s center of excellence for innovation and technology transfer in Africa. It is 
the first for Northmed in Africa and the 10th Northmed innovation Centre globally. In 
November 2015 Northmed completed an acquisition of another local healthcare 
supplier company. This acquisition has now positioned Northmed as a strategic and 
value adding partner to South Africa. 
 
The firm has a strong commitment to contributing to SA’s sustainable development 
especially in skills and small medium enterprise (SMEs) development. Their 
commitment to localization focuses on expanding local supplier’s capabilities through 
skills development and technology transfer. Further to this, Northmed Healthcare has 
embarked on a Supplier Development Vehicle (SDV) program that is focused on the 
development of black owned SME’s through business development services and 
technical development services. This program was implemented in respond to the SA 
government’s B-BBEE regulatory requirements. Beyond this company program, their 
overall goal is to incorporate these suppliers into the Northmed supply chain. 
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Northmed Healthcare is transforming healthcare delivery in SA with 6000 clinical 
devices installed such as anaesthesia equipment and monitor. Northmed Healthcare 
ships over $2 million worth of parts per year to other Africa countries, Europe and the 
US. In 2017, the firm donated $1million to the Nelson Mandela Children’s Fund for 
the construction of the Nelson Mandela Children’s Hospital. The hospital’s radiology 
division is a showcase of Northmed Healthcare technology designed to make imaging 
more inviting for paediatric patients. 
 
Effects of the REDs regulation on Northmed Healthcare’s investment capability 
The introduction REDs regulation provided protection to radiology segment of 
medical devices and prompted investment from the Northmed to develop local 
business operations by bringing in more foreign direct investment, one example being 
the shipment of over $2 million worth of parts per year. The Projects Manager of 
Northmed comments,  
 
“Well, because the radiology devices to some extent are now well protected than the 
rest of the devices in SA from a regulatory point of view, it became less risk for us to 
invest more in such machines” (Projects Manager - Northmed 2016). 
 
As a result of REDs regulation, the firm is now one of the key producers and 
disseminators of applied knowledge in SA’s medical devices industry. Northmed 
disseminate knowledge directly through licensing agreements and through its 
operations in SA. The operations include: the acquisition of another local firm in 
2015, which had a progressive impact on skills development and technology transfer 
and its involvement in the SDV program that is focused on the development of black 
owned SMEs. The Projects Manager of Northmed comments,  
 
“As I have mentioned earlier, I think the regulatory change worked well to our 
advantage, we are now considered as one the big key players in knowledge transfer 
as far as sharing medical diagnostics production and regulation information is 
concerned, maybe because we have been in this field for quite some time now or 
because of our policy company strategies” (Projects Manager - Northmed 2016). 
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In addition, the firm is now often the first to introduce new products, processes, or 
business and management methods in SA, providing examples and ideas for imitation 
by domestic companies. Due to REDs safety requirements, the license holder must 
ensure that persons who perform routine tests are competent to execute the tests. As a 
result, Northmed now strongly support and offer training to its radiation workers, 
managers and researchers and creates a potential for local knowledge transfer. The 
Projects Manager of Northmed noted,   
 
“It is important for us to have people that would be able to interpret the QC tests, and 
adjust specific parameters” (Projects Manager - Northmed 2016). 
 
The radiation safety training contributes substantially to attaining the critical cross- 
field outcomes by promoting effective and safe patient care practices to fulfil the 
patient's needs by taking into consideration medical law requirements. The training 
further promotes total quality management in the radiography profession by planning 
the frequency and executing the QC tests. The training is in line with international 
trends - the QC testing was only implemented in 2008 (DRC 2012) 
 
Effects of the REDs regulation on Northmed Healthcare’s production capability 
Northmed Healthcare highlighted that even though additional regulatory requirements 
increased the time and costs associated with bringing new products to market but their 
innovation activities actually increased. As a result of increased innovation activities, 
the firm opened a R500 million Africa Innovation Centre in Johannesburg, SA. The 
Projects Manager of Northmed mentioned that: 
 
“Regulation helped to increase our innovation as it removed uncertainty, so we have 
to be constantly innovating to avoid falling behind because there is a lot of 
competition out there (Projects Manager - Northmed 2016). 
 
The quality control measures of Northmed healthcare significantly improved with the 
additional requirements of Essential Principle 11.5 that addresses medical devices 
intended to emit ionising radiation. The requirements means that if the device is 
intended to be used for diagnostic radiology, the device must be designed and 
produced in a way that ensures that, when used in relation to a patient for a purpose 
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intended by the manufacturer: the device achieves an appropriate image or output 
quality for that purpose; and the exposure of the patient, or the user, to radiation is 
minimized. The requirements for quality control tests were implemented in SA by the 
DoH only on 31 March 2009 (DRC 2012). 
 
Effects of the REDs regulation on Northmed Healthcare’s linkage capability 
In respond to the SA government’s B-BBEE regulatory requirements, Northmed 
Healthcare has embarked on a Supplier Development Vehicle program that is focused 
on the development of black owned SME’s through business development services 
and technical development services.  This is a relatively recent trend that is becoming 
more viable and noticeable in the growing interest on the part of large MNCs to 
partner with domestic firms. These linkages or relationships are primarily driven by 
the B-BBEE regulatory requirements and reduction of product development costs by 
tapping cheaper scientific labor in South Africa. The benefits to domestic firms 
included; access to financing for innovative projects, technological learning, and 
reputational advantages of working closely with major global enterprises.  
 
Summary of Northmed Healthcare’s implementation actions 
After the introduction of the REDs regulation, Northmed’s investment activities 
and/or mergers and acquisitions in SA give good indicators of how the firm and the 
market is developing. All these activities contribute to SA’s medical device industrial 
growth. Therefore, foreign investment made a positive contribution to SA by 
supplying capital, management resources and technology that would otherwise not be 
available and this increased the country’s economic growth rate, enhanced technology 
prowess, which in turn stimulated further economic development and 
industrialization. This firm supported the 2011 Code of Practice and the QC test 
requirements by determining the specific capability outcomes needed to attain to 
comply with the guidelines, in order to develop the company further. 
8.2.3 Medtech Solutions  
Medtech Solutions is a private group of bio-technology companies that was launched 
in 1987, originating from the work of two South African mechanical engineers. The 
company had revenues of $31.9 million for 2016. The two engineers first started a 
Cardiac devices company which was focused on developing a heart valve. As young 
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engineers in those days, the founders changed their devices focus because they needed 
some form of cash flow or income since the heart valve was long in generating funds, 
and there were no venture funds in those days available, so they had to fund 
themselves. The company's innovative activities have led to the commercialization of 
several other products, with other candidates at various developmental stages. 
 
In 1988, the company founders saw an opportunity in dental implants, so they 
changed the name of cardiac devices company to Medtech Solutions. When Medtech 
Solutions was established, dental implant science on a worldwide basis was in its 
infancy. The company has been one of the pioneers in this field contributing 
extensively to the enhancements with respect to implant devices, surgical techniques, 
patient education and options of treatment. The firm is not only one of the leading 
dental implant companies in South Africa, but is an international player in the USA, 
Europe and Australia. 
 
The parent company develops and manufactures dental implants and associated 
prosthetic devices. It focuses on the more specialized section of the market, not the 
generic implants but on the bespoke solutions, on high-end solutions and working 
with the specialists. The firm has directly owned offices in UK, Australia and USA. In 
addition they are represented in most parts of the world. In recognition of its role and 
activities in the medical device sector in SA, Medtech Solutions received the Gauteng 
export of year award and SABS innovation award for innovative design. Medtech 
Solutions has FDA approval and CE Mark, and was the first biomedical company 
producing locally to have those qualifications or those registrations. 
 
In 1994, the founders, decided to also relook at the heart valve, and they established 
an associate company called GY (Pty) Ltd. GY became the second company in the 
group of companies and was established to manufacture and develop the applications 
for cross-linked collagenous membranes. Products include hernia repair patches, dural 
membranes, and cardio-vascular patches. Successful implementation of international 
quality standards enabled the establishment of a plant for the processing of 
pericardium tissue, and the development of heart valves, and patches. These are class 
3 products that are more difficult from a CE regulatory perspective and has FDA 
approval.  
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In 1998 they started manufacturing pedicle screws for spinal use within Medtech 
Solutions. The development of orthopaedic implant devices benefited from the 
extensive experience of Medtech Solutions with respect to precision machining and 
processing of implantable materials, as well as knowledge of surface treatments for 
enhanced integration. This prompted the formation of the third spinal company in the 
group in 2001 which is dedicated to the development of orthopedic and neurosurgical 
implantable devices. The company is comprised of spinal surgery, foot surgery, 
maxillofacial surgery, and neurosurgery, as well as equipment divisions.  
 
The third spinal company designed a disk replacement for spinal use and that product 
is a class 2B in Europe but is a class 3 in the USA. In the USA they took the product 
through the Pre-market Approval (PMA) trial. It was a very expensive trial, but the 
firm raised venture funding for that trial in the order of approximately $100 million, a 
hugely expensive trial, but they did prove their superiority.  In parallel to the time of 
the firm’s PMA trial, there was a (Johnson & Johnson and its subsidiary, DePuy 
Orthopaedics) recall of the Articular Surface Replacement (ASR) metal-on-metal hip 
replacement system. This was one the events that triggered regulatory reform in 
Europe. Medtech Solutions’ design was also metal-on-metal, so they decided at the 
end of trial not to commercialize but to change materials, so at the time of the 
interview, the firm was in the process of doing a secondary trial based on what they 
did the first but this time around with poly framing materials.  
 
Then the fourth company in the group was formed in 2002. It's originally an 
Australian company which manufacture electronic implantable hearing aids, x-ray 
units, x-ray machines and the accessory devices. Medtech solutions group has a 
successful partnership with them. It's not products that the SA firm produce but 
products they represent, and for that, they work together with their UK branch as their 
representative. This company is therefore a proud distributor of the electronic 
implantable hearing aids, x-ray units, x-ray machines and conforms to the highest 
standards of quality and biocompatibility.  
 
Furthermore, the Medtech group of companies in 2002 formed MDSA (Pty) Ltd. 
MDSA develops advanced wound care products. The wound care products range 
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from honey-based ointments to nanofiber temporary skin substitutes. Tissue engineers 
have successfully implemented a cellular expansion facility for fibroblasts, 
keratinocytes and chondrocytes. Other successes in the SA market have been the 
development of the first South African hyaluronic acid visco-surgical device and also 
the most advanced partial and full thickness biological skin replacement devices. So 
the fifth company in the group is a specialized wound care focused firm. 
 
With a team of R&D scientists in the wound care, skin care line, and human resources 
that span the disciplines of bio-medical engineering, tissue engineering, bio-
technology, bio-chemistry and microbiology Medtech Solutions dedicated a team to 
develop the foremost skin rejuvenation products that are also medical devices 
according to regulations.  
 
Medtech Solutions has representation in the United States through its affiliate 
companies and is firmly committed to ensuring not only excellence in medical 
devices, but ensuring that these devices are cost effective. The group's employees 
count in excess of 150 staff, which includes strong R&D departments. Currently, the 
company commits 5% of its annual budget for R&D. The group is developing and 
evaluating numerous devices to ensure that it remains the leading biotechnology 
group in South Africa. It has recently built a state-of-the-art manufacturing facility 
according to international standards to allow good manufacturing practice production 
of devices, especially those targeted to export markets.  
 
Product licensing is a central component of Medtech's growth strategy in the short 
term, which it hopes will allow the company to access proprietary products and build 
on its technological capability. Medtech adhere to the highest medical device quality 
standards. The firms are ISO 13485 certified companies with many of the products 
bearing CE marks. The skin rejuvenation products are ISO 9001 certified with 
products registered for sale in the UK and the United Arab Emirates. 
 
Effects of the REDs regulation on Medtech Solutions’ investment capability 
One of the regulatory obligations in the Code of Practice 2011 is that, the license 
holder of medical X-ray equipment is responsible for the education and training of 
radiation workers. As a license holder, this regulatory requirement forced Medtech 
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Solutions to increase its in-house training as well as sponsored some of the workers to 
go to the universities and be trained in targeted radiography courses in order to 
comply with the new requirements and stimulate its business development. This result 
is in line with a study by Audretsch (1995) that suggest that while technology and 
knowledge transfer from universities and research institutes to companies has been a 
major stimulator of technology development, in-house training within companies is 
also considered an important factor for innovation. The author has shown that overall 
R&D expenditure is associated with knowledge production and innovation within 
firms (Audretsch, 1995). Medtech has even received compliments from their 
international auditors about their high standards of regulatory affairs as a result of 
increased in-house training. The Director of Medtech summarised this issue in the 
following quote: 
  
“We had the first skilled regulatory people who were in-house trained, and from us, I 
think a lot of expertise has gotten into the industry from the Medtech group because 
our regulatory people have trained other regulatory people and are constantly busy 
sharing their knowledge to try and up to the whole regulatory knowledge. So we have 
the regulatory manager who is also in the regulatory committee of SAMED. She is a 
microbiologist by trade, but have done the auditing courses and has been in our 
regulatory side for 10-12 years, so she very well trained, and we get quite a lot of 
compliments when we are audited from Europe about the standard of our regulators” 
(Director - Medtech, 2016). 
 
The firm acknowledged the importance of education and training in reducing patient 
doses while maintaining image quality of their products. However the firm identified 
Diagnostic Radiography as a scarce skill in SA, indispensable in both the public and 
the private sectors as part of a multidisciplinary team providing a holistic health care 
service. The qualification is recognised by the relevant Professional Health Council as 
a requirement for registration to practise in the field of Diagnostic Radiography. 
According to the South African Qualifications Authority (SAQA), the exit-level 
outcomes for this qualification describe the foundational, practical and reflexive 
competencies required for Diagnostic Radiography regulatory requirements. The 
Director of Medtech summed up this issue by saying: 
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“Training must be considered at different levels, not only for entry users but also for 
retraining and certification” (Director - Medtech, 2016). 
 
Effects of the REDs regulation on Medtech Solutions’ production capability 
The REDs regulation influenced the group of companies’ arrangements and processes 
established to produce and distribute products since the delivery of their products 
needed them to be at least fast adopters, use and improve new technology in order not 
to fall behind and meet local conditions. This did put a great deal of pressure on 
firms’ technological capabilities. Moreover, innovation is not just a matter of the 
simple creation and launching of new products. It is also about how services, are 
delivered, how business process are integrated, how companies and institutions are 
managed, how knowledge is transferred, how public policies are formulated and how 
enterprises, communities, and societies participate in and benefit from it all 
(Palmisano, 2006). The Director of Medtech captured this sentiment by stating: 
 
“Well yes we were affected operationally in that we had to revisit our production 
process and changed some of ways of doing business so that we could meet our local 
regulatory conditions” (Director - Medtech, 2016). 
 
SA’s September 2000 regulatory requirement that suppliers and users of diagnostic x-
ray equipment, for example medical and dental facilities, must ensure that a series of 
QC tests are done on all diagnostic x-ray units and processors was highlighted as one 
of the best regulatory requirement for the industry as it resulted in increased product 
and process safety. The aim of radiation safety is to minimize the potential harmful 
effects of radiation to patients, radiation personnel and the general public. This is 
necessary to enable suppliers and practitioners to comply with the mission statement 
of the DRC, which is “the promotion and maintenance of health within the 
framework of the National Health Plan and specifically the protection against injury 
or disease caused by technological devices, including hazardous sources of radiation, 
by furthering the safe and legal use of such devices” (DoH South Africa, 2011). 
Medtech indicated that the REDs influenced the firm’s process of supplying their 
products, leading to improvements in quality and safety of their products. This in turn 
gave a competitive advantage of the firm in the local and international markets. The 
Director of Medtech commented that: 
 213 
 
“Clearly the safety of our products increased and I think that’s how it should be. So 
that provided us with a market competitive advantage, now we are an international 
player in the USA, Europe and Australia” (Director - Medtech, 2016). 
 
Due to mergers and acquisitions, Medtech Solutions group was forced to adhere to the 
local and international medical device quality standards. The firms are ISO 13485 
certified companies with many of the products bearing CE-marks. According to 
Deloitte (2014), the implementation of the EN ISO 13485 QMS is the critical path for 
CE-mark approval and must be taken into account. In addition, to QMS requirements, 
Medtech was faced with increased scrutiny by regulatory authorities in forms of 
inspections and audits in order to ensure compliance to the requirements. This had an 
implication for the manufacturer as well to emphasize more product testing. 
 
Effects of the REDs regulation on Medtech Solutions’ linkage capability 
As from 31 March 2009 an Inspection Body (IB) approved by the Department of 
Health (DoH) or an appropriately trained professional registered with the HPCSA as a 
medical physicist must be used to perform all the acceptance tests as well as the 
routine test.  New equipment acceptance tests are the responsibility of the company 
that installed the equipment and in most cases it’s the manufacturer or distributors 
who install their product offering. If they don’t have the capability to install they 
subcontract these services.  
 
These new requirements called for close collaboration of not only Medtech’s group of 
companies (internal linkages capabilities) but also of different actors within the 
supply chain of the diagnostic medical systems (external linkage capabilities). The 
new requirements called for better support infrastructures. In this respect we agree 
with the Director of Medtech that:  
 
“Strong collaboration was needed in this innovative industry. As a group the 
introduction of SANAS and IBs inspections just made us to work together more 
closely. More to that and in a way it has harmonised the industry” (Director - 
Medtech, 2016). 
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We would extend Medtech’s observation to suggest that when it comes to medical 
devices innovation it is not only competition among firms that matters, but also 
increasingly cooperation among them. In fact, the external or networking 
technological capabilities involved in the new requirement include:  
• Accessing external knowledge - for example, the license holder was required to 
have an in depth knowledge of the x-ray unit (make, model, system ID and 
product license number) in order to implement the requirements with proof of 
compliance (DoH: QC Diagnostic).  
• Managing the producer/user relationship, which is central to successful 
innovation. 
• Accessing other partners who have useful complementary assets and capabilities 
such as the use of medical physicist to preform QC tests   
 
Summary of Medtech Solutions’ implementation actions 
Medtech was a proactive proponent of the REDs regulatory changes. The REDs 
regulation was a major stimulator of firm in-house training. The firm emphasized that 
training must be considered at different levels, not only for entry users of radiology 
devices but also for retraining and certification. Overall, adopting the new REDs 
regulation contributed significantly in enhancing the safety of the firm’s products, the 
safety of radiation workers, and the compliance of the Medtech as a license holder of 
medical X-ray equipment and as result, safety of the patients.  
8.3 Summary of empirical accounts 
8.3.1 REDs regulation summary 
The analysis shows that REDs regulation was a major milestone in SA’s medical 
device history. The “Regulations” laid down the legal status of REDs’ supervision 
and management. They also gave the DRC authority to oversee medical devices that 
emit radiation and ensure their safety and effectiveness, and protect human health and 
life. In fact, an earlier study suggested that regulative institutions represent the legal 
aspect of the institution and exert a coercive pressure on the participating 
organizations through formal mechanisms, including rule-setting, monitoring, and 
sanction (Scott, 2005, Scott, 1995). SA government, International bodies and 
directives have confirmed the need for education and training of manufacturers, 
distributers, medical staff and other healthcare professionals in the principles of 
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radiation protection. From a regulation and policy dimension the third regulatory 
change was perceived by many domestic firms as constraining and discriminative as it 
was selective in its targeted products (i.e. only targeting radiation emitting devices). 
 
The current criticism surrounding the implementation of third regulatory change 
regarding radiation protection in South Africa in the light of human error reiterates the 
need for standardized training of manufacturers, radiation workers, and also potential 
license holders. The consultation of experts to establish comprehensive objectives for 
a radiation safety controls ensured that the licensing conditions, which included the 
code of practice and annual QC test, were implemented. From an institutional theory 
point of view, the two licencing conditions were transitional and not turbulent 
changes.  
 
Transitional change in regulative institutions involves new laws and regulations that 
can be traced back to an overall governmental policy and plan, which are issued to 
facilitate the development of a market (Kingston and Caballero, 2009). They reflect a 
long-term orientation, focused on ensuring the market will follow the prescribed 
development plan; therefore changes tend to be gradual. As such, the occurrence of 
the transitional change can be better expected or predicted, as it is most likely to 
follow a timeline established in the policy and plan (ibid). In contrast, turbulent 
change which, some scholars refer to as “revolutionary” occurs in response to market 
shocks, or certain unexpected incidents that disrupt the market (Tihanyi et al., 2012). 
New laws and regulations that are considered turbulent change are issued with the aim 
of fixing the situation quickly by controlling the negative impact resulting from these 
shocks and ensuring a fast recovery. Turbulent change is therefore short term 
oriented, and may involve the implementation of many laws in rapid succession. As a 
result, the market order may be completely altered. Since market shocks cannot 
normally be anticipated, the occurrence of turbulent change is also not easily expected 
or predicted  
8.3.2 SA firms – Investment capability empirical account summary 
A growing number of firms viewed product R&D as an important component of their 
business models. However, the extent of commitment to R&D and the nature of their 
involvement varied across the firms. The effects of regulation under the Hazardous 
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Substances Act 15 on R&D elicited various responses among the medical device 
firms. A common view, however, amongst respondents was that, compared with the 
UK, which has a large number of R&D investments, most of SA’s SMEs do not have 
strong product R&D capabilities as it is an importer’s market, therefore regulation had 
little effect on a large number of local manufacturing SMEs firms. The underpinning 
argument why there is less R&D is the limited local manufacturing base and 
following the reasoning of most respondents that is an existential criterion to have in 
place for R&D. Because of this base being so small, no critical mass is created for 
R&D investments to result in a positive Return-On-Investment (ROI). 
 
On the other hand, for a few MNCs that were involved in R&D activities, the 
introduction of REDs regulation induced them to start investing more in radiology 
devices. A good example was Northmed Healthcare, a MNC that was proactive to 
REDs regulatory change and in turn became one of the firms that brings in a lot of 
foreign direct investments to SA, over $2 million shipment worth of parts per year. 
 
One of the most common challenges faced by innovation-inspired firms in SA was 
related to clarity and effective enforcement of regulations governing health products. 
Again, while the outcome mainly manifested in delays in regulatory approval, the 
underlying causes varied across the firms. Lack of practical experience on the part of 
South African regulators was thought to make product approval challenging. Other 
challenges in South Africa were primarily related to delays in approval of clinical 
trials, which was perceived to detract from a major competitive advantage possessed 
by the country. 
 
On key finding of this analysis is that REDs regulation enhanced the need for more 
training of radiation workers in almost all firms interviewed. What is clear is that 
SA’s ambitious regulatory infrastructure building policies, as part of its overall goal to 
build an innovative and globally competitive technological environment, will 
continue to create demands for specialized skills in the REDs segment and other 
various healthcare technological areas. It remains to be seen whether current 
initiatives will be sufficient to meet this demand. 
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8.3.3 SA firms – Production capability empirical account summary 
The analysis focused on capabilities of firms across the health product development 
value chain that firms used to advance their innovation objectives. The analysis 
collectively reveals various degrees of regulatory effects across different firms. A 
common strategy however, for entrepreneurs in SA has been to begin with 
technologically and financially less demanding products and/or services and to 
venture into more sophisticated areas as capabilities and revenues improve. Since 
REDs such as X-ray, CT, and MRI are on high end of technology, also the falling on 
the product category that is heavily regulated, very few SMEs were willing to or had 
the capability to invest in such products. 
 
Most firms indicated that REDs regulation did not have a significant effect on radical 
or disruptive innovations into the SA market, which involves discontinuities in 
innovation pathways but instead it had an influence on incremental innovations. This 
was because product development and commercialization in SA at present mostly 
involves local improvements of technologies developed elsewhere and modifying 
imported technologies to suit local conditions. 
 
Overall, this analysis on production capability reveals a striking similarity across the 
firms with respect to how REDs regulatory changes affected the firms’ R&D and 
innovation capabilities. These commonalities include; less regulatory impact on R&D 
and innovation on most of SMEs due a low manufacturing base and their preference 
for collaboration with international firms. 
8.3.4 SA firms – Linkages capability empirical account summary 
The REDs regulation enabled a strong collaborative relationship in the SA medical 
device industry. As a result, the collaboration of SA medical devices and diagnostics 
value chain which include; the product role players, the regulators, funders, 
government departments and the industry associations facilitated the development of 
the new regulations relating medical devices and In Vitro Diagnostic Medical Devices 
(IVDs) published on December 9, 2016. Some stakeholders within the medial device 
sector in SA have been lobbying for this regulatory effect in the past years.  
  
In order to meet the clinical evidence regulatory requirements, the firms involved in 
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R&D activities tend to have increased reliance on partnerships with domestic 
universities and research institutes as well as foreign entities. Firm-university linkages 
typically served to fill in gaps in internal R&D capabilities and access 
facilities/equipment and, to a lesser extent, to the transfer of new technologies to 
firms. There appears to be a strong correlation between the levels of R&D interest 
among firms and their linkages with domestic universities and research institutes. 
 
In the same vein, these results were predicted in literature that supports the notion 
that, strong collaboration or close interactions between manufacturers and regulators 
in niche markets lead to the creation of knowledge, innovation and regulatory 
solutions (Malerba, 2007). In fact, the sectoral systems of innovation (Malerba, 2004)  
places interaction between heterogeneous actors at the centre of the focus where firms 
interact with non-firm organizations such as government agencies and universities in 
processes of learning and knowledge accumulation (Metcalfe, 1998).  
8.4 Conclusion 
Most MNCs indicated that the third regulatory change (REDs) influenced their 
process of supplying their products, leading to improvements in quality and safety of 
their products. This in turn gave them a competitive advantage in local and 
international markets. SA domestic firms were expected to have a capability to 
import, manufacture or fully refurbish any listed electro-medical device on a global 
basis, to comply with radiation emitting device regulatory requirements. Respondents 
argued that it is a tall challenge for most firms. Such stringent requirements made it 
more difficult for domestic suppliers in SA to enter the supply chain. The next chapter 
presents a cross-case analysis of the three regulatory change cases selected for this 
study. 
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CHAPTER NINE 
CROSS-CASE ANALYSIS 
----------------------------------------------------------------------------------------------------- 
9.0 Introduction  
In the previous two chapters, individual case analyses of regulatory changes and their 
impact on firm technological capabilities were presented. As discussed in chapter 6, 
there were three regulatory change cases, two in the UK context and one in a South 
Africa context. This chapter will present a cross-case analysis of these regulatory 
change cases using empirical data from the UK and SA based firms. In this regard, the 
chapter addresses research sub-question 3.  
 
To achieve the above intention, this chapter will be structured as follows. Section 1 
sets out the analytical approach undertaken during the analysis of regulatory change 
effects. In addition, the three regulatory changes that have been identified will be 
briefly described, before the cross-case analysis is summarized and presented in Table 
9.1. The chapter will then proceed (in sections 2-4) to present data relating to 
investment, production and linkage capabilities. Within these capabilities, the chapter 
will analyze in some depth each regulatory change case looking for generalizable 
conclusions from the study’s various empirical firm data. At the end of the chapter, 
the results will be summarized so as to provide an overall empirical and conceptual 
perspective. 
9.1 Analytical Strategy 
The data analysis strategy discussed in Chapter 5.5.3 is employed to build an 
understanding of the effectiveness of the three regulatory changes in achieving their 
aims and also their impact on firms’ capabilities. This simplified analytical structure 
is designed to facilitate identification of similarities and differences between the 
effects of the three regulatory changes. For example, the analysis shows that while 
REG1 (Software) was perceived as discriminating and enabling because the changes 
drove most UK-based firms to invest substantial resources in R&D to standardize 
their software products, REG3 (REDs) was perceived as discriminating and 
constraining through its indirect influence on R&D investment decisions as described 
in section 4.7. Based on this analytical model, the thesis argues, with empirical 
evidence, that a more enabling and discriminating regulation that takes into 
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consideration firms’ technological capabilities can achieve intended goals more 
efficiently and effectively, than a constraining and indiscriminate regulation.  
9.1.1 Identified regulatory change cases in the United Kingdom and South 
Africa: brief overview 
This section starts with a brief summary description of the three specific regulatory 
changes influencing the two national medical device industrial systems. 
  
As discussed in chapter 6, the European directive (REG1: MDD 2007/47/EC) 
introduced software into medical device regulation and tightened the specifications by 
requiring manufacturers to validate software whether integrated or standalone, 
regardless of device class and to provide additional documentation to prove 
compliance with further safety and efficacy standards. The ultimate objectives of this 
regulatory change were to ensure medical devices produced and used in the EU region 
not only are effective and safe but also provide more benefits to users (European 
Commission, 2007). 
 
REG2: EC 2013/473/EU: As of January 2014, UK Notified bodies were required to 
conduct unannounced production audits on manufacturers at least once every three 
years and more often for high-risk devices, frequently non-compliant devices or in 
case of suspected nonconformities.  The unannounced audit involves checks on a 
recently produced adequate product sample for its conformity with the technical 
documentation and with legal requirements. Also included is a file review and 
verification of the traceability of all critical components and materials and of the 
manufacturer’s traceability system (European Commission, 2013a). 
 
In respect to REG3: Radiation emitting devices (REDs), the SA government imposed 
additional restrictions by introducing two licensing conditions guidelines, namely the 
“Code of Practice for industrial radiography - X-ray Equipment 2011” and the 
“Requirements for license holders with respect to quality control tests for diagnostic 
X-ray imaging systems”.  The first licensing condition was drawn up in order to limit 
the risk of overexposure of workers and members of the public, and to keep radiation 
doses as low as is reasonably achievable (DoH South Africa, 2011). The second 
licensing condition enforces annual quality assurance according to a prescribed list 
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(Herbst and Fick, 2012). The REDs regulatory changes called for a number of 
administrative and medical device requirements from those applying for the license as 
discussed in chapter 6. These requirements have a significant impact on the license 
holders, as they must show that they possess the necessary equipment, facilities and 
trained personnel to ensure that the radiographic work will be performed in a safe 
manner. Table 9.1 summarizes how each regulation has influenced firm level 
technological capabilities. 
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Table 9.1: Summary of the firms’ responses to the three regulatory changes 
INVESTMENT  
CAPABILITIES  
UK REGULATION 1 
(Software) 
Product regulation 
UK REGULATION 2 
(Unannounced Audit visits) 
Process regulation 
SA REGULATION 3 
(Hazardous Substances Act) 
Product and process regulation 
Research and 
Development 
• Created substantial shifts in the distribution 
of inventive efforts to meet market 
requirements 
• Some firms indicated that this regulatory 
change curtailed R&D considerably.  
• Other firms’ R&D expenditure increased as 
new inventive efforts to meet market 
requirements were now needed 
• The core EC 2013/473/EU did not have a 
big impact on firms’ innovation activities, 
apart from the fact that they ended up with 
a suitable and appropriate quality 
agreements and commercial contracts in 
place to make sure they identify the roles 
and the responsibilities for those within the 
supply chain 
• Influenced R&D investment decisions 
• Little impact on R&D as the 
environment is an importer’s market. 
• MNCs tend to depend on parent 
companies to develop new products 
using R&D resources close to 
headquarters. 
Recruitment & 
training 
• Created competitiveness among the firms 
as the staff members received training to 
keep up-to-date with emerging rules and 
standards regulating software design 
processes, and technological scalability. 
• Increased the cost of the skilled personnel 
that firms needed to employ. 
• Created more jobs within the firm and 
increased in-house training efforts.  
• Increased training programmes for 
employees responsible for regulatory 
compliance. Creating a full QMS requires 
skills, expertise and resources. 
• Forced implementation of new recruitment 
strategies that would have to factor 
recruitment of staff with international 
regulatory exposure for most firms that 
outsource production via subcontractors  
• Enhanced the need for firms to recruit 
skilled personnel or the need to provide 
adequate periodic staff training. 
• Increased technology transfer 
• Induced a tall challenge on firms given 
that the regulatory environment in SA 
lack regulatory affairs human resources 
and that there is quest for skilled 
manpower 
Standard 
procurement 
• Technical constraints were imposed by the 
standards e.g. ISO 13485 and IEC 62304 
which are uniformly applied to an entire 
medical device software development 
process. 
• Brought positive reputation and helped to 
gain confidence among customers 
•  • Procurement of ISO standards e.g. ISO 
13485 in order to get CE certification 
proved very costly for most of the firms 
• Brought positive reputation and helped 
to gain confidence among customers 
• Enhanced firm positioning 
• Increased competitiveness 
PRODUCTION 
CAPABILITIES 
UK REGULATION 1 
(Software) 
UK REGULATION 2 
(Unannounced Audit visits) 
SA REGULATION 3 
(Hazardous Substances) 
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Innovation  
 
• Some innovative firms became more risk 
averse towards novelty. Thus, they became 
incremental instead of radical innovators. 
• Slowed down product development time 
and innovation substantially. 
• Forced some firms to drop off potential 
ideas and opportunities due to the risk of 
not meeting the regulatory requirements. 
• Enhanced the creation of completely new 
processes because it was too costly to fulfill 
the regulatory requirements with the 
existing technology, and significant 
technological change was required 
• Indirectly influenced investment decisions 
whether to innovate new medical devices 
• Enabled modification of imported 
technologies to suit local conditions. 
• Some firms argued that the bureaucratic 
protocols caused by the regulatory 
environment slowed the process of 
innovation 
Safety and 
Quality control 
• Improved the quality and ensured the safety 
of products entering the market. 
• Brought positive reputation to the product 
quality and helped it gain confidence 
among customers 
• Firms had to formulate new strategies 
including altering QMS safety and 
performance processes, processes for the 
device design and development, 
subcontracting, manufacturing, etc. 
• Most firms were in agreement that the 
introduction of the acceptance test and 
annual Quality Control (QC) tests plays 
an important role in diagnostic imaging 
to limit the population dose growth, 
thereby improved quality control. 
Operations • Although complying with the new 
regulation was burdensome, some firms 
that were proactive increased their sales. 
• Firms that failed to realise the possibilities 
inbuilt in regulatory change requirements, 
ended up as failures in the market 
• Business operations disrupted by the 
multiple visits (scheduled and unscheduled) 
and staff having to spend time with 
inspectors or auditors (substitution 
approach recommended). 
• Business operations affected by the 
discriminating BBBEE regulation or 
preferential procurement policy. 
 
Cost of 
compliance  
 
• Due to a series of harmonised standards 
which go alongside the 2007/47EC, the 
firms had to increase the appropriate level 
of software testing and the complexity of 
setting up and validating all the appropriate 
test methods, that meant increased cost of 
products, time and manpower. 
• Coerced compliance cost and in turn 
resulted in firms needing to divert resource 
• Increased NB inspection cost (Inspection 
time spent with inspectors by staff or 
management of the firms, during which 
they were not able to perform other work) 
• Increased costs of putting the business in 
compliance following the inspection’s 
findings and inspector’s improvement 
notice. 
• Increased auditor’s travelling costs and 
• Increased SANAS inspection cost 
(Preparation time when visit scheduled, 
Inspection time spent with inspectors by 
staff or management of the firms, during 
which they were not able to perform 
other work) 
• Increased burden of compliance cost 
especially when it comes to bringing in 
auditors for CE certification purposes 
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outflows to meet regulatory requirements 
• The firms incurred unique costs such as 
forgone opportunity costs associated with 
much longer product approval times 
costs of sampling and testing all of which 
are incurred by the manufacturer 
• Lost turnover or profit as a result of delayed 
or suspended operations. 
 
Product market 
entry 
• Approval time increased, the delay was 
considered more critical to the firms’ 
decisions and operations. This was because 
regulatory approval directly determines 
when the product can enter the 
marketplace, and determine the return on 
investment for businesses. 
• Products’ speed to market reduced, thus the 
time to market got longer therefore, net 
present value of their products went down. 
• Delayed product market entry when firms 
are putting the business in compliance 
following the inspection’s findings and 
inspector’s improvement notice or 
suspension of its certification. 
 
LINKAGE 
CAPABILITIES 
UK REGULATION 1 
(Software) 
UK REGULATION 2 
(Unannounced Audit visits) 
SA REGULATION 3 
(Hazardous Substances) 
 
 
 
Local linkages 
• It became increasingly necessary for firms 
to develop relationships with all the links in 
their supply chain. 
• Some firms had to learn how to collaborate 
better and how to share resources 
• Forced firms to move from adversarial 
relationship towards collaborative 
relationship with their suppliers. 
• Enhanced a long-term relationship with 
critical subcontractors and crucial suppliers. 
• Fostered improved collaborative and 
target based interactions between 
government and private sector, 
harmonized the industry actors and in 
turn ignited growth of the industry. 
 
 
 
International 
linkages  
 
• Most firms successfully broadened their 
outsourcing models to include foreign firms 
with offshore production facilities. 
• Increased outsourcing denoted more 
dependence on suppliers and implied the 
need to manage the supplier base and 
develop relationships with suppliers. 
• Increased the firms’ focus on the development of 
close collaborative relationships with their 
suppliers in search of competitive advantage and 
improved market positioning 
• Forced some firms to re-negotiate supply chain 
agreements, and alter documentation and QMS. 
• Improved the exchange of information between 
the local and international regulatory bodies. 
• Enabled international company-to-
company partnerships, usually with 
European companies. 
 
Compiled by author from research data
 225 
In order to analyze in some depth each regulatory change case and have a better 
understanding of how the changes influenced the firms, I adopted a regulation and 
policy instrument proposed by Chataway et al. (2006), presented earlier in Chapter 4. 
“Its focus is on the effectiveness and efficiency of the governance achieved by a 
particular policy or regulatory instrument”. First the authors categorized policies and 
regulations according to whether they are perceived as enabling (providing 
encouragement or inducements to undertake a desired course of action) or 
constraining (creating disincentives to undertaking undesirable actions) by industry 
managers. The second category of policies and regulations was based on whether they 
are indiscriminating or discriminating among products” (Chataway et al., 2006, p. 
177). Figure 9.1 allows us to map the enabling, constraining, discriminating and 
indiscriminating within the Medical devices regulation and policy dimensions. The 
next three sections present empirical data showing the effects of the three regulatory 
changes on investment, production and linkage capabilities. 
9.2 Effects of regulatory change on Investment Capability: cross-case analysis 
Investment capability involves the ability to prepare for the identification and 
acquisition of design technology, equipment, management, and to develop a new 
product or upgrade the current one. This initial stage is crucial for defining the goals 
and objectives or the strategy that the firm should follow. Below is an analysis of the 
effects on firms’ R&D, human resource training and standards capabilities. 
 
Research and Development (R&D) 
R&D capability is an important investment contributor to financial, marketing and 
innovation performance. The analysis summarized in Figure 9.1 highlights that from a 
regulation and policy dimension, REG1 was perceived as discriminating, enabling and 
constraining in relation to R&D. REG2 was seen indiscriminating and constraining 
and the REG3 was perceived as discriminating and constraining. The cross-case 
analysis indicates that all regulatory change cases had some form of influence on the 
R&D capabilities of some firms in both the UK and SA.  
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Figure 9.1: Medical devices regulation and policy dimensions: Effects on R&D 
Compiled by author  
 
The product regulation REG1 has been observed as a driver of requirements for new 
technology. This comparative review of the firms’ actions has unearthed clear patterns 
that firms that invest in R&D extend their technical knowledge base, which allows 
them to design and develop new innovative products or services. Some firms’ R&D 
expenditure increased after the new regulation. Some respondents argued that 
investment in this area should be a prerequisite for the success of their companies in 
the medium to long-term future. Other firms indicated that the regulatory change 
created substantial shifts in the distribution of inventive efforts to meet market 
requirements. Thus, from the regulation and policy metrics in Figure 9.1, REG1 was 
mainly perceived as enabling.  
 
On the contrary, some firms perceived this regulation as constraining due to the fact 
that before the changes, the process of R&D and placing of a medical device on the 
market, as long as it was safe, was fairly easy to do. After the regulatory change, 
almost any product change or new product development has to go through a series of 
regulatory hoops before one can get a CE mark. For example, clinical evaluation: 
REG1 emphasized the need for manufacturers to provide clinical evidence for all 
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REG1: software 
• Some firms’ R&D expenditure 
increased as new inventive efforts 
to meet market requirements were 
now needed 
• Created substantial shifts in the 
distribution of inventive efforts to 
meet market requirements 
 
REG 2: unannounced audits  
• Influenced R&D investment 
decisions 
 
REG1: software 
• Some firms indicated that this 
regulatory change curtailed R&D 
considerably.  
 
REG 3: REDs 
• Little impact on R&D as the 
environment is an importer’s 
market 
 
Research and Development Capability 
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devices. All devices were now in need of such data, including devices for Class I. 
Additionally, this imposes more stringent requirements for what constitutes “clinical 
trial” and calls for a stronger attention from the authorities. Annex X on clinical 
evaluations was changed (European Commission, 2007). Consequently, 
manufacturers must now analyse and review the clinical part during the planning 
stage to identify any problem that needs further investigation. Such control measures 
are then inserted in the document risk analysis at the design stage and also after the 
commercialization of the product in order to keep updated on the state of the art of all 
the technical data of the medical device. In fact, for a better demonstration on the 
compliance of the medical device, manufacturers are obliged to implement a 
procedure to review the production of the device even after its commercialization, 
with the duty to report to the authorities any accidents or withdrawal from the market. 
Such regulatory hoops were perceived as constraining, especially at the R&D stage of 
the products as compliance costs limited the R&D budget of some firms. 
 
In contrast to the product regulation REG1, the product and process regulation REG3 
was perceived as constraining through its indirect influence on investment decisions. 
Subject to debate, the most important effect of regulatory inspections is not through 
the direct amount of administrative burden it creates, but through its impact on 
investment decisions whether to engage in an R&D activity, to expand, procure or 
innovate new medical devices, hire staff etc. All these decisions are affected by many 
factors of the investment environment and regulations but it is clear that the way 
enforcement and inspections are done or perceived has a significant role. Indeed, one 
of the most important aspects of regulatory changes for firms when making 
investment decisions is predictability. Some of the SA firms referred to the 
introduction of the SANAS inspections under the Hazardous Substance Act as 
ambiguous and constraining in which case they called for transparent enforcement 
that could help their businesses to understand what they actually mean, and what to 
expect.  The CEO of MGD Health Solutions noted: 
 
“SANAS inspections are so complex and technical that we do not know how to 
understand them. If no official guidance clarifying what to expect is available, we will 
often refrain from investing in R&D or introduce new products altogether” [Res 002 
(MAN), Oct, 2016].  
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The quote above reinforces the notion that R&D investment in new equipment or new 
activity, be it by existing or new businesses, MNC or SME, will be significantly 
reduced if the manufacturing firms are not sure of how the regulators will assess 
compliance, and if they cannot get appropriate guidance.  In many developing 
countries, not only is an officially published guidance not available, but also 
regulators will even refuse to give any prior consultation or visit that would be 
binding on them, thus leaving the whole risk on manufacturing firms (Monk, 2012). 
The cross-case analysis revealed that good regulatory delivery that is enabling and 
discriminating can improve confidence and control. This simply means firms need to 
understand how regulatory inspections impact upon them to enable them to identify 
the most cost-effective means of compliance for their business context. Good risk 
assessment should be transparent to the business and should be supported by 
assurance that enables investment decisions to be made on a sound understanding of 
future inspection and enforcement compliance requirements. 
 
SA firms faced a wide diversity of regulatory challenges related to investment and 
innovation activities. One important and common barrier that hinders innovation 
activities in the context of SA is the ability to finance innovation activities. In terms of 
business investment in R&D, the analysis reveals that SA spends very little, compared 
to the UK. SA’s investment as reflected by its Gross Expenditure on R&D (GERD) 
has always been very small, it has never exceeded 1% (SAMED, 2016).  
 
Respondents in SA were in general agreement that government policies and 
regulatory changes did not directly influence the type of innovation in their firms (e.g. 
R&D of multinational companies were influenced by their corporate strategy rather 
than be subjected to the policies of the emerging country). According to SAMED 
(2016) the underpinning argument why this is the case is the limited local 
manufacturing base that is an existential criterion to have in place for R&D. Because 
of this base being so small, no critical mass is created for R&D investments to result 
in a positive Return-On-Investment (ROI) (SAMED, 2016). Most MNCs confirmed 
this by stating that most of their R&D was done in developed countries where their 
head offices are located, mainly in the US, the UK, Switzerland, France, and German. 
The cross-case analysis revealed that only a few MNCs have control of their product 
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development activities and spending on R&D is inadequate. Since investment in R&D 
has a direct effect on output, if output is to be increased then investment will have to 
be increased proportionately (Cullmann et al., 2012). Unfortunately, most respondents 
indicated that there was lack of R&D funding, whether it be through universities, 
subsidies from government or medical schemes. Some firms argued that the R&D 
investment climate is more business friendly in other African countries like Kenya 
thus resulting in decisions to move R&D activities outside South Africa. Lastly, other 
respondents feel there is no true R&D culture in the country and there is little appetite 
and uptake from universities to invest in the medical device industry. 
 
It can be argued without equivocation that product regulation had a huge impact on 
the UK firms’ R&D capabilities compared to SA firms, but there were both 
affirmative and negative impacts in classification. This can be attributed to the fact 
that UK innovators had more access to resources and capabilities available to them 
compared to those in SA. This also goes to show that, in high-income countries, R&D 
efforts may result in innovations driven by technology, despite the stringency of 
regulation or a high degree of uncertainty. From a regulation and policy perspective as 
shown in Figure 9.1, a discriminating and enabling regulation REG1 produced desired 
outcomes effectively and efficiently for the case firms even though more favorable 
regulatory conditions should be created for the introduction of appropriate technology 
to vitalize the industry. 
 
Training and Recruitment  
Successful industrial production requires a range of different skills. Figure 9.2 
captures the key findings related to the effects of regulatory changes on training and 
recruitment. The findings indicate that all regulatory change cases have composite 
training and recruitment implications. The findings indicate all regulation whether 
categorized as discriminating or indiscriminating, they all were perceived by the 
stakeholders interviewed as enabling and constraining. 
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Figure 9.2: Medical devices regulation and policy dimensions: Effects on training and 
recruitment. Compiled by author. 
 
It is evident that all regulatory change cases enabled all firms to acquire experts and 
skilled personnel as vital sources of knowledge and learning to fill their inherited 
knowledge gap in order to address the new regulatory requirements and the demand 
for innovative products, processes, and further organization-wide change. Moreover, 
such engagements not only support new product development, but also help firms’ 
R&D teams provide innovative ideas and future products concepts to upgrade existing 
products and processes.  
 
For engagement with experts, Figure 9.2 captures the four most important reasons 
across firms. The findings identified “ability to innovate”, “improve business 
performance”, “improvement in medical devices production,” and “ability to meet 
new regulatory requirements” as the predominant motives for engaging with experts.  
 
The findings showed that REG1 enabled the creation of new job opportunities related 
to innovation and regulatory affairs management, a good example being the industry 
of medical consulting. In terms of readability of the clinical evaluation guidelines, 
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Enabling Constraining 
REG 2: unannounced audits 
• Increased training programmes for 
employees to improve business 
performance. 
• Introduced the need for a qualified 
person to meet new regulatory 
requirements  
 
 
 
REG1: software 
• Created more innovation related jobs 
within the firm and increased in-house 
training efforts to meet requirements. 
• Created competitiveness among firms 
REG 3: REDs  
• Increased technology transfer 
• Enhanced the need for firms to recruit 
skilled personnel or the need to 
provide adequate periodic staff 
training 
REG 2: unannounced audits 
• Forced implementation of new 
recruitment strategies that would 
have to factor recruitment of staff 
with international regulatory 
exposure for many firms that 
outsource production via 
subcontractors or suppliers 
 
REG1: software 
• Increased the cost of the skilled 
personnel that firms needed to 
employ 
REG 3: REDs  
• Induced a tall challenge on firms 
given that the regulatory 
environment in SA lack regulatory 
affairs human resources  
Training and Recruitment Capability 
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they have changed from a document that was fairly easy to comprehend by any 
medical device manufacturer representative to a heavy document that requires expert 
knowledge on the regulatory background of the EU medical device policy and 
experience in working with EU legislative documents. This is a clear sign from the 
European Commission that the clinical evaluation process was not to be taken lightly 
and a significant addition to the skillset of the enterprise was needed, as most firms 
had to choose between leveling up their knowledge of the new requirements or use the 
help of external consultants.  
 
Institutional theory has traditionally been concerned with how organizations better 
secure their positions and legitimacy by conforming to the rules (such as regulatory 
structures, governmental agencies, laws, and other societal and cultural practices that 
exert conformance pressures) and norms of the institutional environment (DiMaggio 
and Powell, 1991). For the firms to be able to conform to the rules as suggested by the 
theory, expertise in regulatory affairs become vital in the medical device sector. 
Expertise in regulatory affairs is critical to the medical device industry, as each new 
and improved product must be approved in every country in which it is to be sold and 
the requirements for approval are constantly evolving.  
 
The cross case findings as depicted in Figure 9.2 indicated that on one hand, REG1 
forced firms to devote a large number of staff to regulatory affairs after its 
introduction. On the other hand, REG2 forced implementation of new recruitment 
strategies that would have to factor recruitment of staff with international regulatory 
exposure for many firms that outsource production via subcontractors or suppliers. 
However, some firms echoed that the need to devote substantial resources to 
regulatory matters often reduced resources that would otherwise be available to 
support product development and commercialization therefore perceived the two 
regulatory changes as constraining. The Quality Manager of Alpha Ltd noted: 
 
“Due to skills shortages firm outsourced design therefore increasing the need to 
externally monitor the supplier’s QMS” (Quality Manager - Alpha Ltd, (UK), 2017). 
 
In addition, Figure 9.2 reveal that REG3 was perceived as constraining because it 
induced a tall challenge on firms given that the regulatory environment in SA lack 
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regulatory affairs human resources. Unlike in the UK, official reviews (KPMG, 2014) 
and interviews suggest that there is a scarcity of South African nationals with 
knowledge and expertise in the area of ISO certifications and regulatory systems. The 
Strategic and Key Account Manager of SSA Ltd noted: 
 
“The rigorous rule-following, documentation centered culture required by regulatory 
changes is unfamiliar for some of our staff and that slows us down so we have 
embarked on a series of in-house training” [Res 014 (MAN), Oct, 2016]. 
 
On a positive note, REG3 was also perceived as enabling from the regulation and 
policy dimensions, due to the fact it enhanced the need for firms to recruit skilled 
personnel or the need to provide adequate periodic staff training. The Director of 
Medtech Solutions reflected on the increased training needs in the following quote; 
 
“In response to the new regulation, we took in-house responsibility for training of 
personnel while engaging the help of another distributor for regulatory support” 
Director - Medtech, (SA), 2016. 
 
Finally, from a regulation and policy dimension as displayed in Figure 9.2, all the 
three different regulatory change cases placed some huge training cost constrains on 
firms as all the firms were forced to increase their in-house training. However the two 
product-focused regulations REG1 and REG3 were perceived as discriminating and 
enabling, because they created more innovation related jobs, upgraded quality of in-
house talent, increased technology transfer, and enhanced the knowledge base of the 
regulation targets. 
 
Standards Procurement 
In terms of the effect of regulatory change on standards procurement, it has been 
argued that good-quality and affordable products, whether imported or locally 
produced, depend largely on the outcome of standards-based competition (Narayanan 
and Chen, 2012). Figure 9.3 captures the key findings related to the influence of 
regulatory changes on standard procurement. The findings indicate that the REG 1 
and REG 3 had enabling and constraining effects on standards procurement. It is 
important to note that international standards play a very significant function in the 
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regulatory systems of the two study countries, and in product safety. Standards are 
core components underpinning firms’ operational strategies. They are developed in 
respect of each directive in order to provide manufacturers with a set of technical 
specifications recognized in the directive as giving a presumption of conformity to the 
essential requirements. Use of international standards remains voluntary: 
manufacturers are able to put on the market products, which either meet other 
standards or no standards at all, subject to fulfilling the procedures for assessment of 
conformity laid down by the Directive.  
 
 
Figure 9.3: Medical devices regulation and policy dimensions: Effects on standards 
procurement. Compiled by author. 
 
The analysis revealed to us that some firms perceived the REG1 as constraining when 
it comes to standards procurement. The respondents in the UK were in general 
agreement that the technical constraints were imposed by the Directive’s aligned 
standards such as the ISO 13485 (Quality Management Systems), IEC 14971 
(Application of Risk Management) and IEC 62304 (Software Lifecycle Processes) 
which are uniformly applied to an entire medical device software development 
process. Requirements contained in these standards have imposed direct constraints 
on firm’s conduct, foreclosing product innovation. The processes involved in order to 
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Enabling Constraining 
 
 
 
 
REG1: software 
• Improve the process of achieving 
regulatory conformance  
• Brought positive reputation and 
helped to gain confidence among 
customers 
• Enhanced company brands 
REG 3: REDs  
• Enhanced firm positioning and 
competitiveness 
  
 
REG1: software, 
• Technical constraints were imposed 
by the standards such which are 
uniformly applied to an entire medical 
device software development pro 
REG 3: REDs  
• Procurement of international 
standards such the ISO 13485 in order 
to get CE certification proved very 
costly for most of the firms 
Standards Procurement Capability 
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procure these standards were viewed as constraining and stringent in production of 
medical device software especially for the small companies. The financial cost 
involved in complying with software standards proved to be a significant barrier for 
small companies in UK to upgrade their innovations.  
 
Furthermore, the cross-case analysis indicated that the content of standards was highly 
technical thereby required expert knowledge of technology and practice in the 
medical device sector. Accordingly, experts inevitably come predominantly from 
industry, although academics and consultants are also involved. The involvement of 
personnel from competitors or companies making different products within the same 
sector produced uncompetitive results in some cases. Also, the increasing length and 
complexity of standards meant that manufacturers need sufficient understanding in 
how to apply them. 
 
In SA, the requirements with regard to the application for a licence to import, 
manufacture or fully refurbish any listed electro-medical device under REG3 
mandates that “the manufacturer of a particular electro-medical device in South 
Africa will be permitted to manufacture but not distribute that device in any way until 
the applicable and valid EC compliance documentation30 has been submitted to and 
accepted by the Directorate: Radiation Control” (Doh South Africa, 2012). The 
acquirement of a CE Mark requires ISO 13485 standard procurement and annual 
auditing. However, the cross-case findings indicated that there is limited local 
capacity for auditing facilities for this ISO certification and the SABS certification has 
no recognized value outside of South Africa. Therefore, the cross-case analysis 
indicated that most firms faced daunting challenges in order to procure the standards 
required for the smooth flow of their operations. Most companies experienced 
unexpected delays on product registration and license renewal, and bureaucracy 
hurdles. Manufacturers spend significant time and incur financial expenses to obtain 
 
30 The following documentation must be submitted by the manufacturer in South Africa in order to get 
a licence to import, manufacture or fully refurbish any listed electro-medical device: 
• Completed application form 41BM-1(MAN); and 
• Colour brochure (including technical specifications); and 
• Copy of the EC Certificate(s) issued by a recognised Notified Body to the manufacturer in South 
Africa in terms of EC Directive 93/42/EEC or 90/385/EEC (whichever one is applicable); and  
• Copy of the EC Declaration of Conformity issued by the manufacturer in South Africa in terms of 
EC Directive 93/42/EEC or 90/385/EEC (whichever one is applicable). 
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CE registration from European certified bodies. Moreover, they must cover 
transportation and accommodation costs to fly representatives from these Notifying 
Bodies to South Africa for facility and product inspection. Implementation of these 
higher standards by local firms and achieving certification requires high investments. 
Against this backdrop, standard procurement was perceived as constraining. 
 
On the positive side, the cross-case findings as indicated in Figure 9.3 show that 
REG1 was perceived as discriminating and enabling with regard to standards 
procurement. The findings identified that firms that had evidence of the applicable 
standards improved the process of achieving regulatory conformance. This finding 
resonates with an earlier study by Mugwagwa et al. (2015) that argued that when 
regulatory standards or mechanisms conflict, they may prevent one another from 
achieving their intended benefit. For instance, manufacturers that attained ISO 13485 
compliance argued that they had an easier time bringing their products to international 
markets.  Compliance streamlined the processes and ultimately helped to run a more 
efficient, profitable and risk-averse operation. Compliance with ISO 13485 helped 
firms with overall quality control, traceability, process validation and risk 
management. Furthermore, there was an increase in acceptance and demand for new 
products among consumers and promotion of barrier free trade throughout the global 
trade markets. The Director of Neiva Medical reflected on this notion in the following 
quote: 
 
“The introduction of software products standards has been crucial to the success of 
the 2007 regulatory changes in promoting barrier free trade throughout the European 
Community and in international markets. These standards have also enabled products 
to reach the high levels of safety achieved in the sector” [Res O73 (MAN), Apr, 
2017]. 
 
The analysis indicated that SA firms that managed to procure standards and CE 
certifications enhanced their legitimacy in the local market. Standards procurement 
enabled positive reputation, helped the firms to gain confidence among customers and 
ultimately increased competitiveness. Institutional theory places emphasis on how 
organizations establish their positions and achieve legitimacy in order to survive and 
make profit (Scott, 2008). These standards legitimized the operations of the case firms 
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and gained acceptance of their offerings even in the international market. Therefore, 
under these circumstances and from a policy and regulation dimension, REG3 was 
viewed as enabling. The Director of Bioweb Ltd noted: 
 
“In order to work with international clients, we have to comply with their 
international standards as well. We acquired certifications. We are certified by ISO-
13485” [Res 001 (MAN), Oct, 2016].  
9.3 Effects of regulatory change on Production Capability: cross case analysis 
Firms’ technological capabilities are core determinants of their ability to compete 
(Lall, 1992). Many of the regulatory challenges faced by firms concern production 
capabilities, and the ability to manage and document the work processes following the 
Essential Principles of Safety and Performance guidelines. For medical devices firms, 
such capabilities determine their market access, both locally (achieving product 
registration and sustaining quality when products are tested) and for access to regional 
and international markets. This section analyses four elements of production 
capability: production itself, quality control, operations, and regulatory compliance. 
 
Innovation in production 
Regulatory changes may impact products, processes, marketing or organizational 
innovations. The changes may be incremental or disruptive, enabling or constraining.  
The analysis summarized in Figure 9.4 highlights that product-focused regulations 
REG1 and REG3 enabled new products to substitute older ones, which had been 
banned by regulation or as imported products were modified to suit local conditions in 
the case of SA firms. Thus, it is clear that product regulation can have a positive effect 
and has been a key driver of many innovations. 
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Figure 9.4: Medical devices regulation and policy dimensions: Effects on innovation 
in production. Compiled by author. 
 
The cross-case analysis revealed that, on the one hand, REG1 was perceived as 
discriminating and enabling. Perhaps the most significant influence of this regulatory 
change was that it enhanced the creation of completely new innovative processes 
because it was too costly to fulfill the regulatory requirements with the existing 
technology, and significant technological change was required. The new innovative 
process included validating medical device software according to the state of the art 
taking into account the principles of development lifecycle, risk management, 
validation and verification. This meant developing new software in accordance with 
international harmonised standards.  
 
On the other hand, the analysis indicated that REG1 was seen as discriminating and 
constraining. Some firms became more risk averse towards novelty and in turn 
became incremental innovators instead of radical innovators. The analysis indicated 
that regulatory change forced some firms to even drop off potential innovative ideas 
and opportunities due to the risk of not being able to meet the new software regulatory 
requirements. Moreover, there was a general consensus by respondents that to some 
extent, the changes in regulation restricted market entry of innovative newcomers. 
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Enabling Constraining 
REG 2: unannounced audits 
• Enhanced key innovation 
processes such as design control, 
purchasing and control of 
incoming material and 
components, assembling, 
sterilization, batch realize, 
packaging and product quality 
control 
  
REG1: software 
• Enhanced the creation of 
completely new processes or 
products 
REG 3: REDs  
• Enabled modifying imported 
technologies to suit local 
conditions. 
 
 
REG 2: unannounced audits  
• Indirectly influenced investment 
decisions whether to innovate 
REG1: software 
• Some innovative firms became more 
risk averse toward novelty 
• Slowed down product development 
time and innovation substantially 
• Forced some firms to drop off 
potential ideas and opportunities 
REG 3: REDs  
• Caused bureaucratic protocols and 
slowed the process of innovation 
Innovation in Production Capability 
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Examples of requirements that were perceived as constraining innovation in order to 
prove compliance with further safety and efficacy standards include: ‘clinical data 
requirement’31 that must be supplied when seeking regulatory approval regardless of 
device classification, the ‘evaluation’ requirements, ‘transparency’ requirements and 
design changes32 in software requirements.  
 
Furthermore, some firms highlighted that innovative development of medical device 
software, was hugely constrained by “software localization”. Under the REG1, 
software sold or used within the EU must be localized into the language of each of the 
EU countries that the product will be marketed i.e. MDD 2007/47/EC, Article 4.4. 
Essentially, if a UK medical device manufacturer wishes to market a medical device 
into France, the graphical user interface (GUI) must be available in French. A number 
of difficulties can arise when attempting to perform a software translation such as 
differing file formats, different character encoding, character size constraints and 
errors caused in code caused by repossessing. Thus, REG1 was perceived as 
constraining in this regard by some firms.  
 
As indicated in Figure 9.4, REG2 was viewed as indiscriminating and enabling 
regulation. The regulatory change had a significant impact on firms’ innovation 
processes. The respondents indicated that the key mandatory process affected by 
unannounced audits include: design control, establishment of material specifications, 
purchasing and control of incoming material and components, assembling, 
sterilisation, batch release, packaging, and product quality control. This list is not an 
exhaustive list and other relevant processes may be examined as well.  The ultimate 
goal of this regulatory change was to ensure that innovative products that enter the 
market are safe and of good quality. 
 
 
31 Clinical data is defined as safety and/or performance information that is generated from the use of a 
medical device MCCAFFERY, F., CASEY, V. & MCHUGH, M. How can software SMEs become 
medical device software SMEs.  European Conference on Software Process Improvement, 2011. 
Springer, 247-258. 
32 Design changes may necessitate notification to the notified body that audited the software before it 
was altered and should be included in the manufacturer’s technical file KLÜMPER, M. & 
VOLLEBREGT, E. 2009. Navigating the New EU Rules for Medical Device Software. RAJ Devices, 
17, 1-8. ibid. 
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The low level of manufacturing capacity in SA made the REG3 changes have less 
impact on firms’ innovation activities. The cross-case analysis revealed that, 
regulation did not have a significant effect on radical or disruptive innovations, which 
involve discontinuities in innovation pathways but instead had more impact on 
incremental innovations as discussed in chapter 8.1.1 and in section 9.2 of this chapter 
under research and development capabilities.  
 
To sum up, the regulated environment plays a significant role on the level of 
regulatory impact or effectiveness. If the regulated environment is subjugated by low 
product manufacturing capacity, the effects of any regulation irrespective of its nature 
or type will also be of little impact. Further, it can also be argued from a regulation 
and policy dimension that discriminating and enabling regulation as indicated in 
Figure 9.4 above can attain better and desired industry outcomes. Based on this cross-
case analysis of the medical device innovation system and the interplay of regulation, 
there were more constraining effects than enabling ones, key affirmative impact being 
the creation of completely new innovative processes. These need to be addressed in 
order to improve regulation effects on innovation. Policy-makers should be aware of 
the various effects. Political decisions, including those on regulation, need to be 
increasingly based on evidence. This holds true for new regulation as well as for those 
under scrutiny, which may face an amendment, replacement or abolishment. Each 
decision will almost inevitably bring about different incentives and thus also have 
different innovation consequences for different stakeholders. 
 
Quality control 
With respect to quality control, Figure 9.5 captures the key findings related to the 
effects of regulatory changes on quality and safety. It is interesting that the cross-case 
findings show that there was no constraining regulation when it comes to quality and 
safety of products. Quality assurance was therefore considered to be the most 
important concern in outsourcing by most firms in the UK and SA. The findings 
indicated that most firms emphasized the importance of a sufficiently robust and 
effective regulatory enforcement policy that is clear from the safety perspective. The 
firms considered that rigorous inspections have contributed to the high quality of 
authorized medical devices. 
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Figure 9.5: Medical devices regulation and policy dimensions: Effects on quality 
control. Compiled by author. 
 
Firms perceived the product-focused REG1 as discriminating and enabling because it 
created incentive to develop new processes with higher work safety. It improved the 
quality and ensured the safety of products entering the market. The new regulatory 
changes further placed emphasis on supplier compliance for any part of the 
manufacturing process which in turn resulted in better quality outcomes. Firms were 
now keeping a close eye on their suppliers making sure that they were fully utilizing 
QMS such as the ISO 13485. To ensure patient safety, ergonomic design was now 
considered an essential requirement of the medical device. To that effect, the cross-
case findings showed that REG1 brought positive reputation to the firms as the 
improved product quality helped in gaining customer confidence. 
 
Reference to Figure 9.5 above, the analysis reveals that REG2 was perceived as 
indiscriminating and enabling. The regulatory change fostered firms into formulating 
new strategies including altering QMS safety and performance processes, processes 
for the device design and development, subcontracting, manufacturing, etc. The 
selection of suppliers occurs early in the product development process. Thus, firms 
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Enabling Constraining 
REG 2: unannounced audits 
• Firms had to formulate new 
strategies including altering QMS 
safety and performance processes, 
processes for the device design 
and development, subcontracting, 
manufacturing, etc. 
 
 
 
REG1: software 
• Improved the quality and ensured 
the safety of products entering the 
market 
• Brought positive reputation to the 
product quality 
REG 3: REDs  
• Limit the population dose growth, 
thereby improved quality control. 
 
 
 
Quality Control Capability 
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were forced to apply rigid and sophisticated qualifications to ensure quality and that 
suppliers must comply with complex documentation requirements and that the final 
product meets regulatory demands. 
 
Furthermore, the analysis as indicated in Figure 9.5 shows that REG3 was seen as 
discriminating and enabling. Most firms were in agreement that the introduction of 
the acceptance test and annual Quality Control (QC) tests plays an important role in 
diagnostic imaging to limit the population dose growth, thereby improved quality 
control. 
 
In brief, the findings reveal to us that, there was consensus among manufacturers 
interviewed on the fact that, although all the firms faced pressure for continuous 
improvements in terms of quality and reliability of their medical devices in a 
consistent manner, it appears the pressure resulted in positive outcomes. The firm 
managers all agreed that the three regulatory changes were engineered in such a way 
that quality is built-in and checked for at various stages and the evidence meticulously 
documented. From regulation and policy dimensions as depicted in Figure 9.5 above, 
all the three regulatory change cases were perceived as enabling. 
 
Operations 
Figure 9.6 captures the key findings related to the effects of regulatory changes on 
business operations. The summary identified that all the three regulatory change cases 
had enabling and constraining effects. 
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Figure 9.6: Medical devices regulation and policy dimensions: Effects on business 
operations. Compiled by author. 
 
The findings indicate that REG1 was perceived as discriminating, enabling in relation 
to business operations. First, the regulatory change enabled brand enhancement. 
Compliance with REG1, with its focus on public safety, enhanced companies’ 
standing and brand as trusted partners in their internal and external business 
operations in health care. Second the regulation enabled firms’ competitive 
positioning. As different companies adopted different strategies in response to the 
new legislation, based on their capacity to undertake the extensive changes, this 
presented market expansion opportunities and or acquisition targets for the business. 
Even though complying with the new regulation was burdensome, the cross-case 
findings indicated that some firms that were proactive increased their medical devices 
sales. A positive approach to the regulations was a key business operations success 
factor. The findings indicated that firms that used the regulatory changes as a 
framework and process to ensure their devices are as safe as possible and perform 
reliably and consistently enjoyed quicker and greater commercial success. This was 
evidenced by the following remark from the Associate Director Regulatory Affairs of 
Delta Ltd: 
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Enabling Constraining 
REG 2: unannounced audits 
• Supply chain operations improved 
•  Complying with regulations 
enabled restructuring operations 
and planning future business 
•  
 
 
 
REG1: software 
• Some firms that were proactive increased 
their medical devices sales  
• Enabled restructuring operations, planning 
future business and enhanced firm’s brand 
REG 3: REDs  
• The operations lines become a lot 
more process focused 
• Enabled restructuring operations and 
planning future business 
 
REG 2: unannounced audits 
• Business operation disrupted by 
the multiple audit visits 
(scheduled and unscheduled) 
 
REG1: software 
• Firms that fail to realise the 
possibilities inbuilt in regulatory 
change requirements, ended up as 
failures in the market 
REG 3: REDs  
• Business operations affected by the 
discriminating BBBEE regulation or 
preferential procurement policy 
Operations Capability 
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“Because we invested more in R&D and regulatory compliance, we improved the 
overall company performance and turnover increased over the years after 2007 
regulatory changes” [Res 057 (MAN), Jan, 2017] 
 
On the contrary, the findings indicate that REG1 was perceived as discriminating and 
constraining. Some UK firms’ business operations slowed down as market 
authorization timelines became protracted, curtailing patients’ access to technology 
innovations and the costs of operating in Europe increased. Firms’ overall operations 
were affected by the regulation as more regulatory and technical documentation were 
introduced, that meant more in-house control operations and scrutiny needed and the 
more the regulatory cost, the less the investors. 
 
On the one hand, Figure 9.6 highlights that REG2 was perceived as indiscriminating 
and enabling by firms that had high experience of the medical device review process. 
Some firms indicated that an intensive scrutiny of their business practices and 
processes through the unannounced audits left the companies considerably better 
equipped for the future regulation.  Complying with this regulatory change enabled 
restructuring of operations and planning for future business. On the other hand, the 
regulation was perceived as constraining because business operations were disrupted 
by the multiple audit visits (scheduled and unscheduled). Furthermore, the findings 
indicated that after the introduction of REG2, there was a shake-up of the notified 
body network that led to closing down of a few notified bodies and in turn led to 
bottlenecks in getting products to market. This had a significant impact on firms’ 
business operations. Some respondents expressed concern about the uncertain future 
of their businesses operations given the ad-hoc and abrupt policy changes by the EU 
community. The Chairman of Kilo Ltd reported;  
 
“We cannot properly plan how to grow our business given the current practice 
whereby the governments just make abrupt decisions without proper consultation” 
[Res O66 (MAN), Jan, 2017]. 
 
Similarly, the analysis shows REG3 in SA was perceived as discriminating and mainly 
enabling with regard to operations capabilities. The regulation enabled restructuring 
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operations and planning future business. Most firms expanded their business 
operations mainly as a means to meet regulatory requirements.  
 
However, REG3 was perceived as discriminating and constraining with respect to the 
associated preferential procurement system and the BBBEE regulation. The way in 
which purchasing decisions are structured and regulated impact profoundly on the 
way in which firm operations happen. Lall (1987) identified firms’ procurement 
capabilities, as well as those of governments, as elements of cumulative industrial 
improvement. Procurement can act as a financing and incentive mechanism to 
improve technological capabilities, a key element of medical device industry 
development. The findings indicate that many existing local companies without 
BBBEE qualification faced difficulties in competing in the procurement system and 
collectively called for a transparent system and a level playing field.  
 
The case analysis shows that industry associations such as SAMED and SALDA in 
response, have been attempting to influence the institutional environment and its 
actors by lobbying for less stringent regulation in the BBBEE space. Overall, there 
seems to be a consensus that the cost of BBBEE regulation imposed by government 
has developed into a political issue over concerns about the excessive cost and 
administrative burden imposed by complying with regulatory requirements.  
 
Based upon the medical devices regulation and policy dimensions model in Figure 
9.6, we are able argue that a discriminating and enabling regulation is capable of 
assisting firms to develop better strategies, restructure operations, improve processes, 
implement key business initiatives, plan future business and help the firms to 
effectively manage regulatory changes. The importance of regulation and industrial 
policies that foster the operations of business into local medical devices production 
cannot be overemphasized. Local production of medical devices benefits local 
economy, such as savings on foreign exchange through import substitution, 
employment creation and the development of exports. 
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Cost of Compliance  
It should be noted that most firms generally viewed regulatory compliance33 as a 
driver of complexity and costs for businesses, whose regulatory teams are tasked with 
ensuring that their companies are compliant with legislation and minimizing the risks 
associated with it. The firms that seek to leverage the opportunities inherent in 
compliance with new regulation had fruitful outcomes for their businesses. The 
analysis summarized in Figure 9.7 highlights that regulatory compliance is costly and 
absorbs significant resources. 
 
Figure 9.7: Medical devices regulation and policy dimensions: Effects on cost of 
compliance. Compiled by author. 
 
The findings indicate that REG1 was seen as discriminating and constraining in 
relation to compliance. Due to a series of harmonised standards which go alongside 
REG1, firms had to increase the appropriate level of software testing and the 
complexity of setting up and validating all the appropriate test methods, meant 
increased cost of products, time and manpower. Furthermore, the firms incurred 
unique costs such as forgone opportunity costs associated with much longer product 
approval times. However, trying to reduce compliance costs by compromising on 
 
33 Regulatory compliance refers to organizational activities that are induced or stimulated by 
requirements issued by the regulatory authority. 
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Enabling Constraining 
 
 
 
•  
 
 
REG 2: unannounced audits 
• Increased NB inspection cost 
• Increased costs of putting the business 
in compliance following the 
inspection’s findings  
• Increased auditor’s travelling costs, 
costs of sampling and testing  
• Lost turnover or profit as a result of 
delayed or suspended operations 
REG1: software 
• Increased cost of standards acquiring 
• Firms incurred unique costs such as 
forgone opportunity costs associated 
with longer product approval times  
REG 3: REDs  
• Increased SANAS inspection cost 
• Increased burden of compliance cost 
especially when it comes to bringing 
in auditors for CE certification 
purposes 
Compliance Capability 
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standards would lead to fewer medical devices entering the market, instead ensuring a 
cost-effective and sustainable compliance with standards would be good for all the 
actors in sector in the short and long runs. 
 
REG2’s routine unannounced audits and REG3’s SANAS inspections share some 
similarities in their inspection requirements. For example, they both called for 
technical inspections that focus on compliance with, broadly speaking, “safety 
requirements” (understood in a very broad sense, as social aspects of regulation), and 
protection of patients’ occupational safety and health, safety and performance of the 
medical device 34 , buildings and premises, market surveillance of products, etc. 
(Blanc, 2012).  
 
The findings summarized in Figure 9.7 shows that REG2 audits were perceived as 
indiscriminating and constraining while REG3 was perceived as discriminating and 
constraining with regard to the cost of compliance. The findings indicated some 
similarities in the way in which inspections were a burden on most firms through the 
time lost and other direct costs of the conformity assessment procedures. Given this, 
manufacturers had to factor the additional costs related to inspections or audits in their 
budgets. These may not, in fact, always be the most important form of inspections 
burden, but they are the most easily quantifiable (Monk, 2012). The type of costs 
directly affected by regulatory inspections include:  
(i) Preparation time, if any, when inspections are announced in advance (e.g. in 
the case of SANAS inspections), including time to retrieve or prepare specific 
documentation.  
(ii)  Inspection time spent with inspectors by staff or management of the firms, 
during which they were not able to perform other work. 
(iii)  Follow up time, if any, for all activities directly resulting from the inspection 
such as preparing documentation or any other administrative tasks.  
(iv) The other costs incurred by the manufacturer include: auditor’s travelling costs 
and costs of sampling and testing.  
 
 
34 Testing of device conformity in the UK is done in accordance to ANNEX III Section 4 of the 
European Commission’s Recommendation 2013/473/EU, with the main focus on the safety and 
performance of the device. Possible tests include: microbiological, mechanical, packing, performance, 
electrical and functional safety testing 
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Trying to get the details of most costs through in-depth interviews was difficult 
especially from the SA firms as the respondents were reluctant to reveal the actual 
regulatory inspection cost 
 
To sum up, as all the three regulatory changes increased compliance cost, in turn this 
resulted in most firms needing to divert resource outflows to meet regulatory 
requirements. However, firms that sought to leverage the opportunities inherent in 
compliance with new regulatory changes had fruitful outcomes for their businesses. 
9.4 Effects of regulatory change on Linkage Capability: cross case analysis 
Linkages offer benefits to foreign affiliates and domestic manufacturers/suppliers, as 
well as to the country in which they are forged as a whole. Linkages can also transmit 
knowledge and skills between the linked firms. A dense network of linkages can 
promote medical device production efficiency, productivity growth, technological and 
managerial capabilities and market diversification for the firms involved in the 
medical device industry. The three regulatory changes in the UK and SA had a major 
impact on both local and international linkage capabilities with influence across 
products and processes. Figure 9.8 captures the key findings related to the effects of 
these changes on linkages. 
 
 248 
 
Figure 9.8: Medical devices regulation and policy dimensions: Effects on linkage 
capabilities. Compiled by author. 
 
The findings indicate that REG1 was seen as discriminating and enabling with respect 
to linkages. There was a general agreement by the respondents from the UK-based 
firms that because both manufacturers and their critical suppliers were technologically 
strong and capable, therefore the regulatory change enabled knowledge flows to run 
in both directions with a focus mainly on new medical software technologies and 
organizational methods. Whereas in SA even though the firm respondents perceived 
REG3 as discriminating and enabling, they indicated that domestic manufacturers’ 
technological capabilities were comparatively weak and the knowledge flows were 
more one-sided, coming from MNCs to domestic firms. 
 
Both product-focused REG1 and process-focused REG2 regulatory changes in the UK 
fostered the formation of an efficient supply chain management, which is critical to 
the competitiveness of firms. On one hand, as part of REG1 changes, the directive 
mandated that, should a device manufacturer outsource any part of the design or 
manufacturing process, then the manufacturer must be able to demonstrate that 
adequate controls over the whole chain of development of the software concerned 
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Enabling Constraining 
REG 2: unannounced audits  
• Forced firms to move from 
adversarial towards collaborative 
relationship with their suppliers 
• Enhanced long-term relationship with 
critical subcontractors  
• Improved the exchange of 
information between the local and 
international regulatory bodies 
REG1: Software  
•  Firms developed better relationships 
with all the links in their supply chain 
• Firms learnt how to collaborate and 
share resources and stepped up their 
accumulation of knowledge 
REG 3: REDs  
• Increased technology transfer 
• Fostered improved collaborative and 
target based interactions 
 
REG 2: unannounced audits 
• Forced some firms to re-negotiate 
supply chain agreements, and alter 
documentation and quality 
management systems 
REG1: Software 
• Monitoring suppliers operations 
constrained 
  
Linkage Capability 
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have been put in place. This new regulatory requirement helped in the creation of an 
efficient supply chain management system though a few respondents argued that it 
was very constraining to monitor the process and the suppliers. 
 
On the other hand, the most radical reformation within the REG2 concerns their audit 
policy or the modalities for conduct of assessments that mandated Notified bodies to 
not only audit the premises and processes of the manufacturer, but also those of its 
critical subcontractors or its crucial suppliers. On average, a manufacturing firm was 
spending more than half its revenue on purchased inputs.  Some firms were 
contracting out the entire manufacturing process to independent “contract 
manufacturers”, keeping only functions such as R&D, design and marketing. In these 
cases, as a result of the regulatory changes, supply chain management became even 
more important. Most of the firms interviewed indicted that they successfully 
broadened their outsourcing models within their supply chain networks to include 
foreign firms with offshore production facilities.  
 
The analysis indicated that firms developed better relationships with all the links in 
their supply chain, learnt how to collaborate and share resources and stepped up their 
accumulation of knowledge in order to meet the new regulatory requirements. The 
motives for close collaborative relationships fostered by the product and process 
regulations between manufacturers and their suppliers was said to be in search of 
competitive advantage and improved market positioning. The supply chain linkage 
formation process was affected by a new regulation and policy environment. Indeed, 
in addition to regulatory changes being a key determinant for the formation of 
efficient supply chain linkages, the technological, managerial and regulatory 
compliance capabilities of the subcontractors or suppliers also determined to a large 
extent the ability of manufacturers to meet new regulatory requirements and benefit 
from the knowledge that supply chain linkages can transfer. Weak capabilities of the 
crucial suppliers increased the chances of medical device manufacturers to outsource 
the most sophisticated and complex parts and components from other capable or 
preferred suppliers within or outside the UK. 
 
Based on Figure 9.8, it can be seen that some respondents perceived REG2 as 
enabling due to the fact that the changes fostered firms to move from predominantly 
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adversarial and transactional relationships towards collaborative relationships with 
their suppliers (see chapter 7). Thus, this type of linkages enhanced long-term 
relationships with critical subcontractors.  
 
On the contrary, there was a general consensus among respondents in the UK that 
REG2 had an enormous constraining effect on supplier agreements between actors 
and throughout the whole supply chain as the level of scrutiny had increased. The 
cross-case analysis showed that a lot of suppliers were not entirely medical device 
suppliers so they found the new inspection regulatory requirements that had been 
extended to them as a market shock and had difficulties in complying with them. 
Moreover, changes in regulation usually have a transition period of three years but 
REG2 was imposed three months after the EC recommendation was passed. Most 
manufacturers were forced to change their supplier contract agreements. The 
manufacturers’ new legal contract agreements with their suppliers had to ensure that 
there was a clause included that the suppliers will be inspected any time by NBs and 
they are to notify the manufacturers of any dates of which they are not available.  
 
As mentioned earlier, in SA, there was a general consensus among the respondents 
that domestic manufacturers’ technological capabilities were comparatively weak and 
the knowledge flows were more one-sided, coming from foreign affiliates to domestic 
firms. The types of linkages affected by REG3 were different from linkages in the 
UK. In section 9.3 under the subsection “operations”, the analysis revealed that the 
BBBEE regulation was perceived as constraining business operations in the way it 
was implemented. However, this regulation, to a certain extent enabled the framework 
for linkages formation. In the search to meet the target based BBBEE regulatory 
requirements and increase the BBBEE company rating in order to have a competitive 
public procurement advantage in the SA market, some foreign affiliates merged with 
the domestic firms that had higher BBBEE ratings. In turn this led to upgrading of 
domestic suppliers’ technological capabilities. Lall (1992) refer to this type of 
linkages as “a special linkages promotion programme” and is a proactive approach, 
which is typically focused on a selected number of industries and firms, with a view 
towards increasing and deepening linkages between foreign affiliates and domestic 
firm.  
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 9.4.1 Joint ventures and strategic partnerships: fostering technology transfer 
Under REG3, there are some requirements that had enabling effects on the 
interviewed firms’ linkage capabilities. The requirements promoted the creation of 
joint ventures, strategic partnerships and in turn fostered technology transfer. These 
regulatory change requirements are in respect to the application for a licence to 
import, manufacture or fully refurbish any listed electro-medical device. As already 
established, two of the shortcomings of SA’s regulatory environment are: (a) local 
manufacturers are organized at the secondary level and hence dependent on foreign 
companies for raw materials and technology sources; and (b) the country imports 
more than 90% of the medical devices. Yet, two of the requirements for importation 
of new or fully refurbished listed electro-medical devices include:  
(i) Providing a copy of the EC Certificate(s) issued by a recognised Notified 
Body to the original manufacturer in terms of EC Directive 93/42/EEC or 
90/385/EEC (whichever one is applicable); and  
(ii)  Proving a copy of the EC Declaration of Conformity issued by the original 
manufacturer in terms of EC Directive 93/42/EEC or 90/385/EEC (whichever 
one is applicable) (DoH South Africa, 2011).  
 
As the SA domestic firms are expected to have a capability to import, manufacture or 
fully refurbish any listed electro-medical device on a global basis, to comply with the 
stated requirements above, the respondents argued that it is a tall challenge for most 
of the firms. Such stringent requirements make it more difficult for domestic suppliers 
in SA to enter the supply chain. In order to overcome these problems, some local 
manufacturers established joint ventures as a strategic partnership with foreign 
companies whose technological capabilities and resources are strong. Some of the 
specific criteria used by the SA local firms in the quest for foreign affiliates include; 
their willingness and potential to establish beneficial linkages, their interest in 
developing strong supply links with domestic enterprises, production capabilities, ISO 
certification and CE mark certification.  
 
As the product and process REG3 raised its constraints, the SA firms were caught up 
in a situation where there are not enough technological capabilities. This dilemma led 
to the formation of ‘horizontal linkages’, which involve interactions with domestic 
firms engaged in competing activities and ‘backward linkages’ that are defined as 
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transactions that go beyond arm’s length and involve longer term relationship with 
firms (Lall, 2003). Thus, external networks and support are vital to survival in the 
race to meet regulatory requirements, upgrade and retain or regain market access.  
 
The analysis indicates that domestic/foreign affiliates enabled relationships that were 
marked by sustained exchanges of information, technology, skills and other assets. 
The linkages are of particular significance to SA firms, because they provided a 
means of diffusing valuable knowledge throughout the medical device sector. Since 
technical requirements to attain CE certification and associated standards are so 
complex, foreign affiliates’ assistance was considered a huge knowledge transfer 
benefit. Some assistance was in the form of human resource development therefore 
often forming part of linkages, and expands the scope for deeper spillovers of skills 
and knowledge. 
 
The benefits provided through linkages with foreign affiliates were of greater 
competitive significance than those among domestic firms because of the stronger 
knowledge and skills base of many foreign affiliates. Foreign affiliates, in turn, 
benefited from backward linkages as they enhanced their access to local tangible and 
intangible resources. Hence there was a substantial mutual interest between foreign 
affiliates and domestic firms to create and deepen backward linkages. Linkages are, 
therefore, a channel towards strengthening the competitiveness of domestic firms, and 
giving them a footing in the international production networks of medical devices. 
Fundamentally, these linkages should be seen as part of a broader set of FDI, SME 
regulation and policies. 
 
Successful local SA companies have, in general, developed internal expertise through 
partnerships or international/multinational collaborations, whether it be manufacturing 
or distribution. The alliances with leading players and suppliers gave the companies 
access to critical skills, resources, and support when developing the latest products, 
processes, and international endeavors. Two examples of firms in SA that benefited 
from backward linkages with foreign affiliates and horizontal linkages with other 
domestic firms as a result of regulatory change include Medtech and Southmed (see 
chapter 8). Medtech successfully merged with its affiliate companies in the USA and 
is now firmly committed to ensuring not only excellence in medical devices, but 
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ensuring that these devices are cost effective. The merger enhanced Medtech’s 
capabilities to become involved in value-added operations and offerings. Similarly, 
Southmed merged with another local firm and consolidated their infrastructures with 
the aim of improving efficiency and quality. The joint venture enhanced Southmed’s 
capabilities and the firm’s client base now spans the entire Southern African region. 
The Director of Medtech respondent noted: 
 
“Our acquired sister company in the UK and USA-based consultants and designers 
feed us with the latest medical device global market information, help us to adopt new 
production and processes and training developments. Such an arrangement put us 
ahead of the game and improved our product quality” (Director - Medtech, (SA) 
2016). 
 
As reflected in the quote above, joint ventures/alliances and partnerships are the most 
dominant ways to adopt new production and processes by the firms. It is important to 
note that partnerships include both alliances with leading market players as well as 
with suppliers in co-product development, marketing, and supplies (Alexiev et al., 
2016). The present findings supports existing studies showing that alliances and 
partnerships are the main sources of opening new opportunities and are a vital mode 
in firm development (Cudjoe and Ibiyemi, 2015),  and learning from partners (Peng 
and Heath, 1996).  Further, the alliances of interviewed firms with international 
players earned them access to critical skills and competences in their new production 
endeavors to overcome their inherited bottlenecks in production, processing and 
operations. This is in line with the learning and acquisition of knowledge from foreign 
partners (Meyer and Nguyen, 2005). 
 
According to institutional theory, alliances can enhance their ability to address 
institutional turbulence or transitions in the business environment, market alienation, 
and competitive intensity (Alexiev et al., 2016). Furthermore, since institutional 
theory is concerned with how organizations establish their positions and achieve 
legitimacy in order to survive and make profit (Scott, 2005),  an effect of being 
associated and connected with the right individuals, networks and organizations was 
that it increased the legitimacy for the case firms. As far as risks with 
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internationalizing goes, not having legitimacy and credibility can be devastating for a 
firm and that was highlighted from all of SA case firms. 
 
Other common channels through which firms have gained useful knowledge in order 
to address regulatory challenges introduced by SANAS inspections under REG3 are 
exhibitions, membership of professional associations and conferences. Manufacturers 
also learn from each other because employees move between firms or meet and have 
informal exchanges at training events and seminars. Flows of knowledge also 
occurred through the industry associations such as SAMED and SALDA, which 
organize training events and other initiatives. 
 
Finally, as previously explained, the accumulation of linkage capabilities occurs over 
time, and the current capabilities are influenced by past events. Because of the 
cumulative nature of technological knowledge, regulation and policy initiatives had a 
long-lasting impact on the linkage capabilities of firms and industries. In the SA’s 
REG3 case, an example of regulation policy intervention that can be said to have 
helped the development of linkage capabilities in the industry is the provisions for 
compulsory licensing of imported new or fully refurbished listed electro-medical 
devices. It can be argued that the compulsory licensing has enabled local firms to 
reach good licensing agreements with foreign MNCs. However, obstacles and 
limitations remain, and the analysis in this chapter has shown that SA firms have to 
upgrade successfully in order to compete effectively against strong imports. There 
are, however, success stories of firms that have reached significant technological 
sophistication, as in the case of Medtech and Southmed. 
9.5 Summary of the cross-case analysis  
As discussed at the beginning of this chapter, Chataway et al., (2006) proposed a data 
matrix analytical strategy that has been employed in this chapter. Based on this 
analytical model, Figure 9.9 shows the overall effectiveness of the three regulatory 
changes from wider medical devices regulation and policy dimensions. 
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Figure 9.9: Medical devices regulation and policy dimensions. Compiled by author. 
 
Based on Figure 9.9, one can see that overall most firms perceived REG1 as enabling 
and discriminating. This is because the introduction of the REG1 enhanced the 
creation of completely new firm processes. The regulatory change drove most UK-
based firms to invest substantial resources in R&D to standardize their software 
products. The changes led to redefining of firm’s training needs for innovations, 
prototyping, design, testing, validation, verification and release processes. The 
regulatory change improved firms’ product quality and ensured safety of software 
products entering markets. The CE marked software brought positive reputation to the 
product quality and helped it gain confidence among customers. Furthermore, it also 
became increasingly necessary for firms to develop relationships with all the links in 
their supply chain. 
 
As far as the industry managers are concerned, REG2 was seen overwhelmingly as 
constraining (Figure 9.9). Criticism particularly came from firms with limited 
regulatory review process experience or the SMEs and was mainly to do with the high 
costs associated with unannounced audits. REG2 had an enormous constraining effect 
on supplier agreements between actors throughout the whole supply chain as the level 
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Enabling Constraining 
 
• REG 1, Medical Device Directive 
2007/47/EC:  targeting only 
Software as medical device. 
 
• REG 3 Hazardous Substances Act 
15 of 1973: selecting only 
electromagnetic medical devices 
and radiation emitting devices. 
• REG 2, EC Recommendation 
2013/473/EU- routine 
unannounced audits by Notified 
Bodies: all medical devices. 
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of scrutiny increased. For most firms, the delivery of products and processes was 
dependent on complements in the chain of production and new regulation prompted 
the inclusion of external process or product providers in audits. Firms had to revisit 
their procedures for planning and execution as well as set up new contracts with the 
NBs and external providers at a higher cost. Many suppliers were also not medical 
device focused and the new inspection requirements operated as a market shock and 
in turn the firms had difficulties complying. 
 
The analysis suggests that majority of firms perceived REG3 as predominantly 
enabling. The regulatory change enhanced the need for firms to recruit skilled 
personnel or the need to provide adequate periodic staff training. The changes enabled 
modifying imported technologies to suit local conditions. Most firms were in 
agreement that the introduction of the acceptance test and annual Quality Control 
(QC) tests played an important role in diagnostic imaging to limit the population dose 
growth, thereby improved quality control. Importantly, the regulatory changes 
improved collaborative and target based interactions between government and private 
sector, harmonized the industry actors and in turn ignited growth of the industry. 
Furthermore, REG3 enabled international company-to-company partnerships, usually 
with European companies. As such, this reinforces the notion that regulatory change 
in SA came about not just as an obligation or as constraining requiring compliance, 
but instead as a possibility for firms to improve their products and competitive 
position in the market through affirmative linkages.  
 
In summary, the findings in the cross-case analysis show that regulatory changes 
affect firms differently according to the resources and capabilities available to the 
firms. In this respect, the analytical approach adapted in this chapter allowed us to 
have a better understanding of the effects of regulation that is more ‘resource-based’. 
The next final chapter presents a summary of the findings, discusses various policy 
implications and addresses the limitations of the study.  
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CHAPTER TEN 
CONCLUSION 
----------------------------------------------------------------------------------------------------- 
10.0 Introduction 
This thesis examines the influence of regulatory changes on industrial capabilities and 
affordable healthcare technology development in the medical devices sector in 
developed and developing countries. The objective was achieved by identifying key 
medical device regulatory changes, the drivers behind these changes and by 
examining how these changes influenced the development process of novel devices in 
two countries, the UK and South Africa. This final chapter presents a summary of the 
findings, discusses various policy implications and addresses the limitations of the 
study.  
10.1 Addressing Research Sub-Question 1 
What changes have been made to regulation of medical devices and what 
approaches were utilised by regulators to implement the changes in the UK and 
SA? 
 
This question was addressed in its two parts. We begin by summarizing each case of 
regulatory change from our main findings in chapters 7-9.  
10.1.1 First regulatory change case: Medical Device Software in the UK 
These regulatory changes marked the introduction into the EU of stricter rules for 
software used with medical devices. They included the following key changes:  
a) The requirement for risk-based validation of software.  
b) The requirement for manufacturers to provide precise and detailed technical 
documentation of the medical device. 
c) Clinical data was now required on all devices regardless of classification. The 
regulatory change introduced stricter requirements for clinical investigations and 
clinical evaluation. 
d) Requirement on manufacturer to demonstrate adequate controls over the whole 
chain of software development, including outsourced design and manufacturing.  
e) The requirement on manufacturer’ subcontractors to report any design changes in 
their software. 
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10.1.2 Second regulatory change case: introduction of unannounced audit visits 
in the UK 
This regulatory change (on audits) involved the following key changes:  
a) Notified Bodies (NBs) were mandated to audit the premises and processes of the 
manufacturer, and also those of its subcontractors and crucial suppliers.  
b) NBs were instructed to perform unannounced audits at least once every three 
years.  
c) The changes further instructed the NBs to pay special attention to the production 
of the devices and any critical processes such as subcontracting.  
d) The requirement for NBs to verify the manufacturer’s system ensuring traceability 
of materials and components. At each audit, the notified bodies were now required 
to verify that the manufacturer correctly applied the approved quality management 
system and the post-market surveillance plan. 
10.1.3 Third regulatory change case: Radiation Emitting Devices (REDs) in 
South Africa 
Key changes of this regulatory change were:  
a) The requirement for manufacturers/suppliers to apply international standards as 
legal requirements and guidelines through the Radiation Control Directorate 
(DRC) and obtain a license of compliance.  
b) The manufacturer/supplier was required to comply with the rules contained in two 
documents supplied with the license. 
c) The requirements for the manufacturer/supplier/user to obtain a joint product and 
premises license for X-ray equipment before installation and commissioning, 
together with requirement to perform acceptance tests on the equipment.  
d) The License holder of a diagnostic X-ray facility was made ultimately responsible 
for the entire scope of radiation safety. 
10.1.4 Regulatory approaches used to implement change by the regulators 
The second part of the research question addresses the nature of the regulatory 
approaches utilised by regulators in the UK and SA.  
 
The first key finding is that the three cases used different regulatory approaches with 
consequent differential impact on the behavior of firms. The first regulatory change 
case (software product regulation) used a proactive regulatory approach. Whereas the 
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second regulatory change on audits was a reactive and rapid response measure mainly 
triggered by market shocks e.g., the Poly Implant Prothèse (PIP) scandal in 2010.  
The second key finding is that the software product regulation provided firms a 
governance framework for development of medical devices and helped the growth of 
the market. In contrast, the regulatory change on audits had disruptive impact on 
firms’ capabilities and dynamics of the industry structure. Firms, especially SMEs, 
found themselves facing major demands to conform to new regulations from the 
government.  
The third regulatory change case (Radiation Emitting Devices: REDs) in South Africa 
was perceived as disruptive, discriminating and constraining by many domestic firms.   
10.2 Addressing Research Sub-Question 2 
The objective of the second research sub-question was to determine the drivers that 
led to changes in the regulatory frameworks in the UK and SA: 
 
What conditions, processes and events facilitated the changes to regulation of 
medical devices in the UK and SA? 
10.2.1 Drivers that led to the first regulatory change: Medical Device Software in 
the UK 
Chapter six analysed the regulatory changes concerning software products. It showed 
that the regulatory changes were developed in response to increasing technological 
sophistication of devices and the need to extend regulatory reach into software, 
thereby toughening regulatory compliance and regulatory processes. This process was 
driven by the demands of member states and MNCs to establish common rules of 
exchange and by the supply of regulatory proposals from the European Commission.  
The extension of regulatory reach into software suggests that supranational forces 
were driving the regulatory change and activity.  
10.2.2 Drivers that led to second regulatory change: introduction of 
unannounced audit visits in the UK 
Our research suggests there were multiple drivers towards this change, albeit reaction 
to a scandal was a prime mover. 
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Need to address product failures  
In chapter two we found three product failures that facilitated the introduction of the 
second regulatory change introducing unannounced audits in the UK and Europe. 
These product failures included: i) the 2010 recall of ASR metal-on-metal hip 
replacement systems due to a five-year failure rate of the product; ii) the 2011 U.S. 
FDA product warning of serious complications associated with surgical mesh for 
transvaginal repair; iii) and the 2012 Poly Implant Prothese scandal where breast 
implants made with industrial-grade silicone instead of medical-grade silicone were 
sold affecting about 300 000 women. These scandals or externalities (where an 
individual or firm’s action have consequences for others) raised serious questions 
about regulatory systems in the EU. A flurry of regulatory activity ensued to bolster 
the legitimacy of the EU system of medical device governance. 
 
External pressure and the European Commission 
These product failures led to increasing demand from member states and other 
stakeholders for stringent regulatory framework. The EU regulatory framework for 
medical devices, through the Conformité Européenne (CE) marketing process was 
asserted by member states as inadequate to provide sufficient safeguards for 
technologies that affect health-related quality of life. The inadequacies cited included 
inferior regulatory evidence standards, non-transparent decision-making processes, 
and insufficient post-market surveillance to ensure devices’ safety and long-term 
performance. The European Commission echoed such concerns, stating a need to 
“adapt the European regulatory framework in order to secure patients’ safety while 
favouring innovation” (European Commission 2011). This pressure acted as one form 
of “external” pressure for regulatory change. 
 
Public consultation: Influence of industry voice  
The pressure from member states and other stakeholders led to the announcement of 
the public consultation on the “Recast of the Medical Devices Directives” by the 
European Commission in 2008. It received 200 responses with the industry 
(individual companies, mainly manufacturers of medical devices) emerging as the 
principal contributor with 92 responses. Most respondents confirmed that the current 
legal framework for medical devices left some room for improvement to strengthen 
the regulatory system. Some SMEs, however, were concerned that the costs of putting 
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a medical device on the market would multiply. There was unanimous support for 
improving the way in which Notified Bodies were working. Most respondents 
believed that there should be a tightening up of the designation and monitoring of 
Notified Bodies to ensure a uniform high level of competence (EU, 2008)35. 
10.2.3 Drivers that led to the third regulatory change: Radiation Emitting 
Devices (REDs) in South Africa 
Chapter 6 details the drivers leading to regulation of REDs in South Africa. 
 
Internationalization as a driver of regulatory change 
The South African government played a major role in driving the regulatory change. 
The government recognized the need for an internationally recognized national 
accreditation system as a crucial element of a well-functioning technical infrastructure 
aligned with international best practice. The government therefore, assented the 
Accreditation for Conformity Assessment, Calibration and Good Laboratory Practice 
Act, 2006. The purpose of this Act was to provide an internationally recognized and 
effective accreditation and compliance monitoring system for SA by establishing the 
South African National Accreditation System (SANAS) as a public entity. SANAS 
became responsible for carrying out the regulatory accreditations in respect of 
conformity assessment, monitoring of good laboratory practice to comply with 
Organization for Economic Cooperation and Development (OECD) principles. The 
SA government was the major player in this internationalization process that led to 
the third regulatory change (see Chapter 6). 
 
SMEs and home market conditions can push regulators to change regulation 
We found that another driving force behind regulatory change were the SMEs and the 
complexity of the home market. Our analysis indicated that local SMEs experienced 
constraints when internationalizing. For example, the process of ISO 13485 
certification is very expensive for local manufacturers and constraints were 
compounded by the lack of a comprehensive regulatory framework for medical 
devices in South Africa. Local manufacturers needed audit by a notified body in order 
 
35  Recast of the medical devices directives: Summary of responses to the public consultation. 
https://eur-lex.europa.eu/resource.html?uri=cellar:487acc33-213b-4fdf-bdbb-
8840209a8807.0001.04/DOC_4&format=PDF 
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to get the certification and ended up spending significant time and financial resources 
to obtain CE and FDA certification from European and American certified bodies. 
The process is expensive and lengthy so that very few local manufacturers could 
afford it. Local SMEs lobbied for regulatory change that would accredit local 
companies to provide auditing services and change the institutional environment. 
 
Role of MNCs in influencing institutional change 
One key finding was that several established MNCs influenced the regulatory changes 
in South Africa. As regulatory processes pose a barrier and require conformity for 
firms when entering markets, they can be used to benefit established firms. Medtech 
and Northmed are examples of MNCs that played a role in influencing institutional 
change by lobbying for increased regulation. Northmed confirmed that they actively 
promoted the demand for CE labelling in the SA market (see section 8.3.2) with the 
intention to strengthen the competitive advantage of the firm as illustrated by the 
following quote: “We have used our ability to influence market to push through a 
demand for CE labelling in order to do business” (Northmed, 2016). The MNC was 
influential in the implementation of REDs changes and was proactive in lobbying for 
the new regulatory changes under the Medicines and Related Substances Act of 2015 
that were promulgated in June 2017.   
 
Collaboration of actors facilitates lobbying of regulatory changes 
Findings from our analysis of linkage capabilities showed that the RED regulatory 
change enabled the development of a strong collaborative relationship in the SA 
medical device industry. As a result, the collaboration of the manufacturers, 
regulators, funders, government departments and industry associations facilitated the 
development of the new regulations published on December 9, 2016 (see section 
8.4.4). We argue that the lesson for firms, especially SMEs that are weak alone, 
wishing to change regulation, is to collaborate to make a powerful entity that can truly 
influence regulatory change. 
10.3 Addressing Research Sub-Question 3 
How have regulatory changes affected firm level investment, production and 
linkage capabilities of medical device firms in the UK and SA? 
 
 263 
Our detailed findings, presented in the previous chapters, show that three case studies 
give different but in some instances similar perspectives on the way in which 
regulatory changes in medical devices have affected technological capabilities.  
10.3.1 The effects of the first regulatory change: Medical Device Software in the 
UK 
As Malerba and Mani (2009) highlighted, a sectoral system of innovation approach 
considers a wide range of factors that affect innovation and production in a sector. In 
particular a sectoral system approach examines innovation as the result of firm’s 
specific capabilities. 
 
 Regulatory change increases firm’s investment capability in R&D 
Chapter seven shows that this product-focused regulatory change drove most UK-
based firms to invest substantial resources in R&D to standardize their software 
products. Adner (2002) argues that if innovators have sufficient financial support to 
invest in their R&D departments, they will continue innovation improvement efforts 
to attain a dominant position in the market. In this study, we found that most 
manufactures of medical devices software had positive income returns that improved 
after they invested towards compliance with the regulatory change. Results from this 
study strongly indicate that R&D capabilities are vital to the early growth of 
innovative healthcare technology development ventures. Firm R&D capabilities 
included an ability to sense and seize opportunities from compliance with the 
regulatory changes. Existing and enhanced R&D capabilities of these firms allowed 
them to develop products with higher market value.  
 
Regulatory change and its harmonized standards enhanced and extended the 
medical device market 
Our analysis in chapter 6 shows that the software product-focused regulatory change 
emerged as an important step to guarantee the acceptance of products in a broad 
geographical market. The changes enabled the opening of new software market 
opportunities to companies that invested heavily in R&D to comply with the safety 
and efficacy standards outlined in the EN/IEC 62304, a software development 
standard that emerged as a global standard for the software development life cycle. 
The introduction of this regulatory change repositioned medical device software in a 
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more transparent manner because manufacturing standards, procedures, tests, 
validation, and accountability were all improved to reduce device recall statistics. Our 
results indicate that the regulatory change on software enabled overwhelming 
international competitive advantages for complying device manufacturers, with 
special certification and quality marks on products. This finding resonates with 
Salvador et al., (2002) who argued that cross-national agencies and regulatory bodies 
promote standardization to encourage firms to sell the same product across national 
markets. The key finding is that product-focused regulation enabled the enhancement 
and extension of the market. 
 
Software product-focused regulatory change increased firm’s investment in 
training and recruitment capability 
As Lall (1992) argued, the development of investment capabilities not only requires 
the improvement of existing competencies, but also the acquisition of new 
knowledge. In this study, in chapter 7, we found that regulatory changes for software 
led to redefining of firm’s training needs for innovations, prototyping, design, testing, 
validation, verification and release processes. Staff training was needed to ensure 
better efficacy and accountability from the medical device firms. The changes also 
called for the recruitment of highly skilled specialized employees who could provide 
the companies with, regulatory affairs knowledge, skills and productivity that would 
propel profitability. This finding supports the observation by Lundvall (2000) that 
innovation is rooted in learning and learning is rooted in doing, using and interacting 
among users and producers.  
 
Software product-focused regulatory change influenced production capability by 
firms’ altering structures and processes 
Malerba and Mani (2009) suggest that a central place in evolutionary theory is 
occupied by the processes of variety creation in technologies and products. In this 
study, we found that the regulatory change concerning software prompted most firms 
to alter their structures, processes and resources to adequately address regulatory 
threats and opportunities.  In view of these findings, we argued in Chapter nine that 
the software product-focused regulatory change had a huge influence on firms’ design 
structures and processes while the audit process-focused regulatory change induced a 
significant influence on firms’ linkage capabilities and interdependencies. 
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Software product-focused regulatory change influenced production capabilities by 
creating entry barriers that locked out small firms due to high costs of compliance. 
Our results indicated that one of the biggest weaknesses of product regulation 
governing medical device software is that approval is very costly. For example, 
clinical tests are very expensive to conduct. The expected return on a device limits the 
amount of testing that a firm is willing to perform. Clinical trials increase fixed costs 
and may make it unfeasible to develop devices for small markets. Analysis has 
revealed that this has created entry barriers that lock out small companies that cannot 
afford to go through the approval process.  
10.3.2 The effects of the second regulatory change: introduction of unannounced 
audit visits in the UK 
Our analysis of the effects of audits, a process-focused regulatory change, had three 
key findings: 
 
Move towards collaborative relationship between manufacturers and suppliers 
As discussed in chapter nine, the audits process-focused regulatory change enabled 
the formation of efficient supply chain management, which is critical to the 
competitiveness of firms. Importantly, firms that extensively utilized external 
providers after regulatory changes were found to be more successful in the 
development of affordable healthcare technologies. This finding resonates with earlier 
research on the importance of establishing relations between firms in the supply chain 
that enhances absorptive capacity, which leads to upgraded technological capabilities 
(Lall, 1980; Shandya et al., 2002). Wu (2008) argued that creating supply chain 
knowledge requires interlinked processes that enable information sharing as well as 
associated information technology infrastructures. In this study, we found that the 
regulatory changes enabled manufacturing firms to move from adversarial 
relationship towards collaborative relationship with their suppliers. This collaborative 
relationship between the manufacturer and the supplier became one where both 
parties communicated more regularly, cooperatively shared relevant regulatory 
information and resolved conflicts through dialogue. Such relationships led to 
operational efficiencies that allowed processes to be streamlined and simplified, 
higher levels of performance and economic benefits over the long-term.  
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Audits process-regulation affected firm’s linkage by prompting the actors to alter 
supplier agreements 
Second, as argued by Jaspers et al., (2012) regulatory demands can change conditions 
for firm collaboration due to new challenges in the interface between actors. As 
discussed in Chapter nine, we found that the second regulatory change on audits had 
an enormous constraining effect on supplier agreements between actors throughout 
the whole supply chain as the level of scrutiny increased. Many suppliers were not 
medical device focused and the new inspection requirements operated as a market 
shock and had difficulties complying.  
 
Regulatory change created turbulence in the sector  
Third, we found that the indiscriminate regulatory change was perceived by most 
SMEs leaders as constraining because it introduced considerable turbulence to the 
sector, with long-term consequences. The changes came into force three months after 
the EU recommendation without going through the normal three-year transition 
period.  
10.3.3 The effects of the third regulatory change:  Radiation Emitting Devices 
(REDs) in South Africa 
Our analysis in chapter 8 found that since radiation emitting devices such as X-ray, 
CT, and MRI are on high end of technology and the fall under product category that is 
heavily regulated, very few SMEs were willing to or had the capability to invest in 
such products. The domestic firms were expected to have a capability to import, 
manufacture or fully refurbish any listed electro-medical device on a global basis, to 
comply with the radiation emitting device regulatory requirements, the respondents 
argued that it was a tall challenge for most of the firms. Such stringent requirements 
made it more difficult for domestic suppliers in SA to enter the supply chain. 
 
REDs product-focused regulatory change influenced linkage capabilities by 
enabling overseas collaborations 
As discussed in Chapter nine, we found that the REDs product-focused regulatory 
change enabled the creation of joint ventures and strategic partnerships which, 
fostered technology transfer. The stringent requirements made it more difficult for 
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domestic suppliers to enter the supply chain. In order to overcome these problems, 
some local manufacturers established joint ventures as a strategic partnership with 
foreign companies whose technological capabilities and resources were strong. The 
foreign companies involved in these partnerships were mainly MNCs.  
 
Summary 
As shown in Table 10.1, we found that the influence of regulatory change affects the 
entire cycle of innovation, which includes resource allocation for the innovation 
process, the innovation process itself, production, firm linkages and the sales/use of 
final products. A summary of the key findings applicable to all three regulatory 
changes is presented in Table 10.1 below. 
 
Table 10.1: Summary of Key findings 
 Regulation 1-Software 
UK 
Regulation 2-Audits 
UK 
Regulation 3-REDs 
SA 
In
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1. Firms with limited experience of the medical device review process had 
difficulties adapting, and innovation activities from these firms were impeded 
after regulatory changes. 
2. Increased investment in 
R&D 
 Little impact on R&D as 
the environment is an 
importer’s market 
3. Firms acquired experts and skilled personnel as vital sources of knowledge and 
learning to fill their inherited knowledge gap in order to address the new 
regulatory requirements.  
4. Introduction of IEC 62304 
software standard 
enhanced and extended the 
medical device market 
 Procurement of ISO 13485 
in order to get CE 
certification proved very 
costly for most of the firms 
P
ro
d
u
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5. Regulatory change facilitated firms to create new strategies and innovation 
processes required to achieve efficient and effective operations within the 
parameters of the new requirements 
6. The regulatory change 
diverted innovation 
direction from radical to 
incremental innovation 
considering the technical 
difficulties firms needed to 
confront 
 Enabled modifying or 
refurbishments of 
imported technologies to 
suit local conditions. 
7. Regulatory changes coerced compliance cost and in turn resulted in firms 
needing to divert resource outflows to meet regulatory requirements.  
8. Regulatory changes ensured product quality and safety of products entering the 
market, CE-mark increased positive reputation of the firms and helped in 
gaining customer confidence. 
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9. Regulatory changes enabled firms to develop close collaborative relationships 
with external providers in search of competitive advantage and improved market 
positioning.  
10. Audits process-
regulation affected 
firm’s linkage by 
prompting the actors 
to alter supplier 
agreements 
 
Regulatory changes 
induced firms to create 
joint ventures, strategic 
partnerships.  
Compiled by author 
 
In general, the three regulatory case study analysis of firms’ investment, production 
and linkage capabilities shows that the process of complying with the regulatory 
changes in the UK and SA has become more arduous as the requirements have 
become stricter. That is especially true for SMEs for whom the long and resource-
heavy process of bringing a medical device to the market is associated with high risk. 
However, the regulatory changes enabled new software markets and new linkages 
between actors to take off, and as such they prompted the emergence of new modes of 
organizing firm capabilities in the medical device sectoral system of innovation. 
Therefore, governments and regulators can influence the development of market 
infrastructure and affect the role of technology, thereby influencing firms’ 
implementation decisions (Jacobides, 2005). 
10.4 Answers to the Overall Research Question  
The overall research question that guided this study is: 
 
How and to what extent has the evolution of medical device regulations in the UK 
and SA influenced industrial capabilities and contribution towards affordable 
health care technology development? 
 
The thesis assessed the influence of changes to regulatory environments on firms’ 
technological capability. The use of SSI as theoretical framework allows the framing 
of both market and non-market relations in the technological development of products 
and services, particularly for the “creation, production and sale of products” (Malerba, 
2002, p.248). By using Chataway et al., (2006)’s policy and regulatory instrument 
empirically, in detail, we were able to show the often-contradictory influences of 
regulatory change and need for extreme care as regulation is formulated.  
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Our results suggest that the influence of regulation may also be enabling or 
facilitative. In this study, the analysis showed that enabling and discriminating 
regulatory changes matter immensely and that constraining and indiscriminate 
regulation can be very damaging, particularly to SMEs and firms in developing 
countries.   
 
We summarize below some key findings in answer to our main research question.  
 
 Firms with limited experience of the medical device review process had difficulties 
adapting, and innovation activities from these firms were impeded after regulatory 
changes. 
As discussed in section 9.2, we found that when regulations were changed, firms, in 
particular SMEs, with limited experience of the medical device review process had 
difficulties adapting, and innovation activities from these firms were impeded. SMEs 
with limited regulatory review experience typically try to receive market approval for 
their products as soon as they feel that their product is ready. Such firms are under 
pressure to get products onto the market as they have undertaken significant 
investments and the development process of the product is usually long and 
burdensome. Of course, this is equally the case for large firms. However, we found 
that limited-experience firms can afford to hesitate less to see how a regulatory 
change might affect their approval application relative to other firms. Such firms 
generally have limited knowledge of Notified Bodies, particularly about the 
application process for market approval. The findings show that firms (MNCs), which 
have gained experience with the regulatory process, were able to benefit from this 
experience in turbulent periods of regulatory change, whereas firms with limited 
experience were adversely affected by regulatory shocks to the industry. This was 
uniformly applicable to all three regulatory changes.  
 
Regulatory changes enabled firms to acquire experts and skilled personnel as vital 
sources of knowledge and learning 
As discussed in section 9.2, we found that, all the three regulatory changes required 
greater skill, technical knowledge and experience in regulatory review processes that 
may not previously have been possessed by firms. Thus, the changes prompted firms 
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to acquire experts and skilled personnel and increase their in-house training as vital 
sources of knowledge and learning to fill their inherited knowledge gap in order to 
address the new regulatory requirements and the demand for innovative products, 
processes, and further organization-wide change.  
 
Regulatory change facilitated firms to create new strategies and innovation 
processes  
This research shows that the regulatory changes largely had a positive impact on large 
medical device manufacturing firms’ key innovation processes required to achieve 
efficient and effective operations. Chapter seven emphasized that the first regulatory 
change introduced new set of processes such as validation & verification procedures, 
provided new harmonized standards and new functionalities, which influenced the 
development process of products. Mandatory processes influenced by regulatory 
change requiring unannounced audits include; design control, establishment of 
material, purchasing and control of incoming material and components, assembling, 
packaging, and product quality control. In SA the regulatory change influenced 
adaptations and improvement processes such as electro-medical devices 
refurbishment and QMS safety and performance process. The firms responded to 
regulatory changes by adopting a path of building technological capabilities. In short, 
firms conformed to the argument by Dierickx and Cool (1989) that their survival and 
success depended on their ability to create a set of distinctive capabilities that enable 
them to stand out in the competition. 
 
Regulatory changes ensured product quality and safety of products entering the 
market 
We found that regulatory changes improved firms’ quality control systems and 
ensured the safety of products entering the market. The findings showed that the 
changes brought positive reputation to the firms and the improved product quality 
helped in gaining customer confidence. Most firms had a general belief that the 
regulatory change and the rest of the applicable standards had met expectations in 
enhancing the safety of medical devices.  
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The cascading effects of high compliance cost negatively affect the development of 
affordability healthcare technologies 
As discussed in Chapter seven and eight, the study found that all firm respondents 
argued that compliance costs were significant. Compliance with the regulatory change 
targeting software was viewed as a costly venture. As for the compliance costs 
associated with unannounced audits, we found that the cost had to be met by the 
manufacturer, including the audits performed on the premises of its critical 
subcontractors/crucial suppliers. The large costs and delays associated with placing 
medical devices on the SA market, were found to be inducing some SMEs to 
withdraw from the market or ending up focusing on low end, low risk technologies 
that are not heavily regulated. The cascading effect of high compliance cost 
significantly affected affordability of healthcare technologies. 
 
Regulatory changes enabled firms to develop close collaborations  
The three regulatory changes influenced linkage capabilities by enabling collaborative 
relationships. Most firms increased their focus on the development of close 
collaborative relationships with their suppliers in search of competitive advantage and 
improved market positioning. Firms that extensively utilized external providers after 
regulatory changes in both countries were found to be more successful in the 
development of affordable healthcare technologies. Most small firms with higher in-
house technological capabilities initiated innovative activities in collaboration with 
local or global subcontractors or research institutions to respond to regulatory 
changes. This led to production capability enhancement, such as time to market, as 
discussed in Chapter nine, through collaborative learning and very intense 
communication mechanisms. Over a period, many SMEs’ production capability was 
enhanced by these experiences and accumulation of knowledge. 
 
In summary, the influence of regulatory changes on firm level capabilities crosses 
over the entire cycle of innovation. Regulatory change adds cost to firms and causes 
an often-unwelcome diversion of technical and management resources away from 
business innovation. Regulatory approval may postpone the time a product can enter 
the market and negatively influence the expected rate of return. But regulatory change 
can also create opportunities for firms to improve the development process of 
affordable healthcare technology and stimulate creativity. Regulation may change the 
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expected profitability by providing a guarantee of product quality. Table 10.2 
summaries the key findings that were uniformly applicable to three regulatory change 
case studies. 
 
Table 10.2: Summary of key findings uniformly applicable to all three regulatory 
changes. 
 Regulation 1-Software Regulation 2-Audits Regulation 3-REDs 
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1. Firms with limited experience of the medical device review process had 
difficulties adapting, and innovation activities from these firms were impeded 
after regulatory changes. 
2. Firms acquired experts and skilled personnel as vital sources of knowledge and 
learning to fill their inherited knowledge gap in order to address the new 
regulatory requirements. 
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3. Regulatory change facilitated firms to create new strategies and innovation 
processes required to achieve efficient and effective operations within the 
parameters of the new requirements 
4. The constraining effect of the three regulatory changes on innovation capability 
was that firms became more risk adverse toward novelty and in turn became 
incremental innovators instead of radical innovators. 
5. Coerced compliance cost and in turn resulted in firms needing to divert resource 
outflows to meet regulatory requirements. Due to the cascading effect of high 
compliance cost, affordability of healthcare technologies was significantly 
affected. 
6. Regulatory changes ensured product quality and safety of products entering the 
market, CE-mark increased positive reputation of the firms and helped in 
gaining customer confidence. 
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 7. Regulatory changes enabled firms to develop close collaborative relationships 
with external providers in search of competitive advantage and improved market 
positioning. 
Compiled by author 
 
This study adopted critical realism as the philosophical position. The fundamental 
assumption of the realist position is that there is a reality “out there” waiting to be 
discovered and that reality is independent of us” (Easton, 1995, p.372). In this study, 
the “discoverable reality out there” is maintained and reproduced by established firms, 
guided by shared beliefs. Thus, from a philosophical perspective, the effects of 
regulatory changes on firm technological capabilities explored in this research are 
real. The “discoverable reality out there” was that the lengthy and demanding nature 
of the three regulatory changes have induced changes in firms’ strategies, processes, 
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market environment, entry of new firms and creation of new collaborative 
relationships among firms and between firms and non-firm agents. These, to a certain 
degree, systematically transformed the medical devices sectoral systems of innovation 
and production of the UK and SA to be stronger and less fragmented. However, the 
study found that the lack of comprehensive regulatory framework in SA upsurge the 
likelihood of having substandard and spurious healthcare technologies that pose 
serious public health problems in the market.  
10.5 Policy Implications and lessons 
This study has shown five important factors that must be considered carefully in any 
discussion on policy within and also outside the UK and SA. These are discussed in 
points a-e below: 
a) The study shows that regulatory change impacts on firm’s investment and 
innovation capabilities. Product makers need to be aware of that, to include in 
their internal management policies, the opportunity cost of foregone innovation 
and dynamic efficiency into their benefit-cost evaluation of regulation and 
regulatory change. In the case of medical technologies, foregone innovations can 
hinder opportunities coming to fruition.  
b) Our results have important implications for policymakers. When policymakers 
introduce strict regulation, they often think about health and security of final 
users. However, they should also need to consider the “side-effects” for the 
economy. A more stringent regulation might discourage innovative firms from 
introducing new health care technologies. Regulators should listen to the opinions 
of small companies and medical device experts in order to introduce norms that 
guarantee patient safety, but at the same time, meet the needs of the sectorial 
operators 
c) To anticipate the effects of regulatory change is not an easy task. However, 
building awareness that regulatory change will have consequences, some 
unintended, is a step in the right direction. This study reminds decision makers in 
medical device regulation that the safety and efficacy of medical devices depends 
on smart regulatory governance, which requires policy measures for the 
effectiveness and efficiency of governance. 
d) This study has implications for positive social change from regulatory 
compliance. This study showed that the changes in the software medical device 
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regulation had a positive impact on the safety and reliability of software 
embedded medical devices. Members of the Council on medical devices of the 
European Commission believed that consistent and coherent implementation of 
the MDD 2007/47/EC was necessary to ensure the protection of human health 
(European Council, 2007). As a result, the medical device manufacturers have 
fortified their internal management policies to synchronize with industry 
innovations classes and times. Thus, the MDD 2007/47/EC regulation has 
realigned the social technological links and methodology for medical device 
manufacturers. 
e) This study reinforces conclusions that there is no one optimal policy in medical 
device regulation. A choice for one policy always excludes other alternatives and 
possible choices and prevents experience with other paths. It can therefore never 
be absolutely known which policy might offer “optimal’’ solutions to a given 
policy dilemma. 
10.5.1 Recommendations 
This thesis provides following recommendations based on a limited number of case 
studies:  
1).   The SA medical device market is currently one of the most promising and fastest 
growing markets in Africa with market drivers such as the aging population and 
number of hospital visits expanding demand. SA’s high-end medical device market is 
dominated by foreign companies, based on this market profile, the government and 
policy makers should pay more attention to scientific and technological innovation, 
give financial and policy support to companies’ innovation, encourage the SA 
companies’ R&D on medical devices. Moreover, SA firms should deepen the 
transnational cooperation with international companies; increase the training and the 
introduction of human talent. 
 
2). The policy makers might give more attention to the development of an enabling 
regulation and policy framework. Enabling regulation can serve both as the legislative 
mandate for the competent authorities to act, and as a starting point for regulator 
discretion and oversight. The building of an enabling context for regulatory systems 
could be helped with a well-defined and focused set of objectives, perhaps focused 
first on the life science sectors. 
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10.6. Limitations of the Study  
Even though the results of this study provided a robust methodological contribution 
and considerable empirical evidence to support our argument as pointed out in section 
10.7, limitations stemming from the nature of the topic being investigated are 
acknowledged.  
First, there is likelihood that some firms, which flout medical devices health and 
safety regulations, will be reluctant to truthfully answer questions. Although 
participants were assured that their responses would be treated confidentially and, that 
results of the research will not have any adverse implications on the operations of 
their businesses, it is difficult to assess the extent to which this allayed their fears. We 
addressed this problem by interviewing in a large number of firms, in three case 
studies and by triangulating results as described in our empirical chapters. 
 
Second, due to obvious limitations of time, cost and relevance of context, focus was 
given to the regulatory changes on software, audits and radiation emitting devices 
subdivisions rather than the entire medical devices category within the industry. Other 
subdivisions might present different outcomes of regulatory changes. Thus, other 
scholars could conduct the similar research on other regulatory changes and compare 
the results to provide a broader understanding of the effects of regulatory changes in 
medical markets.  
 
Third, collecting data in emerging markets, such as SA, posed challenges, as there 
was limited published literature on medical device regulatory changes. Moreover, the 
new draft proposals of medical device reforms, in both case study countries were still 
under debates during writing of this thesis. Therefore, some information in the papers 
may not be entirely reflective of the changes ultimately adopted. Nevertheless, the 
documents studied in literature review were published at a time when relevant 
developments were still unfolding, and therefore served to inform current debates in 
these areas. 
10.7 Contributions of the Study  
This thesis makes six contributions to the literature on the effects of regulatory 
changes on industrial technology, but particularly with respect to the medical device 
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software and unannounced audit regulations in the UK and radiation safety regulation 
in SA. 
 
First, the thesis argues, with empirical evidence, that a more enabling and 
discriminating regulation that takes into consideration of firms’ technological 
capabilities can achieve intended goals more efficiently and effectively, than a 
constraining and indiscriminate regulation. In this regard, this study makes important 
contributions to health technology regulatory science literature by answering calls for 
deep empirical research to examine the influence of regulation on the ability of 
industries to innovate (Altenstetter, 2012, Blind, 2012) and calls for more research to 
assess new regulatory developments and evolutions in practice (Sorenson and 
Drummond, 2014). 
 
Second, the context of two very different countries has allowed investigation of in-
depth regulatory changes devised and implemented in diverse socio-economic, 
industrial and infrastructural context. Previous studies on health technology regulation 
in low and middle-income countries emphasized the need to investigate health 
technology developments, relevant policy and regulatory systems especially in Africa 
to encourage a more coherent regulatory approach (Rugera et al., 2014, Saidi, 2016). 
In line with these studies, this research was not confined to the UK, but also included 
SA, a country from the global south. Such a perspective is less often included in 
comparative studies but offers valuable insights to the healthcare technologies 
(Rugera et al., 2014). The present research studied the institutions that affect actors in 
the medical device industry and also allowed investigation of what happens to 
technological capabilities when these institutions were radically changed or greatly 
stressed. Regarding this point, the research results point to the importance of a clear, 
enabling regulatory framework, coordinated science and technology policy, political 
stability and the gaps that policy must consider when radical change takes place.  
 
Third, the selected regulatory changes have not previously been analyzed at this 
depth. Two regulatory changes have involved the collection and analysis of a rich and 
unique EU dataset, which offers potential for further insights into the industrial 
dynamics of the medical device industry, and particularly its high-risk sector.  
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Fourth, as methodological and empirical contribution, a regulation and policy matrix 
was applied (see Chapter nine) that provides a unique way of integrating diverse 
policies and regulations according to whether they are perceived as enabling or 
constraining by industry leaders and whether regulations and policies are 
indiscriminate or discriminating among products; or in some cases whether they 
discriminate on an inappropriate basis (Chataway et al., 2006). The matrix allows 
individuals or organizations to focus on the effectiveness and efficiency of the 
governance achieved by a particular policy or regulation, taking into consideration the 
resources and capabilities available to innovators.  
 
Fifth, our analysis highlights the importance of compliance capabilities in firms to 
underlie health technology innovation process success. The study has shown that 
compliance capability is a crucial element that ensures medical device safety for 
patients, enables firms to get medical device approval from regulatory bodies and 
smooths medical device audits. 
 
Sixth, the study has also contributed theoretical and methodological insights and 
empirical evidence to the debates on streamlined regulatory bureaucracy, safety and 
efficacy and the benefits of harmonized standards. Finally, to the best of my 
knowledge this research is the first study that makes a rigorous assessment of the 
innovation dynamic changes in SA radiation medical device sector, and particularly 
considers regulation as a defining element of these dynamics 
10.8 Boundaries and generalization 
The empirical material in this thesis has been collected using a multiple case study 
methodology. Case study methodology has been criticized as non- or weakly- 
generalizable. However, this thesis has used the case study methodological approach 
of Eisenhardt who developed comparative case study method, and Yin with his highly 
systematic multi-method approach to intensive investigation (chapter 5). They argue 
that such methods are able to build generalizable findings. 
The focus of the thesis, the evolution of medical device regulation and its impact on 
firm-level industrial capabilities, also lends itself to case study methodology because 
there has been relatively little systematic research on this relationship. The use of 
three case studies has allowed the thesis to begin casting light on the causative 
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relationship between enabling or constraining regulation and the drivers/blockers of 
capability enhancement and particularly of innovative capabilities.  
In this thesis, the use of a multiple case study approach together with the regulation 
and policy matrix of enabling or constraining regulation, has allowed some 
generalizable characteristics to be shown concerning the medical devices industry, 
particularly on the strongly constraining nature of some indiscriminate regulatory 
systems. It would be informative to further test and substantiate the methodological 
framework by employing it in other policy areas. For example, the matrix could be 
applied in full to other health care regulators (e.g. food, health care professionals), in 
addition to non-health regulators, and across different jurisdictions. The use of this 
regulation and policy matrix would, this thesis argues, lend greater understanding of 
what constitutes good regulation and the influence (if any) of different policy.  
10.9 Future Research 
Future research might be directed towards a longitudinal analysis of the governance 
structures of firms, which could yield further insights into the resource allocations 
involved in the health technologies innovation experience. Thus a longitudinal study 
might be undertaken using a five to ten year framework to track firms in different 
regions as they undertake their healthcare technology innovation activities. 
 
Such studies would allow better understanding of the political and social 
considerations involved in evidence-based regulation or policy making. Such research 
would enable more effective analysis of decision making around health technologies, 
with respect to the interplay between evidence, political and institutional dynamics, 
stakeholder values and interests, balancing technical, social, and political priorities. 
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List of Appendices 
APPENDIX 1: Study Questionnaire Number 1 – United Kingdom 
SECTION 1: Background information 
Objective 1: The information collected in this section will not be used in any manner 
to identify you. The objective of collecting this information is to be able to find any 
patterns in demography that may have an influence on management practices. 
 
1. Respondent details 
 
1.1 Name (optional)………………………………………………………….. 
1.2 Organisation………………………………………………………………..  
1.3 Year of Establishment…………………………………………………….. 
1.4 Position in organisation…………………………………………………… 
1.5 Number of years with current employer………………………………….. 
1.6 Number of years in the medical device sector……………………… 
1.7 What are your primary responsibilities? 
Policy making     
Policy analysis     
Policy implementation    
Management      
Other, please specify   …………………………… 
 
1.8 Stakeholder category:    Analysis code 
Government/Competent authority Gov     
Research and Development  RD     
Academic and research institution ARI     
Health facility    HF     
Medical device manufacturing MAN     
 Regulatory agency/Notified body RA/NB  
  Industry association   IA   
Other, please specify   ORES  ………… 
  
1.9 Main products of your organisation/firm? 
            (a)…………………………………………………………………… 
 (b)…………………………………………………………………….. 
 (c)……………………………………………………………………. 
 
1.10     What medical device type do you manufacture? 
Low-risk devices (Class I)   
Medium-risk devices (Class IIa)  
Medium-risk devices (Class IIb)  
 296 
High-risk devices (Class III)   
Other, please specify   ………………………  
   
SECTION 2: Understandings on regulation and regulatory changes 
Objective 2: To assess the market structure, CONTENT and DRIVERS of regulatory 
changes. 
 
2. How is the medical device industry structured in the United Kingdom?  
 
3. Who are the key players involved in the medical device industry in the UK? and 
what role do they play? 
 
4. Evidence/Literature suggests that the UK regulatory framework has often been 
viewed as superior to many countries, given its somewhat faster regulatory 
process for devices and earlier access to some high-risk technologies. What could 
be the reasons for this situation? 
 
5. How are medical devices regulated, and what is the role of the government in the 
regulatory processes in UK? 
 
6. What is your understanding of regulatory changes in the context of the Medical 
device sector?   
 
7. In the last 30 years, different regulations in the medical device sector have been 
enacted/implemented. What are the key 2 or 3 regulatory changes that have 
affected your organisation’s operations? And How? 
 
8. Reflecting on your company’s experience, which medical device software 
regulatory compliance were you required to follow before 2007? 
 
9. What are the new regulatory requirements that control medical device software as 
of 2007? Could you compare quality of regulatory content in the past and the 
present? 
 
10. Other than the domestic or EU regulations, are there any other international 
regulatory standards you required to comply with? If yes how do you comply? 
E.g. 
 
(1) ISO 13485 (Medical Devices-Quality Management Systems-Requirements for 
Regulatory Purposes).  
(2) ISO-9001 (Quality systems-model for quality assurance in design, 
development, production, installation and servicing).  
(3) Other, please specify ……………………………………………………. 
 
11. In UK’s medical device’s regulatory history, what events or circumstances could 
have led to changes in medical device regulations?  
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SECTION 3: Understandings of the impact of regulatory changes 
Objective 3: To assess the EFFECTS of medical device regulation and regulatory 
changes on industry capabilities and development of medical devices. 
12. How has the past regulatory changes affected your firm’s Investment capability in 
terms of: 
• Research and Development (R&D) of new technology? 
• Recruitment and training of skilled personnel? 
• Equipment acquirement? 
• Standard procurement? 
12. How has the past regulatory changes affected your firm’s Production capability in 
terms of: 
• Innovation? 
• Quality control? 
• Operations? 
• New product technology licensing? 
• Compliance? 
• Monitoring (pre and post market)? 
• Maintenance? 
 
13. How has the past regulatory changes affected your firm’s Linkage capability in 
terms of: 
• Local acquirement of goods and services? 
• Exchange of information with suppliers? 
• Exchange of information with regulatory bodies? 
• Exchange of information with industry associations? 
• Importing from and exporting to other countries? 
14. What steps are involved in the process of obtaining the CE mark?  
 
15. How long on average does the approval process for medical devices take?  
 
16. How have regulations or regulatory costs affected affordability and appropriate 
healthcare technologies in the UK? 
 
17. Lastly, What can be done to ensure effective medical device regulations and at the 
same time affordable and appropriate healthcare technology in the UK. 
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APPENDIX 2: Study Questionnaire Number 2 – South Africa 
SECTION 1: Background information 
Objective 1: The information collected in this section will not be used in any manner 
to identify you. The objective of collecting this information is to be able to find any 
patterns in demography that may have an influence on management practices. 
 
1. Respondent details 
 
1.1  Name (optional)……………………………………………………………. 
1.2 Organisation………………………………………………………………..  
1.3 Year of Establishment…………………………………………………….. 
1.4 Position in organisation…………………………………………………… 
1.5 Number of years with current employer………………………………….. 
1.6 Number of years in the medical device sector………………………. 
1.7  What are your primary responsibilities? 
Policy making     
Policy analysis     
Policy implementation    
Management      
Other, please specify   …………………………… 
 
1.8  Stakeholder category:    Analysis code 
Government/Competent authority Gov     
Research and Development  RD     
Academic and research institution ARI     
Health facility    HF     
Medical device manufacturing MAN     
 Regulatory agency/Notified body RA/NB  
  Industry association   IA   
Other, please specify   ORES  ………… 
            1.9 Main products of your organisation/firm? 
            (a)………………………………………………………………… 
 (b)………………………………………………………………… 
 (c) ………………………………………………………………… 
1.10        What medical device type do you manufacture? 
Low-risk devices (Class I)   
Medium-risk devices (Class IIa)  
Medium-risk devices (Class IIb)  
High-risk devices (Class III)   
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Other, please specify   ………………………  
   
SECTION 2: Understandings on regulation and regulatory changes 
Objective 2: To assess the market structure, CONTENT and DRIVERS of regulatory 
changes. 
 
2. How is the medical device industry structured in South Africa?  
 
3. Who are the key players involved in the medical device industry in SA? and what 
role do they play? 
 
4. Evidence/Literature suggests that 90% of medical devices are imported and 10% 
are locally manufactured. What could be the reasons for this situation? 
 
5. How are medical devices regulated, and what is the role of the government in the 
regulatory processes in SA? 
 
6. Currently, only electromagnetic medical devices or radiation emitting devices are 
regulated through the Hazardous Substances Act, No. 15 of 1973 while the rest of the 
devices are not regulated. What could be the reason for this and how does this affect 
the whole process of medical device regulation in SA?  
 
7. In the last 30 years, different regulations in the medical device sector have been 
enacted/implemented. What are the key 2 or 3 regulatory changes that have affected 
your organisation’s operations? And How? 
 
8. Other than the domestic regulations, are there any other international regulatory 
standards you required to comply with? If yes how do you comply? 
 
9. In South Africa’s medical device’s regulatory history, what events or circumstances 
could have led to changes in medical device regulations?  
 
SECTION 3: Understandings of the impact of regulatory changes 
Objective 3: To assess the EFFECTS of medical device regulation and regulatory 
changes on industry capabilities and development of medical devices. 
10. How has the past regulatory changes affected your firm’s Investment capability in 
terms of: 
• Research and Development (R&D) of new technology? 
• Recruitment and training of skilled personnel? 
• Equipment acquirement? 
• Standard procurement? 
11. How has the past regulatory changes affected your firm’s Production capability in 
terms of: 
• Innovation? 
• Quality control? 
• Operations? 
• New product technology licensing? 
• Compliance?  
• Monitoring (pre and post market)? 
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• Maintenance? 
 
12. How has the past regulatory changes affected your firm’s Linkage capability in 
terms of: 
• Local acquirement of goods and services? 
• Exchange of information with suppliers? 
• Exchange of information with regulatory bodies? 
• Exchange of information with industry associations? 
• Importing from and exporting to other countries? 
 
13. What steps are involved in the process of obtaining the SABS, CE mark and the 
FDA approval?  
 
14. How long on average does the approval process for medical devices take?  
 
15. How has regulations affected affordability and appropriate healthcare technologies 
in SA? 
 
16. Lastly, What can be done to ensure effective medical device regulations and at the 
same time affordable and appropriate healthcare technology in SA 
 
Thank you 
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APPENDIX 3: The Open University Research Ethics Approval Letter 
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APPENDIX 4: Participation Consent Form 
 
 
 
 
 
 303 
APPENDIX 5: List of Interviews Conducted in SA 
 
 
 
Interview	Schedule	SA	
	
Respondent 
Code 
Company 
Position 
Stakeholder 
Category 
Date Place of 
interview 
01 Director  Manufacturer. 6 Oct 2016 Johannesburg, SA 
02 Chairperson Industry association/ 
Manufacturer 
6 Oct 2016 Johannesburg, SA 
 
03 Managing Director  Industry association/ 
Manufacturer 
7 Oct 2016 Pretoria, SA 
04 Senior Manager  Manufacturer 10 Oct 2016 Midrand, SA 
05 Executive Officer Industry association 13 Oct 2016 Johannesburg, SA 
06 Production & Quality 
Manager 
Industry association/ 
Manufacturer 
14 Oct 2016 Cape Town, SA 
07 National Medical Physics 
Manager 
Health facility 17 Oct 2016 Cape Town, SA 
08 Chief Executive Officer Manufacturer 17 Oct 2016 Cape Town, SA  
09 Chief Executive Officer Manufacturer 19 Oct 2016 Pretoria, SA 
1o Programme Director  Academic and 
research institution 
20 Oct 2016 Johannesburg, SA 
 
11 Regional Service Manager Manufacturer 21 Oct 2016 Johannesburg, SA 
 
12 Senior Quality & 
Regulatory Systems 
Manager 
Manufacturer 25 Oct 2016 Johannesburg, SA 
 
13 Projects Manager Manufacturer 25 Oct 2016 Johannesburg, SA 
14 Strategic & Key account 
Manager 
Manufacturer 27 Oct 2016 Midrand, SA 
15 Regulatory Affairs and 
Quality Officer 
Manufacturer 2 Nov 2016 Centurion, SA 
 
16 Head: Technology 
Innovation Programmes at 
Technology Innovation 
Agency 
GOV- Department of 
Science and 
Technology (DST) 
3 Nov 2016 Pretoria, SA 
17 Senior Programme Officer 
-AU/NEPAD Agency. 
Academic and 
research institution 
3 Nov 2016 Midrand, SA 
 
18 The Executive Director: 
Biosciences. 
CSIR 
Academic and 
research institution 
11 Nov 2016 Pretoria, SA 
19 HOD: Medical Imaging 
and Radiation Sciences 
Department (MIRS) - UJ 
Academic and 
research institution 
14 Nov 2016 Johannesburg, SA 
 
20 Director  Manufacturer 15 Nov 2016 Johannesburg, SA 
21 Registrar of Medicines - 
MCC 
Regulator 17 Nov 2016 Pretoria, SA 
22 Deputy Director - 
Radiation Control  
Regulator 
 
17 Nov 2016 Pretoria, SA 
23 The Group Executive - 
CSIR 
Academic and 
research institution 
18 Nov 2016 Pretoria, SA 
24 SAMED/SALDA Focus Group  22 Nov 2016 Pretoria, SA  
25 National Sales manager Manufacturer 22 Nov 2016 Pretoria, SA 
26 The Projects Manager - 
SANAS 
Regulator  
 
25 Nov 2016 
 
Pretoria, SA 
27 Reimbursement and 
Regulatory Affairs 
Manager 
Manufacturer  28 Nov 2016 Pretoria, SA 
28 CEO Manufacturer 28 Nov 2016 Midrand, SA 
29 Engineer - CSIR 
 
Academic and 
research institution. 
1 Dec 2016 Pretoria, SA 
30  Director Department of Trade 2 Dec 2016 Pretoria, SA  
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APPENDIX 5: List of Interviews Conducted in SA 
 
 
 
 
Interview	Schedule	SA	
	
Respondent 
Code 
Company 
Position 
Stakeholder 
Category 
Date Place of 
interview 
31 Vice President for sale  Manufacturer 17 Feb 2017 Durban - Skype 
call 
32 Health Economics & 
Government Affairs 
Manger  
Manufacturer 17 Feb 2017 Johannesburg, SA 
 
33 NEPAD SANBio 
Annual event  
Facilitated a 
session on 
Regulation in the 
diagnostic sector 
21-22 Feb 
2017 
Johannesburg, SA 
 
34 Regulatory Affairs 
Specialist/QA Manager  
Manufacturer 23 Feb 2017 Durban - Skype 
call 
35 Managing Director  Manufacturer 24 Feb 2017 Johannesburg, SA 
 
36 General Sales manager  Manufacturer 27 Feb 2017 Johannesburg, SA 
37 Area Medical Director  Manufacturer 27 Mar 2017  
38 Research and 
development policy 
officer - Path 
Academic and 
research institution. 
28 Mar 2017 Johannesburg, SA 
 
39 Managing Director Manufacturer 28 Mar 2017 Roodepoort, SA 
40 Consultant Other 2 Mar 2017 Durban - Skype 
call 
41 Regulatory Affairs 
Manager  
Manufacturer 3 Mar 2017 Johannesburg, SA 
 
42 Quality & Regulatory 
Affairs Officer at Strait 
Access Technologies 
Manufacturer 6 Mar 2017 Cape Town, SA 
43 Independent Medical 
Devices Professional 
Manufacturer 7 Mar 2017 Cape Town, SA 
44 Business Developer  Manufacturer 9 Mar 2017 Cape Town, SA 
45 Business Unit Manager  Manufacturer 9 Mar 2017 Cape Town – 
Skype Call 
46 Senior Medical 
Representative  
Manufacturer 10 Mar 2017 Midrand, SA 
 
47 Medical Science Liason  Manufacturer 11 Mar 2017 Roodepoort, SA 
48 Sales Account Manager Manufacturer 24 Mar 2017 Midrand, SA 
 
49 Responsible Pharmacist 
and regulatory affairs 
Manufacturer 27 Mar 2017 Midrand, SA 
 
50 QA Manager  Manufacturer  28 Mar 2017 Durban - Skype 
Call 
51 Clinical research 
associate 
Manufacturer 28 Mar 2017 Pretoria, SA 
52 Focus Group Regulator – 
Medical Control 
Authority of 
Zimbabwe 
(MCAZ) 
06 April 
2017 
Harare, 
Zimbabwe Skype 
meeting 
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APPENDIX 6: List of Interviews Conducted in the UK 
 
 
Interview	Schedule	-	UK	
	
Respondent 
Code 
Company 
Position 
Stakeholder 
Category 
Date Place of interview 
53 Quality manager Manufacturer 28 Dec 2016 Hitchin, UK 
54 Medical Devices Principal 
Consultant 
Manufacturer 29 Dec 2016 Huntingdon, UK  
55 Medtech Regulatory 
Affairs Editor 
Manufacturer 12 Jan 2017 London, UK  
Skype call 
56 Director of Regulatory 
Affairs 
Manufacturer 16 Jan 2017 Nottingham, UK 
 
57 Associate Director 
Regulatory Affairs 
Manufacturer  19 Jan 2017 Open University 
 
58 CEO  Manufacturer  23 Jan 2017 Daresbury, UK 
59 Chief operations officer, Manufacturer 26 Jan 2017 Chichester, UK 
60 Technical Manager Manufacturer 27 Jan 2017 London, UK  
61 Director Quality 
Assurance  
Manufacturer 30 Jan 2017 Stanford, UK 
62 Director, Technical & 
Regulatory 
Industry Association 
- ABHI 
1 Feb 2017 London, UK 
63 Technical Director Manufacturer 2 Feb 2017 Uxbridge, UK 
64 Managing Director Manufacturer 3 Feb 2017 Braintree, UK 
65 Independent Consultant  Manufacturer 6 Feb 2017 Telephone interview 
66 Chairman  Manufacturer 7 Feb 2017 High Wycombe, UK 
67 Medical Devices, EU 
Policy Manager 
Competent Authority 
- MHRA 
8 Feb 2017 London, UK  
 
68 Head of Global Medical 
Device Services 
Notified Body 9 Feb 2017 Lync Meeting 
69 Medical Device Consultant Manufacturer 10 Feb 2017 Skype call 
70 Head of Operations and 
Training  
Notified body - BSI 10 Feb 2017 Skype call 
71 Certification Manager UK notified body 22 Feb 2017 Skype call 
72 Manager Manufacturer 4 April 2017 London, UK  
73 Director and Consultant Manufacturer 21 April 2017 Chesham Bois, UK 
74 Director Global Quality  Manufacturer 26 April 2017 Oxford, UK 
75 Director Manufacturer 6 May 2017 Cleveland, UK 
76 Manager, Franchise 
Marketing, Advanced 
Surgical Devices,  
Manufacturer 8 May 2017 Guildford, UK 
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